Your SlideShare is downloading. ×
IMMUNOLOGY
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

IMMUNOLOGY

11,264
views

Published on

Published in: Health & Medicine, Technology

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
11,264
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
139
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. -1- IMMUNOLOGY Thesis Program of the PhD Curriculum N094 CONTENT 1. Coordinator 2 2. Introduction 2 2.1 Aim of the PhD Program Immunology 2 2.2 Recommended Literature 2 3. Courses 3 3.1 Medical Propedeutics 3 3.2 Basic Seminar (2 X 2 Semester hours) 3 3.3 Journal Club and Progress Reports 4 3.4 Program for Elective Courses 5 4. Participating Faculty (Lectures) 7 4.1 PhD Thesis Supervisors 7 4.2 Teachers 9 5. PhD Thesis Projects 10 5.1 Description of Research Interests of Supervisors and 10 available Techniques Barbara Bohle 10 Wilfried Ellmeier 11 Erika Jensen-Jarolim 12 Syliva Knapp 13 Herwig Kollaritsch 14 Rudolf Öhler 15 Winfried F. Pickl 16 Marcus Saeman 18 Wolfgang Schreiner 19 Hannes Stockinger 21 Herbert Strobl 22 Julia Walochnik 23 Thomas Wekerle 24 Ursula Wiedermann-Schmidt 25 Gerhard Zlabinger 26 6. Curriculum Vitae 28 6.1 PhD Thesis Supervisors (index, in alphabetical order) 28 6.2 Teachers (index, in alphabetical order) 132
  • 2. -2- 1. COORDINATOR Wilfried Ellmeier, PhD, Professor of Immunobiology, Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology , Medical University of Vienna , Lazarettgasse 19, 1090, Vienna, Austria. Phone: +43-1-40160-65003, Fax: +43-1- 40160-965006 E-mail: wilfried.ellmeier@meduniwien.ac.at 2. INTRODUCTION 2.1 Aim of the PhD Program Immunology Molecular and cellular defense mechanisms of the innate and the adaptive immune system protect organisms against harmful pathogens and against the development of malignant cells. However, overreactions of the immune system are responsible for the establishment of immune-mediated diseases such as allergy, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, diabetes, psoriasis and atherosclerosis. It is of enormous importance for contemporary biomedical science to increase the knowledge about the mode of action of the immune system in order to design better therapies for the cure of these life- threatening diseases. The objective of the PhD Program in Immunology is to provide to students excellent training opportunities in the field of immunology. This will be achieved by offering students the opportunity to work with faculty members on cutting-edge research projects in stimulating research environments. Furthermore, students will obtain an in-depth education and training on various immunological topics to obtain a broad knowledge in the field of immunology. This should help to prepare the students for a successful scientific career within academia and/or industry. 2.2 Recommended Literature • Janeway’s Immunobiology – The Immune system in health and disease. Seventh Edition, Kenneth M Murphy, Paul Travers, Mark Walport, Garland Science Textbook 2008 (as alternative: Immunobiology, Charles Janeway, Paul Travers, Mark Walport, Mark Shlomchik, Garland Science Textbooks, 2004). • Molecular and Cellular Immunology, 6th Edition, Abul Abbas, Andrew Lichtman, Shiv Pillai. Saunders, 2007.
  • 3. -3- 3. COURSES There are four types of courses offered in the N094 PhD program: 1. Medical Propedeutics (6 Semester hours) 2. Basic Lecture (2 x 2 Semester hours) 3. Journal Clubs and Progress reports (6 x 2 Semester hours) 4. Elective Courses (4 x 2 Semester hours) 3.1 Medical Prodedeutics (6 Semester hours) The propedeutics are an obligatory part of the PhD studies (irrespective of the chosen program). They have to be completed by the end of the fourth semester and comprise a choice of medical and basic courses, of which 6 semester hours are obligatory. The selection has to be done under the supervision of the thesis committee and the program coordinator and is dependent on the undergraduate education and the selected thematic program. Further information about the propedeutics can be found on the PhD N094 homepage. 3.2 Basic Seminar (2 X 2 Semester hours) The aim of the Basic Lecture is to give students an advanced but still broad overview about various immunological topics, which is a prerequisite for a successful career in the field of immunology. The Basic Lecture will be held in two parts, each 2 semester hours during the winter and summer semester. The lectures will take place as two blocks during two weeks in January (winter semester) and June (summer semester). The topics include mechanisms of innate and adaptive immune responses, as well as the immunopathology of important immunologically-mediated diseases. BASIC SEMINAR 1 (Winter semester, 2 Semester hours) Topic Lecturer I. Overview of the immune system (1h) 1. General principles, cell subsets and lymphoid architecture (1) Wilfried Ellmeier II. Lymphocyte development and subset generation (2h) 1. B and T cell development (2h) Wilfried Ellmeier III. Innate Immunity (7h) 1. Basic principles of innate immune responses (2h) Sylvia Knapp 2. Pattern recognition receptors (2h) Marcus Saeman 3. Radicals as effectors of innate immune cells (2h) Rudolf Öhler 4. Phagocytosis and endocytosis (1h) Renate Fuchs IV. Lymphocyte Activation (10h) 1. Antigen processing and presentation (2h) Winfried Pickl 2. The biology of antigen presenting cells (2h) Herbert Strobl 3. Structure, function and signaling of immune receptors (4h) Hannes Stockinger 4. Costimulatory molecules (2h) Peter Steinberger V. Effector Mechanisms (5h) 1. The role of cytokines in the immune response (3h) Martin Wilheim 2. Cell-mediated Immunity and peripheral T cell subsets (1h) Wilfried Ellmeier 3. Humoral Immunity (1h) Erika Jensen-Jarolim VI. Tolerance mechanisms (2h) 1. Central and peripheral Tolerance (2h) Gerhard Zlabinger
  • 4. -4- VII. Special tissues of the adaptive immune system (3h) 1. Skin Immunity (1h) Adelheid Elbe Buerger 2. Mucosal Immunity (2h) Erika Jensen-Jarolim BASIC SEMINAR 2 (Summer semester, 2 Semester hours) Topic Lecturer I. Type I allergy (4h) 1. General principles (2h) Rudolf Valenta 2. Therapeutic approaches (2h) Barbara Bohle II. Autoimmunity and inflammatory diseases (6h) 1. General principles (2h) Günther Steiner 2. Clinical aspects of autoimmune diseases (2h) Clemens Scheinecker 3. Molecular and cellular mechanism of inflammatory diseases (2) Peter Pietschmann III. Transplantation immunology (5h) 1. General principles (2h) Gerhard Zlabinger 2. Experimental protocols for transplantation tolerance (2h) Thomas Wekerle 3. Immunogenetic selection criteria (1h) Gottfried Fischer IV. Immunodeficiencies (3h) 1. Primary immunodeficiencies (2h) Winfried Pickl 2. HIV (1h) Johannes Stöckl V. Lymphoproliferative diseases and tumor immunology (4h) 1. Experimental systems for studying lymphomas and leukemia (1h) Veronika Sexl 2. Clinical insight into leukemia (1h) Ulrich Jäger 3. Immune responses to tumors (1h) Erika Jensen-Jarolim 4. Mouse models in cancer research (1h) Maria Sibilia VI. Immunotherapy (5h) 1. General principles (3h) Elisabeth Förster-Waldl 2. Clinical strategies for immunotherapy (2h) Thomas Felzman VII. Infection immunology (Immunity to Microbes) (3h) 1. Viruses and the Immune system (1h) Johannes Stöckl 2. Strategies for vaccinations (2h) Ursula Wiedermann-Schmidt 3.3 Journal Clubs & Progress Reports (6 x 2 semester hours) During the 6 semesters of their PhD studies, students have to participate in Immunology Journal Clubs that will be held regularly at the institutions of the participating faculty members. The topics of the Journal Club should be in accordance (or related) with the thesis subjects of the student, however each Journal Club should be open for all students of the immunology program. The primary aim of the Journal Clubs is to learn critical reading and discussion of scientific papers. Therefore, students will have to read scientific publications, to present them to the other participants and to discuss the presented results, methods and interpretations under the guidance of the university teacher. The objective of the Journal Clubs is to get familiar with the design of experimental studies and the interpretation of results. In addition, Journal Clubs should train students in writing scientific papers. The selection of the papers to be discussed can be made by the faculty member as well as by the students. Another important educational aspect of the PhD program immunology are Progress Reports that should be given at least once a year by the PhD students. The Progress Reports should serve as a basis for the evaluation of the PhD thesis. In addition to the
  • 5. -5- members of the PhD thesis committee, other faculty members and students from the host institutions should listen to the seminar given by the PhD student. As a critical audience they should stimulate the successful development of the PhD thesis, help to critically discuss the data and provide suggestions for new experiments. Ideally, there should be a regular Progress Report Series at each host institution of the participating faculty members. This would allow a regular discussion of ongoing projects and studies of the host institution in front of a rather broad audience and this will prepare the PhD students for future presentations of their own scientific results to a larger and critical audience. Journal Club/Progress Report (Winter and summer semester, 2 Semester hours each) Title Lecturer Current topics in parasitology Aspöck, Auer, Hassl, Walochnik (WS, SS) Immune responses to allergens Bohle (WS, SS) Current topics in immune cell development and function Ellmeier (WS, SS) Structural requirements of antigens and allergens for disease Jensen-Jarolim (WS, SS) mechanisms and therapy. Journal Club of the Surgical Research Laboratories Oehler (WS, SS) Integration of genome- and clinical data for immunology Renauld, Regele, Schreiner (WS, SS) Journal Club & Progress Report Roth, Spittler, Oehler, Wekerle, Weigel, Brostjan (WS, SS) 901840 Journal Club und Progress Report Stockinger (WS, SS) Clinical and basic aspects of human hematopoietic stem cells Strobl (WS, SS) and dendritic cells Journal Club and Progress Report Zlabinger, Pickl, Stöckl (WS, SS) 3.4 Program for Elective Courses /Thesis Seminars (4 x 2 semester hours) The purpose of these seminars is to improve and deepen the knowledge in a particular field of immunology. Topics covered in the seminars go beyond textbook knowledge and will cover recent developments in a particular field. The topics of the seminars are grouped into several subject categories (see below). Ideally, the majority of seminars chosen by the PhD student should be in the subject of the individual thesis, however it is recommended to choose at least one seminar in a subject that is not related to the topic of the student’s PhD thesis. THESIS SEMINARS (each 2 Semester hours) Subject Categories Lecturer Allergy (Immediate Hypersensitivity) Title of Seminar: Therapeutic concepts for Type I allergies Bohle (WS) Immunological Methods Title of Seminar: Immunological methods in allergy research Bohle (SS) Lymphocyte Development Title of Seminar: Transcriptional control of immune cell development Ellmeier (WS) Activation and Regulation of Lymphocytes Title of Seminar: Molecular mechanisms of immune cell function Ellmeier (SS)
  • 6. -6- Tumorimmunology Title of Seminar: TBA Jensen-Jarolim (WS) Allergy (Immediate Hypersensitivity) Title of Seminar: TBA Jensen-Jarolim (WS) Innate Immunity Title of Seminar: TBA Knapp (WS) Immunity to Microbes Title of Seminar: TBA Knapp (SS) Dendritic cells/ Tumorimmunology Title of Seminar: antigen-presenting cells as adjuvants for tumortherapy Pickl (WS & SS) Signal Transduction in Immune Cells Title of Seminar: DissertantInnenenseminar: Molecular basis of interaction- and communication mechanisms of immune cells (topic of seminar varies from semester to semester) Stockinger (WS) Title of Seminar: Recognition mechanisms in immunity (topic of seminar varies from semester to semester) Stockinger (SS) Neutrophils, Monocytes/Macrophages and Dendritic Cells Title of seminar: Differentiation and function of myelomonocytic cells Strobl (WS) Hematopoiesis Title of Seminar: Hematopoietic stem cell pathophysiology and lineage decisions in the hematopoietic system Strobl (SS) Tolerance and Autoimmunity Title of Seminar: Preclinical protocols for tolerance induction upon organ transplantation Wekerle (WS) Immunity to Microbes/ Immunological Methods Title of Seminar: Medical Parasitology Practical Walochnik, together with Auer (WS, SS) Immunity to Microbes Basics in Molecular Parasitology Walochnik (SS) Tolerance and Autoimmunity Title of Seminar: Immune Tolerance Zlabinger (WS, SS) Transplantation Title of Seminar: Immunosuppression Zlabinger (SS)
  • 7. -7- 4. PARTICIPATING FACULTY MEMBERS (LECTURES) Faculty members participating in the PhD program Immunology can be grouped into either PhD thesis supervisors or teachers. PhD thesis supervisors are offering internationally peer-reviewed PhD projects to students and are actively supervising the research of the students. Furthermore, PhD thesis supervisors are teaching in the various courses and lectures. In contrast, Teachers do not offer a PhD project to the Immunology program students, however they provide expertise in a particular field of immunology and therefore help to cover a large variety of immunology topics. 4.1 PhD Thesis Supervisors Surename, first name, Research Institution Research Interests academic title Bohle Barbara, PhD Division of Immunopathology, Allergen-specific immune Univ. Doz. DI. Dr. Dept. of Pathophysiology, Center responses, for Physiology, Pathophysiology Immunomodulation, and Immunology Vaccine development E-mail: barbara.bohle@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/ipp/allergyresearch Ellmeier Wilfried, PhD Division of Immunobiology, Lymphocyte Development, Univ.Prof.Mag.Dr. Institute of Immunology, Center Signal transduction in for Physiology, Pathophysiology immune cells and Immunology E-mail: wilfried.ellmeier@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/immunologie/ellmeier/index.html Jensen-Jarolim Erika, MD Division of experimental Allergy, Food allergy Univ.Prof. Immunology and Oncology, Dept. AllergoOncology, Oncology of Pathophysiology, Center for Physiology, Pathophysiology and Immunology E-mail: erika.jensen-jarolim@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/ipp; www.allergology.at Knapp Sylvia, MD, PhD Division of Infectious Diseases Innate Immunity; Immunity to a.o. Univ.Prof.Dr. PhD and Tropical Medicine, Microbes; Neutrophils, Department of Internal Medicine 1 Monocytes/Macrophages and and Center for Molecular DC Medicine E-mail: sylvia.knapp@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/med1/infektiologie ; http://www.cemm.at Kollaritsch, Herwig Division of Specific Prophylaxis Travel Medicine, Univ-Prof. Dr. and Tropical Medicine, Center for Vaccinology, Epidemiology Physiology, Pathophysiology and Immunology E-mail: herwig.kollaritsch@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/tropenmedizin/
  • 8. -8- Oehler Rudolf PhD Department of Surgery, Research Transplantation Immunology, Ao.Univ-Prof.Mag.Dr. Laboratories Tumorimmunology, Neutrophils, Monocytes/Macrophages and Dendritic Cells E-mail: rudolf.oehler@meduniwien.ac.at Pickl Winfried F, MD Division of Cellular Immunlogy Activation and Regulation of Ao.Univ.Prof.Dr. and Immunehematology, Center Lymphocytes, Tumor for Physiology, Pathophysiology Immunology, Immunity to and Immunology Mocrobes E-mail: winfried.pickl@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/immunologie/ Säemann Marcus, MD Internal III/Clinical Division of Transplantation Biology, Doz. Dr. Nephrology & Dialysis Innate Immunity, Immunosuppression E-mail: marcus.saemann@meduniwien.ac.at Schreiner Wolfgang, PhD Division of Biomedical Informatics and Modeling in o.Univ.Prof.Dr. Computersimulation and Medicine, Models, Bioinformatics Immunological Computational Biology E-mail: wolfgang.schreiner@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/msi/biosim/ Stockinger Hannes, PhD Department of Molecular Activation and Regulation of Univ.Prof. Dipl.-Ing. Dr. Immunology, Center for Lymphocytes, Physiology, Pathophysiology and Signal Transduction in Immunology Immune Cells, Immunological Methods E-mail: hannes.stockinger@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/immunology Strobl Herbert, MD Institute of Immunology, Center Human hematopoietic stem Ao.Univ.Prof for Physiology, Pathophysiology cells, dendritic cells, and Immunology transcription control of differentiation, gene therapy, leukemia, autoimmune diseases, inflammation E-mail: Herbert.strobl@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/immunologie Walochnik Julia, PhD Department of Medical Tolerance induction in Univ.Doz.Mag.Dr. Parasitology, Clinical Institute of transplantation and allergy Hygiene and Medical Microbiology E-mail: julia.walochnik@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/hygiene/?s=parasitologie Wekerle, Thomas, MD Div. of Transplantation, Dept. of Tolerance and Autoimmunity, Ao.Univ.Prof.Dr.med.univ. Surgery Transplantation Immunology, E-mail: thomas.wekerle@meduniwien.ac.at Homepage: http://www.muw.ac.at/transplant-lab
  • 9. -9- Wiedermann-Schmidt Ursula, Department of Specific Mucosa Immunity MD, PhD, Univ.Prof. Dr. Prophylaxis and Tropical Immunity to Microbes Medicine, Center for Physiology, Allergy Pathophysiology and Immunology E-mail: ursula.wiedermann@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/tropenmedizin Gerhard J. Zlabinger, MD Division of Clinical and Allergy, Univ. Prof. Dr. experimental Immunology, Food allergy Institute of Immunology, Center AllergoOncology, for Physiology, Pathophysiology Oncology and Immunology E-mail: gerhard.zlabinger@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/immunologie/content/research/zlabinger.htm 4.2 Teachers Ao.Univ.Prof.Dr. Herbert Auer Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology Ao.Univ.Prof. Dr. Adelheid Elbe-Buerger Department of Immundermatology, University Clinic of Dermatology Univ.Doz. Dr. Thomas Felzmann Children Cancer Research Institute Ao.Univ.Prof. Dr. Gottfried Fischer University Clinic for Blood Group Serology and Transfusion Medicine Ao.Univ.Prof. Dr. Elisabeth Förster-Waldl Department of Pediatrics and Adolescent Medicine Ao.Univ.Prof. DI. Dr. Renate Fuchs Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Univ.Prof. Dr. Ulrich Jäger Clinical department of Hematology und Hämostaseology, University Clinic for Internal Medicine I Ao.Univ.Prof. Dr. Peter Pietschmann Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Ao.Univ.Prof. Dr. Clemens Scheinecker Department of Rheumatology, University Clinic for Internal Medicine III Univ.Prof. Dr. Veronika Sexl Institute of Pharmacology, Center for Biomolecular Medicine and Pharmacology Univ.Prof.Dr. Maria Sibilia Institute of Cancer Research, University Clinic for Internal Medicine I Ao.Univ.Prof. Dr. Günter Steiner Department of Rheumatology, University Clinic for Internal Medicine III Univ.Doz. Dr. Peter Steinberger Immune Receptors and T-cell Activation, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Ao.Univ.Prof.Dr. Johannes Stöckl Division of Immune Regulation, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Ao.Univ.Prof. Dr. Martin Willheim Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology
  • 10. - 10 - 5. PhD THESIS PROJECTS 5.1 Description of Research Interests of Supervisors Barbara Bohle, Division of Immunopathology, Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Characterization of allergen-specific immune responses Abstract The long-term research interest of the Allergy Research group is to elucidate the immunological mechanisms underlying the induction, maintenance and immunotherapy of Type I allergy and to develop novel concepts for an efficient and safe specific immunotherapy of Type I allergy. (1) Cellular and molecular basis of Type I allergies We have a long lasting expertise in the isolation and characterization of allergen-specific T cells. Allergen-specific T cell cultures are applied to gain insights into the cellular response to allergens. We have shown that the immune response in allergic individuals is dominated by allergen-specific Th2 cells and lacks counter-regulating allergen-specific Th1 and regulatory T cells. On the other hand, we employ allergen-specific T cell cultures to characterize allergens with regard to their T cell epitopes and cellular cross-reactivity. These data lay the foundation for the development of novel vaccines for allergen-specific immunotherapy, such as hypoallergenic variants with reduced IgE-binding and retained T cell stimulatory capacity. (2) Novel vaccines for allergen-specific immunotherapy Allergen-specific immunotherapy (SIT) is the only treatment of Type I allergy that induces a modulation of the disease-eliciting immune response. Conventional SIT consists of multiple subcutaneous injections of crude allergen extracts into allergic individuals in order to induce a state of clinical tolerance to natural allergen exposure. However, the administration of allergens bears the risk to induce local and systemic side effects. Furthermore, SIT is not always effective. Therefore, a major goal of my group is to develop more efficient and safer vaccines for specific immunotherapy. For this purpose we link allergens with agents targeting the innate immune system in order to modulate the disease-eliciting immune response towards a more physiological response. Techniques “State of the art” immunological, biochemical and molecular biology techniques, such as the production and purification of recombinant allergens, RT-PCR, real-time PCR, ELISA, ELISPOT, SDS-PAGE, Western blotting, different applications of flow cytometry including cell surface staining, intracellular cytokine detection and determination of cell proliferation by CFSE staining; basic tissue culture techniques, isolation and characterization of allergen- specific T cells; allergen-induced mediator-release experiments with rat basophil leukemia cells (RBL) transfected with the human Fc epsilon receptor I and human basophils, basic allergological methods, i.e. skin prick tests, prick to prick tests and rhinomanometric measurements.
  • 11. - 11 - Wilfried Ellmeier, Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Molecular mechanisms of immune cell development and function Abstract Our long-term research interest is to understand molecular mechanisms that regulate the development and function of immune cells. The research in our laboratory focuses on studies to understand epigenetic and transcriptional control mechanisms that regulate CD8 coreceptor gene expression, on the identification of genes that control developmental processes such as CD4/CD8 cell fate decisions during T cell differentiation, and on studies to reveal the various roles of Tec family kinases in different cell lineages of the immune system. (1) Epigenetic gene regulation during T cell development Our laboratory is studying the regulation of CD8 coreceptor expression, a key molecule in the immune system for the development of the cytotoxic T cell lineage. CD8 coreceptor expression is tightly regulated during thymocyte development by the activity of at least five different cis-regulatory elements. We recently linked Cd8 enhancer function with chromatin remodelling of the adjacent genes Cd8a and Cd8b1 (Cd8) and demonstrated epigenetic control of the Cd8 gene complex. We have further identified that the zinc finger protein MAZR is an important regulator of CD8 expression. Ongoing studies in the laboratory aim to further characterize Cd8 cis-regulatory elements and to study MAZR function in more detail. (2) The role of Tec family kinases for immune cell function Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) form the second largest class of non-receptor protein tyrosine kinases. The analysis of mice lacking Tec family kinases has uncovered important functions for Tec kinases in cells of lymphoid origin. In addition, numerous reports exist that describe the expression and activation of Tec kinases in every cell type of the myeloid compartment. Tec family kinases can get activated by a broad range of signalling pathways including also non-immune-globulin like receptors such as: receptor tyrosine kinases, interleukin and toll-like receptors, integrins, G-protein coupled receptors and so-called "death" receptors. In order to shed further light into the function of Tec kinases in myeloid cells, we are analysing the function of a variety of primary myeloid cell types (e.g. mast cells and monocytes/macrophages) lacking single and/or multiple Tec kinase family members. Since some of the Tec family kinases are also involved in processes that when deregulated (such as Th1/Th2 differentiation, mast cell activation) can lead to diseases such as autoimmunity or allergy in man. Thus, the molecular analysis of the various Tec family kinase-deficient mice may not only contribute to our basic understanding of the role of Tec kinases in cells of the immune system, but may also help to indicate ways for potential therapeutic intervention. Techniques „State of the art“ basic molecular and cellular biology techniques, biochemical analysis of signal transduction pathways, yeast one-hybrid screens, chromatin immunoprecipitations, RNAi approaches, FACS, in vitro and in vivo immunological assays, retroviral-mediated gene transduction of bone marrow stem cells followed by the generating of bone marrow chimeras, (conditional) ES cell technology, and mouse molecular genetics tools (knockout and transgenics).
  • 12. - 12 - Erika Jensen-Jarolim, Division of Experimental Immunology and Oncology, IPP - Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology Allergology, oncology, allergooncology Abstract The group analyses the molecular features of allergens and antigens leading to sensitization and immunity. Both, mechanistic and therapeutic principles are being investigated. Techniques Molecular and cellular biology techniques, in vitro and in vivo immunological assays, and mouse models of allergy and tumor disease.
  • 13. - 13 - Sylvia Knapp, Division of Infectious Diseases and Tropical Medicine, Department of Internal medicine 1, Medical University Vienna; and Center for Molecular Medicine of the Austrian Academy of Sciences Innate Immune Response to Bacterial Infections Abstract Our research projects are addressing important clinical problems and focusing on innate immune mechanisms with relevant bacterial infections simulated under laboratory conditions. While our general objectives are in furthering our understanding of clinically relevant pathogens and host-pathogen interactions; our primary objectives are to positively impact and substantially enhance the current diagnostic procedures and ultimately influence therapies and survival. (1) Host recognition receptors and signaling pathways Our laboratory is investigating the role of pattern recognition receptors during clinically relevant bacterial infections, such as pneumonia induced by Streptococcus pneumoniae and Pseudomonas aeruginosa or septic infections like peritonitis. In doing so we were able to identify and characterize the distinct roles of e.g. TLRs, CD14, or LBP in vivo. Ongoing studies are aimed at a better understanding of the biological role of co-receptors such as TREM-1 or CD36. In a second line we are interested in understanding the impact of pre-existing tissue alterations on the course of infection. This question specifically addresses clinically important situations observed in hospitalized patients that are at increased risk for infections. Our studies are based on the concept that tissue damage (e.g. trauma, mechanical ventilation or non-infectious inflammation) results in the release and/or modification of endogenous molecules that in turn impact the function of immune effector cells. In accordance with this idea we recently demonstrated that oxidized phospholipids seriously impact host defense against E. coli in vivo. It is the aim of current projects to explore the generation of these lipid products in humans and to better characterize elicited effects in vitro and in vivo. (2) The role of bacterial virulence factors (toxins) during pneumonia. Pathogenic bacteria developed mechanisms to counteract host defense pathways. Among those, the secretion of pore-forming toxins is known to be a potent mechanism and associated with aggravated disease, tissue damage and potentially lethal outcome. We aim at understanding the molecular mechanism by which selected bacterial toxins attack host cells in order to identify novel targets for therapeutic interventions. Techniques In vitro and in vivo bacterial infection models (pneumonia, and peritonitis), basic cellular and molecular biology techniques, biochemical analysis of signal transduction pathways, RNAi approaches, FACS, in vitro immunological assays, basics in confocal microscopy.
  • 14. - 14 - Herwig Kollaritsch, Division of Travel Medicine and Infectious Disease Epidemiology, Institute for Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology Epidemiology and Travel Medicine Abstract Our group is working in 2 major research fields: (1) Clinical Studies with new vaccines and proof of concept of recommended vaccination schedules: Clinical phase II-IV studies as well as post marketing surveillance and observational studies are performed. Currently, the focus is on immunogenicity and tolerability of different vaccinations such as a new genereation of bird flu vaccines or new vaccinations against Japanese Encephalitis. Ongoing projects are long term surveillance of antibody decline after TBE vaccination and seroprevalence of vaccine derived antibodies in 5-7 year old children. (2) Epidemiological Studies: In a nationwide surveillance system the epidemiology of vaccine-preventable diseases (Pertussis, Rotavirus, invasive pneumococcal disease, Hepatitis A, B, C, Measles, Mumps Rubella, Haemophilus influezae B) has been monitored for more than ten years by now. Data from this surveillance are used to i) evaluate current vaccination concepts, ii) establish and monitor new vaccination recommendations, iii) observe replacement phenomena under vaccination pressure, iv) give cost-benefit analyses for established vaccination programs and v) use the data from this project to induce new research projects in basic research and applied science.
  • 15. - 15 - Rudolf Oehler, Department of Surgery, Research laboratories Response of the immune system to therapy in surgical patients Abstract Our long-term research interest is to utilise the understanding of the response of the immune system to therapy in order to improve the clinical outcome. (1) Effect of chemotherapy on the immune response Our aim is to avoid undesired immunosuppression by chemotherapy and boost the immune response to cancer. Chemotherapeutic treatment of cancer patients supposedly mediates its effect via direct elimination of tumor cells. However, there is growing evidence that activation of immune cells in tumour's micro environment is essential for tumour regression. Our focus is the effect of chemotherapeutics on the immune response in cancer patients. Therefore we investigate circulating as well as tumour-infiltrating immune cells in patients during chemotherapy. Special emphasis is given to monocytes/macrophages and their responsiveness to stimuli. In addition we perform in vitro models with primary cells to investigate the hypotheses raised on the basis of the analysis of the clinical samples. (2) Non-HLA donor-specific antigens in transplantation immunology Our interest is to improve the donor-recipient matching in renal transplantation to prolong graft survival. About the half the renal graft recipients encounter late loss of organ transplants in renal transplantation. Although it is well established that major histo-compatibility complexes (HLA) are the main targets of humoral immunity there is evidence that non-HLA specific antibodies contribute substantially to late loss of organ transplants. Using proteomics technologies we identify antigens of pre-existing as well as transplantation-induced non-HLA donor-specific antibodies and develop analytical application platforms for their analysis. These platforms are then used to investigate the association of the specific antibodies with graft survival. Techniques „State of the art“ quantitative electrophoretic proteomics techniques, in vitro and in vivo immunological assays, FACS, biochemical analysis.
  • 16. - 16 - Winfried F. Pickl, Division of Cellular Immunology and Immunhematology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology The immunological synapse Abstract T cell activation is the result of a sustained antigen-specific interaction of a T lymphocyte with a professional antigen-presenting cell (pAPC) in a secondary lymphatic tissue. The detailed description of the molecular and functional events within the immunological synapse formed by T cells and pAPC is one of the keys to the better understanding of adaptive immune responses and their modulation. Model systems in which the immunological synapse can be rebuilt with receptors relevant for human diseases shall enable us to study the pathophysiology of allergies, autoimmune and infectious diseases as well as cancer in greater detail and may thus lead to novel strategies for their cure. (1) Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with TCR/CD3 ligands plus costimulatory molecules Inducible virus-like particles (VLP), decorated with T cell ligands of choice can be directly immunogenic for purified T lymphocytes. We found that lipid rafts are the keys to inducible VLP production and the selective enrichment on VLP of immunologically relevant molecules. VLP expressing combinations of T cell ligands plus antigen were produced and their impact on T cell activation was evaluated. Functional analyses showed, that they mediate strong, accessory cell-independent, antigen-specific T lymphocyte activation. Our data move virus biology, lipid rafts and aspects of lymphocyte activation into a novel biological context. We expect that both basic and applied research will profit from our reductionist system for antigen presentation and T lymphocyte activation. (2) A general strategy for decoration of virus (like) particles with functionally active lipid- modified cytokines Augmentation of immune responses against antigens by co-administration of appropriate adjuvants became general practice following the demonstration by Ramon more than 80 years ago that increased antitoxin responses in the presence of “helper substances” can be achieved. In proof of principle studies we have evaluated the ability of membrane anchored human and murine cytokines to “pseudotype” Moloney murine leukemia virus (MoMLV) particles. Based on this mechanism we have developed a system for the predictable decoration of enveloped viruses (or VLP) with functionally active cytokines that circumvents the need to modify viral proteins themselves. Virus (like) particles decorated with lipid- modified cytokines might help to improve viral strains for vaccination purposes, improve artificial antigen presenting platforms, facilitate the propagation of factor-dependent cell types, as well as gene transfer by viral systems in the future. (3) Molecular and functional analysis of antigen receptors of allergen-specific helper T lymphocytes T lymphocytes play a central role in the pathogenesis of allergic diseases. During the sensitization phase, priming of allergen-specific (CD4+) T helper 2 (TH2) cells results in the production of TH2 cytokines, which are responsible for class switching to the epsilon Ig heavy chain, allowing IgE production by B-cells. Although TCR gene usage by allergen-specific T lymphocytes has been studied to a considerable degree in the past, no molecular or functional analyses of cloned and ectopically expressed human allergen-specific TCR have been reported so far. Consequently, biological model systems based on human allergen- specific TCR were still missing. Hence, one of our research-interests is devoted to test the feasibility of engineering allergen-specific T lymphocytes by genetic TCR transfer. Expressible allergen-specific TCRs may contribute to a better definition of the ‘allergen- specific synapse’ and thus the processes leading to allergic diseases and their cure in the
  • 17. - 17 - future. In a next step, w e plan to clone TCRs specific for other relevant allergens within the Christian Doppler Laboratory “Immunomodulation”. (4) Novel biomarkers to identify active chronic graft-versus-host disease patients with severe immunodeficiency Chronic graft-versus-host-disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT) and a leading cause of nonrelapse mortality resulting from profound immunodeficiency. Currently, biology-based markers both for diagnosis and monitoring activity of cGVHD as well as its functional consequences on the immune system are lacking. In close cooperation with the research group of Prof. Hildegard Greinix, Department of Internal Medicine I, Medical University of Vienna, we have identified memory B cell subsets a novel biomarkers to identify patients with severe immunodeficiency. A prospective study is currently being initiated in order to confirm and extend our earlier findings. Techniques Cellular and molecular biological techniques for the expression and functional evaluation of immune receptor molecules including retroviral gene transfer and transgenesis and flow cytometry. Immunological characterization of patients with leukemia and primary and acquired immunodeficiencies.
  • 18. - 18 - Marcus Säemann , Internal Medicine III, Clin. Division of Nephrology & Dialyis Experimental Immunsuppression and regulation of innate immunity Abstract: Our research is primarily devoted to understand immunological effector arms that can be manipulated in order benefit the host, e.g. to down-regulate immune responsiveness against alloantigens in organ transplantation. Furthermore, molecular mechanisms and targets of currently employed immunosuppressants are analyzed to gain more insights into the molecular drug action and also the basic regulation of the immune response. Another part of our research is focused on the potential link between arteriosclerosis and inflammation. In particular we study the potent immunomodulatory capacity of high-density lipoprotein hypothesizing that its atheroprotective and thereby life-enhancing potency is due to its anti- inflammatory action rather than being a simple cholesterol transport molecule. Finally, we have a prime interest in the diverse immunological mechanisms operative during host cell evasion also to take advantage from evolutionary driven strategies that can be mimicked for therapeutic purposes. (1) Regulation of innate immunity by mTOR Our laboratory is studying the regulation innate immune responses evoked by monocytes and peripheral dendritic cells by the mammalian target of rapamycin, a key molecule traditionally associated with translational control of eukaryotic cells, cell-cycle regulation and cell survival and currently therapeutically targeted by its naturally occurring inhibitor rapamycin or its dereivatives as immunosuppressant and anticancer drug. We recently identified mTOR as negative regulator of proinflammatory cytolkines as IL-12 and IL-23 but suppressor of the prototypical anti-inflammatory cytokine IL-10 in murine and human monocytes and peripheral myeloid dendritic cells. We have further identified that its regulatory role is exerted by the specific control of NF-kB activity, a pivotal proinflammatory transcription factor. Finally, in a relevant murine disease model employing Listeria monocytogenes we demonstrated that genetically-susceptible mice display an increased survival after mTOR inhibition by differentially regulating protective cytokine production. Ongoing studies in the laboratory aim to further elucidate the relative contribution of the mTOR subunits mTORC1 or Raptor versus mTORC2 or Rictor in dictating the final outcome of innate and adaptive immune responses including studies on optimized vaccination protocols or preventing virally-mediated immune escape. (2) The role of HDL as immunomodulatory molecule Several pivotal studies indicate that the quality rather than the quantity of HDL is decisive for its atheroprotective potency. Our studies could demonstrate that HDL exerts very potent effects on innate immune cells like monocytes/macrophages and dendritic cells by suppressing e.g. the production of various inflammatory cytokines. Interestingly, this potent immunomodulatory role is lost in high-risk populations such as end-stage renal disease patients exhibiting both a state of chronic inflammation and an excessively increased mortality rate. This study project aims to define the molecular pathways underlying this peculiar property of HDL envisioning a translational approach in patients with qualitatively inferior HDL and also identifying such high-risk patients with immunological methods. Techniques Current basic molecular and cellular biology techniques, biochemical analysis of signal transduction pathways (western blooting, immunoprecipitation, EMSA), RNAi approaches, FACS, in vitro and in vivo immunological assays and cell culture and finally mouse molecular genetics tools (knockout mouse models).
  • 19. - 19 - Wolfgang Schreiner, Division of Biomedical Computer Simulation and Bioinformatics, Core facility of Medical Statistics and Informatics Informatics and Modeling in Medicine Abstract My overall goal is the application of IT (information-techniques) within biomedical settings. It is achieved by combining and applying relevant IT to specific biomedical fields, in an interdisciplinary approach. Projects may relate to biomedical research as well as to clinical settings close to patient treatment. Research & Research Support: In the more simple cases, novel IT-tools are adapted and made available to support particular biomedical research projects within interdisciplinary cooperations. Within these projects, the IT then becomes an indispensable part of the final, overall achievement. In more advanced cases, those IT-tools already available are found insufficient, and new tools (algorithms) have to be developed so as to meet the needs of a given biomedical research endeavour. Then, IT-research and development in its own right is carried out. Finally, the most intriguing scenario is modeling of biomedical systems, with the intention to acquire further clues about a biomedical system’s internal functionality. For example, biomolecules can be modeled, the mutual forces and movements computed so as to understand and predict binding affinities and even enzyme functions in silico before being tested in a wet lab-setting. Or else, vascular models may be generated via optimization rules and then be checked to which extent resulting models match reality. We then make implications if the optimization rules applied may be similar to those criteria relevant in evolutionary shaping of physiological structures. Clinical Settings and Patient Treatment: Modern IT, if designed properly, lends itself as a very efficient support of patient treatment. The IT-people’s task is then to listen, pick up the clinician’s need and re-formulate it in a way that can be cast into an IT-application. Examples are applications for patient documentation and signal acquisition in clinical research. Integration of heterogeneous data sources, such as gene-sequence, gene-expression, proteomics, bio-signals and images is an ongoing an ever changing challenge. Another important aspect is consulting clinicians in IT-projects, such as AKIM, that are carried out by third parties. AKIM aims at renewing and fully integrating the IT-infrastructure of the 2000- bed Vienna General Hospital, including the research facilities of Medical University of Vienna. (1) Computational immunomics, also known as in-silico immunomics Our main interest is on the molecular interaction between T-cell-receptor (TCR), T-cell- epitope, and major-histocompatibility-complex (MHC). For that purpose we apply software engineering, mathematical and statistical methods on experimental x-ray data (see techniques). Investigations regard side chain placement of the peptide inside the MHC- binding-groove and prediction of the binding affinity of a TCRpMHC molecule for high throughput screening without pre-assigned calibration. We also perform stochastic simulation to investigate TCR activation. In particular, we evaluate how cooperative mechanisms between TCRs amay be essential in providing a high discrimination power between different peptides, despite binding affinities are rather similar. (2) Blood vessel modelling and visualization Vessel trees are generated by the algorithm of "Constrained Constructive Optimization" (CCO), which has been developed by our group. For a suitable choice of boundary conditions and constraints, each model tree is generated by stepwise adding new segments and optimizing the tree according to a given target (cost) function. The resulting trees are highly realistic structures, resembling corrosion casts of real arterial trees. Visualizations are
  • 20. - 20 - made in high-quality 3-D-representation, with optional shading and lighting. Recently, an interactive tool to manipulate and slice the model structures has been developed. (3) Medical Informatics consultancy and project management. I take part as a consultant to MUW in several IT-projects, among others AKIM (Allgemeines Krankenhaus Informations Management). The main challenge is to integrate different sources of data and enable the clinician to handle them in a seamless fashion. Techniques Modeling of peptides (side chain placement, backbone adjustment), scoring conformations (structure- and sequence-based), molecular dynamics simulations blood vessel modelling, stochastic simulations of particle- and molecule interactions, hemodynamic modeling, statistics, graphical display, data-integration of genome and patient- related data within the AKIM-framework at MUW-AKH, IT-consultancy for biomedical projects. Programming languages: FROTRAN, Java, SAS, Matlab.
  • 21. - 21 - Hannes Stockinger, Department of Molecular Immunology, Center for Physiology, Pathophysiology and Immunology Analysis of T cell antigen receptor and accessory receptor signaling to understand T cell regulation Abstract Hannes Stockinger is the chairman of the D e pa rt me nt of M ol ec ul ar I m m u n ol o gy o f the M e di c a l U niv ers ity of V ie n na th at has outstanding expertise in the field of leukocyte biology with special emphasis on the function and signal transduction of plasma membrane receptors of T cells. For an immune response to occur, T cells must be exposed to two types of stimuli. The first signal, an antigen, ensures the specificity of activation and is transduced via the T cell antigen receptor. Second signals for T cells are transmitted via costimulatory receptors and cytokines that promote clonal expansion of the specific T cells and their differentiation into effector and memory cells. In addition, the immune system provides for control mechanisms, which maintain homeostasis after active immune responses to foreign antigens, and prevent or abort responses to self-antigens. The Department is particularly interested to uncover latter pathways aiming to identify targets to correct pathological and unwanted immune reactions, which occur during autoimmunity, allergy or transplantation. As tools for the experiments, a team of 16 young enthusiastic scientists generated a large panel of monoclonal antibodies towards immune cells receptors and established a number of “gain of function” and “loss of function” assays by using recombinant and tagged forms as well as siRNA sequences of membrane receptors and submembrane signaling molecules. In the course of these studies we contributed also substantially to the identification and characterization of lipid rafts, special membrane microdomains that control signal transduction across the plasma membrane. Currently, together with the Institute for Biophysics from the Johannes Kepler University in Linz, we are developing methods for detecting and tracking single molecules in living cells. We are now able to trace individual fluorescently labeled molecules in living cells in real time as well up to 1000-fold time lapse. The ability to follow molecules on the microsecond time scale and locate them with a resolution of a few dozen nanometers proves extremely useful when studying reorganization processes of membrane components or compartments within the membrane. The use of these high-resolution microscopy techniques are thought to open completely new vistas for studying signaling processes in living cells and develop novel diagnostic assays. The results of our studies were published in approximately 130 scientific papers, a variety of them in the very top journals such as Cell, Science and The Journal of Experimental Medicine that were cited nearly 5000 times. Four patents are currently active. Thesis Subjects Molecular interactions and transmembrane signaling of surface receptors of T cells. Techniques and infrastructure Cell culture, flow cytometry, molecular cloning, transfection and infection techniques, siRNA technology, immunological techniques (isolation, cultivation and stimulation of immune cells, ELISA, immunofluorescence, Western blotting, immunoprecipitation, etc), chromatography, advanced imaging (single molecule analysis, confocal microscopy).
  • 22. - 22 - Herbert Strobl, Division: “Molecular Biology of Hematopoietic Stem Cells and Dendritic Cells”, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Human hematopoietic stem cells and dendritic cell biology Abstract We focus on questions in cell biology applied to human immunology and molecular hematopoiesis. We aim to elucidate the transcriptional mechanismsunderlying the lineage differentiation of granulocytes, monocyte and dendritic cells from common myeloid progenitor/ stem cells. Furthermore, we study how certain dendritic cell subsets such as environmental exposed epithelial Langerhans cells get activated, and how they might be involved in tolerance induction. As a main model cytokine dependent unilineage differentiation cultures of human CD34 pos.cord blood progenitor/stem cells are combined with inducible retroviral vector systems. Furthermore, we performed functional genetic screens to identify novel regulatory proteins involved in myeloid progenitor/stem cell differentiation and leukemia. Techniques Differentiation cultures of primary human CD34 pos. hematopoietic progenitor cells, multiparamter FACS, molecular/biochemical analyses, DNA cloning, construction of retroviral gene transfer vectors, functional genetic cDNA libarary screens. In all our projects we use retroviral/lentiviral gene transfer experiments. Specific ongoing projects: Role of transcription factors in lineage decidisons of hematopoietic stem- and progenitor cells: We are currently studying several transcription factors: the role of Aryl hydrogen carbon receptor in myelopoiesis and dendritic cell differentiation; Interplay between nuclear hormone receptors VDR/RXRα with the master transcription factors GATA-1 and PU.1 in the lineage decisions of normal and leukemic stem cells; how are lineage decisions between monopoiesis versus granulopoiesis regulated? Dendritic cells We study transcriptional regulators of DC subset differentiation and maturation. Among several questions: How do common monocytic precursors develop into Langerhans cells in the steady state versus into monocyte-derived DCs in inflammatory lesions? What is the role of microRNAs in DC subset differentiation and activation? What is the role of RelB during Langerhans cell activation? Identify novel transcriptional regulators in Langerhans cell differentiation. How are epithelial adhesion molecules induced during Langerhans cell differentiation. Apply organotypic epidermal cultures for studying Langerhans cell function. Clinical leukemia immunophenotyping Identify novel markers for identifying monocytic leukemias and Langerhans cell histiocytosis. Identify novel approaches for monitoring residual leukemic blasts after therapy, by using flow cytometry. Multicenter standardization efforts within the European group of Immunologic Leukemia lassification (EGIL).
  • 23. - 23 - Julia Walochnik, Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology Molecular parasitology Abstract The broader field of our working group is medical protozoology, with a general focus on molecular biological questions. Our main research topics are pathomechanisms, immunobiology, phylogeny and biocide susceptibility mainly in Leishmania spp., Toxoplasma gondii, Trichomonas vaginalis, and, particularly also in Acanthamoeba spp. Moreover, considerable research work has been done on vector-borne pathogens. During the past years we have established an extensive protozoal strain collection of well-defined clinical and environmental isolates. (1) Pathomechanisms and immunobiology of Acanthamoeba infections Our long-term research goal is to understand what makes certain Acanthamoeba strains virulent and what makes certain individuals susceptible to infection. Acanthamoebae are the causative agents of two very different disease entities. On one hand they evoke the so-called Acanthamoeba keratitis, a very often seriously progressing inflammation of the cornea occurring predominantly in contact lens wearers. On the other hand acanthamoebae are responsible for several highly destructive disseminating infections in the immunocompromised host, including dermatitis, pneumonitis and the usually fatal granulomatous amoebic encephalitis. We are currently the only department in Austria with an Acanthamoeba research group. The focus of our hitherto work has been the characterisation and classification of pathogenic and nonpathogenic Acanthamoeba strains employing morphological, physiological, molecular biological and immunological methods and the correlation of various characters with respect to pathogenicity. We also want to understand the regulation of cyst formation, because the cysts are the major problem in therapy. Moreover, we have been working on the immunoreactivities of Acanthamoeba spp. and on the serological reactivities of patients. (2) Anti-protozoal biocides Another major aim of our working group is to find substances active against Acanthamoeba and other parasitic protozoa as there currently is no specific treatment available for any of the different Acanthamoeba infections and also in other protozoal diseases treatment is highly problematic. We have been involved in several projects on biocides, including contact lens disinfectants, antibiotics and bioactive substances, and their activities on various parasitic protozoa. (3) Phylogeny of the amoebozoa The classification of the amoebae is especially controversial and has been revised many times. In the recent years molecular biological investigations, particularly rDNA sequencing, have brought some astonishing changes concerning the diversity and also the evolutionary and systematic positions of numerous amoebic lineages. But the vast majority of amoebae has not been thoroughly investigated or is even known to date. Our aim is to contribute to the elucidation of amoebozoan phylogeny. Techniques Cell culture, microscopy, „state of the art“ basic molecular techniques, PCR, DNA sequencing, 2D-electrophoresis, ÄKTA purification, in vitro immunological assays.
  • 24. - 24 - Thomas Wekerle, Division of Transplantation, Deptartment of Surgery Abstract The research efforts of my group focus on translational research in the area of two common immunological conditions: organ transplantation and allergy. We are interested in the development of experimental tolerance regimens with relevance for these two indications and the in-depth mechanistic analysis of such models. In particular, we pursue the concept of chimerism induction through the transplantation of hematopoietic stem cells which leads to robust, lasting tolerance towards antigens expressed on the transplanted cells. Protocols of allogeneic mixed (cellular) chimerism generated through the transplantation of donor bone marrow for the induction of donor-specific tolerance in transplantation, and protocols of molecular chimerism generated through the transplantation of syngeneic hematopoietic stem cells that have been retrovirally transduced ex vivo with a disease-causing antigen are being investigated.
  • 25. - 25 - Ursula Wiedermann-Schmidt Tropical Medicine, Center for Physiology, Pathophysiology and Immunology The research unit focuses on immunoprophylaxis and vaccination against infectious diseases, allergies and cancers, the development and validation of novel vaccine candidates and antigen delivery systems and the assessment of immediate and memory immune responses as well as vaccination failure after immunization. Vaccine development from bench to bedside in cooperation with clinical departments is performed with support of international vaccine companies. The following topics are being focused on: • New antigen-delivery systems for vaccination: Lactic acid bacteria as edible vaccines; expression of recombinant allergens, tumor antigens (her-2/neu) and protozoal antigens (e.g. Toxoplasma gondii) Virosomes as adjuvants for systemic and mucosal vaccination with tumor antigens/peptides, allergen peptides etc. • Use of mucosal adjuvants for enhanced immunogenicity, e.g. cholera B subunit, LTB from E. coli • Development of a polyvalent allergy vaccine: development of novel allergen-chimers for nasal or oral vaccination against multisensitivities • Development of a cancer vaccine against breast cancer and melanoma • Immunological assessment of phase I clinical trial with cancer vaccines • Characterization of cellular and humoral immune responses in responder versus non/low-responder vaccinees • Immunological tolerance as vaccination strategy against immunological hyperresponsiveness (incl. allergy, autoimmunity)
  • 26. - 26 - Gerhard J. Zlabinger, Division of Clinical and experimental Immunology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology Bacterial and experimental Immunomodulation Abstract A longstanding interest of my research group concentrates on the issue of naturally occurring ways of immunomodulation as particularly operating in local immunity and on clinical conditions in consequence of inappropriate immune reactivity as observed after transplantation or in autoimmune diseases. Identification of immunological deregulation as early as possibly and the understanding of the ongoing processes are pivotal for early diagnosis and the development as well as implementation of purposeful interference strategies. (1) Mediators of Local Immunity Tamm Horsfall Protein (THP) is a heavily glycosylated protein, which is exclusively expressed in the thick ascending limb of the Henle’s loop in the kidney in amounts of 30 – 50 mg/day and therefore comprises the most abundant protein in the urine. THP is normally expressed only at the luminal surface of renal tubular epithelial cells and excreted to the urine. Considering the properties of THP, this protein is thought to be an essential defense molecule against UTI for at least two reasons: 1) Recent data unequivocally demonstrated that THP is pivotal to combat bacterial infection in vivo. THP-/- mice were shown to be profoundly hampered to combat colonization of the bladder tissue when infected with uropathogenic type-1 fimbriated E. coli. In addition, it has been demonstrated that the absence of THP predisposes the host to severe urinary tract infection. 2) Additionally to this physical - competitive action, which takes place in the lumen of the urinary tract, we have recently identified THP as an endogenous molecule that potently mediates immunomodulation. Because of its restricted expression the activity of THP can be expected to exclusively take place in the genitourinary tract. We found that THP is a strong activator of human DCs and initiates the upregulation of costimulatory molecule and MHC expression, inducing de novo cytokine production and optimal T cell stimulation. Interestingly, THP was shown to induce DC maturation via activating a TLR4 dependent cell signaling machinery. (2) Hallmarks of Antibody-mediated rejection In clinical transplantation, up to now, diagnostic and therapeutic efforts have mainly focused on T-cell-mediated immunity. However, over the last fifteen years there has been an increase in evidence for a critical role of B cell immunity and antibody-mediated effector mechanisms on graft loss. Although in the early days of transplantation humoral immunity was recognised to be causal for hyperacute graft rejection due to preformed anti-donor antibodies, only recently the important contribution of alloantibodies to more “common” rejection types could be established, e.g. acute or chronic rejection. Pivotal for the progress in the field have been the definition of acute Antibody-Mediated Rejection (AMR) as a novel clinical entity, the description of capillary deposition of C4 complement split product C4d as marker of AMR, and the establishment of efficient “anti-humoral” treatment, most importantly apheresis. Since it would be of great benefit if the reactivity of donor specific B cells (i.e. alloantibody production) could be accurately assessed prior to transplantation as well as for monitoring purposes in the post transplant phase we have started to implement a test procedure for ex vivo testing of alloantibody production. Appropriate stimulation of B-cells reveals the release of particular alloantibody specificities both in healthy individuals and in sensitized transplant patients. Follow-up studies in transplant patients will demonstrate the clinical relevance of such testing. Techniques
  • 27. - 27 - „State of the art“ basic molecular and cellular biology techniques, biochemical analysis of signal transduction pathways, FACS, in vitro immunological assays.
  • 28. - 28 - 6. CURRICULUM VITAE 6.1 PhD Thesis Supervisor Barbara Bohle 29 Wilfried Ellmeier 38 Erika Jensen-Jarolim 44 Sylvia Knapp 51 Herwig Kollaritsch 57 Rudolf Öhler 70 Winfried F. Pickl 73 Marcus Saeman 78 Wolfgang Schreiner 86 Hannes Stockinger 89 Herbert Strobl 96 Julia Walochnik 101 Thomas Wekerle 107 Ursula Wiedermann-Schmidt 115 Gerhard Zlabinger 126
  • 29. - 29 - Curriculum Vitae Barbara Bohle Division of Immunopathology, Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Phone: +43-1-40400-5114, Fax: +43-1-40400-5130; Email: barbara.bohle@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/ipp/allergyresearch Personal Data Date of Birth: 15.09.1967 Place of Birth: Bregenz Nationality Austria Education 1997 - 2000 PhD thesis at the Institute of General and Experimental Pathology, University of Vienna, with distinction 1992 – 1997 Undergraduate study "Food- and Biotechnology" at the University of Natural Resources and Applied Life Sciences, Vienna, awarded Master of Food and Biotechnology with distinction 1985 - 1987 Academy for Medical and Technical Assistants, Vienna, with distinction 1985 Highschool degree at the Bundesgymnasium Dornbirn with distinction Career History Since 01/2008 Head of the Christian Doppler Laboratory for Immunomodulation Since 2002 Associate Professor since 2002 Head of the research group “Allergy Research” in the Dept. of Pathophysiology, Medical University of Vienna, Vienna 2002 Venia docendi in Immunology 2000 University Assistant at the Dept. of Pathophysiology
  • 30. - 30 - (formerly: Inst. of General and Experimental Pathology) 1985 – 1990 Medical Technical Assistant at the Institute of General and Experimental Pathology, University of Vienna, Vienna Career-related Activities Since 2007 Managing Editor for “International Archives of Allergy and Immunology” Since 2006 Treasurer of the Austrian Society of Allergology and Immunology Since 2006 Scientific Advisory Board member of the Paul Ehrlich Institute, Langen, BRD Since 2005 Secretary of the Immunology Section of the European Academy of Allergology and Clinical Immunology (EAACI) Awards 2007 WAO Henning Loewenstein Award 2007 2007 “Förderungspreis für Wissenschaft”, City of Vienna 2006 Clemens von Pirquet Award by the Austrian Society of Immunology and Allergology (ÖGAI) 2006 International Award of the Pharmacia Allergy Research Foundation (PhARF) 2005 Novartis Prize in Biology, Austria 2005 Allergopharma Award for allergy research 2004 Special Award “Food allergy. New insight in cross- reactivity” by the Foundation for Allergy Research in Europe (FARE) 2002 Dr. Karl Schleinzer Award of the University of Agricultural Sciences, Vienna 2001 Allergopharma Award for allergy research 2000 Thesis prize of the Austrian Society of Immunology and Allergology (ÖGAI) Memberships Austrian Society for Allergology and Immunology European Academy of Allergology and Clinical Immunology (EAACI) Sources of funding in last 6 years (2002-2008)
  • 31. - 31 - Period Organization Short Title K€/year 2008 - 2015 CDG + Biomay Christian Doppler Laboratory for 370 Immunomodulation 2008 - 2011 FWF SFB F01807-B13 "The role of cell-mediated 446 immunity in Type I food allergies" 2007 - 2010 FWF + MUW DK W1212: Inflammation and Immunity 44 2007 Federal Bank of ÖNB 12158 “Immunological characteristics 67 Austria of monomeric and self-assembled allergen-S layer fusion proteins” 2005 - 2007 FWF SFB F01807-B04 "The role of cell-mediated 48 immunity in Type I food allergies" 2005 - 2007 Biomay Entwicklung von Impfstoffen und 108 Toleranzstrategien für Typ I Allergien 2001 - 2004 FWF FWF-SFB F01807 "The role of cell-mediated 42 immunity in Type I food allergies" 2004 - 2005 FWF SS 8808-MED 186 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic Since 2008 Marija Geroldinger-Simic In vivo immune responses to pollen-related food allergens Since 2007 Veroniqué Schulten Characterization of in vivo absorbed food allergens Since 2004 Marianne Gerstmayr Novel adjuvants for specific immunotherapy of Type I allergies 2006 - 2008 Sonja Mutschlechner Characterization of naturally processed peptides of Bet v 1 and hypoallergenic Bet v 1 isoforms isolated from MHC class II molecules 2004 - 2006 Eva Maria Schimek Effects of cooking on the immunological properties of food allergens Publications 65 peer reviewed publications in scientific journals, 9 reviews and book chapters, > 40 invited lectures, 3 patents Peer reviewed manuscripts 2002-2008 (original research and reviews)
  • 32. - 32 - First, last or corresponding author manuscripts: Gerstmayr, M., N. Ilk,I. Schabussova, B. Jahn-Schmid, E.M. Egelseer, U.B. Sleytr, C. Ebner and B. Bohle. A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-S- Layer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells that Prime Th0/Th1 and IL-10- Producing Regulatory T Cells. J Immunol, 179:7270, 2007 Bohle, B., Kinaciyan, T., M. Gerstmayr, A. Radakovics, B. Jahn-Schmid, and C. Ebner. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T cell tolerance and immune deviation. J Allergy Clin Immunol, 120:707, 2007 Kinaciyan, T., B. Jahn-Schmid, A. Radakovics, B. Zwölfer, C. Schreiber, J.N. Francis, C. Ebner and B. Bohle. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1- homolog Mal d 1. J Allergy Clin Immunol, 119:937, 2007 Bohle, B., B. Zwölfer, A. Heratizadeh, B. Jahn-Schmid, Y. Dall Antonia, M. Alter, W. Keller, L. Zuidmeer, R. van Ree, T. Werfel and C. Ebner. Cooking birch pollen-related food: divergent consequences for IgE- and T cell-mediated reactivity in vitro and in vivo. J Allergy Clin Immunol 118:242, 2006 Schimek, E.M., B. Zwölfer, P. Briza, B. Jahn-Schmid, L. Vogel, S. Vieths, C. Ebner and B. Bohle. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing but not T cell-activating capacity. J Allergy Clin Immunol 116:1327, 2005 Jahn-Schmid, B., A. Radakovics, D. Lüttkopf, S. Scheurer, S. Vieths, C. Ebner and B. Bohle. Bet v 1142-156 is the dominant T cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens. J Allergy Clin Immunol 116:213, 2005 Bohle, B., A. Radakovics, D. Lüttkopf, S. Vieths and C. Ebner. Characterisation of the T cell response to the major hazelnut allergen, Cor a 1.04: evidence for a relevant T cell epitope not cross-reactive with homologous pollen allergens. Clin Exp Allergy 35:1392, 2005 Bohle, B., B. Zwölfer, G.F. Fischer, U. Seppälä, T. Kinaciyan, C. Bolwig, M.D. Spangfort and C. Ebner. Characterisation of the human T cell response to Antigen 5 from Vespula Vulgaris (Ves v 5). Clin Exp Allergy 35:367, 2005
  • 33. - 33 - Konakci, K.Z., B. Bohle+, R. Blumer, W. Hoetzenecker, G. Roth, B. Moser, G. Boltz- Nitulescu, M. Gorlitzer, W. Klepetko, E. Wolner and H.J. Ankersmit. Alpha-Gal on Bioprostheses: Xenograft Immune Response In Cardiac Surgery. J Eur Clin Invest 35:17, 2005. +both authors contributed equally Bohle, B., A. Breitwieser, B. Zwölfer, B. Jahn-Schmid, M. Sára, U. B. Sleytr and C. Ebner. A Novel Approach to Specific Allergy Treatment: The recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v1) combines reduced allergenicity with immunomodulating capacity. J Immunol 172:6642, 2004 Bohle, B., A. Radakovics, B. Jahn-Schmid, K. Hoffmann-Sommergruber, G. F. Fischer, and C. Ebner. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level. Eur J Immunol 33:3303, 2003 Bohle, B., W. Hirt, P. Nachbargauer, H. Ebner, and C. Ebner. Allergy to millet: another risk for atopic bird keepers. Allergy 58:325, 2003 Co-author manuscripts: Mittermann, I., R. Reininger, M. Zimmermann, K. Gangl, J. Reisinger, K.J. AichbergerJ, E.K. Greisenegger, V. Niederberger, J. Seipelt, B. Bohle, T. Kopp, C.A. Akdis, S. Spitzauer, P. Valent, and R. Valenta. The IgE-Reactive Autoantigen Hom s 2 Induces Damage of Respiratory Epithelial Cells and Keratinocytes via Induction of IFN-gamma. J Invest Dermatol, in press Leb, V.M., B. Jahn-Schmid, K.G. Schmetterer, H. J. Kueng, D. Haiderer, A. Neunkirchner, G. F. Fischer, K. Nissler, A. Hartl, J. Thalhamer, B. Bohle, B. Seed, W. F. Pickl. Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol. In press Admyre, Ch., B. Bohle, S.M. Johansson, M. Focke-Tejkl, R. Valenta, A. Scheynius, and S. Gabrielsson. B-cell-derived exosomes can present allergen peptides and activate allergen- specific T-cells to proliferate and produce Th2-like cytokines. J Allergy Clin Immunol, 120:1418, 2007 Wallner, M., A. Stöckliner, T. Thalhamer, B. Bohle, L. Vogel, P. Briza, H. Breiteneder, S. Vieths, A. Hartl, A. Mari, C. Ebner, P. Lackner, P. Hammerl, J. Thalhamer, and F. Ferreira. Allergy multi-vaccines created by DNA shuffling of tree pollen allergens. J Allergy Clin
  • 34. - 34 - Immunol, 120:374, 2007 Fuchs, H.C, B. Bohle, Y Dall'Antonia, C. Radauer, K. Hoffmann-Sommergruber, A. Mari, O. Scheiner, W. Keller and H. Breiteneder. Natural and recombinant molecules of the cherry allergen Pru av 2 show diverse structural and B cell characteristics but similar T cell reactivity. Clin Exp Allergy 36:359, 2006 Ma,Y., L. Zuidmeer, L., B. Bohle, S.T. Bolhaar, G. Gadermaier, E. Gonzalez-Mancebo, M. Ferdandez-Rivas, A.C. Knulst, M. Himly, R. Asero, C. Ebner, R. van Ree, F. Ferreira, H. Breiteneder and K. Hoffmann-Sommergruber. Characterization of recombinant Mal d 4 and its application for component-resolved diagnosis of apple allergy. Clin Exp Allergy 36:1087, 2006 Ma,Y., G. Gadermaier, B. Bohle, S. Bolhaar, A. Knulst, Z. Markovic-Housley, H. Breiteneder, P. Briza, K. Hoffmann-Sommergruber and F. Ferreira. Mutational analysis of amino acid positions crucial for IgE-binding epitopes of the major apple (Malus domestica) allergen, Mal d 1. Int Arch Allergy Immunol 139:53, 2006 Fernandez-Rivas, M., S. Bolhaar, E. Gonzlez-Mancebo, R. Asero, A. van Leeuwen, B. Bohle, Y. Ma, C. Ebner, N. Rigby, A.I. Sancho, S. Miles, L. Zuidmeer, A. Knulst, H. Breiteneder, C. Mills, K. Hoffmann-Sommergruber and R. van Ree. Apple allergy across Europe: How allergen sensitization profiles determine the clinical expression of allergies to plant foods. J Allergy Clin Immunol 118:481, 2006 Dehlink, E., T. Eiwegger, M. Gerstmayr, E. Kampl, B. Bohle, K.W. Chen, S. Vrtala, R. Urbanek, and Z. Szépfalusi. Absence of systemic immunologic changes during dose-build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy, 36:32, 2006 Roth-Walter, F., B. Bohle, I. Schoell, E. Untersmayr, O. Scheiner, G. Boltz-Nitzlescu, F. Gabor, D. Brayden, and E. Jensen-Jarolim. Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol Lett 100:182, 2005 Jahn-Schmid, B., GF. Fischer, B. Bohle, I. Faé, G. Gadermaier, A. Dedic, F. Ferreira and C. Ebner. Antigen-presentation of the immunodominant T cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1*01. J Allergy Clin Immunol 115:399, 2005
  • 35. - 35 - Ballmer-Weber, B.K., A. Wangorsch, B. Bohle, S. Kaul, T. Kündig, K. Fötisch, R. van Ree, and S. Vieths. Component-resolved in vitro diagnosis in carrot allergy: Does the use of recombinant carrot allergens improve the reliability of the diagnostic procedure? Clin Exp Allergy, 35:970, 2005 Reisinger J., A. Triendl, Kuchler E, B. Bohle, MT. Krauth, I. Rauter, P. Valent, F. Koenig, R. Valenta, and V. Niederberger. IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. J Allergy Clin Immunol, 115:937, 2005 Aichberger, K.J., I. Mittermann, I., R. Reininger, R., S. Seiberler, I. Swoboda, S. Spitzauer, T. Kopp, G. Stingl, W. R. Sperr, P. Valent, A. Repa, B. Bohle, D. Kraft and R. Valenta. Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins can induce T helper cell type 1-mediated autoractivity. J Immunol, 175:1286, 2005 Batard, T., A. Didierlaurent, H. Chabre, N. Mothes, L. Bussieres, B. Bohle, M.N. Couret, T. Ball, P. Lemoine, M. Focke-Teijkl, A. Chenal, G. Clement, F. Dupont, P. Valent, M.T. Krauth, C. Andre, R. Valenta and Moingeon, P. Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy. Int Arch Allergy Immunol, 136:239, 2005 Novak, N., R. Valenta, B. Bohle, S. Laffer, J. Haberstok, S. Kraft, and T. Bieber. FcepsilonRI engagement of Langerhans cell-like dendritic cells and inflammatory dendritic epidermal cell- like dendritic cells induces chemotactic signals and different T-cell phenotypes in vitro. J Allergy Clin Immunol 113:949, 2004 Repa, A., C. Wild, K. Hufnagl, B. Winkler, B. Bohle, A. Pollak and U. Wiedermann. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clin Exp Immunol 137:12, 2004 Wagner, M., H. Poeck, B. Jahrsdoerfer, S. Rothenfusser, D. Prell, B. Bohle, E. Tuma, T. Giese, J. W. Ellwart, S. Endres, and G. Hartmann. IL-12p70-Dependent Th1 Induction by Human B Cells Requires Combined Activation with CD40 Ligand and CpG DNA. J Immunol 172:954, 2004 Reininger, R., I. Swoboda, B. Bohle, A. Hauswirth, P. Valent, H. Rumpold, R. Valenta, and S. Spitzauer. Characterization of recombinant cat albumin. Clin Exp Allergy 33:1695, 2003
  • 36. - 36 - Jahn-Schmid, B., C. Harwanegg, R. Hiller, B. Bohle, C. Ebner, O. Scheiner, and M. Mueller. Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E. Clin Exp Allergy 33:1443, 2003 Himly, M., B. Jahn-Schmid, K. Pittertschatscher, B. Bohle, K. Grubmayr, F. Ferreira, H. Ebner, and C. Ebner. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 111:882, 2003 Sengoelge, G., J. Kletzmayr, M. Papagiannopoulos, B. Bohle, W. H. Horl, M. Fodinger, and G. Sunder-Plassmann. TGF-beta1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. Transpl Int 16:843, 2002 Loibichler, C., J. Pichler, M. Gerstmayr, B. Bohle, H. Kisst, R. Urbanek, and Z. Szepfalusi. Materno-fetal passage of nutritive and inhalant allergens across placentas of term and pre- term deliveries perfused in vitro. Clin Exp Allergy 32:1546, 2002 Jahn-Schmid, B., P. Kelemen, M. Himly, B. Bohle, G. Fischer, F. Ferreira, and C. Ebner. The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J Immunol 169:6005, 2002 Fritsch, R., D. Eselbock, K. Skriner, B. Jahn-Schmid, C. Scheinecker, B. Bohle, M. Tohidast- Akrad, S. Hayer, J. Neumuller, S. Pinol-Roma, J. S. Smolen, and G. Steiner. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol 169:1068, 2002 Breitwieser, A., E. M. Egelseer, D. Moll, N. Ilk, C. Hotzy, B. Bohle, C. Ebner, U. B. Sleytr, and M. Sara. A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen. Protein Eng 15:243, 2002 Rausch-Fan, X., F. Leutmezer, M. Willheim, A. Spittler, B. Bohle, C. Ebner, E. Jensen- Jarolim, and G. Boltz-Nitulescu. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 128:33, 2002
  • 37. - 37 - Invited Talks 2002-2008 2006 • XXV EAACI 2006, Vienna • Hautklinik Johannes Gutenberg-Universität Mainz, Germany • University of Salzburg, Austria • Paul Ehrlich Institut, Langen, Germany • 1st International Symposium on Molecular Allergology, Rome, Italy • IV European Asthma Congress, Teneriffe, Canary Islands 2007 • Interdisziplinäres Freiburger Allergiesymposium, Freiburg, Germany • 2.Gemeinsamer Allergiekongress Lübeck , Germany • Pirquet-Club, Kinderklinik, Medical University of Vienna • XXVI EAACI 2007 Göteborg, Sweden • Gesellschaft der Ärzte Wien • 5th EAACI GA2LEN Davos Meeting in Davos, Switzerland • AAAAI, San Diego, USA • 2nd International Symposium on Molecular Allergology, Rome, Italy 2008 • 12th International Paul Ehrlich Seminar, Bad Homburg, Germany • World Immune Regulation Meeting WIRM II, Davos, Switzerland, 17.3.-20.3.2008 • AAAAI, Philadelphia, USA • Paul Ehrlich Seminar, Bad Homburg, Germany • 3rd International Symposium on Molecular Allergology, Salzburg, Austria • XXVII EAACI 2008 Barcelona, Spain • Symposium on Specific Allergy (SOSA) , Copenhagen, Denmark
  • 38. - 38 - Curriculum Vitae Wilfried Ellmeier Division of Immunobiology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Lazarettgasse 19, 1090 Wien, Austria; Phone: +43-1- 40160-65003, Fax: +43-1-40160-965006; Email: wilfried.ellmeier@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/immunologie/ellmeier Personal Data Date of Birth: 09.09.1966 Place of Birth: Mödling Nationality Austria Education 1990 – 1994 PhD studies (Biochemistry, Molecular Biology), University of Vienna, with distinction 1989 – 1990 Diploma thesis at the Institute for Molecular Pathology (IMP) in Vienna 1985 – 1990 Studies in Biochemistry, University of Vienna 1985 University entrance qualification, HTL-Mödling Career History Since 07/2007 Full Professor of Immunobiology 2005 - 2007 Associate Professor (a.o.Univ.Prof) 12/2002 Habilitation in Immunology, University of Vienna Medical School 2000 Group Leader, Institute of Immunology, University of Vienna 1995 - 1999 Postdoctoral Fellow at the Skirball Institute, Howard Hughes Medical Institute, New York University Medical Center, New York, NY, USA 1999 - 1994 PhD Thesis performed at the Institute for Molecular Pathology (IMP) in Vienna Career-related Activities 2006 – present Member of the APART and DOC committee of the Austrian Academy of Sciences 2005 - present Speaker and Coordiantor of the FWF Special Research Program (Spezialforschungsbreich) SFB F23 „Immunological
  • 39. - 39 - Tolerance“ Awards 2005 “Förderungspreis für Wissenschaft”, City of Vienna 2005 Novartis prize 2004 in Biology 2003 Habilitation prize “Verein zur Förderung von Wissenschaft und Forschung in den Neuen Universitätskliniken am AKH der Stadt Wien” (VFWF). 2001 START Prize, BMBWK und FWF 2000 - 2002 APART Habilitation Fellowship, Austrian Academy of Sciences 1997 - 1999 Postdoctoral Fellowship of the Howard Hughes Medical Institute 1995 - 1997 Erwin-Schrödinger Postdoctoral Fellowship, FWF 1993 EMBO "short-term" Fellowship, EMBO Memberships Austrian Society for Allergology and Immunology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2007 - 2010 FWF Molecular characterization of the transcriptional 130 regulator MAZR 2007 - 2010 FWF + MUW DK W1212: Inflammation and Immunity, 44 subproject 3 2005 - 2009 FWF SFB F23 Immunological Tolerance: 100 SFB Coordination 2005 - 2009 FWF SFB F23 Immunological Tolerance: Subproject 5 110 2006 - 2009 EU EU Marie Curie Research & Training Network 100 (MRTN-CT-2006-035733) 2004 - 2006 Federal Bank of Molecular Anaylsis of the function of a C2H2 30 Austria zinc finger containing DNA binding molecules during T cell development 2003 – FWF Epigenetic and transcriptional regulation of 100 2007 CD8a and CD8b gene expression 2002 Federal Bank of The regulation of T cell development: 80 Austria Identification and characterization of candidate genes 2001 - 2008 FWF and BM:WF Molecular mechanisms of Lymphocyte 150 START Development and Activation
  • 40. - 40 - 2000 - 2004 K-Plus BMT Molecular Analysis of Dendritic Cell Function 100 2000 - 2003 FWF Molecular characterization of CD8 coreceptor 110 Gene Expression and Lineage Decisions During T cell Development Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2000 - 2004 Colin Feik Molecular and functional characterization of the CD8 enhancer E8III 2001 - 2005 Christina Kösters Gain and Loss of Function Approaches to Study Immune Cell Development and Function: B-4C- a Key Player in Dendritic Cell Biology? 2001 - 2005 Bernd Unger Molecular Analysis of dendritic cells and macrophages 2000 - 2005 Ivan Bilic Epigenetic mechanisms in the transcriptional regulation of CD8 coreceptor expression during T cell development 2001 -2006 Martin Melcher The role of Tec family kinases in macrophages 2004 – Shinya Sakaguchi Molecular Analysis of CD8 gene expression present 2005 – Julia Raberger Tec family kinases and T cell function present 2007 – Wolf Gebhardt Identification of MAZR interacting factors present 2007 – Derya Köprölü The role of Tec family kinases in myeloid cells present 2007 – Anastasia Abramova Transcriptional regulation of CD8 gene expression present Publications 33 peer reviewed publications in scientific journals, 2 book chapters, > 30 invited lectures, 4 patents Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Ellmeier, W., Sunshine, M.J., Maschek, R. and Littman, D.R. (2002). Combined deletion of CD8 locus cis-regulatory elements affects initiation but not maintenance of CD8 expression. Immunity, 5, 623-34. Kioussis D. and Ellmeier, W. (2002) Chromatin and CD4, CD8A and CD8B gene expression
  • 41. - 41 - during thymic differentiation. Nat Rev Immunology, 12, 909-19. Taniguchi, I., Ellmeier, W., and Littman, D.R. (2004). The CD4/CD8 Lineage Choice: New Insights into Epigenetic Regulation During T Cell Development. Adv Immunol, 83, 55-89. Feik, N., Bilic, I., Tinhofer, J., Unger, B., Littman, D.R. and Ellmeier, W. (2005). Functional and Molecular Analysis of the Double-Positive Stage-specific CD8 Enhancer E8III During Thymocyte Development. The Journal of Immunology, 174, 1513-2. Bilic, I., Kösters, K., Unger, B., Hertweck, A., Maschek, R., Wilson, C.B. and Ellmeier, W. (2006) Negative regulation of CD8 expression via CD8 enhancer-mediated recruitment of the zinc finger protein MAZR. Nature Immunology, 7, 392-400. Christina Koesters, C. Bernd Unger, B. Bilic, I., Bluml, S., Lichtenberger, B., Schreiber, M., Stockl, J. and Ellmeier, W. (2007). Regulation of dendritic cell differentiation, maturation and subset distribution by the zinc finger protein CTCF. Immunology Letters, 109, 165-74. Bilic, I, and Ellmeier, W. (2007). The role of BTB domain-containing zinc finger proteins in T cell development and function. Immunology Letters, 108, 1-9. Melcher M, Unger B, Schmidt U, Rajantie IA, Alitalo K, Ellmeier W. 2008. Essential Roles for the Tec Family Kinases Tec and Btk in M-CSF Receptor Signaling Pathways That Regulate Macrophage Survival. Journal of Immunology, 180: 8048-56 Co-author manuscripts: Keppler, O.T., Welte, F.J., Ngo, T.A., Kathryn S. Patton, K.S., Tsou, C.L., Abbey, N.W., Sharkey, M.E., Yun You, Y., Scarborough, J.D., Ellmeier, W., Littman, D.R., Stevenson, M., Charo, I.F., Herndier, B.G., Speck, R.F., and Goldsmith, M.A. (2002). Progress Toward a Human CD4/CCR5-Transgenic Rat Model for de Novo Infection by Human Immunodeficiency Virus Type 1. The Journal of Experimental Medicine, 195, 719-36. Atkinson, B., Ellmeier, W., Watson, S.P. (2003). Tec regulates platelet activation by GPVI in the absence of Btk , Blood, 3592-9. Madakamutil, L.T., Gangadharan, D., Chrtisten, U., Lena, C.J., Wang-Zhu, Y., Attinger, A., Ellmeier, W., von Herrath, M.G., Jensen, P., Littman, D.R. and Cheroutre, H. CD8aa+ primary effector cell selectively differentiate into memory CD8 T cells. (2004). Science, 304, 590-93. Schmidt, U., van den Akker, E., Parren-van Amelsvoor, M., , Litos, G., de Bruijn, M., Hendriks, R.W., Ellmeier, W., Beug, H. and von Lindern, M. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. Journal of Experimental Medicine,199, 785-95. Wu, P.Y., Tabuchi, R.S., Kato, R.M., Astrakan, A., Humblet-Baron, S., Kipp, K., Chae, K., Ellmeier, W., Witte, O.N., and Rawlings, D.J. (2004) Sustained correction of B cell development and function in a murine model of X-linked agamaglobulinemia (XLA) using retroviral.mediated gene transfer. Blood, 104, 1281-90. Sarafova, S.D., Erman, B., Yu, O., Van Laethem, F., Guinter, T., Sharrow, S.O., Feigenbaum, L., Wildt, F.L., Ellmeier, W. and Singer, A. (2005). Transcriptional Modulation of Coreceptor Expression during Positive Selection Dictates Lineage Fate Independently of TCR Specificity and Coreceptor Protein Identity, Immunity, 23:75-87. Marquez, M.E., Ellmeier, W., Sanchez-Guajardo, V., Freitas, A.A:, Acuto, O. and Di Bartolo, V.
  • 42. - 42 - (2005). CD8 T cell sensory adaptation dependent on TCR avidity for self-antigens. The Journal of Immunology, 175, 7388-97. Taschner, S., Koesters, C., Platzer, B., Jörgl, A., Ellmeier, W., Benesch, T. and Strobl, H. (2007). Downregulation of RXR expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood, 109, 971-9. Park JH, Adoro S, Lucas PJ, Sarafova SD, Alag AS, Doan LL, Erman B, Liu X, Ellmeier W, Bosselut R, Feigenbaum L, Singer A. (2007). 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol. 10:1049-59. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. (2007). The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. PNAS, 104:13283-8. Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H. 2008. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell, 132, 794-806. Invited Talks 2002-2008 2002 • St. Anna Kinderspital, Wien • Institut für Molekulare Pathologie, Wien • Universität Würzburg, Deutschland 2003 • Institute for Medical Biology and Human Genetics, University of Innsbruck • Institute for Pathophysiology, AKH Wien • Institut für Entwicklungsbiologie, Marseille, Frankreich • Talk at the “ThymOz” Conference on Heron Island, Australia 2004 • Technical University of Munich • Selected talk at the Cold Spring Harbor Conference "Gene Expression and Signaling in the Immune System", Cold Spring Harbor, New York, USA • Invitation to Chair and to talk at the minisymposium „Chromatin remodeling during lymphocyte differentiation“ at the 12th International Congress of Immunology, Montreal, 2005 • University of Erlangen, Germany • RIKEN Institute of Allergy and Immunology • Tokyo Medical and Dental University • University of Salzburg • Invited talk at the T cell workshop: “The immunological synapse – kinases in T cell signaling as potential drug targets”. Grossziethen, Germany 2006 • University of Munich, Germany • Karolinska Institute, Sweden • Selected to talk at the Cold Spring Harbor Conference "Gene Expression and Signaling in the Immune System", Cold Spring Harbor, New York, USA • Invited talk at the 3rd Aegean conference on “gene regulation in lymphocyte development. • Invited talk at the 7th EFIS Tatra Immunology Conference. • Invited talk at the EU MC RTN Minisymposium on Immunological mouse models
  • 43. - 43 - 2007 • University of Oxford, England • Invited talk at the RIKEN workshop on “T cell development and transcription factors”, RIKEN, Yokohama, Japan.
  • 44. - 44 - Curriculum Vitae Erika Jensen-Jarolim Division of Experimental Immunology and Oncology, IPP - Dept. of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43-1-40400 - 5110, Fax: +43-1-40400-5130; Email: erika.jensen-jarolim@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/ipp; www.allergology.at Personal Data Date of Birth: 10.04.1960 Place of Birth: Vienna Nationality Austria Education 1978 – 1985 MD studies, University of Vienna Career History 02/2008 Council member of the Veterinary University Vienna Since 02/2007 Full Professor of Pathophysiology 07/2006 Head of IPP – Dept. Of Pathophysiology 1999 - 2006 Associate Professor (a.o.Univ.Prof) 05/1999 Habilitation in General and Experimental Pathology, Vienna Medical School 1999 Leader of AllergoOncology Group, IPP 1990-1991 Postdoctoral Fellow at the Inselspital, University of Berne, Switzerland 1989-1990 Postdoctoral Fellow at Rigshospitalet, Allergy laboratory, University of Copenhagen, Denmark Awards 05/2006 Teacher of the Month, Medical University Vienna 12/2005 Great Central-European Prize for Innovative Interdisciplinary Cancer Research of the Funds of the City of Vienna 05/2005 Researcher of the Month, Medical University of Vienna 03/2005 Award of the ECARF (European Centre for Allergy Research Foundation), Clinical Allergology. 2004 Bronze Medal of the Slovac Academy of Sciences.
  • 45. - 45 - 2002 Research Prize of the Austrian Association for Crohn´s disease and Colitis ulcerosa (ÖMCCV). “Förderungspreis für Wissenschaft”, City of Vienna 2000 Pirquet Prize of the Austrian Society of Allergology and Immunology. 1999 Habilitation Prize of the VFWF (Association for the Promotion of Science and Research at the New University Departments of the Vienna General Hospital). 1998 Research Prize of the ÖMCCV (Austrian Association for Crohn´s disease and Colitis ulcerosa). 1990 Research Prize of the Hoechst AG, Frankfurt/Main, Germany (later continued by Aventis Foundation). 1989 Research Prize of the Danish Allergy Foundation (founded in 1981), University Hospital, Copenhagen, Denmark. Memberships Austrian Society for Allergology and Immunology Collegium Internationale Allergologicum Verein zur Förderung von Wissenschaft und Forschung in den Neuen Universitätskliniken am AKH der Stadt Wien (VFWF). Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2000-2003 Biomay “Neue Impfstrategien bei Typ I Allergie” 293 2002-2004 FWF “The role of allergen-specific antibodies and 75 anti-antibodies in molecular models of type I allergy“ 2001-2007 BioLifeSciences “Mimotope zur Therapie maligner Tumore” 101 2002 FWF FWF P14339-B08 „Mimotopes for 56 Immuntherapy of Allergic Disease II“ 2003-2005 Fördergesellschaft “GD2 Mimotope DANN-vaccines for active 25 Kinderkrebs immunotherapy of neuroblastoma” 2003-2005 Jubiläumsfonds der ÖNB 10326 “Generation of mimotopes of the 53 ÖNB major fish allergen parvalbumin for the treatment of food allergy – application of phage display peptide libraries” 2004 Jubiläumsfonds der ÖNB 10965 “Development of an active 55 ÖNB immunotherapy for childhood neuroblastoma
  • 46. - 46 - with mimotope technology” 2004-2005 Hans und Blanca “Translation of disialoganglioside epitope in 9 Moser-Stiftung an immunogenic mimotope for immunotherapy of neuroblastoma” 2005-2008 FWF “Allergen mimotopes for epitope studies and 105 vaccination” 2005-2007 Wiener Wirtschafts- FA648A0201 “Biokompatible Partikel für 36 förderungsfonds Schluckimpfung gegen Allergien” 2005-2006 Institut Danone “Das Sensibilisierungspotential von Bet v 1- 14 Homologen in älteren Patienten und Mäusen beeinflusst durch antiazide Therapie“ 2005-2008 FWF FWF P18238-B13 “Development of an oral 85 mimotope vaccine against tumors“ 2005-2006 Medizinisch 2484 “Development of an active 24 Wissenschaftlicher immuntherapy against carcinoembryonic- Fonds des antigen (CEA-) overexpressing tumors Bürgermeisters der Stadt Wien 2005-2007 Jubiläumsfonds der ÖNB 11375 “The effect of total gastrectomy 49 ÖNB on the development of food allergy in humans” 2005 DAAD A/04/42152 “Magensäure-supprimierende 4 Medikamente während der Schwangerschaft führen zur Sensibilisierung gegen Nahrungsmitteln bei neugeborenen Mäusen” 2005 Alexander-von- OST/11119407S “Magensäure-hemmende 13 Humboldt-Stiftung Medikamente während der Schwangerschaft führen zu Nahrungsmittelallergie im Mausmodell“ 2005-2006 Hans und Blanca “Orale Mimotop-Immunisierungen zur IgE 7 Moser-Stiftung Induktion gegen Tumorantigene“ 2005-2006 Hans und Blanca “Testung der anti-Tumor-Wirkung von 5 Moser-Stiftung Pertuzumab-Epitop-spezifischen anti-HER-2- Impfstoffen“ 2006 FWF FWF H220-B13 “Mechanisms in the 38 sensitization and effector phase of food allergy“
  • 47. - 47 - 2006-2009 FWF, CCHD FWF W1205-B09 “Cellular interactions 31 decisive for the type of immune response to orally applied antigens” 2006-2007 Funds of the City of AP00181OFF “Immunogenicity and 10 Vienna for Innovative therapeutic potency of mimotopes for the Interdisciplinary carcinoembryonic antigen (CEA) in Cancer Research transgenic mouse tumor models” 2006-2009 FWF FWF T283-B13 “Antazida induzieren 58 Nahrungsmittelallergie in Neugeborenen” 2006-2007 Hochschuljubiläums- H-2182/2006 “IgE induzierte Ausschüttung 5 stiftung der Stadt von TNF alpha bei Mastzellen und Wien basophilen Granulozyten und die Wirkung auf Tumorzellen“ 2006-2007 Funds of the City of “Testung der anti-Tumor-wirkung von epitop- 20 Vienna for Innivative spezifischen HER-2 Impfstoffen in human- Interdisciplinary HER-2 transgenen Mäusen” Cancer Research 2007-2008 Hans und Blanca AP00253OFF “Charakterisierung der 9 Moser-Stiftung molekularen Mechanismen von Antikörpern nach aktiver Impfung gegen das Carcinomembryonale Antigen“ 2007-2008 Hochschuljubiläums- H-02325/2007 “Effektorzellen der IgE- 5 stiftung der Stadt vermittelten Überwachung des Wien Tumorwachstums“ 2007-2010 FWF, CCHD FWF FA102A004 “Cellular interactions 44 decisive for the type of immune response to orally applied antigens“ 2008-2009 Hans und Blanca AP00326OFF “Investigating the tumoricidic 5 Moser-Stiftung properties of an anti HER-2 antibody of the IgE subclass 2008-2012 FWF “Allergen mimotopes for epitope studies and 154 vaccination” Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2001-2004 Schöll, Isabela PhD: Mechanism of type I allergy and novel
  • 48. - 48 - vaccination strategies for treatment. 2003-2006 Schöll, Isabella MDSci: Characterization of conformational epitopes of allergenic molecules and generation of mimotopes for active immunotherapy of type I allergies. 2002-2004 Riemer, Angelika B. PhD: Generation of epitope mimics of tumor- inhibitory monoclonal antibodies: Targeting HER-1 and HER-2. 2003-2006 Untersmayr-Elsenhuber, MDSci: Mechanisms of food allergy. Eva 2001-2005 Hantusch, Brigitte PhD: Epitope mimics of grass pollen allergen Phl p 5 from phage display libraries: tools for anti-allergen immunizations. 2002-2004 Walter, Franziska PhD: Design of an oral vaccine against birch pollen. 2003-2005 Walter, Franziska MDSci: Oral immunisation of allergen-loaded microsphere with bioadhesive properties and their impact on the immune system. 2003- in Szalai, Krisztina MDSci: Mapping and characterization of epitopes of progress prevalent inhalative allergens with the mimotope technology. 2004- in Szalai, Krisztina PhD: Generation of peptide-mimotopes to allergen- progress specific IgE treatment of food allergy. Application of phage display libraries. 2005 – in Kntittelfelder, Regina PhD: Molecular and immunological aspects of the progress tumor antigen HER-2: a target for immunotherapy. 2006- in Brämswig, Kira PhD: Therapeutic potency of mimotopes in a progress transgenic tumor mouse model. 2006- in Wallmann, Julia PhD: Immunotherapeutical approaches with different progress constructs of grass pollen mimotopes in allergic asthma. 2008- in Lukschal, Anna PhD: Epitop specific IgE detection. progress 2007- in Starkl, Philipp PhD: Cellular and molecular mechanisms of the progress intestinal uptake of food allergens. 2007- in Krishnamurthy, Durga PhD: The role of the liver in the induction and control progress of food allergy. 2008- in Weichselbaumer, Marlene Dr. med. Vet.: Immunization with carcinoembryonic progress antigen (CEA) mimotope vaccine inhibits growth of
  • 49. - 49 - CEA positive mammary carcinomas in canine patients. Publications >100 peer reviewed publications in scientific journals, 57 invited lectures, patents see depatisnet Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Jensen-Jarolim E, Untersmayr E. Gender Medicine Aspects in Allergology. Allergy, in press. Hantusch B, Jensen-Jarolim E. Von der Allergenerkennung durch Antikörper zu neuen therapeutischen Konzepten. Wiener Med. WSchr, in press. Untersmayr E, Diesner S, Brämswig KH, Bakos N, Wallmann J, Knittelfelder R, Szalai K, Schöll I, Scheiner O, Duschl A, Jensen-Jarolim E. Characterization of intrinsic and extrinsic risk factors for celery allergy in immuno-senescence. Mechanisms of Ageing and Development, in press. Untersmayr E, Lukschal A, Hemmer W, Jarisch R, Jensen-Jarolim E. Exercise with latex sport bands represents a risk for latex allergic patients. Immunol. Letters, in press Szalai, K., Fuhrmann J, Pavkov T, Keller W, Wallmann J, Vrtala S, Scheiner O, Saint-Remy J-M, Neumann D, Pali-Schöll I, Jensen-Jarolim E*. Mimotopes identify conformational B-cell epitopes on the two major house dust mite allergens Der p 1 and Der p 2. Mol Immunol, 2007 Oct 25; (Epub ahead of print). Brämswig KH, Knittelfelder R, Riemer AB, Gruber S, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Mimotope immunization prevents growth of CEA-positive tumors in BALB/c mice. Clin Cancer Res, 2007 Nov 1; 13(21): 6501- 6508. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Research 2007, Cancer Res. Apr.1; 67 (7): 3406-11. 2007. Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, Pali- Schöll I. The impact of aluminum in acid-suppressing drugs on the immune response of BALB/c mice. Clin. Exp. Allergy, 2007 Oct;37(10):1566-73. Epub 2007 Sep 10. Schöll I, Ackermann U, Blümer N, Özdemir C, Dicke T, Sel Se, Sel Sa, Wegmann M, Szalai K, Knittelfelder R, Untersmayr E, Scheiner O, Garn H, Jensen-Jarolim E, Renz H. Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2 bias in their offspring. FASEB, Apr;21(4):1264-70, 2007. Riemer AB and Jensen-Jarolim E. Mimotope vaccines: Epitope mimics induce anti-cancer antibodies. Immunology Letters. 113(1): 1-5. 2007. Roth-Walter F, Jensen-Jarolim E. Oral immunotherapy against type I allergy. Allergy & Clinical Immunology International., J World Allergy Org, vol. 19, no. 1, pp. 21-26. 2007
  • 50. - 50 - Jensen-Jarolim E and Riemer AB. Small mimotopes are big in identifying B-cell epitopes. Blood, 15 Sept 2006, 108 (6): 1794-1795. 2006. Bakos N, Schöll I, Szalai K, Kundi M, Untersmayr E, Jensen-Jarolim E. Risk assessment for elderly to develop respiratory and food allergy. Immunol. Letters 107 (1): 15-21. 2006. Untersmayr E and Jensen-Jarolim E. Mechanisms of Type I food allergy. Pharmacol. Ther. 2006, Jul 26 (Epub ahead of print). Untersmayr E and Jensen-Jarolim E. The effect of gastric digestion on food allergy. Curr. Opinion in Allergy & Clin Immunol. 6 (3): 214-9. 2006. Schöll I, Kopp T, Bohle B, Jensen-Jarolim E. Biodegradable PLGA particles for improved systemic and mucosal treatment of type I allergy. Immunol Allergy Clin North Am, 26 (2): 349-64. 2006. Riemer AB, Förster-Waldl E, Brämswig K, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol 36 (5): 1267-74. 2006. Hantusch B, Knittelfelder R, Wallmann J, Krieger S, Szalai K, Untersmayr E, Volgel M, Stadler BM, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Internal images: Human anti-idiotypic Fab antibodies mimic the IgE epitopes of grass pollen allergen Phl p 5a. Mol. Immunol. 43 (14): 2180-7. 2006. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with Cetuximab mimotopes induces anti-EGFR antibodies with similar biological properties as the original antibody. J Nat.Cancer Inst 97 (22): 1663-70. 2005. Schöll I, Kalkura N, Sheziankova Y, Bergmann A, Verdino P, Knittelfelder R, Kopp T, Betzel C, Dierks K, Hantusch B, Scheiner O, Boltz-Nitulescu G, Keller W, Jensen-Jarolim E. Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE crosslinking potential in mice. J. Immunol 175 (10): 6645-50. 2005. Untersmayr E, Szalai K, Riemer AB, Hemmer W, Swoboda I, Hantusch B, Schöll I, Spitzauer S, Scheiner O, Jarisch R, Boltz-Nitulescu G, Jensen-Jarolim E. Mimotopes identify conformational epitopes on parvalbumin, the major fish allergen. Mol Immunol. 2006, 43 (9): 1454-61. Epub Sept. 5 2005.. Jensen-Jarolim E, Untersmayr E. Food safety: In vitro digestion assays are non predictive for allergenic potential of food in stomach insufficiency. View letter. Immunol. Letters 102 (1): 118- 119. 2005, Epub 2005 Aug 18. Szalai K, Schöll I, Förster-Waldl E, Polito L, Bolognesi A, Untersmayr E, Riemer AB, Boltz- Nitulescu G, Stirpe F, Jensen-Jarolim E. Occupational sensitization to ribosomal-inactivating proteins (RIPs) in researchers. Clin. Exp. Allergy, 35 (10): 1354-60. Untersmayr E, Jensen-Jarolim E. In vitro tests zur Bestimmung der allergenen Potenz von "novel foods" und GVOs (genetisch modifizierten Organismen): Relevanz in vivo? Wiener Klin. Wochenschrift (117. Jg), 13-14: 437-439. 2005. Roth-Walter F, Bohle B, Schöll I, Untersmayr E, Scheiner O, Boltz-Nitulescu G, Gabor F, Brayden D, Jensen-Jarolim E. Targeting antigens to murine and human M-cells with Aleuria aurantia lectin-functionalized microparticles. Immunol. Letters 2005, May 20 [Epub ahead of
  • 51. - 51 - print] Untersmayr E, Jensen-Jarolim E. Anti-azide Therapie und verdauungslabile Allergene. Allergologie Jg. 28/4: 134-142. 2005. Schöll I, Boltz-Nitulescu G, Jensen-Jarolim E. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Contr. Release 2005; 104 (1): 1-27. Rausch-Fan X, Ulm C, Jensen-Jarolim E, Schedle A, Boltz-Nitulescu G, Matejka M. IL-1b- induced PGE2 production by human gingival fibroblasts is up-regulated by glycine. J. Periodontology 76(7): 1182-1188. 2005. Roth-Walter F, Schöll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine 23(21): 2703-10. 2005. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of the trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu: a new method for epitope definition. Mol. Immunol. 42 (9): 1121-24. 2005. Epub 2005 Jan 8. Untersmayr E, Poulsen LK, Platzer MH, Pedersen MH, Boltz-Nitulescu G, Skov PS, Jensen- Jarolim E. The effects of gastric digestion on codfish allergenicity. J Allergy Clin Immun 115 (2): 377-382. 2005. Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J. 19 (6): 656-8. 2005 Jan 25; [Epub ahead of print] Schöll I, Untersmayr E, Bakos N, Roth-Walter F, Gleiss A, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans. Am J Clin Nutr. 2005 Jan;81(1):154-60. Hantusch B, Schöll I, Harwanegg C, Krieger S, Becker WM, Spitzauer S, Boltz-Nitulescu G, Jensen-Jarolim E. Affinity determinations of purified IgE and IgG antibodies against the major pollen allergens Phl p 5a and Bet v 1a: discrepancy between IgE and IgG binding strength. Immunol Lett. 2005 Feb 15;97(1):81-9. Förster-Waldl E, Riemer AB, Dehof AK, Neumann D, Bramswig K, Boltz-Nitulescu G, Pehamberger H, Zielinski CC, Scheiner O, Pollak A, Lode H, Jensen-Jarolim E. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol. 2005 Feb;42(3):319-25. Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother. 54 (7): 677-684. 2005. [Epub] 2004 Nov 24; Schöll I, Jensen-Jarolim E. Allergenic potency of spices: hot, medium hot, or very hot. Int Arch Allergy Immunol. 2004 Nov;135(3):247-61. Epub 2004 Nov 03. Review. Roth-Walter F, Schöll I, Untersmayr E, Fuchs R, Boltz-Nitulescu G, Weissenbock A, Scheiner O, Gabor F, Jensen-Jarolim E. M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol. 2004 Dec;114(6):1362-8.
  • 52. - 52 - Hantusch B, Krieger S, Untersmayr E, Schöll I, Knittelfelder R, Flicker S, Spitzauer S, Valenta R, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Mapping of conformational IgE epitopes on Phl p 5a by using mimotopes from a phage display library. J Allergy Clin Immunol. 2004 Dec;114(6):1294-300. Untersmayr E, Ellinger A, Beil WJ, Jensen-Jarolim E. Eosinophils accumulate in the gastric mucosa of food-allergic mice. Int Arch Allergy Immunol. 2004 Sep;135(1):1-2. Epub 2004 Jul 29. No abstract available. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol. 2004 Jul 1;173(1):394-401. Brunner M, Krenn C, Roth G, Moser B, Hetz H, Dworschak M, Jensen-Jarolim E, Wolner E, Spittler A, Sautner T, Bonaros N, Boltz-Nitulescu G, Ankersmith HJ. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med., 30 (7): 1468-73. 2004. Epub 2004 Feb 28. Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods. 2004 Mar;32(3):321-7. Review. Walter F, Schöll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen- Jarolim E. Functionalization of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. Biochem Biophys Res Commun, 315/2, 281-287. 2004. Schoell I, Weissenböck A, Foerster-Waldl E, Untersmayr E, Walter F, Willheim M, Boltz- Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Allergen-loaded biodegradable PLGA nanoparticles down-regulate an ongoing Th2-response in the BALB/c mouse model. Clin Exp Allergy, 34(2):315-21. 2004. Foerster E, Marchetti C, Focke M, Schoell I, Boltz-Nitulescu G, Scheiner O, Schmid E.R, Jensen-Jarolim E. Type I allergy to elderberry is elicited by a 33.2 kDa allergen with significant homology to ribosomal inactivating proteins (RIPs). Clin Exp Allergy, 33(12): 1703-1710. 2003. Untersmayr E, Schöll I, Swoboda I, Beil WJ, Förster-Waldl E, Walter F, Riemer A, Kraml G, Spitzauer S, Kinaciyan T, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E. Antacid medication inhibits digestion of dietary proteins and causes food allergy: An fish allergy model in Balb/c mice. J Allergy Clin Immun, 112: 616-623. 2003. Schöll I, Boltz-Nitulescu G, Jensen-Jarolim E. Mimotope und ihre Bedeutung für die Allergologie. Allergo Journal 6: 339-404. 2003. Jensen-Jarolim E, Gscheidlinger R, Oberhuber G, Neuchrist C, Lucas T, Bises G, Radauer C, Willheim M, Scheiner O, Liu FT, Boltz-Nitulescu G. The constitutive expression of galectin-3 is downregulated in intestinal epithelia of Crohn's disease patients, and tumour necrosis factor alpha decreases the level of galectin-3-specific mRNA in HCT-8 cells. Eur J Gastroenterol Hepatol 14: 145-152. 2002. Jensen-Jarolim E, Schmid B, Bernier F, Berna A, Kinaciyan T, Focke M, Scheiner O, Boltz- Nitulescu G. Allergologic exploration of germins and germin-like proteins, a new class of plant allergens. Allergy 57: 805-810. 2002. Untersmayr E, Focke M, Kinaciyan T, Poulsen LK, Boltz-Nitulescu G, Scheiner O, Jensen- Jarolim E. Anaphylaxis to Russian Beluga caviar. J Allergy Clin Immunol 109: 1034-5. 2002.
  • 53. - 53 - Schöll I, Ganglberger E, Förster-Waldl E, Vermes M, Baier K, Boltz-Nitulescu G, Scheiner O, Ebner C, Wiedermann U, Jensen-Jarolim E. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B-cell responses to the natural allergen using bystander help of T-cells. Clin Exp Allergy, 32: 1583-1588. 2002. Co-author manuscripts: Roth-Walter F, Berin CM, Arnaboldi P, Escalante C, Dahan S, Jensen-Jarolim E, Mayer L. Pasteurization of milk proteins promotes allergic sensitization in mice by enhancing uptake through Peyer’s patches. J Allergy Clin Immun., in press. Untersmayr E, Vestergaard H, Malling H-J, Bjerremann Jensen L, Platzer MH, Boltz-Nitulescu G, Scheiner O, Skov PS, Jensen-Jarolim E, Poulsen LK. Indigestion of codfish represents a risk factor for anaphylaxis in allergic patients. JACI 119(3): 711-7. 2007. Brunner R, Wallmann J, Szalai K, Karagiannis P, Kopp T, Scheiner O, Jensen-Jarolim E, Pali- Schöll I. The impact of aluminum in acid-suppressing drugs on the immune response of BALB/c mice. Clin. Exp. Allergy, 2007 Oct;37(10):1566-73. Epub 2007 Sep 10. Jin C, Bencurova M, Borth N, Ferko B, Jensen-Jarolim E, Altmann F, Hantusch B. Immunoglobulin E specifically bind plant N-glycans with high affinity could be generated in rabbits but not in mice. Glycobiology 16 (4): 349-57. 2006. [Epub 2005 Dec 21]. Fest S, Huebner N, Weixler S, Bleeke M, Zeng Y, Strandsby A, Volkmer-Engert R, Landgraf C, Gaedicke G, Riemer AB, Michalsky E, Jaeger IS, Preissner R, Förster-Waldl E, Jensen-Jarolim E, Lode HN. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66 (21): 1-9. 2006. Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Heighthened levels of circulating S20 proteasome in critically ill patients. J. Clin. Invest. 35: 399-403. 2005. Wagner S, Radauer C, Hafner C, Fuchs H, Jensen-Jarolim E, Wuthrich B, Scheiner O, Breiteneder H. Characterization of cross-reactive bell pepper allergens involved in the latex-fruit syndrome. Clin Exp Allergy. 2004 Nov;34(11):1739-46. PMID: 15544599 Beil W, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, Jensen-Jarolim E, Pabst R, Pammer J. Selective alterations in mast cell subsets and eosinophil infiltration in two types of intestinal inflammation: Ascariasis and Crohn´s disease. Pathobiology. 2002-2003;70(6):303-13. Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, Calugaru A, Galatiuc C, Regalia T, Tamandl D, Spittler A, Boltz-Nitulescu G. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol, 33: 2197-2205. 2003. Ankersmith HJ, Moser B, Roth G, Bruinner M, Buchta C, Wolner E, Jensen-Jarolim E, Boltz- Nitulescu G, Volf I. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. Am J Transplant. 3: 754-759. 2003. Hafner C, Samwald U, Wagner S, Felici F, Heere-Ress E, Jensen-Jarolim E, Wolff K, Scheiner O, Pehamberger H, Breiteneder H. Selection of mimotopes of the cell surface adhesion molecule Mel-CAM from a random pVIII-28aa phage peptide library. J Invest Dermatol 119:865-869. 2002. Rausch-Fan X, Leutmezer F, Spittler A, Bohle B, Jensen-Jarolim E, Ebner C, Boltz-Nitulescu G. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-
  • 54. - 54 - specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 128:33-41. 2002.
  • 55. - 55 - Curriculum Vitae Sylvia Knapp, MD, PhD Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences and Department of Medicine 1, Division of Infectious Diseases & Tropical Medicine, Medical University Vienna; Währinger Gürtel 18-20, 1090 Vienna Phone: +43-1-40400-5139 or 5140, Fax: +43-1-40400-5167 E-mail: sylvia.knapp@meduniwien.ac.at Personal Data Date of Birth: 15.09.1968 Place of Birth: Innsbruck Nationality Austria Education 24.11.2006 Ph.D. degree conferred by the University of Amsterdam, the 2001-2005 Netherlands Ph.D. studies at the Academic Medical Center, University of Amsterdam, the Netherlands 29.3.2004 Habilitation in Internal Medicine 1.5.2000 Licence in Internal Medicine 1994-2000 Residency in Internal Medicine, MUW 12.7.1993 M.D. degree conferred by the University of Vienna 1986 – 1993 Study of Medicine, University Vienna, Austria 03/91 – 10/91 Study of Medicine, Free University Berlin, Germany Career History 10/2006 – Appointment as Head of Laboratory of the Division of Infectious Diseases, Medical University Vienna 04/2006 – Principle Investigator at the Research Center for Molecular Medicine (CeMM) of the Austrian Academy of Sciences 2005 – 9/2006 Staff member Intensive Care Unit, Dept. of Internal Med. I, Medical Univ. Vienna: clinical duties and set-up of research lab 2001 – 2005 PhD study at the University of Amsterdam, Lab. of Experimental Internal Medicine: research topic: Role of Toll-like receptors during bacterial infections, supervisor: Prof. Dr. T. van der Poll 1994 – 2001 Residency in Internal Medicine, Medical University Vienna 1992 – 1994 Research fellow at Dept. of Internal Med. I, supervisor: Prof. Dr. U. Jäger; topic: t14;18 breakpoint region binding proteins in follicular lymphomas
  • 56. - 56 - 08/1991 Summer Training Course in Laboratory Virology, National Institute of Health, Department of Pathology, Tokyo, Japan, Prof. Dr. T. Kurata 05-07/1989 Undergraduate Research Training in the field of Kinins, Institute of Physiology, University of Vienna, Prof. Dr. B. Binder Career-related Activities 2003 – Reviewer for: J. Immunol, J. of Leukocyte Biology, Am. J. Physiol, Clin. Immunol., J. of Endotoxin Res., Microbes and Infection, Expert Review of Clinical Immunology, FEBS Letters, Scand. J. of Infectious Diseases 2007 – Editorial Board Member: Clinical Immunology 2006 Member of Local Organizing Committee: International Cytokine Conference, held in Vienna, 08/06 2004 – Reviewer for Hongkong Grant Council Review Board, Austrian Academy of Sciences 2005 – Lecturer Tertial: Emergency and Intensive Care Medicine, MUW 2006 – PhD Supervisor (2) 1998 – (Co-)Supervision of MD-thesis students (6) 1994 – Attendance of various clinical courses, such as bronchoscopy, gastroscopy, pacemaker, respirator,.. 1996 – Various lectures for students and postgraduate lectures for clinicians Awards 2007 Forschungspreis der Erste Bank 2006 Förderpreis of the Austrian Society of Antimircobrial Chemotherapy 2005 Förderpreis of the Austrian Society of Antimicrobial Chemotherapy 2005 Erwin Deutsch Award by the Austrian Society of Intensive Care Medicine 1999 Award for Emergency Medicine 1994 Türck-Award by the Austrian Society of Hematology 1993 Hans and Blanca Moser Student’s fellowship 1990 Scholarship (Leistungsstipendium) of the University of Vienna Memberships Austrian Society of Internal Medicine Austrian Society of Hematology Austrian Society for antimicrobial Chemotherapy Society of Critical Care Medicine
  • 57. - 57 - Austrian Society of Intensive Care Medicine Sources of funding in last 5 years (2002-2007) Period Organization Short Title K€/year 2000- Bürgermeister Stadt Intracellular Cytokines in Sepsis 8 2003 Wien 2001- FWF (Schrödinger) The role of TLRs in infection 24 2002 2002- FWF (Schrödinger) The role of TLRs in infection 24 2003 2006- FWF (P18232-B11) Immunmodulatory role of oxidized 90 * 2009 phospholipids (together with V. Bochkov, * = 45% share) 2006- CeMM Innate immune response to bacterial 230 2009 infections 2006- Jubiläumsstiftung Stadt Leukozyte-migration during pneumonia 45 2007 Wien, via Österr. Akad. Wissenschaften PhD supervision in last 5 years (2003-2008) Period Name of student Topic 2003 – Ulrich Matt Endogenous modulators of inflammation – impact on infectious diseases 2003 – Ana Zivcovic Role of PVL in S. aureus pneumonia Publications 58 peer reviewed publications in scientific journals, 2 book chapters, 22 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Knapp, S., von Aulock, S., Leendertse, M., Haslinger, I., Draing, C., Golenbock, D., van der Poll, T. (2008) Lipoteichoic Acid-induced Lung Inflammation depends on TLR2 and the concerted action of TLR4 and Platelet-activating Factor Receptor. J Immunol 180, in press Knapp, S., Matt, U., Leitinger, N., van der Poll, T. (2007) Oxidized phospholipids inhibit phagocytosis and impair outcome in gram-negative sepsis in vivo. J Immunol 178, 993-1001 Knapp, S., Florquin, S., Golenbock, D. T., and van der Poll, T. (2006) Pulmonary LPS- binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol 176, 3189- 3195 Knapp, S., Wieland, C. W., Florquin, S., Pantophlet, R., Dijkshoorn, L., Tshimbalanga, N., Akira, S., and van der Poll, T. (2006) Differential role of CD14 and Toll-like receptors 2 and 4 during Acinetobacter pneumonia. Am J Respir Crit Care Med 173, 122-129
  • 58. - 58 - Knapp, S., Schultz, M. J., and Poll, T. V. (2005) Host defense mechanisms in murine pneumoniae models. Shock 24 Suppl 1, 12-18 Knapp, S., van der Poll, T. (2004) Update on CD14, LBP and Toll-like receptors in acute infections. Yearbook of Intensive Care and Emergency Medicine (Vincent, J. L., ed), pp. 3- 14, Springer Verlag, Brussels Knapp, S., Wieland, C. W., van 't Veer, C., Takeuchi, O., Akira, S., Florquin, S., and van der Poll, T. (2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172, 3132-3138 Knapp, S., Gibot, S., de Vos, A., Versteeg, H. H., Colonna, M., and van der Poll, T. (2004) Cutting Edge: Expression Patterns of surface and soluble TREM-1 in Human Endotoxemia. J Immunol 173, 7131-7134 Knapp, S., Hareng, L., Rijneveld, A. W., Bresser, P., van der Zee, J. S., Florquin, S., Hartung, T., and van der Poll, T. (2004) Activation of Neutrophils and Inhibition of the Proinflammatory Cytokine Response by Endogenous Granulocyte Colony-Stimulating Factor in Murine Pneumococcal Pneumonia. J Infect Dis 189, 1506-1515 Knapp, S., De Vos, A. F., Florquin, S., Golenbock, D. T., and Van Der Poll, T. (2003) Lipopolysaccharide binding protein is an essential component of the innate immune response to Escherichia coli peritonitis in mice. Infect Immun 71, 6747-6753 Knapp, S., Leemans, J. C., Florquin, S., Branger, J., Maris, N. A., Pater, J., van Rooijen, N., and van der Poll, T. (2003) Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 167, 171-179. Knapp, S., Branger, J., and van der Poll, T. (2002) Advances in research of the inflammatory response: The importance of Toll-like receptors. Wien Med Wochenschr 152, 552-554 Co-author manuscripts: Dessing, M., Knapp, S., Florquin, S., de Vos, A.F., van der Poll, T. (2007) CD14 facilitates invasive respiratory tract infections by Streptococcus pneumoniae. Am J Respir Crit Care 175, 604-611 Renckens, R., Roelofs, J. J., Knapp, S., de Vos, A. F., Florquin, S., and van der Poll, T. (2006) The acute phase response and serum amyloid A inhibit the inflammatory response to Acinetobacter. J Infect Dis 193, 187-195 van Westerloo, D. J., Knapp, S., van't Veer, C., Buurman, W. A., de Vos, A. F., Florquin, S., and van der Poll, T. (2005) Aspiration pneumonitis primes the host for an exaggerated inflammatory response during Klebsiella pneumonia: the role of tumor necrosis factor-α. Crit Care Med 33, 1770-1778 Branger, J., Knapp, S., Weijer, S., Leemans, J. C., Pater, J. M., Speelman, P., Florquin, S., and van der Poll, T. (2004) The role of Toll-like Receptor 4 in Gram-positive and Gram- negative pneumonia in mice. Infect Immun 72, 788-794 Branger, J., Florquin, S., Knapp, S., Leemans, J. C., Pater, J. M., Speelman, P., Golenbock, D. T., and van der Poll, T. (2004) LPS-Binding Protein-deficient mice have an impaired Host Defense against Gram-negative but not Gram-postive pneumonia. Int. Immunol. 16, 1605- 1611
  • 59. - 59 - Wieland, C. W., Knapp, S., Florquin, S., De Vos, A. F., Takeda, K., Akira, S., Golenbock, D. T., Verbon, A., and Van Der Poll, T. (2004) Toll-like Receptor (TLR) 2, but not LBP, CD14 or TLR4, mediates lung inflammation by non-capped lipoarabinomannan: relevance for atypical mycobacterial infections. Am J Respir Crit Care Med 170: 1367-1374 von Aulock, S., Morath, S., Hareng, L., Knapp, S., van Kessel, K. P., van Strijp, J. A., and Hartung, T. (2003) Liopteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology 208, 413-422 Schultz, M. J., Knapp, S., Florquin, S., Pater, J., Takeda, K., Akira, S., and Van Der Poll, T. (2003) nterleukin 18 impairs the pulmonary host response against Pseudomonas aeruginosa. Infect Immun 71, 1630-1634. Delle Karth, G., Koreny, M., Binder, T., Knapp, S., Zauner, C., Valentin, A., Honninger, R., Heinz, G., and Siostrzonek, P. (2002) Complicated infective endocarditis necessitating ICU admission: clinical course and prognosis. Crit Care 6, 149-154 Invited Talks 2002-2008 2003 • Toll-like receptors: Week of Allergy, EAACI, Ghent, Belgium, 18. Nov 2003 • The role of LBP in the innate immune response to bacteria, Seminar of the Dept. of Infectious Diseases, Academic Medical Center, Univ. Amsterdam, 13. Feb 2003 • Role of alveolar macrophages during pneumococcal pneumonia: Van Loghem Research Meeting, Amsterdam, The Netherlands, Jan 2003 2004 • The role of Toll-like Receptors during pulmonary inflammation: International Symposium on Thrombocyte and Leukocyte Immunobiology, Rust, Austria, May 2004 • The role of TLR2 during pneumococcal pneumonia: Van Loghem Research Meeting, Amsterdam, the Netherlands, 9. Feb. 2004 2005 • Treatment of Sepsis: Euroconference: Interactions between innate and adaptive immunity in mammalian defense against bacterial infections, Joachimstal (Berlin), Germany, June 2005 2006 • Innate Immune response to bacterial infections, Vet. Med. Seminars of the Institute of genetics and animal breeding, Vienna, 4.12.2006, Host: Prof. Dr. M. Mueller • Host defense mechanisms during bacterial pneumonia: Innate Immunity, Receptors, Response, Regulation: Joint Meeting of the Society of Leukocyte Biology and Int. Endotoxin and Innate Immunity Society, San Antonio, Texas, 11. Nov. 2006 • Pneumonie auf der Intensivstation: Expertpanel on Pneumonia, Linz, 26. June 2006 • Pathophysiologie der Sepsis: Wiener Intensivmedizinische Tage, Vienna, Feb. 2006 • Deutsch-österr. Kongress für Intensivmedizin, Saarbrücken, Germany, June 2006 2007 • Novel treatment options in sepsis, Annual Meeting of the Austrian Society of Lung diseases, Salzburg, 5.10.2007 • Toll and Toll-free Receptors in Sepsis: Sepsis workshop, Austrian Sepsis Society, Vienna, 5.5.2007, Host: Prof. Dr. H. Burgman • Innate Immune Response Mechanisms during bacterial infections: Infection and Immunology Seminars, University of Innsbruck, 7.2.2007, Host: Prof. Dr. G. Weiss • Role of Toll-like Receptors during bacterial Pneumonia: Seminar of the Max Perutz
  • 60. - 60 - Laboratory, Inst. of Microbiology and Immunology, 26.1.2007, Host: Prof. Dr. T. Decker • Abwehrmechanismen bei Pneumonie: Fortbildung der CeMIC, Vienna, 16.1.2007 2008 • Innate Immunity, KIT (Meeting of Infectios Diseases and Tropical Medicine), Innsbruck 28.2.2008 • TLR and NLR in Sepsis, Wilheminenspital Vienna, 14.1.2008
  • 61. - 61 - Curriculum Vitae Herwig Kollaritsch Division of Travel Medicine and Infectious Disease Epidemiology, Institute for Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Wien, Austria; Phone: +43-1-40490 64850, Fax: +43-1-403 83 43 90; Email: herwig.kollaritsch@meduniwien.ac.at Personal Data Date of Birth: 11.02.1956 Place of Birth: Vienna Nationality Austria Education 1993 Tropical Medicine update, London School of Hygiene and Tropical Medicine 1991 Intensive Course on Tropical Medicine, Liverpool, UK 1990 Speciality in Hygiene, Microbiology and Preventive Medicine 1989 Speciality in Specific Prophylaxis and Tropical Medicine 1985-1987 Field education Tropical Medicine, Nigeria 1982 DTM at Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany 1981- Assistant Institute of Specific Prophylaxis and Tropical Medicine, Univ.Vienna 1980/1981 Assistant, Infectious Disease Unit, Kaiser Franz Josef Spital, Vienna 1974-1980 Medical doctor, University of Vienna 1974 University entrance qualification, Theresianum Wien Career History 2004- Group Leader, Travel Medicine and Infectious Disease Epidemiology 1997-2004 Head, Institute of Specific Prophylaxis and Tropical Medicine 1996- Associate Professor (a.o.Univ.Prof) 1989 Habilitation in Specific Prophylaxis and Tropical Medicine, University of Vienna Medical School
  • 62. - 62 - Career-related Activities 2007- Member of the Scientific Board of the Ministry of Defense Republic of Austria 2007- Member of the Scientific Board of the Ministry of Defense, Republic of Austria 2003- Board Member of the Comission for International Development at the Austrian Academy of Sciences 1999- Co-chair of the Advisory Board for Immunization Practices of the Republic of Austria 1999- Member of the “Arzneimittelsicherheitsausschuss” (supreme board for supervision of adverse drug reactions) of Austria 1996- Member of TROPMEDEUROP (association of the Tropical Institutes in Europe) 2000 - Board Member and Founding Member Austrian Society for Travel- and Touristic Medicine 1984 - Local Secretary, The Royal Society of Hygiene & Tropical Medicine, UK 1983 - Board Member, Austrian Society of Tropical Medicine and Parasitology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2000-2003 FWF Field validation of a HRP2-assay 30 1999-2003 Federal Bank of Surveillance of vaccine preventable diseases 15 Austria in Austria (Project 6165) Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2003-2005 Ulrich Gerstner Interactions between bloodchizontocidal arylaminoalkohols and other substance classes against Plasmodium falciparum in Thailand 2003-2005 Kamala Thriemer Interaction of Retinal and other antimalarials in Plasmodium falciparum 2003-2005 Leila Kyavar In vitro investigations of sensititvity of fresh isolates of Plasmodium vivax against chloroquin and other bloos schizonotocidals 2005-2006 Peter Starzengruber In vitro sensitivity of Plasmodium falciparum against Artemisinin, Chloroquine, Quinine and Mefloquine. Pharmacodynamic interactions between Lumefantrine and Monodesbutyl- Benflumetol
  • 63. - 63 - 2005-2006 Maria Parizek In vitro sensitivity of Plasmodium falciparum against Lumefantrine and Desbutyl-Benflumetol. Pharmacodynamic interactions between Desbutyl- Benflumetol and Retinol Publications Currently ~320 publications overall, 112 in peer-reviewed and Medline indexed scientific journals, 10 books, more than 20 book articles Peer reviewed manuscripts 2002-2008 (original research and reviews) Publications total: 53 (2002-2007) a) first, corresponding or last author total: 24 Top journals: 12 Bröker M, Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: Current positions about post- exposure treatment. Vaccine. 2008 Feb 13;26(7):863-8. Epub 2007 Dec 4. Tauber E, Kollaritsch H, Korinek M, Rendi-Wagner P, Jilma B, Firbas C, Schranz S, Jong E, Klingler A, Dewasthaly S, Klade CS. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet. 2007 Dec 1;370(9602):1847-53. Rendi-Wagner P, Paulke-Korinek M, Stanek G, Khanakah G, Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J. 2007 Sep;26(9):806-10. Rendi-Wagner P, Korinek M, Mikolasek A, Vécsei A, Kollaritsch H. Epidemiology of travel-associated and autochthonous hepatitis A in Austrian children, 1998 to 2005. J Travel Med. 2007 Jul-Aug;14(4):248-53. Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine. 2007 Jun 28;25(27):5097-101. Epub 2007 Feb 20. Kollaritsch H, Wiedermann U. [Examples for vaccines against diarrheal diseases--rotavirus and traveller's diarrhea] Wien Med Wochenschr. 2007;157(5-6):102-6. Review. German. Wiedermann U, Kollaritsch H. Vaccines against traveler's diarrhoea and rotavirus disease - a review. Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):2-8. Review. Kollaritsch H, Maurer W. [Rabies: epidemiology, pre- and postexposure immunization] Wien Klin Wochenschr. 2006 Jun;118(11-12):312-20. Review. German. Rendi-Wagner P, Kundi M, Mikolasek A, Mutz I, Zwiauer K, Wiedermann U, Vécsei A,
  • 64. - 64 - Kollaritsch H. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr. 2006 May;118(9-10):280-5. Rendi-Wagner P, Kundi M, Mikolasek A, Vécsei A, Frühwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine. 2006 Aug 14;24(33-34):5960-5. Epub 2006 May 23. Rendi-Wagner P, Zent O, Jilg W, Plentz A, Beran J, Kollaritsch H. Persistence of antibodies after vaccination against tick-borne encephalitis. Int J Med Microbiol. 2006 May;296 Suppl 40:202-7. Epub 2006 Mar 9. Review. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rümke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine. 2006 Apr 5;24(15):2781-9. Epub 2006 Jan 19. Rendi-Wagner P, Jeschko E, Kollaritsch H; österreichische Expertengruppe für Reisemedizin. [Travel vaccination recommendations for Central and Eastern European countries based on country-specific risk profiles] Wien Klin Wochenschr. 2005;117 Suppl 4:11-9. Review. German. Rendi-Wagner P, Hoeller K, Kollaritsch H; Osterreichische Expertengruppe für Reisemedizin. [Immunization recommendations for travel in the Mediterranean area] Wien Klin Wochenschr. 2004 Oct 30;116(19-20):652-60. German. Rendi-Wagner P, Kundi M, Zent O, Banzhoff A, Jaehnig P, Stemberger R, Dvorak G, Grumbeck E, Laaber B, Kollaritsch H. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine. 2004 Dec 9;23(4):427-34. Loebermann M, Kollaritsch H, Ziegler T, Rendi-Wagner P, Chambonneau L, Dumas R, Lafrenz M. A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther. 2004 Jul;26(7):1084-91. Rendi-Wagner P, Kundi M, Zent O, Dvorak G, Jaehnig P, Holzmann H, Mikolasek A, Kollaritsch H. Persistence of protective immunity following vaccination against tick-borne encephalitis-- longer than expected? Vaccine. 2004 Jul 29;22(21-22):2743-9. Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection. 2004 Jun;32(3):149-52. Erratum in: Infection. 2004 Aug;32(4):249. Rendi-Wagner P, Georgopoulos A, Kundi M, Mutz I, Mattauch M, Nowak J, Mikolasek A, Vecsei A, Kollaritsch H. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria.
  • 65. - 65 - J Antimicrob Chemother. 2004 May;53(5):826-31. Epub 2004 Apr 8. Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children. Vaccine. 2003 Sep 8;21(25-26):3575-83. Rendi-Wagner P, Wiedermann G, Stemberger H, Kollaritsch H. New vaccination strategies for low- and non-responders to hepatitis B vaccine. Wien Klin Wochenschr. 2002 Mar 28;114(5-6):175-80. Review. Wiedermann G, Kollaritsch H, Kundi M, Wernsdorfer WH. Relationships between mefloquine blood levels, gender, and adverse reactions. Am J Trop Med Hyg. 2002 May;66(5):445-6; author reply 446-7. No abstract available. Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis. 2002 Mar 1;34(5):628-33. Epub 2002 Jan 16. Rendi-Wagner P, Noedl H, Wernsdorfer WH, Wiedermann G, Mikolasek A, Kollaritsch H. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop. 2002 Feb;81(2):167-73. b) co-author total: 29 Topjournals: 9 Nothdurft HD, Dahlgren AL, Gallagher EA, Kollaritsch H, Overbosch D, Rummukainen ML, Rendi-Wagner P, Steffen R, Van Damme P; ad hoc Travel Medicine Expert Panel for ESENEM. The risk of acquiring hepatitis A and B among travelers in selected Eastern and Southern Europe and non-European Mediterranean countries: review and consensus statement on hepatitis A and B vaccination. J Travel Med. 2007 May-Jun;14(3):181-7. No abstract available. Lütgendorf C, Rojanawatsirivet C, Wernsdorfer G, Sirichaisinthop J, Kollaritsch H, Wernsdorfer WH. Pharmacodynamic interaction between atovaquone and other antimalarial compounds against Plasmodium falciparum in vitro. Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):70-6. Kyavar L, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer G, Sirichaisinthop J, Wernsdorfer WH. In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in Plasmodium vivax. Wien Klin Wochenschr. 2006;118(19-20 Suppl 3):62-9. Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007 Jan 15;25(5):927-31. Epub 2006 Sep 18. Weinke T, Liebold I, Burchard GD, Frühwein N, Grobusch MP, Hatz C, Kollaritsch H, Nothdurft HD, Reisinger E, Rieke B, Schönfeld Ch, Steffen R, Stich A.
  • 66. - 66 - [Prophylactic immunization against enterotoxin-forming Escherichia coli travellers' diarrhea and cholera: does it make sense and for whom?] Dtsch Med Wochenschr. 2006 Jul 28;131(30):1660-4. Review. German. No abstract available. Thriemer K, Wernsdorfer G, Rojanawatsirivet C, Kollaritsch H, Sirichainsinthop J, Wernsdorfer WH. In vitro activity of artemisinin alone and in combination with retinol against Plasmodium falciparum. Wien Klin Wochenschr. 2005;117 Suppl 4:45-8. Samal D, Rojanawatsirivet C, Wernsdorfer G, Kollaritsch H, Sirichaisinthop J, Wernsdorfer WH. Synergism of desbutyl-benflumetol and retinol against Plasmodium falciparum in vitro. Wien Klin Wochenschr. 2005;117 Suppl 4:39-44. Attlmayr B, Kollaritsch H, Wernsdorfer WH, Miller RS, Sirichaisinthop J, Noedl H. Drug sensitivity of Plasmodium falciparum along the Thai-Myanmar border using the new field-deployable HRP2 in vitro assay. Wien Klin Wochenschr. 2005;117 Suppl 4:35-8. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother. 2005 Aug;49(8):3575-7. Nothdurft HD, Bialek R, Burchard GD, Hatz C, Jelinek T, Kollaritsch H, Schönfeld C, Volkmer KJ; Ausschuss "Reisemedizin" der Deutschen Gesellschaft für Tropenmedizin und Internationale Gesundheit. [Consensus recommendations for malaria prophylaxis] Dtsch Med Wochenschr. 2005 Jun 3;130(22):1392-6. Review. German. No abstract available. Pirker-Krassnig DK, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer WH. Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand. Wien Klin Wochenschr. 2004;116 Suppl 4:47-52. Woitsch B, Wernsdorfer G, Prajakwong S, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer WH. Comparative study of the in vitro sensitivity of Plasmodium falciparum to artemisinin in two border areas of Thailand. Wien Klin Wochenschr. 2004;116 Suppl 4:35-40. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg. 2004 Dec;71(6):711-4. Noedl H, Wernsdorfer WH, Kollaritsch H, Looareesuwan S, Miller RS, Wongsrichanalai C. Malaria drug-susceptibility testing. HRP2-based assays: current data, future perspectives. Wien Klin Wochenschr. 2003;115 Suppl 3:23-7. Wichmann O, Muehlberger N, Jelinek T, Alifrangis M, Peyerl-Hoffmann G, Muhlen M, Grobusch MP, Gascon J, Matteelli A, Laferl H, Bisoffi Z, Ehrhardt S, Cuadros J, Hatz C, Gjorup I, McWhinney P, Beran J, da Cunha S, Schulze M, Kollaritsch H, Kern P, Fry G,
  • 67. - 67 - Richter J; European Network on Surveillance of Imported Infectious Diseases. Screening for mutations related to atovaquone/proguanil resistance in treatment failures and other imported isolates of Plasmodium falciparum in Europe. J Infect Dis. 2004 Nov 1;190(9):1541-6. Epub 2004 Sep 28. Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J, Iversen J, Kotlowski A, Malvy DJ, Kern P, Fry G, Siikamaki H, Schulze MH, Soula G, Paul M, Gómez i Prat J, Lehmann V, Bouchaud O, da Cunha S, Atouguia J, Boecken G. Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malar J. 2004 Mar 8;3:5. Reinthaler FF, Feierl G, Beubler E, Kollaritsch H, Ruckenbauer G, Klem G, Wendelin I, Marth E. Treatment of travelers' diarrhea among Austrian tourists. J Travel Med. 2004 Jan-Feb;11(1):66-8. No abstract available. Wichmann O, Jelinek T, Peyerl-Hoffmann G, Mühlberger N, Grobusch MP, Gascon J, Matteelli A, Hatz C, Laferl H, Schulze M, Burchard G, da Cunha S, Beran J, McWhinney P, Kollaritsch H, Kern P, Cuadros J, Alifrangis M, Gjørup I; European Network on Surveillance of Imported Infectious Diseases (TropNetEurop). Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malar J. 2003 Jun 25;2:17. Epub 2003 Jun 25. Lux D, Prajakwong S, Kollaritsch H, Wernsdorfer G, Wernsdorfer WH. In-vitro sensitivity testing of Plasmodium vivax: response to lumefantrine and chloroquine in northwestern Thailand. Wien Klin Wochenschr. 2003;115 Suppl 3:50-4. Ogwang S, Engl M, Vigl M, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Clinical and parasitological response of Plasmodium falciparum to chloroquine and sulfadoxine/pyrimethamine in rural Uganda. Wien Klin Wochenschr. 2003;115 Suppl 3:45-9. Noedl H, Wongsrichanalai C, Miller RS, Myint KS, Looareesuwan S, Sukthana Y, Wongchotigul V, Kollaritsch H, Wiedermann G, Wernsdorfer WH. Plasmodium falciparum: effect of anti-malarial drugs on the production and secretion characteristics of histidine-rich protein II. Exp Parasitol. 2002 Nov-Dec;102(3-4):157-63. Melzer H, Baier K, Felici F, von Specht BU, Wiedermann G, Kollaritsch H, Wiedermann U, Duchêne M. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):179-83. Steffen R, Kollaritsch H, Fleischer K. Travelers' diarrhea in the new millennium: consensus among experts from German-speaking countries. J Travel Med. 2003 Jan-Feb;10(1):38-45. Review. No abstract available. Erratum in: J Travel Med. 2003 May-Jun;10(3):199.
  • 68. - 68 - Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente S, Burchard G, Gascon J, Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran J, Iversen J, Hatz C, Schmid ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W, Knobloch J, Matteelli A, Schulze MH, Laferl H, Kapaun A, McWhinney P, Lopez-Velez R, Fätkenheuer G, Kern P, Zieger BW, Kotlowski A, Fry G, Cuadros J, Myrvang B; TropNetEurop; Surveillance importierter Infektionen in Deutschland Surveillance Networks. Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data. Clin Infect Dis. 2003 Apr 15;36(8):990-5. Epub 2003 Apr 2. Jelinek T, Peyerl-Hoffmann G, Mühlberger N, Wichmann O, Wilhelm M, Schmider N, Grobusch MP, von Sonnenburg F, Gascon J, Laferl H, Hatz C, Alifrangis M, Burchard G, McWhinney P, Schulze M, Kollaritsch H, da Cunha S, Beran J, Kern P, Gjørup I, Cuadros J. Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malar J. 2002 Oct 11;1:11. Epub 2002 Oct 11. Jelinek T, Schulte C, Behrens R, Grobusch MP, Coulaud JP, Bisoffi Z, Matteelli A, Clerinx J, Corachán M, Puente S, Gjørup I, Harms G, Kollaritsch H, Kotlowski A, Björkmann A, Delmont JP, Knobloch J, Nielsen LN, Cuadros J, Hatz C, Beran J, Schmid ML, Schulze M, Lopez-Velez R, Fleischer K, Kapaun A, McWhinney P, Kern P, Atougia J, Fry G, da Cunha S, Boecken G. Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis. 2002 Mar 1;34(5):572-6. Epub 2002 Jan 21. Melzer H, Fortugno P, Mansouri E, Felici F, Marinets A, Wiedermann G, Kollaritsch H, Von Specht BU, Duchêne M. Antigenicity and immunogenicity of phage library-selected peptide mimics of the major surface proteophosphoglycan antigens of Entamoeba histolytica. Parasite Immunol. 2002 Jun;24(6):321-8. Noedl H, Wernsdorfer WH, Krudsood S, Wilairatana P, Wiedermann G, Kollaritsch H, Looareesuwan S. Predictive role of laboratory and clinical treatment response parameters and glucose-6- phosphate dehydrogenase status in the therapy of falciparum malaria. Wien Klin Wochenschr. 2002 Feb 28;114(4):158-63. Invited Talks 2002-2008 2002: 22.1.2002, Wien, Ana Grand Hotel, Chiron-Behring Encepur-Pressekonferenz 30.1.-1.2.2002, Deutschland, Bayern, Spitzingsee Malaria Expertenworkshop2002 26.2.-2.3.2002, Saalfelden Österr. Apothekertagung, Reisemedizin update 2001 9.3.2002, Wien, Ärztekammer f.NÖ Fortbildung Reisemedizin 16.3.2002, Linz, Reisemedizinischer Tag Impfplan 2002 20.3.2002, Wien, Betriebsärzte-Fortbildung Hepatitiden 4.4.2002, Wien, Aventis Pasteur Bezirksärztefortbildung Reisemedizin aktuell
  • 69. - 69 - 9.4.2002, Glaxo Academy, Hotel Bristol Infektionen rund ums Mittelmeer 12.4.2002, Salzburg, Öst.Bundesheer Impfprävention beim Bundesheer 13.4.2002, Salzburg, 11.Öst.Impftag Pertussisepidemiologie in Österreich 18.4.2002, Pflegeheim Baumgarten, Wien Hepatitiden 29.5.-31.5.2002, Grado, Fortbildung der öst.Arztakademie Reisemedizin 29.6.2002, Bregenz, Ärztekammer Reisemedizin update 3.7.2002, Univ.Kinderklinik Wien Mittagsfortbildung Malaria 17.9.2002, Burgenland, Bezirksärztefortbildung Reisemedizin update 26.9.2002, Apotheke Traismauer, Aventis Pasteur Der österreichische Impfplan 3.10.u.4.10.2002, Gmunden, Impfsymposium Pertussisepidemiologie Pneumokokkenepidemiologie 12.10-13.10.2002, Reisemedizinische Konsenstagung Österreich Malariakonsens 15.10.2002, Linz, Glaxo Academy Hepatitis und Pertussis 26.10/27.10 2002, Taufers/Südtirol, Herbstgespräche f.Pharmazeuten Reisen mit Kindern 5.11.2002, Wien, Pflegeheim Liesing Hepatitiden 2003: 25.1.2003, Wiener Geriartrietage Spezifische Prophylaxe für Senioren 30.1.2003, Fortbildungszyklus der ÖGTP Die neuen Malariaempfehlungen 27.2.2003, Saalfelden/Apothekertage Reisemedizin update 7.3.2003, Bundesministerium f.Inneres Der Pockenalarmplan 15.3.2003, Linzer Reisemedizinische Tagung Der österreichische Malariakonsens 20.3.2003, Firma ABB Impfungen bei Auslandseinsätzen 25.3.2003, MA 15 Gesundheitsamt Der Pockenalarmplan/Schulung für Amtsärzte 1.4.2003, 2.Bundesheerimpftag Pockenschutzimpfung 4.4.2003, Österr.Impftag Die Pockenimpfung 23.4.2003, Sozialmedizinisches Zentrum Ost Impffortbildungsstunde 5.5.-9.5.2003 8th Int.Conf.for Travel Medicine New York Traveler’s Vaccines 29.5.-31.5.2003, Grado, Fortbildung der öst.Arztakademie Reisemedizin
  • 70. - 70 - 26.6.2003, Wiener Rettung Pockenalarmplan 1.7.-3.7.2003, Hamburg, Bernhard Nocht Institut Malariaworkshop 2003-12-16 9.10.2003, Impfsymposium Gmunden FSME-Ergebnisse einer Immunitätsstudie 13.10.2003, Wiener Ärztekammer Impffortbildung für Schulärzte 4.11.2003, Laa an der Thaya Reiseimpfungen/Fortbildung Bezirksärzte 10.11.2003, Salzburg/Renaissance Hotel Epidemiologie von reiseassoziierten Infektionen 2004: 20.3.2004, Fortbildungszyklus der ÖGTP Reisemedizinisches Update 2.3.2004, Saalfelden Apothekertage Impfplan 2004 und Reisemedizinisches update 20.3.2004, Linzer Reisemedizinische Tagung Präsentation des Konsensus für Mittelmeerimpfungen 26.3.2004, Österreichsicher Bundesheerimpftag Flaviviren in der Reisemedizin 27.3.2004, Österreichischer Impftag FSME 24.5.-29.5.2004, Öst.Akademie der Ärzte/Grado Seminar Reisemedizin Seminar Impfplan 3.6.-6.6.2004, 6th Nordic-Baltic Congress on Infectious Diseases Oral Presentation: Travelers Diarrhea 17.9.-18.9.2004, 4. Reisemedizinische Konsensustagung (Leogang/Salzburg) Kongressorganissation Malarialeitlinien 15.10.2004, Impfsymposium Gmunden Oral Presentation: TBE vaccination 2005: 19.1.-22.1.2005, Pädiatrisches Symposium Obergurgl Hepatitis und Typhus 26.1.2005, Ärztekammer Salzburg Fortbildung Reisemedizin 3.3.2005, Saalfelden Apothekertage Impfplan 2005 und Reisemedizinisches update 12.3.2005, Linzer Reisemedizinische Tagung Präsentation des reisemed.Konsensus Osteuropa 17.3.2005, Glaxo Academy Reisemedizinische Fortbildung 31.3.2005, Apothekerkammer Österreich Hepatitis als Reiseimpfung 9.4.2005, Österr.Impftag Salzburg Rotavirusimpfstoffe Tollwutreferenzstelle für Österreich 22.4.2005, ESIDOG (Europ.Soc.for Infections in Obstetrics and Gynecology) Impffortbildung für Gynäkologen
  • 71. - 71 - 28.4.2005, Fortbildungszyklus der ÖGTP Reisemedizinisches Update 14.5.2005, 9th Intl.Conference of Int.Soc.Travel Med Vaccine Boosters-Evidence for Current Recommendations Grazer Impftag (14.5.2005) Rotavirusepidemiologie in Österreich 24.5.-28.5.2005, Öst.Akademie der Ärzte/Grado Seminar Reisemedizin Seminar Impfplan 25.6.2005, Arbeitskreis Vorsorgemedizin Vorarlberg Reisemedizinisches update 2005 5.10.2005, Bezirksärztefortbildung Zams/Tirol Impfplan 2005 7.10.-8.10.2005, Impfsymposium Gmunden Rotavirusepidemiologie in Österreich Rotavirusimpfstoffe 14.10.2005, ESIDOG (Europ.Soc.for Infections in Obstetrics and Gynecology) Impffortbildung für Gynäkologen, Teil 2 20.10.2005, Apothekerkammer Kärnten Impffortbildung für Apotheker 26.10.2005, Pharmazeutische Herbsttagung Triest Avian Influenza 5.11.2005, Pädiatrische Impffortbildung Linz Rotavirusvakzinen 17.11.-19.11.2005, ÖGTP-Jahrestagung 2005 Fortbildung Reisemedizin 21.11.2005, Karl Landsteiner Gesellschaft Symposium Vogelgrippe 15.12.2005, Fortbildungszyklus der ÖGTP Vogelgrippe-facts and fiction 2006: 21.2.2006 and 28.2.2006, European Insurance Company, Vienna Travel risks 23.2.2006, Seminar für Journalisten, Wien Die wirklichen Infektionsgefahren in den Tropen 9.3.2006, Saalfelden Apothekertage Impfplan 2006 und Reisemedizinisches update 16.3.2006, Glaxo Academy Reisemedizinische Fortbildung 6.4.2006, Wiener Arbeiterkammer Influenzapandemie Apothekenfortbildung im Pharmaziezentrum Wien (27.4.2006) 28.4.2006, Impfplan 2006, Rotaviren, Hepatitis ESIDOG Impfseminar Wien (28.4.2006) Grundlagen des Impfwesens 5.5.2006, Auswärtiges Amt Berlin, Reise- und Tropenmedizin Tagung 2 Vorträge: Zeckenübertragene Infektionen; Impfungen und Boosterung 11.5.2006, Glaxo Academy Wien Rotavirusepidemiologie und Rotavirusimpfung 13.5.2006, Pannonischer Impftag Burgenland Auffrischungen von Impfungen 23.5.-26.5.2006, Fortbildung der Wiener Arztakademie Grado 3 Vorträge: Impfseminar Kinderimpfungen; Impfseminar Reiseimpfungen; Symposium
  • 72. - 72 - Rotavirusvakzinen 9.6.2006, Bundeskongress der medizinisch technischen Berufe Wien Infektionsgefahren im Ausland 15.6.2006, ESIDOG Impfseminar Linz Grundlagen des Impfwesens 23.6.2006, Österreichisches Bundesheer Innsbruck Tropen- und Reisemedizin 24.6.2006, Bregenzer Impftag Kampf den Durchfallserkrankungen: Rotaviren, Reisediarrhoe 22.8.-23.8.2006, Österreichische Arztakademie, Velden 2 Vorträge: Reiseimpfupdate, neue Impfstoffe 26.8.2006, Österreichische Parkinsongesellschaft, Jahrestagung, Karlstein Impfnebenwirkungen beim neurologischen Patienten 21.9.2006, Novartis Fortbildung, Baden Influenza 5.10.2006, Landessanitätsdirektion Tirol, Innsbruck Fortbildung über neue Impfstoffe 12.10.2006, Novartis Fortbildung Krems Influenza 19.10.2006, Bundesverband der medizinisch technischen Berufe, Wien Influenza und Pandemie 3.11.2006, Impfsymposium Gmunden 10 Jahre Infektionssurveillance – was hats gebracht? 4.11.2006, Jahrestagung der ÖGTP, Linz Update Reisemedizin 16.11.2006, GlaxoSmithKline Fortbildung, Linz Reisemedizin update 17.11.2006, ESIDOG Vorarlberg Grundlagen des Impfwesens 18.11.2006, ESIDOG Innsbruck, Seefeld Grundlagen des Impfwesens 11.12.2006, GlaxoSmithKline Fortbildung Wien Rotavirusepidemiologie und Impfung 2007: 18.1.2007, Fortbildung Novartis Wien Tollwut Zecken und Co 12.2.2007, Sauerhof, Baden Apothekerkammerfortbildung: Impfupdate 15.2.2007, Naturhistorisches Museum Wien Pharmazeuten: Neue Impfungen 21.2.2007, Krems, Kloster UND Apothekerkammer NÖ, Fortbildung Tollwut 1.3.2007, Saalfelden Öst.Apothekertage. Reisemedizin update 9.3.2007, ESIDOG: Impfseminar f. Gynäkologen Oberösterreich 10.3.2007, Linzer Reisemedizinische Tagung Entsendungseignungsuntersuchung 13.3.2007, GlaxoSmithKline interne Schulung Hepatitis 17.3.2007, Öst.Kongress für Infektionskrankheiten Reiseimpfungen 23.3.2007, Öst.Bundesheerimpftag Japan Encephalitis 24.3.2007, Öst.Impftag
  • 73. - 73 - Infektionssurveillance 29.3.2007, Öst.Gesellschaft f.Infektionskrankheiten Faszination Vakzination 5.5.2007, Bezirksärztefortbildung NÖ Reisemed.update und Hepatitis 8.5.2007, Ärztekammer Salzburg Reisemedizin.update 9.5.2007, Mini-Med-Studium Donauuniversität Impfungen 1.6.2007, ESIDOG Impfseminar für Gynäkologen Salzburg 7.5.2007, Ärzteakademie Grado Lunchsymposium Reisemedizin 8.5.2007, Ärzteakademie Grado Impfupdate öst.Impfplan 23.6.2007, Apothekertage Pörtschach Kinder und Senioren auf Fernreisen 26.9.2007, Fortbildungsakademie Innsbruck Impfupdate 27.9.2007, Impfsymposium Gmunden Pneumokokkensurveillance 2.10.2007, Ärztekammer Wien Giftiger Dienstag. Der öst.Impfplan 11.10.2007, Gesellschaft der Ärzte, Novartis Influenza 19.10.2007, Apotheke Trausmauer Fortbildung Influenza 23.10.2007, Arbeiterkammer Wien Fortbildung Impfwesen 6.11.2007, Europ.Reiseversicherung Mitarbeiterschulung Reisemedizin 7.11.2007, AGES Zukunftskonferenz, Messe Wien: Klimaveränderungen und Tropenkrankheiten
  • 74. - 74 - Curriculum Vitae Rudolf Oehler Dept. of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria; E-mail: rudolf.oehler@meduniwien.ac.at Personal Data Date of Birth: 21.12.1963 Place of Birth: Brixen/Bressanone, Italy Nationality Italian Education 1990 – 1994 Ph.D. work at the Institute of Biochemistry, University of Vienna (Prof. A. Barta) 1988 – 1989 Diploma work at the Institute of medical Microbiology, University of Innsbruck (Prof. G. Stöffler) 1982 – 1989 Studies in Microbiology, University of Innsbruck 1982 High school degree for electric engineering in Bolzano, Italy Career History Since 2001 Associate Professor (a.o.Univ.Prof), Department of Surgery, University of Vienna 2001 Habilitation in Medical Chemistry, University of Vienna Medical School 1994-2001 University Assistant, Department of Surgery, University of Vienna 1989 - 1990 Technical assistant at the Diagnostic Laboratory "Dr. Rohrer", Innsbruck, Austria Awards 2000 Forschungsförderungspreis der Arbeitsgemeinschaft für Klinische Ernährung Memberships 2006 Founding member of the Austrian Proteomic Association (AuPA) 1995 Founding member of the Cell Stress Society International (CSSI)
  • 75. - 75 - Sources of funding in last 6 years (2002-2008) Period Organization 20078 European Society of Organ Transplantation 2006 Commission of the European Communities (MTKI-CT-2005-029946; coordination) 2003 Oestrreichische Nationalbank (#9917), Vienna, Austria 2002 Lorenz Böhler Gesellschaft, Vienna, Austria 2001 ESPEN, Geneva, Switzerland 2000 Oestrreichische Nationalbank (#8311), Vienna, Austria Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student 2004-2007 Wolfgang Winkler 2000-2004 Maria Zellner 2007 - present Anna Michlmayr 2007-present Suzann Baumann 2006-present Senada Skeledzic Publications 27 peer reviewed publications in scientific journals, 1 invited review, 2 book chapters, > 6 invited lectures, 1 patent Peer reviewed manuscripts 2002-2008 (original research and reviews) Exner, R., Weingartmann, G., Spittler, A., Brabec, M., Roth, E., and Oehler, R. (2002) Glutamine deficiency renders human monocytic cells more susceptible to specific apptosis triggers. Surgery 131, 75-80 Oehler, R., Pusch, E., Dungel, P., Zellner, M., Munk-Eliasen, M., and Roth, E. (2002) Reduced expression of the major inducible 70 kDa heat shock protein in glutamine starved leukocytes. Brit.J.Nutr. 87, S17-S21 Roth, E., Oehler, R., Manhart, N., Exner, R., Wessner, B., Strasser, E., and Spittler, A. (2002) Regulative potential of glutamine--relation to glutathione metabolism. Nutrition 18, 217-221 Zellner, M., Hergovich, N., Roth, E., Jilma, B., Spittler, A., and Oehler, R. (2002) Human monocyte stimulation by experimental whole body hyperthermia. Wien. Klin. Wochenschr. 114, 102-107 Oehler, R., and Roth, E. (2003) Regulative capacity of glutamine. Curr Opin Clin Nutr Metab Care 6, 277-282. Oehler, R., and Roth, E. (2003) Glutamine Metabolism. In: Cynober, L., ed. Amino acid metabolism and therapy in health and nutritional disease, 2nd. Ed., pp. 169-185, CRC Press, Boca Raton, FL.
  • 76. - 76 - Roth, E., Zellner, M., Wessner, B., Strasser, E., Manhart, N., Oehler, R., and Spittler, A. (2003) Glycine-an inert amino acid comes alive. Nutrition 19, 817-818. Zellner, M., Gerner, C., Eliasen, M., Wurm, S., Pollheimer, J., Spittler, A., Brostjan, C., Roth, E., and Oehler, R. (2003) Glutamine starvation of monocytes inhibits the ubiquitin- proteasome proteolytic pathway. BBA - Molecular Basis of Disease 1638, 138-148 Zellner, M., Gerner, C., Munk Eliasen, M., Wurm, S., Pollheimer, J., Spittler, A., Brostjan, C., Roth, E., and Oehler, R. (2003) Glutamine starvation of monocytes inhibits the ubiquitin- proteasome proteolytic pathway. Biochim Biophys Acta 1638, 138-148 Pollheimer, J., Zellner, M., Eliasen, M., Roth, E., and Oehler, R. (2005) Increased susceptibility of Glutamine-depleted monocytes to fever-range hyperthermia: The role of 70 kDa Heat shock protein. Annals of Surgery 241, 349-355 Zellner, M., Winkler, W., Hayden, H., Diestinger, M., Eliasen, M., Gesslbauer, B., Miller, I., Chang, M., Kungl, A., Roth, E., and Oehler, R. (2005) Quantitative Validation of different Protein Precipitation Methods in Proteome Analysis of Blood Platelets. Electrophoresis 26, 2481-2489 Eliasen, M. M., Brabec, M., Gerner, C., Pollheimer, J., Auer, H., Zellner, M., Weingartmann, G., Garo, F., Roth, E., and Oehler, R. (2006) Reduced stress tolerance of glutamine-deprived human monocytic cells is associated with selective down-regulation of Hsp70 by decreased mRNA stability. J Mol Med 84, 147-158 Eliasen, M. M., Winkler, W., Jordan, V., Pokar, M., Marchetti, M., Roth, E., Allmaier, G., and Oehler, R. (2006) Adaptive cellular mechanisms in response to glutamine-starvation. Front Biosci 11, 3199-3211 Skeledzic, S., Ahrer, K., Bohmig, G. A., Muehlbacher, F., and Oehler, R. (2007) Identification of non-HLA antigens in renal transplantation by proteomics. Transplant-Internat. 20, 40 Winkler, W., Zellner, M., Diestinger, M., Babeluk, R., Marchetti, M., Goll, A., Zehetmayer, S., Bauer, P., Rappold, E., Miller, I., Roth, E., Allmaier, G., and Oehler, R. (2008) Biological variation of the platelet proteome in the elderly population and its implication for biomarker research. Mol Cell Proteomics 7, 193-203 Invited Talks 2002-2008 2002 • 24th Int. Congress of the Eur. Soc. of Enteral and Parenteral Nutrition, Glasgow, UK 2004 • 2nd Austrian Proteome Research Symposium, Vienna, Austria 2006 • 2nd Int. Workshop on Platelet disorders, oxidative stress and ageing, Rome, Italy 2007 • 1st Central and Eastern European Proteomic Conference, Prague
  • 77. - 77 - Curriculum Vitae Ao. Univ. Prof. Dr. Winfried F. PICKL Division of Cellular Immunology and Immunehematology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse 8A, 1090 Vienna, Austria; Phone: +43-1-4277-64945, Fax: +43-1-4277-9649; Email: winfried.pickl@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/immunologie/ Personal Data Date of Birth: 20.07.1964 Place of Birth: Klagenfurt Nationality Austria Education 1991, July 5th Medical Degree, University of Vienna, Medical School 1989–1991 Doctoral Thesis, Institute for Blood Group Serology and Tissue Typing, University of Vienna, Medical School 1985 – 1990 Studies in Biochemistry, University of Vienna 1983–1989 Medical Student, University of Vienna, Medical School st 1983, June 1 A-Level with distinction: High School for Business Administration, Klagenfurt Career History 09/2004–present Head of Research Unit ‘Cellular Immunology and Immunohematology’, Institute of Immunology, Medical University of Vienna 09/2002–present Principal Investigator, Institute of Immunology, University of Vienna, Medical School, and Medical University of Vienna th 2002, Nov. 25 Board Certification in Immunology, Austrian Medical Association 02/2002–08/2002 Training in Hematology and Internal Medicine, Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Medical School 06/2000–01/2002 Principal Investigator, Institute of Immunology, University of Vienna, Medical School th 1999, March 25 Habilitation and Associate Professorship in Immunology, Institute of Immunology, University of Vienna, Medical
  • 78. - 78 - School 01/1998–05/2000 Research Fellow in Molecular Biology and Genetics, Department of Molecular Biology, Harvard Medical School, Boston (Prof. Brian Seed) 1996, Sept. 1st Assistant Professor in Immunology, Institute of Immunology, University of Vienna, Medical School 06/1995–12/1997 Research Fellow, Institute of Immunology, University of Vienna, Medical School 01/1995–05/1995 Training in Surgery and Dermatology, Austrian Armed Forces Military Hospital, Vienna 10/1994–12/1994 Training as Military Assistant Doctor, Vienna and Innsbruck Medical Corps, Austrian Armed Forces 11/1991–09/1994 Research Fellow, Institute of Immunology, University of Vienna, Medical School 07/1991-10/1991 Research Fellow, Institute for Blood Group Serology and Tissue Typing, University of Vienna Awards 2007 Karl Landsteiner Award of the Austrian Society for Allergology and Immunology 1999 APART research fellowship, Austrian Academy of Sciences 1998 Erwin Schroedinger research fellowship, Austrian Science Foundation 1993 National Award in Rheumatology, Ministry of Health, Science and Education, Austria 1991 Best Thesis, Austrian Society of Immunology and Allergology (ÖGAI) Memberships Austrian Society for Allergology and Immunology Austrian Society for Rheumatology European Group for the Immunological Characterization of Leukemias (EGIL) European Leukemia Network (ELN) American Association of Immunologist (AAI) American Society for Hematologist (ASH) Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year
  • 79. - 79 - 2002-2005 Academy of Sciences Better definition of the immunological 150 synapse 2002-2005 FWF Influencing the allergen-specific immune 80 response 2005-2008 FWF Allergy-SFB:Further development of 80 Anergosomes 2008 - 2011 FWF Allergy-SFB: Rebuilding the allergen-specific 90 synapse 2006 -2009 FFG Membrane anchored cytokines and integral 80 membrane proteins: Novel adjuvants for virus vaccines 2008-2014 Christian Doppler CDG Laboratory for Immunomodulation- 90 Society Subproject #4 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2001-2005 Sophia Derdak Immunosomes: VLP driving primary T cell responses 2003- Victoria Leb Anergosomes and TCR transgenic allergen-specific T present cells 2004- Hans Küng Decoration of enveloped viruses with cytokines present 2005- Klaus Schmetterer Functional genetic screening for immunomodulatory present molecules 2006- Alina Neunkirchner Antigen-presenting platforms induced by viral core present proteins 2006- Daniela Haiderer Development of novel adjuvants for viral vaccines present Publications 60 peer reviewed publications in scientific journals, 9 book chapters, 1 patent application Peer reviewed manuscripts 2002-2008 (original research) Greinix, H. T., Pohlreich, D., Kouba, M., Kormoczi, U., Lohmann, I., Feldmann, K., Zielinski, C., and Pickl, W. F. (2008). Elevated numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells identify patients with active chronic graft-versus- host disease. Biol Blood Marrow Transplant 14, 208-219. Leb, V. M., Jahn-Schmid, B., Schmetterer, K. G., Kueng, H. J., Haiderer, D., Neunkirchner, A., Fischer, G. F., Nissler, K., Hartl, A., Thalhamer, J., et al. (2008). Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol 121, 64-71.
  • 80. - 80 - Sillaber, C., Mayerhofer, M., Bohm, A., Vales, A., Gruze, A., Aichberger, K. J., Esterbauer, H., Pfeilstocker, M., Sperr, W. R., Pickl, W. F., et al. (2008). Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 38, 43-52. Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M. T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Mullauer, L., Agis, H., et al. (2007). Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109, 3031-3041. Attarbaschi, A., Mann, G., Schumich, A., Konig, M., Pickl, W. F., Haas, O. A., Gadner, H., and Dworzak, M. N. (2007). CD44 deficiency is a consistent finding in childhood Burkitt's lymphoma and leukemia. Leukemia 21, 1110-1113. Gleixner, K. V., Mayerhofer, M., Sonneck, K., Gruze, A., Samorapoompichit, P., Baumgartner, C., Lee, F. Y., Aichberger, K. J., Manley, P. W., Fabbro, D., et al. (2007a). Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 92, 1451-1459. Gleixner, K. V., Rebuzzi, L., Mayerhofer, M., Gruze, A., Hadzijusufovic, E., Sonneck, K., Vales, A., Kneidinger, M., Samorapoompichit, P., Thaiwong, T., et al. (2007b). Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 35, 1510-1521. Kondo, R., Gleixner, K. V., Mayerhofer, M., Vales, A., Gruze, A., Samorapoompichit, P., Greish, K., Krauth, M. T., Aichberger, K. J., Pickl, W. F., et al. (2007). Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood 110, 661-669. Kueng, H. J., Leb, V. M., Haiderer, D., Raposo, G., Thery, C., Derdak, S. V., Schmetterer, K. G., Neunkirchner, A., Sillaber, C., Seed, B., and Pickl, W. F. (2007). General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol 81, 8666-8676. Mayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K., Nakamura, H., Derdak, S., et al. (2007). Targeting of heat shock protein 32 (Hsp32) / heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood. Rebuzzi, L., Willmann, M., Sonneck, K., Gleixner, K. V., Florian, S., Kondo, R., Mayerhofer, M., Vales, A., Gruze, A., Pickl, W. F., et al. (2007). Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 115, 320-333. Aichberger, K. J., Mayerhofer, M., Vales, A., Krauth, M. T., Gleixner, K. V., Bilban, M., Esterbauer, H., Sonneck, K., Florian, S., Derdak, S., et al. (2006). The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood 108, 3538-3547. Attarbaschi, A., Mann, G., Konig, M., Steiner, M., Strehl, S., Schreiberhuber, A., Schneider, B., Meyer, C., Marschalek, R., Borkhardt, A., et al. (2006). Mixed lineage leukemia- rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res 12, 2988-2994. Bilban, M., Heintel, D., Scharl, T., Woelfel, T., Auer, M. M., Porpaczy, E., Kainz, B., Krober,
  • 81. - 81 - A., Carey, V. J., Shehata, M., et al. (2006). Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 20, 1080-1088. Derdak, S. V., Kueng, H. J., Leb, V. M., Neunkirchner, A., Schmetterer, K. G., Bielek, E., Majdic, O., Knapp, W., Seed, B., and Pickl, W. F. (2006). Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci U S A 103, 13144-13149. Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Bohm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., et al. (2006). PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107, 752-759. Pfistershammer, K., Klauser, C., Pickl, W. F., Stockl, J., Leitner, J., Zlabinger, G., Majdic, O., and Steinberger, P. (2006). No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36, 1104-1113. Sonneck, K., Florian, S., Bohm, A., Krauth, M. T., Kondo, R., Hauswirth, A. W., Gleixner, K. V., Aichberger, K. J., Derdak, S., Pickl, W. F., et al. (2006). Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma 47, 897-906. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., et al. (2005a). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105, 3303-3311. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Vales, A., Kondo, R., Derdak, S., Pickl, W. F., Selzer, E., Deininger, M., Druker, B. J., et al. (2005b). Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 65, 9436-9444. Mayerhofer, M., Aichberger, K. J., Florian, S., Krauth, M. T., Hauswirth, A. W., Derdak, S., Sperr, W. R., Esterbauer, H., Wagner, O., Marosi, C., et al. (2005). Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Faseb J 19, 960-962. Wohrl, S., Loewe, R., Pickl, W. F., Stingl, G., and Wagner, S. N. (2005). EMPACT syndrome. J Dtsch Dermatol Ges 3, 39-43. Steinberger, P., Majdic, O., Derdak, S. V., Pfistershammer, K., Kirchberger, S., Klauser, C., Zlabinger, G., Pickl, W. F., Stockl, J., and Knapp, W. (2004). Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172, 2352-2359. Selenko-Gebauer, N., Majdic, O., Szekeres, A., Hofler, G., Guthann, E., Korthauer, U., Zlabinger, G., Steinberger, P., Pickl, W. F., Stockinger, H., et al. (2003). B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170, 3637-3644. Javaherian, K., Park, S. Y., Pickl, W. F., LaMontagne, K. R., Sjin, R. T., Gillies, S., and Lo, K. M. (2002). Laminin modulates morphogenic properties of the collagen XVIII endostatin domain. J Biol Chem 277, 45211-45218.
  • 82. - 82 - Curriculum Vitae Marcus Säemann Internal Medicine III, Clin. Division of Nephrology & Dialyis, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43-1-404005593, Fax: +43-1- 404004392; e-mail: marcus.saemann@meduniwien.ac.at; Personal Data Date of Birth: 3.2.1971 Place of Birth: Vienna Nationality Austria Education 2002-2008 Fellowship Internal Medicine, Spec. Nephrology, Vienna 1998-2002 Postdoctoral fellow at the Inst. of Immunology, Vienna 1995-1998 Diploma thesis at the Institute of Immunology, Vienna 1989-1998 Studies in Human Medicine, University of Vienna 1989 University entrance qualification, G3 Vienna Career History 2007 Associate Professor (Privat Dozent) 2006 Establishment of the Pancreas-Transplant Program at the MUV, Minneapolis, Mn, Dep. of Surgery (Prof. DER Sutherland) 04/2006 Habilitation in Internal Medicine, University of Vienna Medical School 2002 Group Leader, Exp. Nephrology & Immunosuppression MUV 1998-2002 Postdoctoral fellow at the Inst. of Immunology, Vienna Memberships Member of the Austrian Society of Allergology und Immunology, 1998 General Secretary of the Austrian Society of Allergology und Immunology, 2006-2008 Member of the Austrian Society of Transplantation, Transfusion und Genetics, 2001 Member of the Transplantation Society, 2000 Member of the European Society of Transplantation (ESOT), 2004 Member of the Austrian Society of Nephrology, 2005 Member of the German Society of Nephrology, 2005 Member of the American Association of Immunology, 2000 Associate Editor of the European Journal of Clinical Investigation, 2002 Editorial Board of Transplant International, 2003 Society of Innate Immunity (Founding member), 2006 Member of the Scientific Comittee for ECI 2009 ("Immune Interventions")
  • 83. - 83 - Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2007-2009 Else-Köner Fund HDL as immunomodulator 75000 2007-2008 Else-Köner Fund THP and the myeoloma kidney 80000 2003-2005 Austrian National JAK3 as immunosuppressive target 25000 Bank Fund Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2004 - 2006 Marko Poglitsch Insights into the molecular mode of malonotrilamides on T-cell activation 2006 - 2008 Barbara Vodenik Inhibition of mTOR prevents the anti-inflammatory action of glucocorticoids 2007 - 2008 Philipp Steininger GSK3 as immunosuppressive target Publications Peer reviewed manuscripts 2002-2008 (original research and reviews) Säemann M.D., Parolini O., Böhmig G.A., Kelemen P., Krieger P.-M., Knarr K., Kammlander W., Neumüller F., Hörl W.H., Diakos C., Stuhlmeier K., Zlabinger G.J. Bacterial metabolite interference with maturation of human monocyte-derived dendritic cells. J Leuk Biol 2002, 71:238-246 Böhmig G., Regele H., Exner M., Derhartunian V., Kletzmayr J., Säemann M.D., Hörl W.H., Druml W., Watschinger B. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002, 13(4):1091-1099 Diakos C., Prieschl E., Säemann M.D., Böhmig G.A., Baumruker T., Zlabinger G.J. Increased nuclear export of NF-AT by the short-chain fatty acid n-butyrate. J Biol Chem 2002, 277:24243-24251 Krieger P.-M., Säemann M.D., Böhmig G.A., Mühlbacher F., Zlabinger G.J. Targeting the ERK1/2-signalling pathway results in alloantigen-specific anergy in human T-cells. Transplant Proc 2002, 34:1403-1404 Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J. CD40- triggered human monocyte-derived DC convert to tolerogenic DC when JAK3 activity is prevented. Transplant Proc 2002, 34:1407-1408 Sanzone S, Zeyda M., Säemann M.D., Soncini M, Holter W, Fritsch G., Knapp W., Candotti F., Stulnig T.M., Parolini O. SLAM-associated protein deficiency causes imbalanced early signal transduction and blocks downstream activation in T cells from X-linked lymphoproliferative disease patients. J Biol Chem 2003, 278(32): 29593-29599 Zeyda M., Szekeres A.B., Säemann M.D., Geyeregger R., Stockinger H., Zlabinger G.J., Waldhausl W., Stulnig T.M. Suppression of T cell signaling by polyunsaturated fatty acids: selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J Immunol 2003, 170(12):6033-6039 Säemann M.D., Zeyda M., Diakos C., Szekeres A.B., Bohmig G.A., Kelemen P., Parolini O.,
  • 84. - 84 - Stockinger H., Prieschl E.E., Stulnig T.M., Baumruker T., Zlabinger G.J. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003, 75(11):1864-1872 Staffler G., Prager E., Zeyda M., Säemann M.D., Stulnig T., Hilgert I., Zlabinger G.J., Horejsi V., Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J Immunol 2003, 171(4):1707-1714 Säemann M.D., Diakos C., Kelemen P., Kriehuber E., Zeyda M., Böhmig G.A., Hörl W.H., Baumruker T., Zlabinger G.J. Prevention of CD40-Triggered Dendritic Cell Maturation and Induction of T-Cell Hyporeactivity by Targeting of Janus Kinase 3. Am J Transplant 2003, 3(11):1341-1349 Fabrizii V., Winkelmayer W.C., Klauser R., Kletzmayr J., Säemann M.D., Steininger R., Kramar R., Hörl W.H., Kovarik J. Patient and graft survival in older kidney transplant recipients: does age matter? J Am Soc Nephrol 2004, 15(4):1052-1060 Wimmer T., Cohen G., Säemann M.D., Hörl W.H.. Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 2004, 19(9):2192-2197 Säemann M.D., Kelemen P., Böhmig G.A., Hörl W.H., Zlabinger G.J. Hyporesponsiveness in alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: resistance to calcineurin inhibition. Am J Transplant 2004, 4(11):1341-1349 Säemann M.D., Weichhart T., Zeyda M., Staffler G., Schunn M., Stuhlmeier K.M., Sobanov Y., Stulnig T.M., Akira S., von Gabain A., von Ahsen U., Hörl W.H., Zlabinger G.J. Tamm- Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest. 2005, 115(2):468-475 Zeyda M., SäemannM.D., Stuhlmeier K.M., Mascher D.G., Nowotny P.N., Zlabinger G.J., Waldhausl W., Stulnig T.M.. Polyunsaturated fatty acids inhibit dendritic cells function without impairment of NF-kB. J Biol Chem 2005, 280(14):14293-14301 Kirsch B., Zeyda M., Grisar J., Smolen J.S., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J. Säemann M.D. The active metabolite of leflunomide A77 1726 interferes with dendritic cell function. Arthritis research and therapy 2005, 2005;7(3):R694-703 Zeyda M., Stuhlmeier K.M., Kirsch B., Watschinger B., Hörl W.H., Stulnig T.M., and Säemann M.D. The malononitrilamide FK778 inhibits Activation of NF-kB in Human Dendritic Cells. Transplant Proc 2005, 37(4):1970-1971 Zeyda M., Geyerreger R., Poglitsch M., Watschinger B., Hörl W.H., Stulnig T.M., and Säemann M.D. The novel immunosuppresant FK778 inhibits Formation of the Immunological Synapse. Transplant Proc 2005, 37(4):1968-1969 Zeyda M., Poglitsch M., Geyeregger R., Smolen J.S., Zlabinger G.J., Hörl W.H., Waldhäusl W., Stulnig T.M., and Säemann M.D. The Active Leflunomide Metabolite Teriflunomide Disrupts the Interaction of T Cells with Antigen-Presenting Cells: Involvement of Impaired Integrin Activation and Immunological Synapse Formation. Arthritis and Rheumatism 2005, 52(9):2730-2739 Zeyda M., Kirsch B., Geyeregger R., Stuhlmeier K., Zlabinger G.J., Hörl, W. H., Säemann M.D., Stulnig T. M. Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778., Transplantation. 2005 27;80(8):1105-1151 Diakos C., Prieschl E.E., Bohmig G.A., Csonga B,, Sobanov Y., Baumruker T., Säemann
  • 85. - 85 - M.D. Zlabinger G.J. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. Biochem Biophys Res Commun. 2006;349(2):863-868 Körmöczi G.F., Säemann M.D., Buchta C., Peck-Radosavljevic M., Mayr W.R., Schwartz D.W., Dunkler D., Spitzauer S., Panzer S. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest. 2006;36(3):202-209 Kirsch B.M., Geyeregger R., Stuhlmeier K., Säemann M.D. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol. 2006;16(3-4):254-257 Zeyda M., Geyeregger R., Poglitsch M, Säemann M.D. Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. J Leukoc Biol. 2007;81(1):319-327 Geyeregger R., Zeyda M., Bauer W., Kriehuber E., Säemann M.D., Zlabinger G.J., Maurer D., Stulnig T.M. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin bundling protein fascin. Blood. 2007; 109(10):4288-95 Grisar J.C., Aletaha D., Steiner C.W., Kapral T., Säemann M.D., Steiner S., Schwarzinger I., Buranyi I., Steinere G., Smolen J. Endothelial progenitor cells in active rheumatoid arthritis: Effects of TNF and of glucocorticoid therapy. Ann Rheum Dis. 2007; 66(10):1284-8 Bobacz K., Sunk IG., Hofstaetter JG., Amoyo L., Toma CD., Akira S., T. Weichhart, Säemann M.D., J. S. Smolen. Toll-like receptors and chondrocytes: The lipopolysaccharide- induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum. 2007;56(6):1880-93 Haidinger M., Gyeregger R., Poglitsch M., Weichhart T., Zeyda M., Vodenik B., Stulnig T.M., Böhmig G.A,, Hörl W.H., Säemann M.D. Anti-thymocyte globulin impairs T-cell/antigen- presentingcell interaction: disruption of immunological synapse and conjugate formation. Transplantation 2007;84(1):117-21 Manfred Hecking, Kainz A, Schillinger M., Posch C., Birsan T., Rasoul-Rockenschaub S., Böhmig GA, Schmaldienst S., Watschinger B., Hörl W.H., Mühllbacher F., Säemann M.D. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. Transpl Int. 2008;21(3):223-33. Pfistershammer K, Klauser C., Leitner J., Stöckl J., Majdic O., Weichhart T., Sobanov Y., Bochkov V., Säemann M.D., Zlabinger GJ., teinberger P. Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. J Leukoc Biol. 2008;83(1):131-8. M.D. Säemann, G.A. Böhmig, Zlabinger G.J. Short-chain fatty acids: physiological mediators of a balanced host-microbial relationship. Wi Kli Wo 2002;8-9: 289-300 M.D. Säemann, Zlabinger G.J. How to make clinical use of bacterial evasion strategies. Eur J Clin Invest 2003;33(3):189-190 M.D. Säemann. Prevention of allograft rejection by selective JAK3 inhibition. European Surgery 2004 M.D. Säemann, Zeyda M, Stulnig T.M., Bohmig G.A., Wekerle T, Hörl W.H., Zlabinger GJ. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic
  • 86. - 86 - transplantation. Transpl Int. 2004;17(9); 481-489 M.D. Säemann, T. Weichhart, W.H. Hörl, Zlabinger G.J. Tamm-Horsfall Glycoprotein: Tamm- Horsfall protein: a multilayered defence molecule against urinary tract infection. Eur J Clin Invest. 2005;35(4):227-235 T. Weichhart, Zlabinger G.J, Säemann M.D. The multiple functions of Tamm-Horsfall Protein in health and disease: a mystery clears up. Wi Kli Wo 2005;117(9-10):316-322 M.D. Säemann, T. Weichhart. Causes of recurrent urinary tract infections: new insights. Dtsch Med Wochenschr. 2005;130(36):2031-2034 M.D. Säemann, W.H. Hörl, T. Weichhart. Uncovering host defences in the urinary tract: cathelicidin and beyond. Nephrol Dial Transplant. 2007;22(2):347-349 T. Weichhart, W.H. Hörl, M.D. Säemann, Biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2008; 51(3):531 Weichhart, M. Haidinger, W.H. Hörl, M.D. Säemann, The current concept of molecular defense mechanisms operative during urinary tract infection. Eur J Clin Invest 2008; in press Invited Talks 2002-2008 2002 Suppression of early T cell activation by selectivev JAK3 targeting. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Nieren und Hochdruckkrankheiten (ERA/EGTA, Denmark) CD40-triggered human monovyte-derived DC convert to tolerogenic DC when JAK3 activity is prevented. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Nieren und Hochdruckkrankheiten (Kongress der Gesellschaft f. Nephrologie, Düsseldorf and ERA/EGTA, Denmark) Induction of allogeneic regulatory cells by differentiated myeloid dendritic cells. Säemann M.D., Kelemen P., Böhmig G.A., Hörl W.H., Zlabinger, Nieren und Hochdruckkrankheiten (Kongress der Gesellschaft f. Nephrologie, Düsseldorf sowie ERA/EGTA, Denmark) Suppression of early T cell activation by selective JAK3 targeting. Säemann M.D., Kelemen P., Zeyda M., Böhmig G.A., Staffler G., Zlabinger G.J.. Acta Chirurgica Austriaca 2003 (Austrotransplant) 2003 Selective inhibition of Jun N-terminale kinase in alloreactive human T cells is primarily immunosuppressive, but enhances activation-induced cell death in conjunction with mTOR targeting. Säemann M.D., M. Soncini, Zeyda M., Zlabinger G.J., Knapp W., Hörl W.H., Parolini O. Nephrol Dial Transplant Vol 18 Suppl 4 2003 (World Congress of Nephrology 2003) Immunosuppressives in the Pipeline (Seminar at the Dep. of Internal Medicine III 2004) 2004 Säemann M.D. Immunostimulatory effects of Tamm-Horsfall Glycoprotein. (Seminar at the Institute for Immunology 2004)
  • 87. - 87 - Säemann M.D., Human monocyte-derived dendritic cells express high levels of angiotensin converting enzyme (ACE): modulation by vitamin-D and implications for renal disease (28. Wiss. Kongress Hypertonie, Hannover) Säemann M.D. Seminar at the Dep. of Internal Medicine III 2004 (“Tamm-Horsfall Glycoprotein: A multilayered defense molecule against urinary tract infection”) Säemann M.D., Geyerreger R., Zeyda M., Weichhart T., Zlabinger G.J., Stulnig T.. NF- B regulates TCR/CD3 complex recruitment into the immunological synapse (3rd Int Congress of Immunosuppression, San Diego) Zeyda M., Poglitsch M., Geyeregger R., Zlabinger G.J., Watschinger B., Hörl W.H., Stulnig T.M., and Säemann M.D.. Profound disruption of the Immunological Synapse Formation by the novel immunosuppressant FK778. (3rd Int Congress of Immunosuppression, San Diego) Zeyda M., Kirsch B., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J.. Säemann M.D.. The novel immunosuppressant FK778 prevents activation of NF-kB in human myeloid dendritic cells. 2005, (3rd Int Congress of Immunosuppression, San Diego) Säemann M.D., Seminar at the Medical University of Innsbruck 2004 (“Janus kinase-3 inhibition as a novel immunosuppressive option for allogeneic transplantation”) 2005 Säemann M.D., Transplantkonferenz 2005 ("C2-Spiegelmonitoring aus der Sicht des Nephrologen") Kirsch B., Zeyda M., Grisar J., Smolen J.S., Watschinger B., Stulnig T.M., Hörl W.H., Zlabinger G.J.. Säemann M.D. The active metabolite of leflunomide A77 1726 interferes with dendritic cell function. (Keystone Symposium on DCs) Säemann M.D. State of the Art: Kidney and pancreas transplantation. (Seminar at the Dep. of Internal Medicine III 2005) Säemann M.D. Zeyda M., Poglitsch M., Geyeregger R., Zlabinger G.J., Watschinger B., Hörl W. Initiating allograft immunity: effect of immunosuppression on evolution of the Immunological Synapse. (5th Basic Science Congress on Transplantation, Nantes, France) Säemann M.D. Tamm-Horsfall Protein: ein antimikrobielles Protein des Urogenitaltrakt. (DgfN Saarbrücken) Säemann M.D. Effect of Immunsuppression the very early manifestations of alloimmuneresponsiveness. (Austrotransplant) Kirsch B., Watschinger B., Hörl W.H.,. Säemann M.D., Alemtzumab induction therapy differentially affects dendritric cell subset distribution in renal transplant patients. (Austrotransplant) Säemann M.D. Bedeutung des Tamm-Horsfall Protein als protektives Molekül bei Harnwegsinfektionen. (KfH Würzburg) 2006 Säemann M.D. Insights into the molecular mechanisms of urinary tract infection (Nephro School, Freising, Germany)
  • 88. - 88 - Säemann M.D. Impact of innate immunity on the process of allogeneic transplantation. (DfGN, Essen, Germany) Säemann M.D. Innate immunity: the neglected arm of transplant effector systems (Astellas TX360 Symposium, Vienna, Austria) Säemann M.D. Innate immunity and allogeneic transplantation. (ÖGN, Semmering, Austria) Säemann M.D. Novel insights into immunosuppressive proteocols (NephroMeeting, Fuschl, Austria) Säemann M.D. Options for Renal Transplant Immunosuppression .(Seminar at the Dep. of Internal Medicine III 2005) Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., The immunosuppressive drug rapamycin promotes proinflammatory responses in antigen-presenting cells", presented at the Annual meeting of the Society of Nephrology, Essen, Austria, September 2006, (Oral) Weichhart T, Hörl W.H., Säemann M.D., Antiinflammatory effects on HDL on innate immune cells: implications for dialysis HDL and ist lost function, presented at the Annual meeting of the Austrian Society of Nephrology, Semmering, Austria, October 2006, (invited Oral) Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., Thomas Weichhart, "The immunosuppressant rapamycin promotes Toll-like receptor-mediated inflammatory responses", presented at the Annual meeting of the Austrotransplant Society, Fuschl, October 2006, (Oral) Vodenik B., Weichhart T, Watschinger B., Hörl W.H., Säemann M.D. Inhibitors of mTOR prevent the anti-inflammatory effecs of corticosteroids: implications for transplant patients, presented at the Annual meeting of the Austrotransplant Society, Fuschl, October 2006, (Oral) 2007 Säemann M.D. MPA and mTOR-Inhibitors: a comprehensive overview (REN, Vienna, Austria) Säemann M.D. Individual immunosuppression for the individual renal transplant patient (Nephro School, Freising, Germany) Weichhart T., Constantini G., Poglitsch M., Mueller M., Zeyda M., Hörl W.H., Hengstschläger M., Säemann M.D. The mammalian target of rapamycin is a negative regulator of NF-kB in professional antigen-presenting cells: impact on innate immunity. (ATC, San Francisco, USA) Säemann M.D. Dual effects of proliferation signal inhibitors: impact for renal transplantation. (PSI Academy, Vienna, Austria) Haidinger M., Gyeregger R., Poglitsch M., Weichhart T., Zeyda M., Vodenik B., Stulnig T.M., Böhmig G.A,, Hörl W.H., Säemann M.D. Anti-thymocyte globulin impairs T-cell/antigen- presentingcell interaction: disruption of immunological synapse and conjugate formation. ERA-EGTA, June 2007 (Travel Award)
  • 89. - 89 - Weichhart T, Costantino G., Zeyda M., Poglitsch M., Soleiman A., Watschinger B., Zlabinger G.A., Hörl W.H., Müller M., and Säemann M.D., Thomas Weichhart, Inhibition of mTORC1 promotes Toll-like receptor-mediated inflammation, European Society of Organ Transplantation, September 2007, (Young Investigator Award) Säemann M.D. Molecular Mechanisms Operative Durino Urinary Tract Infection (Univ. Klinik f. Nephrologie, Zürich, CH) Säemann M.D. Immunsosuppression: now and tomorrow: an overview. (Austrotransplant, Fuschl, Salzburg) 2008 Säemann M.D. Post-Transplant Diabetes mellitus (Nephroschool, Vienna) Saemann M.D. Immunosuppression in living-donor Renal Transplantation. (R.E.N. Meeting Transplant08) Säemann M.D. Innate Immunity during urinaty tract Infection (Nephrology Meeting, Berlin) Säemann M.D. Post-Transplant Diabetes mellitus (Int. Med.III/Dep. of Nephrology, Vienna, MUV)
  • 90. - 90 - Curriculum Vitae Wolfgang Schreiner Division of Biomedical Computer Simulation and Bioinformatics,Core facility of Medical Statistics and Informatics, Medical University of Vienna, Spitalgasse 19, 1090 Wien, Austria; Phone: +43-1-40400-6679, Fax: +43-1-40400-6677; Email: wolfgang.schreiner@meduniwien.ac.at; Homepage: http://www.meduniwien.ac.at/msi/biosim/ Personal Data Date of Birth: 24.06.1954 Place of Birth: Wien Nationality Austria Education 1979 Post Doc Research Fellow (Computer Simulation), Royal Holloway College, London 1978 – 1979 PhD Studies (Computer Simulation), Department of Experimental of Physics, University of Vienna, Austria 1973 – 1978 Studies in Physics and Mathematics, University of Vienna, Austria 1972 - 1973 Military service at army hospital, Vienna 1972 University entrance qualification, AHS-Matura with distinction, Vienna Career History Since 05/1995 Full Professor of Medical Computer Sciences Head of Section for Biomedical Computer Simulation and Bioinformatics, Core Unit for medical Statistics and Informatics, Medical University of Vienna. 1991 – 1995 Group leader for Biomedical Computer Simulation, Department of Medical Computer Sciences, University of Vienna Medical School 1991 Apointed “Unversitätsdozent” for Medical Informatics, University of Vienna Medical School 01/1991 Habilitation in Medical Informatics, University of Vienna Medical School 1985 – 1991 University Assistant at the 2nd Department of Surgery, University of Vienna Medical school. Working field:
  • 91. - 91 - Statistics and Informatics in support of patient treatment and medical research. Numerous projects on IT- applications within a clinical and research setting. 1984 – 1985 Assistent at the Assistant at the 2nd Department of Surgery, University of Vienna Medical school. Working field: Statistics and Informatics in support of patient treatment and medical research. 1983 Scientific Writer, Authorship of the TextBook “Radioation Dose Estimation after Incorporatin of Open Radionuclides”. 1979 – 1983 Assistant at the Department for Experimental Physics, University of Vienna, Austria. Research work on computer simulation of thermodynamic model systems. Career-related Activities 1985- 1987 Software Coordinator for the International Working Group of Coronary Sinus Interventions 1985- 1995 Consultant for IT – support for Ludwig Boltzmann Institute for Research in Cardiac Surgery, University of Vienna. 1991 - 1995 IT – planning delegate for migration of the 2nd Department of Surgery –to the new AKH-building. Initiator of the “Chirurgie-EDV-Paket” (Surgery-IT-software-package), later to become the research support-facility “ArchiMed”. Establishment of close cooperation between Department of Surgery and Department of Medical Computer Sciences. 1995 - 1997 Member of the Executive Board for Clinical Affairs of the Medical Faculty. (“Klinikenkonferenz”). This position made it possible to initiate the AKIM – Projekt together with heads of several clinical departments, the dean of the medical faculty, the medical director of AKH, the technical director of the AKH, administrative director, nursing directrice of the AKH, the Vienna “Gesundheitsstadtrat” and head of the “Wiener Krankenanstaltenverbund”. AKIM was initiated 1997 and ist still ongoing (as of 2008). 1995 - 1999 Member of the Faculty Committee (Fakultätskollegium) and its executive board (Leitungsausschuß), Faculty of Medicine. 1995 - 2002 Member of the “Institutskonferenz” of the Department for
  • 92. - 92 - Medical Computer Sciences 1995 - 1998 Member of the “Strukturkommission” of the Medical Faculty. 1995 - 2002 Member of evaluating commissions for appointments of full professorsof several disciplines 1998 - present Member of the AKIM – Arbeitsgremium 2002 - 2007 Head of the IT-coordination board if the Department of Medical ‘Statisitcs and Informatics 2002- 2002 Founder of bioinformatics -coordination board at the MUW 2005 - present Project leader for AKIM-Bioinformatics - Platform 2006 - present Member of the executive board for the curriculum in Medical Informatics at MUW and coordinator for teaching at MSI. 2006 - present Coordinator for teaching affairs at the MSI. Awards 1992 Best presentation award „Gesellschaft für Biomedizinische Technik“ 1993 Staatspreis für Ersatzmethoden zum Tierversuch: Computersimulation des Coronarkreislaufes Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2005-2006 BMWF Austrian Grid: Immunosimulation 41 2008 –2009 BMWF Austrian Grid: Immunosimulation 36 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2006-2008 Bernhard Knapp Genetic algorithms for pMHC modelling Publications Peer reviewed manuscripts 2003-2008 (original research and reviews) First, last or corresponding author manuscripts: Knapp B, Omasits U, Schreiner W: Side chain substitution benchmark for peptide/MHC interaction. Protein Sci. 17(6):977-82, 2008 Schreiner W, Karch R, Neumann M, Neumann F, Szalowski P, Roedler S: Optimized arterial
  • 93. - 93 - trees supplying hollow organs. Med.Eng.Phys. 28:416-429, 2006 Karch R, Neumann M, Neumann F, Ullrich R, Neumüller J, Schreiner W: A Gibbs point field model for the spatial pattern of coronary capillaries. Physica A. 369:599-611, 2006 Karch R, Neumann F, Ullrich R, Neumüller J, Podesser BK, Neumann M, Schreiner W: The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. Cardiovasc Pathol. 14(3):135-144, 2005 Nadler BA, Karch R, Neumann M, Neumann F, Aharinejad S, Schreiner W: Error estimation of geometrical data obtained by histomorphometry of oblique vessel sections: a computer model study. Comput.Biol.Med. 35:829-844, 2005 Karch R, Neumann F, Podesser BK, Neumann M, Szawlowski P, Schreiner W: Fractal properties of perfusion heterogeneity in optimized arterial trees: A model study. J.Gen.Physiol. 122:307-321, 2003. Karch R, Neumann F, Neumann M, Szawlowski P, Schreiner W: Voronoi polyhedra analysis of optimized arterial tree models. Ann.Biomed.Eng. 31:548-563, 2003. Schreiner W, Karch R, Neumann M, Neumann F, Roedler SM, Heinze G: Heterogeneous perfusion is a consequence of uniform Shear stress in optimized arterial tree models. J.Theor.Biol. 220:285-301, 2003.
  • 94. - 94 - Curriculum Vitae Univ.-Prof. Dipl.-Ing. Dr. Hannes Stockinger Department of Molecular Immunology, Center f or Phy s i ol ogy , Pat h op hy s io lo gy a n d Im m u n ol ogy, Medical University of Vienna, A-1090 Vienna, Lazarettgasse 19, Austria Tel.: +43-1-40160 33001; Fax: +43-1-40160 933001; E-mail: hannes.stockinger@meduniwien.ac.at; Internet: http://www.meduniwien.ac.at/immunology Personal Data Date of Birth: May 8, 1955 Place of Birth: Ried i. I., Upper-Austria Nationality Austrian Education 1985 Ph.D. (Dr. rer. nat. tech.) University of Natural Resources and Applied Life Sciences Vienna, Austria 1982-1985 Postgraduate training and Ph.D. thesis at the Institute of Immunology, University of Vienna, and the Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences Vienna, Austria 1982 Biotechnology diploma University of Natural Resources and Applied Life Sciences Vienna, Austria 1975-1982f University of Natural Resources and Applied Life Sciences Vienna, Field of study: Biotechnology Career History 2004-present Chairman of the Department of Molecular Immunology, Medical University of Vienna, Austria 2004-present Appointment as Full University Professor for Molecular Immunology, Medical University of Vienna, Austria 2004-present Director of the Doctoral Programs of the Medical University Vienna 2002-present CEO Competence Center for Biomolecular Therapeutics Research Vienna 1997-2004 Ao. University Professor, University of Vienna, Austria 1991-1997 Associate Professor, University of Vienna, Austria 1991 Appointment as university lecturer (Univ.-Doz.), University of Vienna, Austria 1989-2004 Head of independent research unit, Inst. Immunology, Univ. Vienna, Austria 1989-1991 Assistant Professor, University of Vienna, Austria 1987 Visitor scientist. Laboratory Dr. Sanna Goyert, New York University, Hospital for Joint Diseases, New York, USA;
  • 95. - 95 - 1985-1989 Research Associate, Inst. Immunology, Univ. Vienna, Austria Career-related Activities 2007-present Treasurer of the Federation of Austrian Scientific Societies (VWGÖ) 2006-present Treasurer of the European Federation of Immunological Societies (EFIS) 2005-present Board member of the Austrian Science Fund 2004-present Member of the International Human Cell Differentiation Molecules Council 2004-2006 Past-president of the Austrian Society for Allergology and Immunology 2003-present Executive editor of Immunology Letters 2002-2004 President of the Austrian Society for Allergology and Immunology 2000-2002 President-elect of the Austrian Society for Allergology and Immunology 2000-2006 Advisory Board member of Signal Transduction – Receptors, Mediators, Genes. 2000-2004 Member of the International Advisory Board of Russian Journal of Immunology 1999-2004 Deputy-chairman of the Institute of Immunology, University of Vienna 1997-present Member of the Editorial Board of International Archives of Allergy and Immunology 1997-2002 Member of the Managing Board of the European Confederation of Laboratory Medicine 1995-present Member of the Clinical Immunology Group of the European Federation of Immunological Societies (EFIS-CIG) 1996-1997 Council member of the Austrian Society for Allergology and Immunology 1994-2004 Deputy speaker of the program project grant Microvascular Injury and Repair 1994-1996 Secretary General of the Austrian Society for Allergology and Immunology 1992-1994 Vice Secretary of the Austrian Society for Allergology and Immunology 1986-1988 Treasurer of the Collegium Immunologicum Vindobonense Awards 2007 UPPER-AUSTRIAN CULTURE PRIZE FOR SCIENCE 1991 KARL LANDSTEINER-PRIZE of the Austrian Society for Allergology and Immunology 1990 CLEMENS VON PIRQUET-PRIZE of the Austrian Society for Allergology and Immunology 1988 WILHELM-TÜRK-PRIZE of the Austrian Society for Hematology and Oncology 1987 INTERNATIONAL CANCER RESEARCH TECHNOLOGY TRANSFER Award supported by the National Cancer Institute of the USA and International Union Against Cancer members 1987 HOECHST-Foundation Prize
  • 96. - 96 - 1986 WOLFGANG-DENK-PRIZE of the Austrian Society for Hematology and Oncology 1985 UPPER-AUSTRIAN AWARD for Young Scientists 1985 THESIS-PRIZE of the Austrian Society for Allergology and Immunology Memberships Austrian Society for Allergology and Immunology American Association of Immunologists German Society for Immunology Austrian Biochemical Society American Society for Biochemistry and Molecular Biology Austrian Society for Hematology and Oncology Austrian Society for Biotechnology Austrian Society for Food- and Biotechnologists International Union Against Cancer Sources of funding in last 5 years (2003-2008) Period Organization Short Title K€/year Receptor microdomains of cells of the 2000-2004 FWF microvascular unit and their role in signal 486,326.61 transduction and cell function Identification of novel pathways for immune- intervention by characterization and molecular 2000-2005 BMT 700,000.00 cloning of genes encoding immunoregulatory proteins of accessory cells and T-cells“ Austrian Student 2001-2004 North South Dialog Program 40,320.00 Exchange Service Defined stimulation of T cells by combined force and optical single molecule microscopy: 2001-2004 FWF 218,190.74 The design and development of the cellular part“ Ultra-sensitive Proteomics and Genomics: Development of protein microarray chips for 2002-2006 GEN-AU investigation of T cell regulation and diagnosis 539,431.00 of T cell-mediated immunological diseases and disorders Austrian Student Exchange Service, 2004-2007 North South Dialog Program 40,320.00 Pakistan Higher Education Commission
  • 97. - 97 - Characterization and generation of killer T cells 2005-2006 BMT 266,714.00 for treatment of malignant diseases 2006-2009 GEN-AU Ultrasensitive Proteomics and Genomics II 311,412.00 Doctoral program Cell Communication in 2006-2009 FWF, MUV 293,853.50 Health and Disease Austrian and Slovak –Austrian Science and Technology Co- 2006-2007 Slovak 3,500.00 operation Republic PhD supervision in last 5 years (2003-2008) Period Name of student Topic Identification of monoclonal antibody recognized 1999-2003 Andreas SZEKERES immuno-modulatory leukocyte surface molecules by retroviral expression cloning The role of the CD147 molecule in negative 2001-2005 Birgit RICHTER regulation of T cells Identification and characterization of functional 2001-2005 Panida KHUNKAEWLA partners of the CD147 molecule Identification and characterization of differentaition 2002-2007 Elke FUERTBAUER factors for natural regulatory T cells Genetically encoded conformation-sensitive 2002-2006 Wolfgang PASTER fluorescence reporters of the Src-family kinase Lck T cell membrane compartmentalization: Molecular 2002-2006 Christa HOLZHAUSER analysis of the T cell receptor signaling Role of CD2 and CD48 in recruitment of signaling 2004-2007 Arshad MUHAMMAD molecules to the TCR/CD3 complex in T cells Characterization of plasma membrane reorganization 2004- Herbert SCHILLER and transmembrane signaling underlying migration of immune cells Spatio-temporal analysis of early signaling events of 2006- Barbara GRAUWALD, T cell activation by live-FRET and single molecule analysis Influence of adhesion receptors to the T cell antigen 2007- Pavan KUMAR receptor signaling pathway Role of homodimers and -multimers of signaling 2008- Paul ECKERSTORFER molecules for function and signal transduction Publications 80 original publications in scientific journals, 47 book chapters, 37 invited lectures 2003-2008, 4 patents Peer reviewed manuscripts 2003-2008 (original research and reviews)
  • 98. - 98 - First, last or corresponding author manuscripts: 1. Staffler, G., A. Szekeres, G.J. Schütz, M.D. Säemann, E. Prager, M. Zeyda, K. Drbal, G.J. Zlabinger, T. Stulnig, and H. Stockinger. 2003. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J. Immunol. 171:1707. Impact Factor: 6,834 2. Leksa, V., S. Godar, H. B. Schiller, E. Fuertbauer, A. Muhammad, K. Slezakova, V. Horejsi, P. Steinlein, U. H. Weidle, B. R. Binder, and H. Stockinger. 2005. TGF-beta induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J. Cell Sci. 11:4577. Impact Factor: 6.910 3. Drbal, K., M. Moertelmaier, C. Holzhauser, A. Muhammad, E. Fürtbauer, S. Howorka, M. Hinterberger, H. Stockinger*, and G. J. Schütz. 2007. Single molecule microscopy reveals heterogeneous dynamics of lipid raft components upon T cell receptor engagement. Int. Immunol. 9: 675. *Corresponding author. Impact Factor: 3,317 4. Khunkaewla, P., H. Schiller, V. Leksa, L. Andera, V. Horejsi, and H. Stockinger. 2008. LFA-1-mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and CD147. Mol. Immunol: 45: 1703. Impact Factor: 4,768 Co-author manuscripts: 1. Säemann, M. D., M. Zeyda, C. Diakos, A. Szekeres, G. A. Böhmig, P. Kelemen, O. Parolini, H. Stockinger and G.J. Zlabinger. 2003. Suppression of early T-cell receptor- triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 75:1864. Impact Factor: 4,035 2. Schütz, G., M. Mörtelmaier, K. Drbal, and H. Stockinger. 2003. Einzelmolekülmikroskopie an lebenden Zellen. Bio-TecReport 27:6. 3. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Höfler, E. Guthann, U. Korthäuer, G.J. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stöckl. 2003. B7-h1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T-cell anergy. J Immunol. 170:3637. Impact Factor: 6,834 4. Zeyda, M., A. Szekeres, M. D. Saemann, R. Geyeregger, H. Stockinger, G. J. Zlabinger, W. Waldhäusl, and T. M. Stulnig. 2003. Suppression of T cell signaling by polyunsaturated fatty acids: Selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J .Immunol. 170:6033. Impact Factor: 6,834 5. Prager, G. W., J. M. Breuss, S. Steurer, D. Olcaydu, J. Mihaly, P. M. Brunner, H. Stockinger, and B. R. Binder. 2004. Vascular endothelial growth factor receptor-2- induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ. Res. 94:1562. Impact Factor: 8,65 6. Moertelmaier, M., M. Brameshuber, M. Linimeier, H. Stockinger, and G. J. Schütz. 2005. TOCCSL: Thinning Out Clusters while Conserving Stoichiometry of Labeling. Appl. Phys. Lett. 87: 263903/1-263903/3. Selected for: Virtual Journal of Biological Physics Research. 11: Jan 1, 2006. Impact Factor: 4,308 7. Chiampanichayakul, S., P. Peng-In, P. Khunkaewla, H. Stockinger, and W. Kasinrerk. 2006. CD147 contains different bioactive epitopes involving the regulation of cell adhesion and lymphocyte activation. Immunobiology 211:167. Impact Factor: 2,274 8. Madl, J., S. Rhode, H. Stangl, H. Stockinger, P. Hinterdorfer, G. J. Schütz, and G. Kada. 2006. A combined optical and atomic force microscope for live cell investigations. Ultramicroscopy 106:645. Impact Factor: 2,215 9. Kirchberger, S., H. Vetr, O. Majdic, H. Stockinger, and J. Stöckl. 2006. Engagement of ICAM-1 by major group rhinoviruses activates the LFA-1/ICAM-3 cell adhesion pathway in mononuclear phagocytes. Immunobiology 211: 537. Impact Factor: 2,274
  • 99. - 99 - 10. Groyer, E., A. Nicoletti, H. Ait-Oufella, J. Khallou-Laschet, A. Varthaman, A. T. Gaston, O. Thaunat, S. V. Kaveri, R. Blatny, H. Stockinger, Z. Mallad, and G. Caligiuri. 2007. Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T cells. J. Am. Coll. Cardiol. 50: 344. Impact Factor: 9,20 11. Wieser, S., M. Moertelmaier, E. Fürtbauer, H. Stockinger, and G. J. Schütz. 2007. (Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution single molecule microscopy. Biophys. J. 92: 3719. Impact Factor: 4,507 12. Wieser, S., M. Cooper, H. Stockinger, and G. J. Schütz. 2007. Single molecule diffusion analysis on cellular nanotubules – implications on plasma membrane structure below the diffraction-limit. Appl. Phys. Lett.: 91:233901/1-3. Impact Factor: 3,977 13. Zola, H., B. Swart, A. Banham, S. Barry, A. Beare, A. Bensussan, B. L, C. D. Buckley, H. J. Bühring, G. Clark, P. Engel, D. Fox, B. Q. Jin, P. J. Macardle, F. Malavasi, D. Mason, H. Stockinger, and X. Yang. 2007. CD molecules 2006 — Human cell differentiation molecules. J.Immunol. Meth. 319:1. Impact Factor: 2,572 14. Beare, A., H. Stockinger, H. Zola, and J. Nicholson. 2007. The CD system of leukocyte surface molecules. Monoclonal antibodies to human cell-surface antigens. In Current Protocols in Immunol. J. E. Coligan, B. Bierer, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico, eds. Wiley-Interscience, New York. In press. 15. Paar, C., W. Paster, H. Stockinger, G.J. Schütz, M. Sonnleitner, and A. Sonnleitner. 2008. Live Cell High Throughput FRET Screening of the Plasma Membrane Based on TIRFM. Cytometry Part A. In press. Impact Factor: 3.293 Invited Talks: 2003 5th Congress of the Federation of African Immunological Societies, Victoria Falls, Zimbabwe 2003 15th European Immunology Congress of the European Federation of Immunological Societies, Rhodes, Greece 2003 4th European Biophysics Congress, Alicante, Spain 2003 12th Symposium on Signals and Signal Processing in the Immune System, Sopron, Hungary 2003 1st GEN-AU Summer School Ultrasensitive Proteomics and Genomics, Litschau, Austria 2004 21. Ernährungskongress des Verbandes der Dipl. DiätassistentInnen & Ernährungsmed. BeraterInnen Österreichs, Vienna, Austria 2004 Faculté de Médecine Necker-Enfants Malades, Paris, France 2004 Minisymposium Advances in Immunology, Academy of Sciences of the Czech Republic, Prague, Czech Republic 2004 Medizinische Hochschule Hannover, Hannover, Germany 2004 Wörthersee-Symposium “What´s New in Allergy, Velden am Wörthersee, Austria 2004 6th EFIS Tatra Immunology Conference, Tatranske Zruby, Slovakia 2004 2nd Slovenian Immunology Congress with International Participation - Tumor Immunology and Immunointerventions. Portoroz, Slovenia 2004 8th International Conference on Human Leukocyte Differentiation Antigens, Adelaide, Australia
  • 100. - 100 - 2005 Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovak Republic 2005 11th Immunology Seminar, Eötvös Lorand University, Budapest, Hungary 2005 2nd GEN-AU Summer School Ultrasensitive Proteomics and Genomics, Litschau, Austria 2005 13th Symposium on Signals and Signal Processing in the Immune System, Balatonöszöd, Hungary 2006 XXIII International Congress of the International Society of Analytical Cytology (ISAC), Quebec, Canada 2006 4th GEN-AU Summer School Ultrasensitive Proteomics and Genomics, Litschau, Austria 2006 1st Joint Meeting of European National Societies of Immunology and 16th European Congress of Immunology, Paris, France 2006 Workshop Clinical Proteomics of the Max Planck Institute of Biochemistry, Martinsried/Munich, Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratorioumsmedizin (DGKL), Deutsche Gesellschaft für Proteomforschung (DGPF) and Deutsche Gesellschaft für Zytometrie (DGfZ), Munich, Germany 2006 University of Salzburg and Austrian Society for Genetic and Gentechnic, Salzburg, Austria 2006 PhD Program of the Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria 2006 Institute for Molecular and Cell Biology, Porto, Portugal 2006 1st Mediterranean Workshop on Clinical Immunology, Evora, Portugal 2006 XXIIIrd Congress of Czech and Slovak Allergologists and Clinical Immunologists, and XIth Congress of Czech and Slovak Immunologists, Hradec Kralove, Czech Republic 2007 Internationales Pädiatrisches Symposium, Obergurgl, Austria 2007 Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic 2007 EFIS-EJI Course on Autoimmunity, Tartu, Estonia 2007 Deutsch-Österreichischer AIDS Kongress, Frankfurt, Germany 2007 Otto-von-Guericke-University, Magdeburg, Germany 2007 13th International Congress of Immunology, Rio de Janeiro, Brazil 2007 ORPHEUS 2007, European PhD Programmes in Clinical Medicine, Helsinki, Finland 2007 14th Symposium on Signals and Signaling Processing in the Immune System, Balatonöszöd, Hungary 2007 Centre de Recherche des Cordeliers, University Pierre et Marie Curie Paris 6, Paris, France 2007 Division of Molecular and Experimental Surgery, Department of Surgery, University of Erlangen, Erlangen, Germany 2008 From Molecules to Clinic, Medical University of Vienna, Vienna, Austria
  • 101. - 101 - Curriculum Vitae Herbert Strobl Divison: Molecular Biology of Hematopoietic Stem Cells and Dendritic Cells. Institute of Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Lazarettgasse 19, 1090 Wien, Austria; Phone: +43-1-40160-65001, Fax: +43-1- 40160-965006; Email: herbert.strobl@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/immunologie Personal Data Date of Birth: 15.11.1964 Place of Birth: Vienna Nationality Austria Education 2001 MD degree: Facharzt für Immunology 1998 2001 Post-doctoral fellow with Garry P. Nolan, Stanford University, Department of Molecular Pharmacology 1996-1998 Clinical training, Vienna General Hospital and Lainz Hospital (Turnusarzt) 1994-1996 Laboratory head, hematopoiesis research laboratory, Institute of Immunology VIRCC at Novartis Research Institute Vienna 1991-1996 Training in immunology laboratory diagnosis and research fellow, Institute of Immunology, University of Vienna 1991 MD University of Vienna 1989-1991 Pre-doctoral research, superivisor: Walter Knapp, Institute of Immunology, University Vienna Career History 07/2004-present Group leader and divison head, Institute of Immunology at VCC A-1090 Vienna, Medical University Vienna 03/2001-07/2004 Group leader, Institute of Immunology at VIRCC at Novartis Research Institute Vienna Since 2002 Associate Professor (a.o.Univ.Prof) Career-related Activities Since 2008 Head Innovation and process optimazation, Clinical immunologic laboratory diagnosis at Institute of
  • 102. - 102 - Immunology, Medical University Vienna 2006 Listenplatz Professur „Pathophysiologie“ Medical University Vienna 2006-present Lecturer at FH Biotechnology, Vienna Biocenter 2006 - present Deputy director„ PhD program “Inflamation and Imunity“ at Medical University Vienna. 2004-present Member of EGIL, European group of immunologic leukemia diagnosis 2001-present Clinical consultant in immunologic laboratory diagnosis, Institute of Immunology, Medical University Vienna Awards 2000 START Prize, BMBWK und FWF Memberships Austrian Society for Allergology and Immunology, European Society of Hematology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2007 - 2010 FWF Transcriptional Networks in human dendritic 117 cell subset differentiation 2007 - 2010 FWF + MUW DK W1212: Inflammation and Immunity, 44 Subproject 2005 - 2009 FWF SFB F23 Immunological Tolerance: 110 Subproject 4 2006 - 2008 Federal Bank of Signal integration by epithelial Langerhans 23 Austria cells 2003 - 2006 Federal Bank of Identification of signaling processes that 23 Austria downregulate antigen-specific immune responses 2001 - 2007 FWF and BM:WF Functional genomic analysis of human 200 START dendritic cell development Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2001 - 2005 Barbara Platzer Molecular analysis of human dendritic cell development 2001 - 2006 Sabine Taschner Functional analysis of nuclear receptor signaling
  • 103. - 103 - in myeloid development 2001 - 2006 Almut Jörgl Molecular analysis of human dendritic cell maturation 2003 - 2007 Florian Göbel Molecular analysis of the differentiation and life cycle of dendritic cells 2005-2006 Peter Reisner 2005- Susanne Richter The role of AhR in Langerhans cell differentiation present 2006- Jennifer Jurkin Identification of regulators of Langerhans cell present differentiation 2007- Thomas Bauer The role of RelB in dendritic cells present Since 2008 Yasmin Nighat Induction of epithelial genes in Langerhans cells Publications 44 peer reviewed publications in scientific journals, 4 book chapters, 6 review articles, 1 patent Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: A. Original research articles: Scholz W, Platzer B, Schumich A, Höcher B, Fritsch G, Knapp W, Strobl H. Initial human myeloid/dendritic cell progenitors identified by absence of myeloperoxidase protein expression. Exp Hematol. 2004 Mar;32(3):270-6. Platzer B, Jörgl A, Taschner S, Höcher B, Strobl H. (2004) RelB regulates human dendritic cellsubset development by promoting monocyte intermediates. Blood, 104(12):3655-63 Heinz LX, Platzer B, Reisner P, Jörgl A, Taschner S, Göbel F and Strobl H. Differential involvement of PU.1 and Id2 downstream of TGF-b1 during Langerhans cell commitment. Blood, 2006 Feb 15;107(4):1445-53. Jörgl, A., B. Platzer, S. Taschner, L. X. Heinz, B. Höcher, P. M. Reisner, F. Göbel, and H. Strobl. Human Langerhans cell activation triggered in vitro by conditionally expressed MKK6 is counter regulated by the downstream effector RelB. Blood 2007; 1;109(1):185-93, Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch, T, Strobl H. Downregulation of RXRa expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood, 2007 109: 971-979 Platzer B, Richter S, Waltenberger D, Wisetschläger M, Strobl H. Aryl hydrocarbon receptor (AhR) activation perturbs myeloid sublineage differentiation by inhibiting PU.1 upregulation,
  • 104. - 104 - submitted Taschner S, Göbel F, Kumerz M, Jurkin J, Richter S, Mühlbacher C, Jörgl A, Strobl H. Interplay between the nuclear receptors VDR, RXRα and the master regulators PU.1, GATA- 1/GATA-1s in normal and leukemic hematopoiesis, submitted Göbel F, Taschner S, Jurkin J, Vaculik C, Richter S, Bieglmayer C, Elbe-Bürger A, Strobl H. GATA-1-mediated repression of vitamin D3 receptor is decisive for inflammatory dendritic cell development, but not for Langerhans cells, submitted B. Review articles Strobl H. Molecular mechanisms in dendritic cell sub-lineage development from human hematopoietic progenitor/stem cells. Int. Archives of Allergy and Immunology. 2003; 131(2): 73-79 (review article) Strobl, H. and W.Knapp. Myeloid cell-associated lysosomal proteins as flow cytometry markers for leukocyte lineage classification. Review J. Biol. Regul. Homeost. Agents 18:335- 9 (2004) (review article) Strobl, H., B.Platzer, A.Jörgl, S.Taschner, L.Heinz, and P.Reisner. Growth Factors. Handbook of Dendritic Cells – Biology, Diseases and Therapies. Steinkasserer, Lutz (Eds). WILEY-VCH, Vol 1, page 27-52 (2006) (book chapter) Co-author manuscripts: Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of Immature and Mature Langerhans Cell-type Dendritic Cells to Infection and Immunomodulation by Human Cytomegalovirus. J Virol. 2003;77(13): 7563-74 Mann G, Attarbaschi A, Steiner M, Simonitsch I, Strobl H, Urban C, Meister B, Haas O, Dworzak M, Gadner H; Austrian Berlin-Frankfurt-Munster (BFM) Group.Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping. Pediatr Hematol Oncol. 2006 Apr- May;23(3):167-76. Strehl, S.,. K.Nebral, M.König, J.Harbott, H.Strobl, R.Ratei, S.Struski, B.Bielorai, M.Lessard, M.Zimmermann, O.A.Haas, S.Izraeli ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clinical Cancer Research 14:977-983 (2008) Selected Invited Talks 2002-2008 2004 • Invited talk at session Stem cell biology ; DgfZ meeting Heidelberg • Invitation to talk at the 12th International Congress of Immunology, Montreal, 2005 • Invited talk at Langerhans cell workshop, Madeira 2006 • Invited seminar talk at ENII 2006 meeting Carbo Caccio, Italy • Invited talk at the stem cell workshop, EHA 2006 meeting Amsterdam
  • 105. - 105 - 2007 • Invited Talk at Institute of Microbiology and Immunology, Technical University Munich • Invited talk at EHA 2007 meeting Vienna
  • 106. - 106 - Curriculum Vitae Julia Walochnik Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology Medical University of Vienna, Kinderspitalgasse 15, 1095 Wien, Austria; Phone: +43-1-40490-79446, Fax: +43-1-40490-79435 e-mail: julia.walochnik@meduniwien.ac.at Homepage: www.meduniwien.ac.at/hygiene/?s=parasitologie Personal Data Date of Birth: 12.12.1973 Place of Birth: Berlin Nationality Germany Education 1997-2000 PhD studies (Medical Parasitology, Microbiology, Electron Microscopy), University of Vienna, with distinction 2000 Training course on free-living amoebae and endocytobiosis at the Ernst-Rodenwaldt-Institute in Koblenz 1996-1997 Diploma thesis, University of Vienna 1991-1997 Studies in Biology (Zoology, Microbiology), University of Vienna 1982-1983 American school of Algiers/ Algeria Career History 2004 Habilitation in Medical Parasitology, Medical University of Vienna since 2001 Full-time scientific collaborator at the Department of Medical Parasitology since 2000 Group Leader, Molecular Parasitology, University of Vienna since 1998 Supervision of students (MS and PhD) in the field of molecular biology and immunobiology of parasites 1997-2001 Parttime Scientific collaborator at the Department of Medical Parasitology, University of Vienna Career-related Activities Since 2006 Collaboration as teacher in a training course for “Médecins Sans Frontières”
  • 107. - 107 - Since 2005 Chief editor of the Austrian Society for Tropical Medicine and Parasitology Since 2003 Editor of the Supplement of the Wiener Klinische Wochenschrift for the Austrian Society for Tropical Medicine and Parasitology 2003 Election into the board of the Austrian Society for Tropical Medicine and Parasitology Awards 2002 Austrian Award of Hygiene 2002 Gerhard Piekarski Award Memberships Member of the Austrian Proteomics Association Member of the Society for Biological Systematics Member of the Austrian Society for Hygiene and Prevention Medicine Member of the German Society for Protozoology Member of the German Society for Parasitology Member of the Austrian Society for Tropical Medicine and Parasitology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2008-2011 FWF Glycosilation in Acanthamoeba (FWF20565); collaborator 2007-2010 FFG Bioactive substances against protozoa and fungi (FFG814280/13094); collaborator 2007-2010 FWF En- and excystation in Acanthamoeba castellanii (FWF19044); project leader 2005-2006 EU Detection of pathogens in thermal waters (EU-PHARE); collaborator 2004-2007 EU Tick-borne pathogens and Borrelia vaccine development (EU-BOVAC); collaborator Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2007-2010 Florian Astelbauer Bioactive substances against protozoa and fungi 2007-2010 Wilawan Pumidonming Identification of pathogenicity related proteins in Acanthamoeba spp. 2004-2008 Ursula Fürnkranz Effectivity of N-chlorotaurine against protozoa 2004 -2008 Marion Blaschitz Molecular detection of pathogens in ticks from Austria 2003-2007 Martina Köhsler Discrimination, encystment behaviour, pathogenicity and drug susceptibility of
  • 108. - 108 - Acanthamoeba Publications 49 peer reviewed publications in scientific journals, 20 book chapters, >20 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Walochnik J, Duchene M, Seifert K, Eibl HJ, Obwaller A, Aspöck H. 2002. Cytotoxic Activities of Various Alkylphosphocholines (APCs) against Clinical Isolates of Acanthamoeba. Antimicrob Agents Chemother 46:695-701. Walochnik J, Michel R, Aspöck H. 2002. Discrepancy between morphological and molecularbiological characters in a strain of Hartmannella vermiformis Page, 1967 (Lobosea, Gymnamoebia). Protistology 2 (3):185-188. Walochnik J, Sommer K, Haller-Schober EM, Obwaller A, Aspöck H. 2004. Characterisation and differentiation of pathogenic and non-pathogenic Acanthamoeba strains by their protein and antigen profiles. Parasitol Res 92(4):289-98. Walochnik J, Michel R, Aspöck H. 2004. A molecularbiological approach to the phylogenetic position of the genus Hyperamoeba (Protozoa). J Euk Microbiol 51:433-440. Walochnik J, Müller KD, Aspöck H, Michel R. 2005. An endocytobiont harbouring Naegleria strain identified as N. clarki De Jonckheere, 1994. Acta Protozoologica 44:301-310. Köhsler M, Leitner B, Blaschitz M, Michel R, Aspöck H, Walochnik J. 2006. ITS1 sequence variabilities correlate with 18S rDNA sequence types in the genus Acanthamoeba. Parasitol Res 98(2):86-93. Blaha C, Duchene M, Aspöck H, Walochnik J. 2006. Comparative studies on the effect of hexadecylphosphocholine on different strains of Trichomonas vaginalis. J Antimicrob Chemother 57(2):273-8. Blaschitz M, Kohsler M, Aspock H, Walochnik J. 2006. Detection of a serine proteinase gene in Acanthamoeba genotype T6 (Amoebozoa: Lobosea). Exp Parasitol. 114(1):26-33. Ertabaklar H, Türk M, Dayanir V, Ertuğ S, Walochnik J. 2007. Acanthamoeba keratitis due to Acanthamoeba genotype T4 in a non-contact lens wearer in Turkey. Parasitol Res 100(2):241-6. Köhsler M, Michel R, Lugauer, Aspöck, Walochnik J. 2007. Molecular identification and classification of Cochlonema euryblastum, a zoopagalean parasite of Thecamoeba quadrilineata. Mycologia 99: 215-221. Köhsler M, Soleiman A, Auer H, Aspöck H, Walochnik J. 2007. First molecular identification of Onchocerca jakutensis as a causative agent of a human filariosis. Emerg Inf Dis. 13: 1749-1752. Walochnik J, Aichelburg A, Assadian O, Steuer A, Visvesvara G, Vetter N, Aspöck H. 2008. Acanthamoeba genotype T2 as causative agent of GAE in an HIV negative patient. J Clin Microbiol 46:338-340. Fürnkranz U, Nagl M, Gottardi W, Köhsler M, Aspöck H, Walochnik J. 2008. Cytotoxic activity
  • 109. - 109 - of N-chlorotaurine (NCT) on Acanthamoeba spp. Antimicrobial Agents Chemother 52:470- 476. Ozkoc S, Tuncay S, Bayram Delıbas S, Akisu C, Ozbek Z, Durak I, Walochnik J. Identification of Acanthamoeba genotype T4 and Paravahlkampfia sp. from two clinical isolates. J Med Microbiol (in press). Blaschitz M, Gföller M, Kanzler M, Walochnik J, Stanek G. Borrelia burgdorferi sensu lato genospecies in questing Ixodes ricinus ticks in Austria. Int J Med Microbiol 297 (Supp 1) (in press). Blaschitz M, Gföller M, Kanzler M, Walochnik J, Stanek G. First detection of Rickettsia helvetica in Austria. Vector-Borne Zoonot (in press). Müller MG, Kinne J, Schuster RK, Walochnik J. Outbreak of Microsporidiosis caused by Enterocytozoon bieneusi in falcons. Vet Parasitol (in press). Köhsler M, Leitsch D, Fürnkranz U, Duchêne M, Aspöck H, Walochnik J. 2008. Acanthamoeba strains lose their abilities to encyst synchronously upon prolonged axenic culture. Parasitol Res. (in press). Co-author manuscripts: Hiti K, Walochnik J, Haller-Schober E M, Faschinger C, Aspöck H. 2002. Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems. Brit J Ophthalmol 86:144-146. Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Hiti B, Aspöck H. 2003. Wirkung von Mikrowellenbestrahlung auf Akanthamöben: eine geeignete Möglichkeit zur Kontaktlinsenbehältersterilisation? Spektrum Augenheilkd 17 (3). Michel R, Walochnik J, Aspöck H. 2003. "Pseudodidymium cryptomastigophorum nov. g., nov. sp.", a Hyperamoeba or a slime mould?" A combined study on morphology and 18S rDNA sequence data. Acta Protozool 42 (4): 331-343. Tsvetkova N, Schild M, Panaiotov S, Kurdova-Mintcheva R, Gottstein B, Walochnik J, Aspöck H, Lucas M, Müller N. 2004. Isolation and taxonomic identification of free-living amoebae in the environment of in Bulgaria. Parasitol Res 92(5):405-13. Obwaller A, Schneider R, Walochnik J, Gollackner, Deutz, Janitschke, Aspöck H, Auer H. 2004. Sequence heterogeneities among cytochrome c oxidase-1 and NADH-dehydrogenase- 1 genes of Echinococcus granulosus isolates and their significance on strain differentiation. Parasitology 128:569-575. Collingro A, Walochnik J, Michel R, Horn M, Wagner M, Obwaller A, Aspöck H. 2004. Chlamydia-related endocytobionts of free-living amoebae alter the growth rate of their hosts. Eur Journal Protistol 40:57-60. Strimitzer S, Obwaller A, Schmoll F, Joachim A, Walochnik J, Juncker M. 2004. Entwicklung und Evaluierung einer Polymerasekettenreaktion (PCR) zum Nachweis von Eperythrozoon (syn. Mycoplasma) suis. Wien Tierarztl Monat 91:120-126. Fürnkranz U, Walochnik J, Grimm F, Deplazes P, Aspöck H. 2004. Vergleichende Versuche zur Etablierung und Optimierung einer Leishmanien-PCR für diagnostische Zwecke. Wien Klin Wochenschr. 116 (Suppl 4): 30-35.
  • 110. - 110 - Obwaller A, Duchene M, Walochnik J, Wiedermann G, Auer H, Aspöck H. 2004. Association of autoantibodies against small nuclear ribonucleoproteins (snRNPs) with symptomatic Toxocara canis infestation. Parasite Immunol 26(8-9):327-33. De Jonckheeere JF, Brown S, Walochnik J, Aspöck H, Michel R. 2005. Morphological investigation of three Tetramitus spp. which are phylogenetically very closely related: T. horticolus, T. russelli n. comb. and T. pararusselli n. sp. Europ J Protistol 41:139-150. Michel R, Müller KD, Zöller L, Walochnik J, Hartmann M, Schmid EN. 2005. Free-living amoebae serve as a host for the Chlamydia-like bacterium Simkania negevensis. Acta Protozool 44:113-121. Hiti K, Walochnik J, Faschinger C, Haller-Schober EM, Aspöck H. 2005. One and Two Step Hydrogen Peroxide Contact Lens Disinfecting Solutions against Acanthamoeba: How effective are they? Eye 19: 1301-1305. Petry F, Torzewski M, Bohl J, Wilhelm-Schwenkmezger T, Scheid P, Walochnik J, Michel R, Zöller L, Werhahn K J, Bhakdi S, Lackner K J. 2006. Early Diagnosis of Acanthamoeba in Routine Cerebrospinal Fluid Cytology. J Clin Microbiol 44(5):1903-4. Hiti K, Walochnik J, Haller-Schober EM, Faschinger C, Aspöck H. 2006. A new Multipurpose Contact Lens Disinfection System in Comparison with eight other Solutions – Effectiveness against Acanthamoeba. Cornea 25(4):423-7. Mitteregger D, Aberle SW, Makristathis A, Walochnik J, Schwarz SM, Kramer G, Marberger M. 2007. Screening for pathogenic microorganisms in advanced benign prostatic hyperplasia (BPH). J Urology 177 (4): 448-449. Murphy TM, Walochnik J, Hassl A, Moriarty J, Mooney J, Toolan D, Sanchez-Miguel C, O'loughlin A, McAuliffe A. 2007. Study on the prevalence of Toxoplasma gondii and Neospora caninum and molecular evidence of Encephalitozoon cuniculi and Encephalitozoon (Septata) intestinalis infections in red foxes (Vulpes vulpes) in rural Ireland. Vet Parasitol 146(3-4):227-34. Meersseman W, Lagrou K, Sciot R, De Jonckheere JF, Claes K, Spriet I, Haberler C, Walochnik J, Wollants E Peetermans WE, Van Wijngaerden E. 2007. Rapidly fatal Acanthamoeba encephalitis and treatment of cryoglobulinemia. Emerg Inf Dis 13 (3):469- 471. Lorenzo-Morales J, Kliescikova J, Gómez-Pérez D, Batista N, Álvarez-Marín J, Bahaya Y, Walochnik J, Valladares B. 2007. Early diagnosis of amoebic keratitis due to a mixed infection with Acanthamoeba and Hartmannella. Parasitol Res 102(1):167-9. Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. 2008. Successful treatment of a married couple for American leishmaniasis with miltefosine. J Eur Acad Dermatol Venereol 22(2):258-9. Schneider R, Gollackner B, Edel B, Schmid K, Wrba F, Tucek G, Walochnik J, Auer H. Development of a new PCR protocol for the detection of species and genotypes (strains) of Echinococcus in formalin-fixed, paraffin-embedded tissues. Int J Parasitol (in press). Haider S, Collingro A, Walochnik J, Wagner M, Horn M. 2008. Chlamydia-like bacteria in respiratory samples of community-acquired pneumonia patients. FEMS Letters. (in press)
  • 111. - 111 - Invited Talks 2002-2008 2002 • Institute of Parasitology, VetUniversity of Zurich, Switzerland • University Hospital of Zurich, Switzerland • Museum for Natural History, Linz, Austria 2003 • Museum for Natural History, Vienna, Austria 2004 • ÖGTP-advanced training, AKH, Vienna, Austria • Giftiger Dienstag, AKH, Vienna, Austria • Department of Microbial Ecology, University of Vienna, Austria 2005 • Institute of Parasitology, University of Bern, Switzerland • ÖGTP-advanced training, AKH, Vienna, Austria • University of Budapest, Hungary 2006 • Institute of Parasitology, VetUniversity of Zurich, Switzerland • Meeting of the Austrian Society for Biotopes, Wels, Austria • Billrothhaus, Vienna, Austria 2007 • Robert-Koch-Institute Berlin, Germany • ÖGTP-advanced training, AKH, Vienna, Austria • Meeting of the German Society of Biological Systematics, Vienna, Austria • Giftiger Dienstag, Ärztekammer Vienna, Austria • St. Anna Kinderspital Vienna, Austria • Meeting of the German Society for Entomology, Berlin, Germany 2008 • Billrothhaus, Vienna, Austria
  • 112. - 112 - Curriculum Vitae Thomas Wekerle Division of Transplantation, Department of Surgery Vienna General Hospital, Medical University of Vienna Waehringer Guertel 18, 1090 Wien, Austria Phone: +43-1-40400-5621, Fax: +43-1-40400-6872; Email: Thomas.Wekerle@meduniwien.ac.at; Homepage: www.muw.ac.at/transplant-lab Personal Data Date of Birth: 26.12.1968 Place of Birth: Vienna Nationality: Austria Education 2003 – 2006 Residency in Immunology, Vienna General Hospital 1998 – 1999 Residency in Surgery, Department of Surgery, Vienna General Hospital 1996 – 1998 Post-doctoral research fellow at the BMT-Section (Head: Megan Sykes, M.D.) of the Transplantation Biology Research Center (Director: David H. Sachs, M.D.), Massachusetts General Hospital, Harvard Medical School, Boston, USA 1994 – 1996 Residency in Surgery, Department of Surgery, Vienna General Hospital January 1994 Graduation (M.D.) 1987 – 1994 University of Vienna Medical School Career History April 2006 Licensure as Specialist in Immunology, Austrian Medical Chamber February 2001 Appointment as Associate Professor of Experimental Surgery at the University of Vienna (now Medical University of Vienna) October 1999 to date Group leader at the Research Laboratories of the Department of Surgery, Vienna General Hospital
  • 113. - 113 - Career-related Activities 2002 to date Co-Editor-in-Chief of Transplant International since 2007 Member of the Basic Science Committee of the European Society of Organ Transplantation (ESOT) 2007 Participation in the 1st Scientific Advisory Council Meeting of „Transplantation Research Integration in Europe” (TRIE), a Specific Support Action supported by the 6th EU- RTD Framework Programme; Brussels since 2007 Member of the Basic Science Committee of the European Society of Organ Transplantation (ESOT) 2006 Member of the Scientific Program Committee for the 20th Annual Meeting of the Austrian Society of Transplantation, Fuschl, Austria 2004 Co-Organizer of the Early Morning Course on Applied Immunology, XX International Congress of The Transplantation Society, Vienna, Austria 2004 Member of the Program Committee for the XX International Congress of The Transplantation Society, Vienna, Austria 2003 Member of the Scientific Program Committee for the 23rd Annual Meeting and Scientific Session of the International Society for Heart and Lung Transplantation, Vienna, Austria 2002 and 2003 Reviewer for the Awards Committee of the International Society for Heart and Lung Transplantation 2001 Faculty-Member of the Basic Sciences Symposium of The Transplantation Society, Bern, Switzerland Awards and Fellowships November 2005 Researcher of the Month: Medical University of Vienna 2002 Habilitation Award of the Association for the promotion of science and research at the Vienna General Hospital 2000 Erste Bank Research Award: 1st place, Medical Chamber of Vienna 2000 Austrotransplant-Award of the Austrian Society of Transplantation 2000 Young Investigator Award: American Society of Transplant Surgeons and the American Society of Transplantation,
  • 114. - 114 - 2000 1999 Young Investigator Award: American Society of Transplantation 1997 – 1998 Erwin Schrödinger Fellowship of the Austrian Science Fund (FWF) 1996 – 1997 Research fellowship of the Max Kade Foundation Memberships since 2007 European Society of Organ Transplantation (ESOT) since 2002 Austrian Society of Surgical Research since 1999 Austrian Society of Transplantation since 1999 The Transplantation Society and International Xenotransplantation Association since 1998 American Society of Transplantation since 1996 International Society for Heart and Lung Transplantation Publications Original articles: 43 Review articles: 19 Book chapters: 3 Editorials: 6 Patent application: 1 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) A. Finished theses: Dr.med.univ. Maximilian Schmid: "The influence of calcineurin-inhibitors on the deletion of donor-reactive T-cells after bone marrow transplantation with costimulation blockade", 2002 (M.D. thesis) Dr.med.univ. Franz Romeder: "Mycophenolate mofetil in renal transplantation – A retrospective single centre analysis", 2005 (M.D. thesis) Dr.rer.nat. Zvonimir Koporc: "Use of mobilized peripheral blood stem cells (mPBSC) for the induction of mixed chimerism and tolerance", 2006 (Ph.D. thesis) Mag.rer.nat. Ines Pree: "The role of IDO (indoleamine 2, 3-dioxygenase) in tolerance induction through mixed chimerism in a murine transplantation model using bone marrow transplantation and costimulation blockade", 2005 (diploma thesis) Mag.rer.nat. Martina Gattringer: "Induction of tolerance through transplantation of Bet v 1- transduced hematopoietic stem cells", since 2007 (diploma thesis) B. Ongoing theses: Mag.rer.nat. Nina Pilat: "The therapeutic use of T regulatory cells in models of mixed
  • 115. - 115 - chimerism", since 2005 (Ph.D. thesis) Mag.rer.nat. Christoph Klaus: since 2006 (Ph.D. thesis) Mag.rer.nat. Martina Gattringer: since 2007 (Ph.D. thesis) Dr.med.univ. Elisabeth Schwaiger: since 2006 (Dr.sci.med. N090) Haley Ramsey, MSc: since 2007 (Ph.D. thesis, N094, PhD program (DK) “inflammation and immunity”) Sources of funding in last 6 years (2002-2008) "Tolerance through hematopoietic cell transplantation with costimulation blockade", international research grant from the independent Roche Organ Transplantation Research Foundation (ROTRF), Meggen, Switzerland, awarded in 2001, 130.000€ (period 2002-2004) "Tolerance through the transplantation of mobilized peripheral blood stem cells: Identifying the factors responsible for their lower tolerogenic potential under costimulation blockade", research grant from the Jubilee Fund of the Austrian National Bank, awarded in 2004, 32.000€ "Research for the development of immunological tolerance strategies for the prevention and treatment of IgE-mediated allergies", research agreement with Biomay Inc., Vienna, ongoing since 2003, 300.000€ (period 2003-2008) "Hematopoietic chimerism for the induction of tolerance"; project is part of the Special Research Program SFB23 on "Mechanisms of the establishment and maintenance of immunological tolerance" of the Austrian Science Fund (FWF), awarded in 2004, 451.000€ (period 2005-2008) “Tolerance induction in organ transplantation and allergy”, Doctoral Program (Doktoratskolleg – DK) “Inflammation and Immunity”; awarded in 2006, 269.000€ (period 2007-2010) Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts Wekerle, T., Kurtz, J., Bigenzahn, S., Takeuchi, Y., and Sykes, M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 14:592-600 (2002). Wekerle, T., Blaha, P., Langer, F., Schmid, M., and Muehlbacher, F. Tolerance through bone marrow transplantation with costimulation blockade. Transpl Immunol 9:125-33 (2002). Wekerle, T., Blaha, P., Asari, R., Schmid, M., Kiss, C., Roth, E., and Mühlbacher, F. Tolerance induction through mixed chimerism. Europ Surgery 34:131-5 (2002). Wekerle, T., Nikolic, B., Pearson, D. A., Swenson, K. G., and Sykes, M. Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int 15:248-53 (2002).
  • 116. - 116 - Wekerle, T., Blaha, P., Koporc, Z., Bigenzahn, S., Pusch, M., and Muehlbacher, F. Mechanisms of tolerance induction through the transplantation of donor hematopoietic stem cells: central versus peripheral. Transplantation 75:21S-5S (2003). Blaha, P., Bigenzahn, S., Koporc, Z., Schmid, M., Langer, F., Selzer, E., Bergmeister, H., Wrba, F., Kurtz, J., Kiss, C., Roth, E., Muehlbacher, F., Sykes, M., and Wekerle, T. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 101:2886-93 (2003). Saemann, M., Muehlbacher, F., Zlabinger, G., and Wekerle, T. Selected commentary to: Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Europ Surgery 36:205-6 (2004). Wekerle, T. and Sykes, M. Induction of tolerance. Surgery 135:359-64 (2004). Heitger, A., Blaha, P., Bigenzahn, S., Muehlbacher, F., and Wekerle, T. The influence of immunosuppressive drugs on cell-induced graft tolerance. Curr Opin Organ Transplant 9:307-13 (2004). Bigenzahn, S., Blaha, P., Koporc, Z., Pree, I., Selzer, E., Bergmeister, H., Wrba, F., Heusser, C., Wagner, K., Muehlbacher, F., and Wekerle, T. The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant 5:1237-47 (2005). Blaha, P., Bigenzahn, S., Koporc, Z., Sykes, M., Muehlbacher, F., and Wekerle, T. Short- term immunosuppression facilitates induction of mixed chimerism and tolerance after BMT without cytoreductive conditioning. Transplantation 80:237-43 (2005). Pree, I. and Wekerle, T. Inducing mixed chimerism and transplantation tolerance through allogeneic bone marrow transplantation with costimulation blockade. In: Immunological Tolerance: Methods and Protocols, P. J. Fairchild, Ed. (Humana Press, 2006)(in press). Pree, I. and Wekerle, T. New approaches to prevent transplant rejection: Costimulation blockers anti-CD40L and CTLA4Ig. Drug Discovery Today: Therapeutic Strategies 3:41-7 (2006). Koporc, Z., Bigenzahn, S., Blaha, P., Fariborz, E., Selzer, E., Sykes, M., Muehlbacher, F., and Wekerle, T. Induction of mixed chimerism through transplantation of CD45-congenic mobilized peripheral blood stem cells after nonmyeloablative irradiation. Biol Blood Marrow Transplant 12:284-92 (2006). Linhart, B., Bigenzahn, S., Hartl, A., Lupinek, C., Thalhamer, J., Valenta, R., and Wekerle, T. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J Immunol 178:3924-31 (2007). Pree, I., Bigenzahn, S., Fuchs, D., Koporc, Z., Nierlich, P., Winkler, C., Brandacher, G., Sykes, M., Muehlbacher, F., Langer, F., and Wekerle, T. CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of indoleamine-2,3-dioxygenase. Transplantation 83:663-7 (2007).
  • 117. - 117 - Co-author manuscripts: Takeuchi, Y., Ito, H., Kurtz, J., Wekerle, T., Ho, L., and Sykes, M. Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L. Am. J Transplant 4:31-40 (2004). Birsan, T., Loinig, C., Bodingbauer, M., Wekerle, T., Rockenschaub, S., Berlakovich, G., Soliman, T., Muehlbacher, F., and Steininger, R. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: Retrospective analysis of a single center experience. Transplantation 78:1787-91 (2004). Saemann, M. D., Zeyda, M., Stulnig, T., Böhmig, G. A., Wekerle, T., Hörl, W. H., and Zlabinger, G. Janus kinase-3 (JAK3) inhibition: a new immunosuppressive modality for allogeneic transplantation. Transpl Int 17:481-9 (2004). Kurtz, J., Wekerle, T., and Sykes, M. Tolerance in mixed chimerism - a role for regulatory cells? Trends Immunol 25:518-23 (2004). Andres, A., Toso, C., Morel, P., Bosco, D., Bucher, P., Oberholzer, J., Mathe, Z., Mai, G., Wekerle, T., Berney, T., and Buhler, L. Macrophage depletion prolongs discordant but not concordant islet xenograft survival. Transplantation 79:543-9 (2005). Andres, A., Toso, C., Morel, P., Bosco, D., Bucher, P., Oberholzer, J., Mathe, Z., Mai, G., Wekerle, T., Berney, T., and Buhler, L. H. Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation. Transplant Proc 37:463-5 (2005). Mai, G., Bucher, P., Morel, P., Mei, J., Bosco, D., Andres, A., Mathe, Z., Wekerle, T., Berney, T., and Buhler, L. H. Role of CD40-CD154 pathway in the rejection of concordant and discordant xenogeneic islets. Transplant Proc 37:460-2 (2005). Mai, G., Bucher, P., Morel, P., Mei, J., Bosco, D., Andres, A., Mathe, Z., Wekerle, T., Berney, T., and Buhler, L. H. Anti-CD154 mAb treatment but not recipient CD154 deficiency leads to long-term survival of xenogeneic islet grafts. Am J Transplant 5:1021-31 (2005). Bucher, P., Mai, G., Morel, P., Mathe, Z., Bosco, D., Pernin, N., Wekerle, T., Berney, T., and Buhler, L. H. Transplantation of discordant xenogeneic islets using repeated therapy with anti-CD154. Transplantation 79:1545-52 (2005). Vincenti, F. , Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P. F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., and Charpentier, B. for the belatacept study group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353:770-81 (2005). Fehr, T., Takeuchi, Y., Kurtz, J., Wekerle, T., and Sykes, M. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation. Eur J Immunol 35:2679-90 (2005). Perco, P., Blaha, P., Kainz, A., Mayer, B., Hauser, P., Wekerle, T., and Oberbauer, R.
  • 118. - 118 - Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl Int 19:146-57 (2006). Bodingbauer, M., Pakrah, B., Steininger, R., Berlakovich, G., Rockenschaub, S., Wekerle, T., and Muehlbacher, F. The advantage of allocating kidneys from old cadaveric donors to old recipients: a single-center experience. Clin Transplant 20:471-5 (2006). Silberhumer, G., Pokorny, H., Hetz, H., Herkner, H., Rasoul-Rockenschaub, S., Soliman, T., Wekerle, T. , Berlakovich, G., Steininger, R., and Muehlbacher, F. Combination of extended donor criteria and changes in the model for end-stage liver disease score predict patient survival and primary dysfunction in liver transplantation: A retrospective analysis. Transplantation 83:588-92 (2007). Bodingbauer, M., Wekerle, T., Pakrah, B., Roschger, P., Peck-Radosavljevic, M., Silberhumer, G., Grampp, S., Rockenschaub, S., Berlakovich, G., Steininger, R., Klaushofer, K., Oberbauer, R., and Muehlbacher, F. Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation. Am J Transplant 7:1763-9 (2007). Hainz, U., Jurgens, B., Seidel, M. G., Wekerle, T., and Heitger, A. Indoleamine 2,3- dioxygenase in hematopoietic stem cell transplantation. Curr Drug Metab 8:267-72 (2007) Invited Talks 2002-2008 2002 • The 16th European Histocompatibility Conference, Strasbourg, Frankreich, März 2002; "Mixed chimerism and transplantation tolerance" • 22nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation, Washington DC, USA, April 2002; "Review of experimental tolerance protocols" • Ninth N.A.T. (Nantes/Actualités/Transplantation), Nantes, Frankreich, Juni 2002; "Tolerance through the induction of macrochimerism" • Austrotransplant 2002, Loipersdorf; "Immunglobuline als Therapie in der Transplantation" 2003 • "Effects of immunosuppressive drugs on tolerance induction through BMT with costimulation blockade", Novartis Research Day, Frankfurt, Germany, 2003 • "Xenotransplantation", Austrotransplant 2003, Gosau, Austria • "Experimental aspects of tolerance induction", Wyeth Symposium on 'Islet transplantation and immune tolerance', Geneva, Switzerland, 2003 • "Immune tolerance - strategies, clinical application", Symposium of the Working Association • 'Transplantation of thoracic organs' of the German Society of Cardiology, Heidelberg, Germany, 2003 2004 • TBRC May 2004: “Studies on the role of regulation and the use of mobilized peripheral blood stem cells in murine mixed chimerism models involving costimulation blockade”, Boston, USA • ROTRF symposium, XX International Congress of The Transplantation Society, "Tolerance through hematopoietic cell transplantation with costimulation blockade", Vienna, Austria • Seminar "From basic science to clinical application", organized by Rudolf Valenta, “Transplantation tolerance through hematopoietic chimerism”, Vienna, Austria
  • 119. - 119 - • Ges. der Chirurgen in Wien: "Organtransplantation: Visionen und Utopien", Vienna, Austria 2005 • Gastroenterologiefortbildung, AKH Wien, "Induktion immunologischer Toleranz in der Organtransplantation" • Ethik-Symposium des Österreichischen Grünen Kreuz, Goldegg, "Xenotransplantation – Eine Alternative?" • 5th Wyeth International Transplantation Symposium on Sirolimus, Athen, "Advances in experimental tolerance induction through hematopoietic cell transplantation" • Akademie für Transplantationsimmunologie - 1. Seminar " Statistik und Medical Writing", München, "Wie kommt ein Journal zustande – Sicht eines Editors" • Symposium "Advances in solid organ and stem cell transplantation", Berlin, Charité, "Non- myeloablative protocols for stem cell transfer to induce tolerance to organ transplants" • 12th Congress of the European Society for Organ Transplantation (ESOT), Genf, opening plenary session, “Peripheral or central tolerance, what is best?” • Austrotransplant, 19. Jahrestagung, Alpbach, “Toleranzinduktion: Gegenwart, Zukunft oder Wunschtraum?” • Hesperis Course, ESOT, Wien, "Experimental tolerance protocols" 2006 • XXV Congress of the European Academy of Allergology and Clinical Immunology, EAACI 2006, Wien, "Progress towards clinical tolerance induction" • Seminar Statistik und Medical Writing, Akademie für Transplantationsimmunologie, Astellas, München, "Wie kommt ein Journal zustande - Sicht eines Editors" • Wissenschaftliches Symposium: "30 Jahre Kinder-Dialyse Wien", Wien, "Derzeitiger Stand der Toleranzinduktion" • Astellas Transplant360 Wien "Tolerance" • 37. Kongress der (Dt.) Ges. f. Nephrologie, Essen, "Möglichkeiten der Toleranzinduktion bei Organtransplantation" • Österr. Ges. für Nephrologie Jahrestagung 2006, Semmering, "Die Rolle von Costimulations-Blockern – einer neuen Klasse an Biologicals – in der Zukunft der Nierentransplantation" • 30. Seminar der Österr. Ges. für Experimentelle Chirurgie, Gosau, "Transplantationsimmunologie" • Universitäres Transplantationszentrum Hamburg, Fortbilungsveranstaltung der Transplantations-Akademie, Hamburg, Deutschland, "Toleranzinduktion in der Organtransplantation: Standortbestimmung" 2007 • “Toleranz: Eine Standortbestimmung”, invited seminar at the Medical Univ. of Innsbruck, March 2007 •“Toleranzinduktion: Realistisch oder Utopie?”, 2. Interdisziplinäres Tübinger Transplantationsgespräch, Tübingen, Germany, April 2007 • “Tolerance: Basic principles and experimental models”, Hesperis Course of ESOT, St. Gallen, Switzerland, November 2007
  • 120. - 120 - Curriculum Vitae Ursula Wiedermann-Schmidt Institute of Specific Prophylaxis and Tropical Medicine, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Kinderspitalgasse 15, 1090 Wien, Austria; Phone: +43-1-404 90/64890, Fax: +43-1-404 90/64899; Email: ursula.wiedermann@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/tropenmedizin Personal Data Date of Birth: 06.08.1965 Place of Birth: Vienna Nationality Austria Education 01/2004 Special degree (Facharzt) in “Specific Prophylaxis and Tropical Hygiene” 01/2002 Special degree (Facharzt) in “Immunology” 2001 - 2002 Physician in training at the Department of Internal Medicine and Department of Clinical Pharmacology of the University of Vienna, General Hospital Vienna, Austria 1999 - 2003 Physician in training in „Specific Prophylaxis and Tropical Hygiene“ at the University of Vienna, Austria 1996 – 1998 Physician in training in „Immunology“ at the University of Vienna, Austria, and at the Allergy Outpatient Clinic 1100 Vienna 05/1993 – 12/1995 PhD-Thesis at the Department of Clinical Immunology, University Göteborg, Sweden 11/1990 – 05/1993 Master-Thesis at the Department of Clinical Immunology, University Göteborg, Sweden 10/1990 Graduation from the Faculty of Medicine, University Vienna, with “Medical doctor” (MD) 1975 – 1983 High School (Gymnasium) and Graduation (Matura), Vienna, Austria 1971 – 1975 Primary School, Vienna, Austria Career History since 10/2006 University Professor for Vaccinology 10/2004 Head of the Department of Specific Prophylaxis and
  • 121. - 121 - Tropical Medicine at the Center for Physiology, Pathophysiology and Immunology, Medical University, Vienna 03/2000 Associate Professor and leader of the researche group “Mucosal Immunity and Vaccination” 11/1999 Venia docendi at the University of Vienna, Medical School 1999 - 2000 University Assistant at the Department of General and Experimental Pathology, University of Vienna 1996 - 1999 Research Assistant at the Department of General and Experimental Pathology, University of Vienna 12/1995 Doctor of Philosophy (PhD9, University of Göteborg, Sweden 05/1993 Master of Science (M. Med. Sci.) Career-related Activities Since 05/2007 Board Member of the “International Archives of Allergy and Clinical Immunology” since 12/2005 Member of the Austrian Advisory Committee of Immunization Practice (AACIP) of the Austrian Supreme Board of Health of the Federal Ministry of Health, Women & Adolescence since 09/2005 Board Member of the Austria Society of Tropcial Medicine and Parasitology Since 11/2003 Chair of the committee “Vaccinology” (“Standeskommittee für Impfwesen”) Awards and Fellowships 2006 Poster prize at the 26th Collegium Internationale Allergologicum, Malta, 5th-10th May 2006 K. Hufnagl, C. Wild, H. Breiteneder, O. Scheiner, M. Wallner, F. Ferreira, U. Wiedermann. Development of a mucosal polyvalent allergy vaccine for primary prevention of multi-sensitization (poster) 2005 Sanofi Aventis award to Stefan Wagner “Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro”. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H,
  • 122. - 122 - Breiteneder H. J Immunol. 2005 15;174(2):976-82 2004 Awards from the Forschungsentwicklungspreis des Fonds der Stadt Wien für Innovative Interdisziplinäre Krebsforschung to Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, Wiltschke C, Breiteneder H, Pehamberger H, Scheiner O, Wiedermann U*, Zielinski CC. 2003. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her- 2/neu. Int. J. Cancer. 107: 976-983. Hafner C., H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, WM. Schmidt, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2004. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int. J. Cancer Dec 1; 2003 Poster Award of the Austrian Society of Allergy and Immunology for the presentation, Salzburg Dec 2003: “Studies on regulatory mechanisms of intranasal tolerance using recombinant Ves v 5, a major wasp venom allergen”, by Winkler B, Bolwig C, Sepälä U, Spangfort M, Ebner C and Wiedermann U. 1990 - 1995 Fellowship from the University of Göteborg, Sweden for a PhD-program Sources of funding in last 6 years (2002-2008) Peer-reviewed projects (FWF, EU and equivalent projects) Period Organization Short Title K€/year 03/2008 – Intercell Infektionsepidemiologie von streptococcus 35 02/2009 pneumoniae 2007 - 2009 ÖNB Genet. Typisierung d. Keuchhustenerregers 45 Bordetella Pertussis bei österr. Patienten 2007 - 2009 Nestlé Prenatal and perinatal intervention against 182 allergic diseases 2006 - 2008 BioLife Science Multiepitope vaccine against breast cancer 158 2005 – FWF SFB – Mucosal tolerance induction: a 732 2012 strategy for prevention and therapy of type I allergy 2004 - 2006 Nestlé Allergene prevention with probiotic 182 preparations/recombinant probiotics 2004 - 2006 Amadeus travel-grant Lactic acid bacteria as expression systems 5
  • 123. - 123 - for vaccine antigens 2006 Fonds des Entwicklung einer eßbaren Vakzine gegen 28 Bürgermeisters Wien Allergien 2002 – EU grant LABDEL Oral Va. Lactic acid bacteria 52 2004 2000 – EU Project TRAFSA Therapeutic recombinant allergens from 317 2002 structual allergology Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Only students in your lab, no external Period Name of student Topic 1999-2000 Birgit Wagner (MD thesis) Mucoal tolerance as therapy of type I allergy 2003 - 2005 Carmen Wild (PhD theis) Production, characterization and in vivo testing of novel allergen chimers 2004 – Martin Sturm (Diploma Mucosal vaccination against Type I allergy: a new 2005 thesis) treatment approach using lactic acid bacteria as delivery system for hypoallergenic molecules 2004 – Maria Korinek Edible vaccines 2005 (Diploma thesis) 2005 - Elisabeth Hoflehner (PhD- “Production and Characterization of allergen chimers for mucosal treatment of thesis) allergic diseases” 2007 - Angelika Wagner (MD-PhD Immunomodulation by Toxoplasma gondii thesis) 2008- Markus Mandl (PhD thesis) Pre-peri-and postnatal intervention by probtiotics Publications Grönlund, H., S. Vrtala, U. Wiedermann, G. Dekan, D. Kraft, R. Valenta, M. Van Hage- Hamsten. 2002. Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy. Immunology 107(4): 523-9. Winkler, B., C. Bolwig, U. Seppala, M. D. Spangfort, C. Ebner, and U. Wiedermann*. 2003.Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 110:376. Repa, A., C. Grangette, C. Daniel, R. Hochreiter, K. Hoffmann-Sommergruber, J. Thalhamer, D. Kraft, H. Breiteneder, A. Mercenier, and U. Wiedermann*. 2003. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 22:87. Jasinska, J., S. Wagner, C. Radauer, R. Sedivy, T. Brodowicz, C. Wiltschke, H. Breiteneder,
  • 124. - 124 - H. Pehamberger, O. Scheiner, U. Wiedermann*, and C. C. Zielinski. 2003. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 107:976. Wiedermann, U*. 2003. Mucosal immunity--mucosal tolerance. A strategy for treatment of allergic diseases. Chem Immunol Allergy 82:11. Hufnagl, K., B. Wagner, B. Winkler, K. Baier, R. Hochreiter, J. Thalhamer, D. Kraft, O. Scheiner, H. Breiteneder, and U. Wiedermann*. 2003. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. Clin Exp Immunol 133:170. Melzer, H., K. Baier, F. Felici, B. U. von Specht, G. Wiedermann, H. Kollaritsch, U. Wiedermann, and M. Duchene. 2003. Humoral immune response against proteophosphoglycan surface antigens of Entamoeba histolytica elicited by immunization with synthetic mimotope peptides. FEMS Immunol Med Microbiol 37:179. Kozakova, H., L. A. Hanson, R. Stepankova, H. Kahu, U. I. Dahlgren, and U. Wiedermann*. 2003. Vitamin A deficiency leads to severe functional disturbance of the intestinal epithelium enzymes associated with diarrhoea and increased bacterial translocation in gnotobiotic rats. Microbes Infect 5:405. Hanniffy, S., U. Wiedermann, A. Repa, A. Mercenier, C. Daniel, J. Fioramonti, H. Tlaskolova, H. Kozakova, H. Israelsen, S. Madsen, A. Vrang, P. Hols, J. Delcour, P. Bron, M. Kleerebezem, and J. Wells. 2004. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 56:1. Focke, M., B. Linhart, A. Hartl, U. Wiedermann, W. R. Sperr, P. Valent, J. Thalhamer, D. Kraft, and R. Valenta. 2004. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 34:1525. Repa, A., C. Wild, K. Hufnagl, B. Winkler, B. Bohle, A. Pollak, and U. Wiedermann*. 2004. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clin Exp Immunol 137:12. Westritschnig, K., M. Focke, P. Verdino, W. Goessler, W. Keller, A. Twardosz, A. Mari, F. Horak, U. Wiedermann, A. Hartl, J. Thalhamer, W. R. Sperr, P. Valent, and R. Valenta. 2004. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J Immunol 172:5684. Wagner, B., K. Hufnagl, C. Radauer, S. Wagner, K. Baier, O. Scheiner, U. Wiedermann, and H. Breiteneder. 2004. Expression of the B subunit of the heat-labile enterotoxin of Escherichia coli in tobacco mosaic virus-infected Nicotiana benthamiana plants and its characterization as mucosal immunogen and adjuvant. J Immunol Methods 287:203. Herz, U., H. Renz, and U. Wiedermann*. 2004. Animal models of type I allergy using recombinant allergens. Methods 32:271. Wiedermann, U*. 2005. Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. Curr Drug Targets Inflamm Allergy 4:577. Hufnagl, K., B. Winkler, M. Focke, R. Valenta, O. Scheiner, H. Renz, and U. Wiedermann*. 2005. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J Allergy Clin Immunol 116:370.
  • 125. - 125 - Linhart, B., A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, M. T. Krauth, P. Valent, F. Horak, U. Wiedermann, J. Thalhamer, C. Ebner, D. Kraft, and R. Valenta. 2005. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J Allergy Clin Immunol 115:1010. Hafner, C., S. Wagner, J. Jasinska, D. Allwardt, O. Scheiner, K. Wolff, H. Pehamberger, U. Wiedermann, and H. Breiteneder. 2005. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol 124:125. Wagner, S., C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U. Wiedermann, H. Pehamberger, and H. Breiteneder. 2005. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 174:976. Hafner, C., H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2005. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 114:426. Wiedermann-Schmidt*, U., and W. Maurer. 2005. Adjuvants and additives in vaccines-- medical relevance. Wien Klin Wochenschr 117:510. Wiedermann, U., and H. Kollaritsch. 2006. Vaccines against traveler's diarrhoea and rotavirus disease - a review. Wien Klin Wochenschr 118:2. Rendi-Wagner, P., M. Kundi, A. Mikolasek, I. Mutz, K. Zwiauer, U. Wiedermann, A. Vecsei, and H. Kollaritsch. 2006. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr 118:280. Daniel, C., A. Repa, C. Wild, A. Pollak, B. Pot, H. Breiteneder, U. Wiedermann*, and A. Mercenier. 2006. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 61:812. Winkler, B., K. Hufnagl, A. Spittler, M. Ploder, E. Kallay, S. Vrtala, R. Valenta, M. Kundi, H. Renz, and U. Wiedermann*. 2006. The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 61:173. Tasanor, O., D. Engelmeier, B. Brem, U. Wiedermann-Schmidt, H. Greger, and W. H. Wernsdorfer. 2006. Development of a pharmacodynamic screening model with Crithidia fasciculata. Wien Klin Wochenschr 118:42. Rendi-Wagner, P., M. Korinek, B. Winkler, M. Kundi, H. Kollaritsch, and U. Wiedermann*. 2007. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine 25:927. Rendi-Wagner, P., M. Paulke-Korinek, M. Kundi, U. Wiedermann, B. Laaber, and H. Kollaritsch. 2007. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 25:5097. Wiedermann, U.*, and A. Mercenier. 2007. New allergy intervention strategies: hitting the mucosal road. Clin Exp Allergy 37:473.
  • 126. - 126 - Kollaritsch, H., and U. Wiedermann. 2007. Examples for vaccines against diarrheal diseases- -rotavirus and traveller's diarrhea. Wien Med Wochenschr 157:102. Wagner, S., J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann*. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. Wild, C., M. Wallner, K. Hufnagl, H. Fuchs, K. Hoffmann-Sommergruber, H. Breiteneder, O. Scheiner, F. Ferreira, and U. Wiedermann*. 2007. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy 62:33. Daniel, C., Repa, A., Mercenier, A., U. Wiedermann, J. Wells. 2007. The European LABDEL project and its relevance to the prevention and treatment of allergies. Allerg. 62/11: 1237- 1242 Bublin, M., E. Hoflehner, B. Wagner, C. Radauer, S. Wagner, K. Hufnagl, D. Allwarth, Scheiner, U. Wiedermann*, H. Breiteneder.2007. Use of a genetic cholera toxin B subunit/allergen-fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 25(50):8395-404 Repa, A., H. Kozakova, T. Hudcovic, R. Stepankova, T. Hrncir, H. Tlaskalova-Hogenova, A. Pollak, U. Wiedermann. 2008. Susceptibility to nasal and oral tolerance induction of the major birch pollen allergen Bet v 1 is not dependent on the presence of the microflora. Immunol. Letters 117(1):50-56 Rendi-Wagner, P., M. Paulke-Korinek, M. Kundi, U. Wiedermann, B. Laaber, H. Kollaritsch. 2008. Seroprotection 4 years following booster vaccination against tick-born encephalitis. Int. J. Med Microbiology, Epub ahead of print. Karin Hufnagl, PhD, Margit Focke, PhD, Florian Gruber, PhD, Peter Hufnagl, PhD, Gerhard Loupal, DVM Otto Scheiner, PhD, Ursula Wiedermann, MD, PhD. 2008. Airway inflammation induced after allergic poly-sensitization can be prevented by mucosal but not by systemic administration of poly-peptides. Clin. Exp. Allergy, In press. Neimert-Andersson, T., S.Thunberg, L. Swedin, U. Wiedermann, G. Jacobsson-Ekman, S. Dahlén, A. Scheynius, H. Grönlund, M. van Hage , G. Gafvelin G. Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy, in press. Invited Talks 2002-2008 (Ärztefortbildungen) 2002 Internationales Pädiatrisches Symposium Obergurgl, Jan 2002 „Allergie und Impfungen“ Immunologischer Fortbildungstag, Weitra, June 2002 „Impferfolgsuntersuchungen“ Reisemedizinische Konsensustagung, Wien, Oct. 2002 „Sinn und Unsinn serologischer Untersuchungen“ 2003 1. Wiener Pädiatr. Infektionssymposium, Kinderklinik Wien, Nov. 2003 „Pneumokokkenerkrankung und Impfung“
  • 127. - 127 - 2004 Immunological Symposium (BMGF), Steyr, Austria, March 2004 “Immunologische Grundlagen des Impfwesens” 4. Reisemedizinische Konsensustagung, Leongang, Styria, September 2004 “Hilfs- und Zusatzstoffe von Impfstoffen – medizinische Relevanz“ Impfsymposium des Grünen Kreuzes, Gmunden, October 2004 „Impfreaktionen und Nebenwirkungen durch Inhaltsstoffe“ 19. Pädiatrischer Impftag, Linz, November 2004 „Mukosale Immunität – Zukunft der Impfstrategien“ 2005 2. Wiener Pädiatr. Infektionssymposium, Kinderklinik Wien, Febr. 2005 „Neue Impfstoffe und neue Impfentwicklungen“ Impfsymposium des österr. Bundesheeres, Grünes Kreuz, Salzburg, April 2005 „Neue Impfstrategien“ 14. Österr. Impftag, Salzburg, April 2005 „Neue Impfstrategien: die Zukunft von nasalen und oralen Vakzinen“ Impfsymposium des Grünen Kreuzes, Gmunden Oct. 200 „Impfungen gegen Reisedurchfallserreger: Dukoral, Einsatz und Wirkung“ 39th Annual meeting of the Austrian Society of Tropical Medicine and Parasitology, Vienna, 17-19 Nov. „Impfstoffe gegen Reisedurchfall: ETEC and Rotavirusinfektionen“ Symposium on Pneumococcal Diseases, 14th Dec 2005, Vienna “Epidemiology of pneumococcal diseases – benefits of vaccination” 2006 15. Österr. Impftag, 25th March 2006 “Wieviele Impfdosen sind genug?” (Hib, Meningokokken, Hep. B) Impffortbildung der Ärztekammer Niederösterreich, 19th April 2006 „Impfen aktuell“ Symposium on Vaccination in Prematures, GNPI Vienna, 20th May 2006 (chair) “Österreichischer Impfplan 2006” 3. Wiener Pädiatr. Infektionssymposium 2006, GNPI Vienna, 20th May 2006 “Welche neuen Impfstoffe für Kinder und Jugendliche sind zu erwarten” 2007 Pädiatr. Immunolog. Symposium u. Pädiatr. Kongreß, Jänner 2007 “Invasive Pneumokokkenerkrankungen” Pädiatr. Immunolog. Symposium u. Pädiatr. Kongreß, Jänner 2007 „Empirie od. evidenzbasierende Medizin?“ ISW-Expert Meeting on FSME, Jänner 2007
  • 128. - 128 - “Travel Expert Advisery Board on TBE-First Outcome Bundesheer Symposium Salzburg, März 2007 “Choleraimpfung – Dukoral Bundesheer Symposium Salzburg, März 2007 „Wie gefährlich ist impfen wirklich?“ Österr. Impftag Salzburg, März 2007 „Ist impfen wirklich gefährlich?“ Österr. Impftag Salzburg, März 2007 „Hep. A Immunität 10 Jahre nach Grundimmunisierung“ Impftagung Bregenz, Juni 2007 “Impfdosen Empirie oder evidenzbasierende Medizin” 4. Wiener Infektionssymposium, September 2007 „Neue Impfungen – Neue Impfentwicklungen“ Impfsymposium in Gmunden, September 2007 „Brustkrebsvakzine – von der Entwicklung zur klinischen Testung“ 41. Jahrestagung der Österr. Gesellschaft für Tropenmedizin und Parasitologie, Nov. 2007 „Neue Impfungen – Neue Adjuvantien“ Pressefrühstück “Kick off Meeting des Sprechergremiums von Forum Impfschutz”, Nov. 2007 „Schutz vor Epidemien durch ausreichende Durchimpfungsrate“ Expertenmeetin „Ambulant erworbene Pneumonie“, Dezember 2007 „Pneumokokkenimpfung“ Wiener Impftag, Jan 2008 „neue Impfungen, neue Adjuvantien“ Reise- und Tropenmedizinische Tagung, Innsbruck, Jan. 2008 „Wie gefährlich ist Impfen wirklich?“ Fortbildungsveranstaltung der Univ. Ärzte AKH, Febr. 2008 „Impfen aktuell – wann soll was geimpft werden?“ ESIDOG, März 2008 „Immunologische Grundlagen des Impfwesens“ Invited lectures at Scientific Meetings 2002-2008 American Academy of Allergy, Asthma and Immunology, San Diego, USA, March 2000 “Oral tolerance and its relation to allergic disease” Gastvortrag beim Immunologischen Seminar an der Medizinischen Fakultät der Universität, Marburg, Dec. 2000. “Mukosale Vakzination, Mukosale Toleranz” Annual meeting of the Society of Immunology and Allergy, Deutsche Gesellschaft für HNO, Ulm, Deutschland. Nov. 2000
  • 129. - 129 - “Mukosale Adjuvantien” European Commission - Joint Research Center, Workshop on GMOs, Ispra, Italy, Febr. 2001 “Use of animal models in allergy research” Deutsche Gesellschaft für Allergologie und Immunologie; Universität Bochum, Bochum, Deutschland , May 2002 „Mukosale Toleranzinduktion“ 24th Symposium of the Collegium International Allergologicum, Bermuda, Nov. 2002 “From mucosal tolerance induction to edible vaccines – possible treatment strategies against allergy?” Berna Biotech, Bern, Switzerland, Februar 2004 „Hepatitis A vaccination – characterization and modulation of immune responses in mice and men“ ALK Abello, Kopenhagen, Demark, April 2004 „Mucosal tolerance induction: a treatment strategy against allergy with multiple sensitivities“ FRM Workshop “Frontier in Allergology Research” Paris May 2004 “Animal Models using recombinant allergens” EU-workshop Brussels “Food allergy in Europe, Future Prospectives” Brussels, June 2004 “Future prospectives for immunotherapy and oral vaccination” Symposium, Institute Pasteur de Lille, May 2005 „Mucosal tolerance induction: a strategy for prevention and therapy of type I allergy“ CESP/EAP European Academy of Pediatrics, Dec 2005, Brussels “Mucosal immunity – impact on nasopharyngeal carriage and on viral shedding at mucosal respiratory surfaces” EMEA (European Medicines Agency), London, Jan 2006 Workshop on “Regulatory and scientific issues related to concomitant administration of vaccine” Mucosal tolerance induction: a strategy for prevention and therapy of type I allergy. Symposium on Immunoregulation, Institute Pasteur de Lille, May 2005 Mucosal immunity – impact on nasopharyngeal carriage and on viral shedding at mucosal respiratory surfaces. CESP/EAP European Academy of Pediatrics, Brussels, 19-20 Dec 2005 Mechanisms of Mucosal Tolerance Induction. XXV EAACI, Vienna, Austria, 10.-14.6.2006 Mucosal Tolerance as treatment strategy against allergic diseases. 5th Meeting of the Mucosal Immunology Group (EMIG), Praque, Czech Republic, 5-7 Oct. 2006 Humoral and Cellular Immune responses 10 years after hepatitis A primary vaccination. 16th Annual Austrian Symposium of Vaccination, Salzburg, 23-24 March 2007. Mucosal tolerance. XXVI EAACI, Göteborg, Sweden, 9.- 13.6.2007. Mucosal tolerance – a treatment strategy against allergies. Seminarreihe "Immunologie, Allergologie, Pneumologie" an der Uni-Klinik Giessen und Marburg, Prof. H. Renz; Marburg,
  • 130. - 130 - Deutschland; 25.-26. Juni 2007. 10th Conference of the Internat. Society of Travel Medicine, Mai 2007 “Travellers Diarrhoea Vaccines – past, present, future 26. EAACI Congress in Göteburg, Juni 2007 “Mucosal Tolerance Induction” Invited Lecture at Univ. Marburg, Deutschland, Juni 2007 “Mucosal Tolerance as a Treatment strategy against allergies” Invited Lecture Institute of Immunology and Infect. Diseases, R. Maizels, Oktober 2007 “Mucosal Tolerance for Treatment of Allergies” Invited Lecture Institute Cell Biology, Univ. Amsterdam, M. Kapsenberg Dezember 2007 “Treatment of allergies on the bases of Mucosal Tolerance Induction” World Immunregulation Meeting, Davos, March 2008 “Mucosal tolerance and Intestinal homeostasis” (chair)
  • 131. - 131 - Curriculum Vitae Gerhard J. Zlabinger Division of Clinical and Experimental Immunology, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse 8a, 1090 Wien, Austria; Phone: +43-1-4277-64971, Fax: +43-1-4277-64972; Email: gerhard.zlabinger@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/immunologie/content/research/zlabinger.htm Personal Data Date of Birth: 30.09.1955 Place of Birth: Traun Nationality Austria Education 1981 - 1988 Medical Specialization in Immunology 1975 - 1981 Study of Medicine, University of Vienna 1974 Matura at Realistisches Gymnasium, Linz Career History 07/2007 Full Professor of Clinical and Experimental Immunology 09/2004 Head of Institute of Immunology 1992 Habilitation in Immunology, University of Vienna Medical School 1987 – 1988 Visiting Fellow at the Department of Internal Medicine II, University of Vienna Austria 1986 Group Leader, Institute of Immunology, University of Vienna Career-related Activities since 09/2007 Curriculumdirektor Humanmedizin 2000 - present Scientific Director of the Academy for Biomedical Scientists at the general Hospital of Vienna Awards 2005 Landeskulturpreis Öberösterreich for Natural Sciences 1993 Förderungspreis der Stadt Wien
  • 132. - 132 - 1993 Dr. Kardinal Innitzer Förderungspreis 1993 Austrotransplantpreis 1991 Förderungspreis der Ersten österr. Sparkasse 1991 Förderungspreis der Österr. Ges. für Nephrologie. 1990 Shaper & Brummer Award for Coumarin Investigators, 1990 Kolassapreis 1989 Talentförderungsprämie des Landes OÖ 1987 Staatspreis für Rheumatologie 1985 Staatspreis für Rheumatologie Memberships Austrian Society for Allergology and Immunology Austrotransplant Austrian Society for Rheumatology Austrian Society for Nephrology Austrian Society for Laboratory Medicine The Transplantation Society Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2008 - 2010 Else Kröner Stiftung Immunological Hallmarks of humoral 59 rejection 2007 - 2010 FWF Identification of functional receptor for Tamm 48 Horsfall Protein 2001 - 2004 FWF Molecular characterization of the anti- 113 inflammatory and immunosuppressive effects of butyrate Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2006 – Johannes Hofer Immunomodulatory effects of C4d present 2007 – Johannes Kovarik Molecular mechanisms of butyrate present 2008 – Markus Hölzl Identification THP receptors present
  • 133. - 133 - Publications 85 peer reviewed publications in scientific journals, 42 reviwes, book chapters and other publications, > 30 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Säemann MD, Parolini O., Böhmig GA, Kelemen P., Krieger PM, Neumüller J, Knarr K, Kammlander W, Hörl WH, Diakos C, Stuhlmeier K, Zlabinger GJ. (2002) Bacterial metabolite interference with maturation of human monocyte-derived dendritic cells. J Leukocyte Biol 71: 238-246. Diakos C, Prieschl EE, Säemann MD, Novotny V, Böhmig GA, Csonga R, Baumruker T, Zlabinger GJ (2002) Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate. J. Biol Chem 27: 24243-51. Säemann MD, Böhmig GA, Zlabinger GJ (2002) Short-chain fatty acids:bacterial mediators of a balanced host-microbial relationship in the human gut. Wien Klin Wochenschr 114: 289- 300. Säemann MD, Zeyda M, Diakos C, Szekeres A, Böhmig GA, Kelemen P, Parolini O, Stockinger H, Prieschl EE, Stuhlnig T, Baumruker T, Zlabinger GJ. (2003) Suppression of early T-cell receptor-triggered cellular activation by the Janus kinase inhibitor WHI-P154. Transplantation 75: 1864 – 72. Saemann MD, Diakos C, Kelemen P, Kriehuber E, Zeyda M, Böhmig GA, Hörl WH, Baumruker T, Zlabinger GJ. Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. Am J Transplant. 3: 1341-9 2003. Säemann MD, Zlabinger GJ. How to make clinical use of bacterial evasion strategies. Eur J Clin Invest 33: 189-90, 2003. Säemann MD, Kelemen P, Böhmig GA, Hörl WH, Zlabinger GJ. Hyporesponsiveness in Alloreactive T-cells by NF-kappaB Inhibitor-Treated Dendritic Cells: Resistance to Calcineurin Inhibition. Am J Transplant 4:1448-58, 2004. Säemann MD, Zeyda M, Stulnig TM, Böhmig GA, Wekerle T, Hörl WH, Zlabinger GJ. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant Int. 17:481-9, 2004. Säemann, MD., Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von Gabain A, von Ahsen U, Hörl W, and Zlabinger GJ. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a TLR4- dependent mechanism. J Clin Invest 115:468-75, 2005. Säemann MD, Weichhart T, Hörl WH, Zlabinger GJ. Tamm-Horsfall Glycoprotein: A multilayered defense molecule against urinary tract infection. Eur J Clin Invest, 35:227-35, 2005. Diakos C, Prieschl EE, Saemann MD, Bohmig GA, Csonga R, Sobanov Y, Baumruker T, Zlabinger GJ. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine
  • 134. - 134 - transcription in mast cells. Biochem Biophys Res Commun. 349:863-8, 2006 Stefanova T, Nikolova N, Michailova A, Mitov I, Iancov I, Zlabinger GJ, Neychev H Enhanced resistance to Salmonella enterica serovar Typhimurium infection in mice after coumarin treatment. Microbes Infect 9:7-14, 2007 Co-author manuscripts: Chiampanichayakul S, Szekeres A, Khunkaewla P, Moosom S, Leksa V, Drbal K, Zlabinger GJ, Hofer-Warbinek, R, Stockinger H, Kasinrerk W Engagement of Na, K-ATPase beta3 subunit by a specific mAb suppresses T and B lymphocyte activation. Int Immunol 14: 1407- 14, 2002 Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, Zlabinger GJ, Pickl WF, Stockinger H, Knapp W, Stöckl J. B7-H1 (PD-L1) on dendritic cells is involved in the induction and maintenance of T-cell anergy. J Immunol 170:3637-44, 2003. Stollberger C, Finsterer J, Zlabinger GJ, Weihsengruber F, Redtenbacher S, Bonner G, Herkner K, Deutsch M. Antineutrophil cytoplasmic autoantibody-negative antiproteinase 3 syndrome presenting as vasculitis, endocarditis, polyneuropathy and Dupuytren's contracture. J Heart Valve Dis. 12: 530-4, 2003. Staffler G, Szekeres A, Schutz GJ, Saemann MD, Prager E, Zeyda M, Drbal K, Zlabinger GJ, Stulnig TM, Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. J Immunol 171: 1707-14, 2003. Zeyda M, Szekeres AB, Saemann MD, Geyeregger R, Stockinger H, Zlabinger GJ, Waldhausl W, Stulnig TM. Suppression of T cell signaling by polyunsaturated fatty acids: selectivity in inhibition of mitogen-activated protein kinase and nuclear factor activation. J Immunol 170: 6033-9, 2003. Wahrmann M, Exner M, Regele H, Derfler K, Körmöczi GF, Lhotta K, Zlabinger GJ, Böhmig GA. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 275: 149-60, 2003 Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, Klauser C, Zlabinger G, Pickl WF, Stöckl J, Knapp W. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol. 172:2352-9, 2004. Koller H, Hochegger K, Zlabinger GJ, Lhotta K, Mayer G, Rosenkranz AR. Apoptosis of human polymorphonuclear neutrophils accelerated by dialysis membranes via the activation of the complement system. Nephrol Dial Transplant. 19:3104-11, 2004. Pfistershammer K, Majdic O, Stöckl J, Zlabinger G, Kirchberger S, Steinberger P, Knapp W. CD63 as an activation-linked T cell costimulatory element. J Immunol. 173:6000-8, 2004. Zeyda M, Säemann MD, Geyeregger R, Zlabinger GJ, Waldhäusl W, Stulnig TM. Polyunsaturated fatty acids inhibit dendritic cells function without impairment of NF-kB. J Biol Chem, 280:14293-301,2005. Geyeregger R, Zeyda M, Zlabinger GJ, Waldhäusl W, Stulnig TM. Polyunsaturated fatty acids interfere with formation of the immunological synapse. J Leukoc Biol. 77: 680-8, 2005. Weichhart T, Zlabinger GJ, Säemann MD. The multiple functions of Tamm-Horsfall Protein in
  • 135. - 135 - health and disease: a mystery clears up. Wien Klin Wochenschr 117:316-22, 2005. Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Research & Therapy, 7:R694-R703, 2005. Bluml S, Kirchberger S, Bochkov VN, Kronke G, Stuhlmeier K, Majdic O, Zlabinger GJ, Knapp W, Binder BR, Stockl J, Leitinger N. Oxidized Phospholipids Negatively Regulate Dendritic Cell Maturation Induced by TLRs and CD40. J Immunol. 175:501-8, 2005. Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Horl WH, Waldhausl W, Stulnig TM, Saemann MD. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum. 52:2730-9, 2005. Kirchberger S, Majdic O, Steinberger P, Bluml S, Pfistershammer K, Zlabinger G, Deszcz L, Kuechler E, Knapp W, Stockl J. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol. 175:1145-52. 2005 Zeyda M, Kirsch BM, Geyeregger R, Stuhlmeier KM, Zlabinger GJ, Horl WH, Saemann MD, Stulnig TM. Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778. Transplantation 80:1105-11. 2005 Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O, Steinberger P. No evidence for dualism in function and receptors. PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36:1104-13, 2006 Zeyda M, Geyeregger R, Poglitsch M, Weichhart T, Zlabinger GJ, Koyasu S, Horl WH, Stulnig TM, Watschinger B, Saemann MD. Impairment of T cell interactions with antigen- presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF- {kappa}B in immunological synapse formation. J Leukoc Biol. 81:319-27, 2007. Mechtcheriakova D, Wlachos A, Sobanov J, Kopp T, Reuschel R, Bornancin F, Cai R, Zemann B, Urtz N, Stingl G, Zlabinger G, Woisetschlager M, Baumruker T, Billich A. Sphingosine 1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal. 19:748-60, 2007 Mechtcheriakova D, Wlachos A, Sobanov J, Bornancin F, Zlabinger G, Baumruker T, Billich A FTY720-phosphate is dephosphorylated by lipid phosphate phosphatase 3. FEBS Lett. 7581:3063-8, 2007 Geyeregger R, Zeyda M, Bauer W, Kriehuber E, Saemann MD, Zlabinger GJ, Maurer D, Stulnig TM. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 109:4288-95, 2007 Hochegger K, Eller P, Huber JM, Bernhard D, Mayer G, Zlabinger GJ, Rosenkranz AR Expression of granzyme A in human polymorphonuclear neutrophils. Immunology. 121:166- 73, 2007 Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond). 31: 1420-8, 2007 Pfistershammer K, Klauser C, Leitner J, Stöckl J, Majdic O, Weichhart T, Sobanov Y,
  • 136. - 136 - Bochkov V, Säemann M, Zlabinger G, Steinberger P. Identification of the scavenger receptors SREC-I, Cla-1 (SR-BI), and SR-AI as cellular receptors for Tamm-Horsfall protein. J Leukoc Biol. 83:131-8, 2008
  • 137. - 137 - 6.2 Teachers Herbert Auer 133 Adelheid Elbe-Bürger 139 Thomas Felzmann 143 Gottfried Fischer 147 Elisabeth Förster-Waldl 151 Renate Fuchs 155 Ulrich Jäger 160 Peter Pietschmann 169 Clemens Scheinecker 177 Veronika Sexl 180 Maria Sibilia 184 Peter Steinberger 188 Günter Steiner 191 Johannes Stöckl 197 Martin Willheim 201
  • 138. - 138 - Curriculum Vitae Herbert Auer Department of Medical Parasitology, Clinical Institute of Hygiene and Medical Microbiology, Medical University of Vienna, Kinderspitalgasse 15, 1095 Vienna, Austria Phone: +43 1 40490-79443, Fax: +43 1 40490-79435 Email: herbert.auer@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/hygiene/ Personal Data Date of Birth: 21.02.1953 Place of Birth: Zams/Tyrol Nationality Austria Education 1971-1977 PhD studies (Zoology, Botany, Limnology), University of Innsbruck 1971 University entrance qualification, Gymnasium Landeck/Tyrol Career History 10/2004 Leader of the Dept. Med. Parasitology 10/1997 Associate Professor 01/1991 Habilitation in Med. Parasitology, University of Vienna Medical School Awards 1987 Filmpreis (wissenschaftlicher Film) Budweis und Barcelona „Echinococcus multilocularis: Protoscolices in vivo und in vitro.“ 2003 Hovorka Medal, Slovak Academy of Science, Helminthological Institute Kosice/Slovak Republic
  • 139. - 139 - Memberships Austrian Society of Tropical Medicine and Parasitology (Member of the Executive Board: since 11/1983; as Treasurer, Secretary, President and Vice-President) German Society of Parasitology Sources of funding in last 6 years (2002-2008) Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 1995-1998 Barbara Bauder Experimentelle Untersuchungen zur B- und T- Zell-Immunantwort bei primärer alveolärer Echinokokkose 1995-1999 Andreas Obwaller Toxocarosis in humans: Antibodies and antigens involved in the humoral immune response Publications Peer reviewed manuscripts 2002-2008 (original research and reviews) Deutz A, Fuchs K, Auer H, Schuller W, Nowotny N, Kerbl U, Aspöck H, Köfer J. (2002): Seroepidemiologische Untersuchungen disponierter Personen auf ausgewählte Kontaktzoonosen. Fleischwirtschaft 82 (1), 101 – 104. Kinceková J, Auer H, eiterová K, Dubinský P, Szilagyiová M, Lauko L, Aspöck H. (2002): The
  • 140. - 140 - first case of autochthonous human alveolar echinococcosis in the Slovak Republic (Case report). Mitt. Österr. Ges. Tropenmed. Parasitol. 23, 33-38. Westritschnig K, Sibanda E, Thomas W, Auer H, Aspöck H, Pittner S, Vrtala S, Spitzauer S, Kraft D, Valenta R. (2003): Analysis of the sensitization profile towards allergens in central Africa. Clin. Exp. Allergy 33: 22-27. Kern P, Bardonnet K, Renner E, Auer H, Pawlowski Z, Ammann RW, Vuitton DA, Kern P. (2003): European echinococcosis registry: human alveolar echinococcosis, Europe, 1982- 2000. Emerg Infect Dis 2003 Mar;9(3), 343-9. Deutz A, Fuchs K, Schuller W, Nowotny N, Auer H, Aspöck H, Stünzner D, Kerbl U, Klement Ch, Köfer J. (2003): Seroepidemiologische Untersuchung von Jägern auf Zoonosen in Südostösterreich – Prävalenzen, Risikopotentiale und Vorbeugemaßnahmen. Berl. Münch. Tierärztl. Wschr. 116: 306-311. Auer H. (2003): Toxocara-Infestationen und Toxokarose in Mitteleuropa: Eine Übersicht. In: Infektiologie – Aktuelle Aspekte (O. Janata, E. Reisinger, Hrsg.). Jahrbuch 2003/2004, pm- Verlag: 77-92. Deutz A, Fuchs K, Nowotny N, Auer H, Schuller W, Stünzner D, Aspöck H, Kerbl U, Köfer J (2003): Seroepidemiologische Untersuchungen von Jägern auf Zoonosen – Vergleich mit Untersuchungen bei Tierärzten, Landwirten und Schlachthofarbeitern. Wien. Klin. Wschr. 115 Suppl 3):61-67. Auer H, Vander-Möse A, Aspöck H (2003): Die verwirrende Vielfalt der IgM-Tests in der Diagnostik von Toxopalsma-Infektionen: Versuch einer optimalen Strategie. Wien. Klin. Wschr. 115 (Suppl 3): 18-22. Rauhofer U, Prager G, Hörmann M, Auer H, Kaserer K, Niederle B (2003): Cystic echinococcosis of the thyroid gland in children and adults. Thyroid 13, 497-502 (Impact 2000: 2,047) Westritschnig, Sibanda A, Thomas W, Auer H, Aspöck H, Pittner G, Vrtala S, Spitzauer S,
  • 141. - 141 - Kraft D, Valenta R (2003): Analysis of the sensitization profile towards allergens in central Africa. Clin. Exp. Allergy. 33: 22-27. Obwaller A, Schneider R, Walochnik J, Gollackner B, Deutz A, Janitschke K, Aspöck H, Auer H. (2004): Echinococcus granulosus strain differentiation based on sequence heterogeneity in mitochondrial genes of cytochrome c oxidase-1 and NADH dehydrogenase-1. Parasitology 128: 569-575. Auer H, Aspöck H (2004): Nosologie und Epidemiologie der Toxokarose des Menschen – die aktuelle Situation in Österreich. Wien Klin Wochenschr 116 (Suppl. 4): 7-18. Obwaller A, Duchêne M, Walochnik J, Wiedermann G, Auer H, Aspöck H. (2005): Association of autoantibodies against small nuclear ribonucleoproteins (snRNPs) with symptomatic Toxocara canis infestation. Parasite Immunol 26 (8-9): 327-333. Auer H, Aspöck H. (2005): Vertikale Transmission von Helminthen beim Menschen. Nova Acta Leopoldina 89 (334): 351-363. Aspöck H, Auer H, Walochnik J. (2005): Die Prävention der pränatalen Toxoplasmose: Strategien, Stand der Kenntnis, aktuelle Probleme. Nova Acta Leopoldina 89 (334): 229-268. Juncker-Voss M, Prosl H, Lussy H, Enzenberg U, Auer H, Lassnig H, Müller M, Nowotny N. (2005): Untersuchungen auf Antikörper gegen Zoonoseerreger bei Angestellten des Wiener Tiergartens Schönbrunn. Berl. Münch. Tierärtztl. Wschr. Heft 09/10: 404-409. Deutz A, Fuchs K, Auer H, Kerbl U, Aspöck H, Köfer J. (2005): Toxocara-infestations in Austria: a study on the risk of infection of farmers, slaughterhouse staff, huntes and veterinarians. Parasitol Res. 97: 390-394. Auer H, Vander-Möse A, Picher O, Aspöck H. (2005): Toxoplasmose-Ringversuche in Österreich: Ergebnisse und Grenzen des serologischen Schwangeren-Screenings. Wiener Klinische Wochenschrift 117: 20-28. Auer H. (2005): Die Trichinellose des Menschen in Österreich. Vet. Med. Austria/Wien. Tierärztl. Mschr 92: 288-294.
  • 142. - 142 - Auer H, Aspöck H. (2006): Die Diagnostik der Toxocara-Infestationen und der Toxokarose des Menschen. Journal of Laboratory Medicine 30: 1-12. Finsterer J, Mei Li , Rasmkogeler K, Auer H. (2006): Chronic Long-Standing Headache due to Neurocysticercosis. – Headache, 46: 523-524. Auer H. (2006): Die Bedeutung laboratoriumsdiagnostischer Untersuchungen für die Klinik, Epidemiologie und Prävention der alveolären Echinokokkose – Erfahrungen zweier Jahrzehnte in Österreich. - Wien. Klin. Wochenschr 118: 18-26. Hörweg CH., Sattmann H., Auer H. (2006): Cercarial dermatitis in Austria: Questionnaires as useful tools to estimate risk factors. - Wien. Klin. Wochenschr 118: 77-80. Cetin E, Sotoudeh M, Auer H, Stanek G. (2006): Paradigm Burgenland: Risk of Borrelia burgdorferi sensu lato infection indicated by variable seroprevalence rates in hunters. – Wien Klin Wochenschr 118/21-22: 677-681. Kinčeková J, Hrčková G, Auer H, Szilágyiová M, Hudačková J, Stanislayová M, Poláček H, Šimeková K. (2006): Clinical and serological study of human alveolar echinococcosis in Slovakia in relation to the outcome of chemotherapy. – Helminthologia 43, 4: 213-219. Koehsler M, Soleiman A, Aspöck H, Auer H, Walochnik J. (2007): Onchocerca jakutensis Filariasis in Humans. – Emerg Infect Dis. 13: 1749-1752. Hrčkova G, Velebný S, Obwaller A, Auer H, Kogan G. (2007): Evaluation of follow-up of therapy with fenbendazole incorportated into stabilized liposomes and immunomodulator glucan in mice infected with Toxocara canis larvae. – Acta Tropica 104: 122-132. Schnedl J, Auer H, Fischer M, Tomaso H, Pustelnik T, Mooseder G. (2007): Kutane Leishmaniose – Import aus Belize. – Wien KlinWochenschr 119: 102-105. Auer H, Leskowschek H, Engler J, Leitner G, Wentzel Ch, Wolkerstorfer W, Schneider R.
  • 143. - 143 - (2007): Epidemiologie und Nosologie der Anisakiose, einer in Mitteleuropa selten diagnostizierten Helminthozoonose – zwei Fallberichte. – Wien Klin Wochenschr 119: 106- 109. Finsterer J, Auer H. (2007): Neurotoxocarosis. – Rev. Inst. Med. trop. S. Paulo 49: 279-287. Wöhrl S, Schnedl J, Auer H, Walochnik J, Stingl G, Geusau A. (2007): Successful treatment of a married couple for American leishmaniasis with miltefosine. – Jorunal of the European Academy of Dermatology and Venerology 22: 258-259. Schneider R, Gollackner B, Edel B, Schmid K, Wrba F, Tucek G, Walochnik J, Auer H. Development of a new PCR protocol for the detection of species and genotypes (strains) of Echinococcus in formalin-fixed, paraffin-embedded tissues Int J Parasitol. 2007 Dec 4 [Epub ahead of print]
  • 144. - 144 - Curriculum Vitae Adelheid Elbe-Bürger Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Vienna Competence Center, Medical University of Vienna, Lazarettgasse 19, 1090 Vienna, Austria; Phone: +43-1-40160-63001, Fax: +43-1-40160-963005; Email: adelheid.elbe-buerger@meduniwien.ac.at Homepage: www.meduniwien.ac.at/immundermatologie/?main Personal Data Date of Birth: 11.12.1961 Place of Birth: Globasnitz Nationality Austria Education 1984 – 1987 PhD studies (Cellular Immunology, Immunodermatology), Department of Dermatology, University of Vienna Medical School, and University of Vienna, Faculty of Natural Sciences 1980 – 1984 Studies in Biology, University of Vienna 1980 University entrance qualification, Bundesoberstufenrealgymnasium Klagenfurt Career History Since 1997 Associate Professor (a.o.Univ.Prof.) 01/1996 Habilitation in Immunology and Immunodermatology, University of Vienna Medical School 1992 - 1995 Faculty position (Univ. Ass.) Group Leader, Department of Dermatology I, University of Vienna Medical School 1988 - 1992 Postdoctoral fellow at the Department of Dermatology I, and at the Laboratory of Molecular Biology of Retroviruses, Memorial Sloan-Kettering Cancer Center, New York, USA 1984 - 1988 PhD thesis performed at the Department of Dermatology I, Division of Immunobiology, University of Vienna Medical School
  • 145. - 145 - Career-related Activities 1996 - 1997 Board Member of the Austrian Society of Allergology and Immunology Awards 1993 Karl Landsteiner Award, Austrian Society of Allergology and Immunology 1988 Thesis Award, Austrian Society of Allergology and Immunology Memberships Arbeitsgemeinschaft Dermatologische Forschung (ADF; German Society for Investigative Dermatology) Deutsche Gesellschaft für Stammzellforschung European Society for Dermatological Research (ESDR) ITERA – Life-Sciences Forum Österreichische Gesellschaft für Transplantation, Transfusion und Genetik (AUSTROTRANSPLANT) Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI; Austrian Society for Allergology and Immunology) Österreichische Gesellschaft für Dermatologie und Venerologie (ÖGDV; Austrian Society of Dermatology and Venerology) Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2006 - 2009 FWF Ontogeny of human cutaneous 81 dendritic cells 2008 - 2008 HJST Effects of glucocorticosteroids on neonatal 5 and infant skin 2005 - 2007 HJST Isolation, purification and ex vivo expansion 3 of human dermal stem/progenitor cells 2004 - 2008 FWF Dermal hematopoietic stem cells 68 2003 - 2004 HJST Characterization of human dermal 10 hematopoietic stem cells 2000 - 2003 FWF Search for Langerhans 62 stem/progenitor cells Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008)
  • 146. - 146 - Period Name of student Topic 2000 - 2004 Souyet Chang-Rodriguez Phenotypical, maturational and functional characterization of dendritic epidermal leukocytes in fetal and neonatal mice 2001 - 2004 Wolfram Hötzenecker Effects of topical immunomodulators on the immune system of the skin 2001 - 2005 Simone Meindl Characterization, purification and differentiation potential of cells expressing hematopoietic stem cell markers in newborn and adult mouse skin 2004 - Christine Vaculik Characterization of human dermal cells present exypressing stem cell markers 2008 – Nousheen Iram Molecular analysis of Toll like receptors in present differentiating human skin cells Publications 41 peer reviewed publications in scientific journals, 4 reviews, 10 book chapters, 4 varia, >250 presentations at national and international meetings Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Elbe-Bürger A., Egyed A., Olt S., Klubal R., Mann U., Rappersberger K., Rot A., Stingl G. (2002). Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol, 118:767-778. Hoetzenecker W., Meingassner J.G., Ecker R., Stingl G., Stuetz A., Elbe-Bürger A. (2004). Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol, 122:673-684. Chang-Rodriguez S., Ecker R., Stingl G., Elbe-Bürger A. (2004). Autocrine IL-10 partially prevents differentiation of neonatal dendritic epidermal leukocytes into Langerhans cells. J Leukoc Biol, 76:657-666. Elbe-Bürger A., and Stingl G. (2004). Dendritic cells: role in skin immunity and potential clinical uses. Ann Dermatol Venereol. 131:93-103. Meindl S., Rot A., Hoetzenecker W., Kato S., Cross H., Elbe-Bürger A. (2005). Vitamin D receptor ablation alters skin architecture and homeostasis of dendritic epidermal T cells. Br J Dermatol, 152: 231-241. Chang-Rodriguez S., Hoetzenecker W., Schwärzler C., Biedermann T., Saeland S., Elbe- Bürger A. (2005). Fetal and neonatal murine skin harbors Langerhans cell precursors. J Leukoc Biol, 77:352-360. Hoetzenecker W., Ecker R., Kopp T., Stuetz A., Stingl G., Elbe-Bürger A. (2005). Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol, 115:1276-1283.
  • 147. - 147 - Hoetzenecker W., Meindl S., Stuetz A., Stingl G., Elbe-Bürger A. (2006). Both pimecrolimus and corticosteroids deplete plasmacytoid dendritic cells in patients with atopic dermatitis. J Invest Dermatol, 126:2141-2144. Meindl S., Schmidt U., Vaculik C., Elbe-Bürger A. (2006). Characterization, isolation and differentiation of murine skin cells expressing hematopoietic stem cell markers. J Leukoc Biol, 80:816-826. Co-author manuscripts: Meingassner J.G., Kowalsky E., Schwendinger H., Elbe-Bürger A., Stütz A. (2003). Pimecrolimus does not affect Langerhans cells in murine epidermis, in contrast to corticosteroids. Br J Dermatol, 149:853-857. Ortiz-Urda S., Elbe-Bürger A., Smolle J., Marquart Y., Chudnovsky Y., Ridky T.W., Bernstein P., Wolff K., Rappersberger K. (2003). The plant lectin wheat germ agglutinin inhibits the binding of pemphigus foliaceus autoantibodies to desmoglein 1 in a majority of patients and prevents pathomechanisms of pemphigus foliaceus in vitro and in vivo. J Immunol, 171:6244-6250. Tripp C., Chang-Rodriguez S., Stoitzner P., Holzmann S., Stössel H., Saeland S., Koch F., Elbe-Bürger A., Romani N. (2004). Ontogeny of Langerin / CD207 expression in the epidermis of mice. J Invest Dermatol, 122:670-672. Abrahamsberg C., Fuchs P., Osmanagic-Myers S., Fischer I., Propst F., Elbe-Bürger A., Wiche G. (2005). Targeted ablation of plectin isoform 1 uncovers role of cytolinker proteins in leukocyte recruitment. PNAS, 102:18449-18454. Invited Talks 2002-2008 2002 • Klinik für Pathophysiologie, Wien, Österreich 2003 • Novartis Forschungsinstitut, Wien 2004 • ISAC XXII International Congress. Montpellier, Frankreich 2005 • 6. GD Jahrestagung, Wien • 35th ESDR Annual Meeting. Tübingen, Deutschland 2006 • Universitätshautklinik Innsbruck
  • 148. - 148 - Curriculum Vitae Thomas Felzmann Laboratory of Tumour Immunology, St. Anna Children’s Cancer Research Institute, Kinderspitalgasse 6, 1090 Vienna, Austria; Phone: +43-1-40170-4060, Fax: +43-1-40170-7150; Email: thomas.felzmann@ccri.at; Homepage: www.ccri.at Personal Data Date of Birth: 15.11.1960 Place of Birth: Vienna Nationality Austria Education 2007 Habilitation in Immunology, Medical University Vienna 2003-2005 Executive MBA program of the Danube University Krems, graduation as Master of Business Administration, November 25, 2005 1999 Board certification as Clinical Immunologist 1986-1989 Training in group dynamics 1980-1987 Medical University, Vienna, A, graduation as Medical Doctor, December 11, 1987 1975-1980 Secondary College for Chemical Technology, specialization in Biochemistry and Biochemical Technology, Vienna, A, graduation, June 3, 1980 Career History 2003- Founder and CEO, I-Med Cancer Immune Therapy GmbH 1995- Group leader, Laboratory of Tumor Immunology, St. Anna Children’s Cancer Research Institute, Vienna, A 1995-1998 Clinical training in pediatric oncology at the St. Anna Children’s Hospital, Vienna, A 1992-1995 Research Fellow at the Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institute of Health, Bethesda, MD, USA 1991-1992 Clinical training in oncology at the I. Medical Department, Wilhelminenspital, Vienna, A
  • 149. - 149 - 1988-1992 Postdoctoral fellow at the Institute of Immunology, Medical University, Vienna, A 1987-1989 Physician at the blood bank of the Austria Red Cross, Vienna, A. 1987 Social worker as ambulance physician for the Austria Red Cross, Vienna, A. 1975-1987 Various full and part time jobs as a working student Awards 2003 Fellowship for the Executive MBA program of the Danube University Krems, A 1994 Fogarty Fellowship, National Institute of Health, Bethesda, MD, USA 1992 Max Kade Fellowship, Austrian Academy of Science Memberships Austrian Society for Allergology and Immunology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2005 - 2006 Austrian Research Gemodec 450 Promotion Fund 2003 - 2006 EU FP6 Dendritophages 500 2002 - 2008 Vienna Busniess Clinical Development of a DC Cancer 1000 Agency Vaccine 2001 - 2006 Austrian Research Biology of DC Cancer Vaccination 500 Promotion Fund 2000 - 2002 Mayor of Vienna Xenogenisation of Tumour Cells 200 1999 - 2001 Austrian National Genetic Engineering of Tumour Cells 200 Bank Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2000 - 2004 Katharina Hüttner Development of a mouse tumour model for dendritic cell cancer vaccination 2004 - 2008 Mareike Lindbauer Knock down of IDO in a mouse tumour model to improve dendritic cell cancer vaccination
  • 150. - 150 - 2006 - 2007 Petra Paul Two-step maturation of dendritic cells 2007-2008 Romana Luger Lentiviral engineering of dendritic cells 2007-2008 Michael Traxlmayr Immun eregulation by γδ T-cells. Publications 20 peer reviewed publications in scientific journals, 3 international patent families Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Dohnal A, Witt V, Hugel H, Holter W, Gadner H, Felzmann T.Phase I study of tumor Ag- loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy. 2007 Oct;9(8):755-70 Hüttner KG, Breuer SK, Paul P, Majdic O, Heitger A, Felzmann T. Generation of potent anti- tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother. 2005 Jan;54(1):67-77. Felzmann T, Hüttner KG, Breuer SK, Wimmer D, Ressmann G, Wagner D, Paul P, Lehner M, Heitger A, Holter W. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother. 2005 Aug;54(8):769-80. Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P, Huttner K, Fritsch G. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy. 2003;5(5):391-8. Felzmann T, Gadner H, Holter W. Dendritic cells as adjuvants in antitumor immune therapy. Onkologie. 2002 Oct;25(5):456-64. Felzmann T, Buchberger M, Lehner M, Printz D, Kircheis R, Wagner E, Gadner H, Holter W. Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes. Cancer Lett. 2001 Jul 26;168(2):145-54. Felzmann T, Buchberger M, Jechlinger M, Kircheis R, Wagner E, Gadner H. Xenogenization by tetanus toxoid loading into lymphoblastoid cell lines and primary human tumor cells mediated by polycations and liposomes. Cancer Lett. 2000 Dec 20;161(2):241-50. Felzmann T, Ramsey WJ, Blaese RM. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett. 1999 Jan 8;135(1):1-10. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther. 1997 Dec;4(12):1322-9. Felzmann T, Gisslinger H, Ludwig H. Immunological findings in patients with myelodysplastic syndrome. Leuk Lymphoma. 1994 Oct;15(3-4):201-8. Review. Felzmann T, Gisslinger H, Krieger O, Majdic O, Ludwig H, Koller U. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome. Br J Haematol. 1993 Jul;84(3):428-35.
  • 151. - 151 - Felzmann T, Gadd S, Majdic O, Maurer D, Petera P, Smolen J, Knapp W. Analysis of function-associated receptor molecules on peripheral blood and synovial fluid granulocytes from patients with rheumatoid and reactive arthritis. J Clin Immunol. 1991 Jul;11(4):205-12. Co-author manuscripts: Lehner M, Stockl J, Majdic O, Knapp W, Huttner K, Felzmann T, Holter W. MHC class II antigen signaling induces homotypic and heterotypic cluster formation of human mature monocyte derived dendritic cells in the absence of cell death. Hum Immunol. 2003 Aug;64(8):762-70. Lehner M, Felzmann T, Clodi K, Holter W. Type I interferons in combination with bacterial stimuli induce apoptosis of monocyte-derived dendritic cells. Blood. 2001 Aug 1;98(3):736- 42. Kircheis R, Kichler A, Wallner G, Kursa M, Ogris M, Felzmann T, Buchberger M, Wagner E. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther. 1997 May;4(5):409-18. Maurer D, Felzmann T, Holter W, Petera P, Smolen J, Knapp W. Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis. Clin Exp Immunol. 1992 Mar;87(3):429-34. Gadd SJ, Felzmann T, Majdic O, Maurer D, Petera P, Chen WJ, Smolen J, Knapp W. Phenotypic analysis of functionally associated molecules on peripheral blood and synovial fluid monocytes from arthritis patients. Rheumatol Int. 1992;12(4):153-7. Szekeres T, Fritzer M, Pillwein K, Felzmann T, Chiba P. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin. Life Sci. 1992;51(16):1309-15. Maurer D, Fischer GF, Felzmann T, Majdic O, Gschwantler E, Hinterberger W, Wagner A, Knapp W. Ratio of complement receptor over Fc-receptor III expression: a sensitive parameter to monitor granulocyte-macrophage colony-stimulating factor effects on neutrophils. Ann Hematol. 1991 Apr;62(4):135-40. Maurer D, Felzmann T, Knapp W. A single laser flow cytometry method to evaluate the binding of three antibodies. J Immunol Methods. 1990 Dec 31;135(1-2):43-7.
  • 152. - 152 - Curriculum Vitae Gottfried Fischer Division of Blood Group Serology, Department for Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43-1-40400 5320, Fax: +43-1-40400 5321; Email: gottfried.fischer@meduniwien.ac.at; Homepage: n.e. Personal Data Date of Birth: 16.09.1960 Place of Birth: Vienna Nationality Austria Education 1985 Promotion Dr. med. Univ 1978 – 1985 Studies in Medicine, University of Vienna 1978 University entrance qualification, BG Bruck/Leitha Career History 1993 Habilitation in Blood Group Serology, University of Vienna Medical School Since 1987 Assistant Doctor at the Institute for Blood Group Serology 1985 – 1987 Post Doctoral Stay at the Institute for Immunology, University of Vienna Medical School, Group Prof. Knapp Career-related Activities 2002-2007 Commissioner for Region 05, Accreditation Committee of the European Federation for Immunogenetics Since 2007 – present Chairman of the Accreditation Committee of the European Federation for Immunogenetics Awards 1991-1993 Erwin-Schrödinger Postdoctoral Fellowship, FWF Memberships Austrian Society for Allergology and Immunology, Deutsche Gesellschaft für Immungenetik
  • 153. - 153 - Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2005 - 2008 EU EU Marie Curie Research & Training 40 Network (TRANSNET) Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) None Publications >25 peer reviewed publications in scientific journals, >2 book chapters, >5 invited lectures, 0 patents Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Ludajic, K., Balavarca , Y., Bickeböller H., Pohlreich D., Kouba M., Dobrovolna M, Vrana M., Rosenmayr A., Fae, I., Fischer, G.F, Kalhs P. & Greinix H.T. (2008) Impact of HLA-DPB1 Allelic and Single Amino Acid Mismatches on HSCT. Br. J Haematology, in press Ludajic, K., Fae, I. & Fischer, G.F. (2006) Characterization of a new HLA-DPB1 allele, DPB1*010103. Tissue Antigens, 67, 255-256. Greinix, H.T., Fae, I., Schneider, B., Rosenmayr, A., Mitterschiffthaler, A., Pelzmann, B., Kalhs, P., Lechner, K., Mayr, W.R. & Fischer, G.F. (2005) Impact of HLA class I high- resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant, 35, 57- 62. Fischer, G. (2002) Immunogenetic selection of donors for haematopoietic stem cell transplantation: an approach. Transpl Immunol, 10, 223-225. Co-author manuscripts: Leb, V.M., Jahn-Schmid, B., Schmetterer, K.G., Kueng, H.J., Haiderer, D., Neunkirchner, A., Fischer, G.F., Nissler, K., Hartl, A., Thalhamer, J., Bohle, B., Seed, B. & Pickl, W.F. (2008) Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol, 121, 64-71. Mrazek, F., Fae, I., Ambruzova, Z., Raida, L., Kriegova, E., Indrak, K., Fischer, G.F. & Petrek, M. (2006) A single amino acid exchange shifts the serological reactivity of the novel HLA-B*4442 allele product from HLA-B44 to HLA-B21. Int J Immunogenet, 33, 197- 200. Penn, D.J., Oberzaucher, E., Grammer, K., Fischer, G., Soini, H.A., Wiesler, D., Novotny, M.V., Dixon, S.J., Xu, Y. & Brereton, R.G. (2007) Individual and gender fingerprints in human body odour. J R Soc Interface, 4, 331-340. Tiercy, J.M., Fischer, G. & Setterholm, M. (2007) Quality control for registry HLA data. Tissue Antigens, 69 Suppl 1, 13-14. Vidan-Jeras, B., Ambroz, N., Fae, I., Kemperle, I. & Fischer, G. (2007) HLA-B*350802, a novel allele, which has arisen by silent mutation at codon 67. Tissue Antigens, 69, 363. Worel, N., Greinix, H.T., Supper, V., Leitner, G., Mitterbauer, M., Rabitsch, W., Fischer, G., Rosenmayr, A., Hocker, P. & Kalhs, P. (2007) Prophylactic red blood cell exchange for
  • 154. - 154 - prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion, 47, 1494-1502. Danzer, M., Polin, H., Proll, J., Hofer, K., Fae, I., Fischer, G.F. & Gabriel, C. (2007) High- throughput sequence-based typing strategy for HLA-DRB1 based on real-time polymerase chain reaction. Hum Immunol, 68, 915-917. Karvunidis, T., Jindra, P., Fischer, G., Venigova, P., Dorner, A. & Koza, V. (2007) Identification of a novel HLA-DRB1*14 allele, HLA-DRB1*1458, by sequence-based typing. Tissue Antigens, 70, 348-349. Meraner, P., Horejsi, V., Wolpl, A., Fischer, G.F., Stingl, G. & Maurer, D. (2007) Dendritic cells sensitize TCRs through self-MHC-mediated Src family kinase activation. J Immunol, 178, 2262-2271. Vidan-Jeras, B., Kunilo, S., Fae, I., Kandus, A. & Fischer, G.F. (2006) A novel HLA-B*2730 allele found in a Slovene patient affected with IgA nephropathy. Int J Immunogenet, 33, 371-373. Danzer, M., Polin, H., Fae, I., Fischer, G.F. & Gabriel, C. (2006) Exon 1-4 sequence analysis of a novel HLA-A allele, HLA-A*2458. Tissue Antigens, 68, 177-178. Bohle, B., Zwolfer, B., Fischer, G.F., Seppala, U., Kinaciyan, T., Bolwig, C., Spangfort, M.D. & Ebner, C. (2005) Characterization of the human T cell response to antigen 5 from Vespula vulgaris (Ves v 5). Clin Exp Allergy, 35, 367-373. Jahn-Schmid, B., Fischer, G.F., Bohle, B., Fae, I., Gadermaier, G., Dedic, A., Ferreira, F. & Ebner, C. (2005) Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 *01. J Allergy Clin Immunol, 115, 399-404. Mrazek, F., Fae, I., Ambruzova, Z., Raida, L., Indrak, K., Petrek, M. & Fischer, G.F. (2005) A novel HLA-B*420502 allele identified by PCR-SSO/SSP routine typing and confirmed by Sequencing-based typing. Tissue Antigens, 65, 275-277. Danzer, M., Leitner, D., Gangl, E., Fae, I., Fischer, G.F. & Gabriel, C. (2004) A novel HLA- DRB1*13 allele (DRB1*1357) identified by polymerase chain reaction with sequence- specific primers and direct sequencing. Tissue Antigens, 64, 213-214. Fae, I., Lau, M., Voorter, C., Mayr, W.R. & Fischer, G.F. (2004) HLA-B*8102*, a new allele found in an external proficiency testing scheme. Tissue Antigens, 64, 608-610. Voorter, C.E., Fischer, G.F. & van den Berg-Loonen, E.M. (2004) Identification of a new HLA-C allele, Cw*0316, by sequence-based typing. Tissue Antigens, 63, 484-486. Weiwad, M., Werner, A., Rucknagel, P., Schierhorn, A., Kullertz, G. & Fischer, G. (2004) Catalysis of proline-directed protein phosphorylation by peptidyl-prolyl cis/trans isomerases. J Mol Biol, 339, 635-646. Bohle, B., Radakovics, A., Jahn-Schmid, B., Hoffmann-Sommergruber, K., Fischer, G.F. & Ebner, C. (2003) Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level. Eur J Immunol, 33, 3303-3310. Spatz, M., Eibl, N., Hink, S., Wolf, H.M., Fischer, G.F., Mayr, W.R., Schernthaner, G. & Eibl, M.M. (2003) Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol, 221, 15-26. Vogelsang, H., Panzer, S., Mayr, W.R., Granditsch, G. & Fischer, G.F. (2003) Distribution of HLA class I alleles differs in celiac disease patients according to age of onset. Dig Dis Sci, 48, 611-614. Winter, D., Fiebiger, E., Meraner, P., Auer, H., Brna, C., Strohal, R., Trautinger, F., Knobler, R., Fischer, G.F., Stingl, G. & Maurer, D. (2003) Definition of TCR epitopes for CTL- mediated attack of cutaneous T cell lymphoma. J Immunol, 171, 2714-2724. Jahn-Schmid, B., Kelemen, P., Himly, M., Bohle, B., Fischer, G., Ferreira, F. & Ebner, C. (2002) The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by
  • 155. - 155 - one epitope. J Immunol, 169, 6005-6011. Worel, N., Biener, D., Kalhs, P., Mitterbauer, M., Keil, F., Schulenburg, A., Hocker, P., Dieckmann, K., Fischer, G., Rosenmayr, A., Linkesch, W., Hinterberger, W., Lechner, K. & Greinix, H.T. (2002) Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant, 30, 619-626. Worel, N., Greinix, H.T., Keil, F., Mitterbauer, M., Lechner, K., Fischer, G., Mayr, W., Hocker, P. & Kalhs, P. (2002) Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion, 42, 1293-1301. Invited Talks 2002-2008 2005 • Invited talk at the DGI Tagung, Dresden 2006 • Invited talk at the DGI Tagung, Innsbruck 2007 • Invited talk at the Balcanic Immunogentics Conference, Bukarest 2008 • Invited Talk at the East West Conference, Prague
  • 156. - 156 - Curriculum Vitae Elisabeth Förster-Waldl Department of Pediatrics & Adolescent Medicine, Division of General Pediatrics & Neonatology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43-1-40400-3232, Fax: +43-1-40400-3238; Email: elisabeth.foerster-waldl@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/kikli Personal Data Date of Birth: 07.12.1960 Place of Birth: Pittsburgh, Pa., U.S.A. Nationality Austria Education 1988 Graduation as Doctor Medicinae (M.D.) 1979-1988 Graduate studies at the University of Vienna Medical School 1971-1979 High school in Vienna, Austria 1966-1971 French elementary school (Lycée français de Vienne) in Vienna, Austria Career History since 2007 Consultant for Pediatric Immunology at the St. Anna Children’s Hospital, Vienna, Austria since 2005 Head of the Pediatric Immunology Outpatient Ward at the Department of Pediatrics, Medical University of Vienna since 2005 Group leader of the Working Group Pediatric & Neonatal Immunology at the Department of Pediatrics, Medical University of Vienna, Austria since 11/2004 Associate Professor of Pediatrics (a.o.Univ.Prof) 11/2004 Habilitation in Pediatrics, Medical University of Vienna since 2002 Medical specialist for Immunology 2001 Guest Scientist at the Institute of Immunology, Medical University of Vienna since 2000 Medical specialist for Pediatrics & Adolescent Medicine 1992 – 1999 Resident in pediatrics at the Dept. of Pediatrics, Univ. of
  • 157. - 157 - Vienna. Special training in clinical immunology and allergology/pulmology 1996 – 1998 Research Fellow (Erwin Schrödinger Grant of the Austrian Science Fund) at the Dept. of Pediatric Immunology (Head: Prof. Dr. G.A. Holländer), Basel, CH. Topic: The role of CD40-mediated costimulation in T-cell activation and tolerance (in a mouse allogeneic transplantation model) 1991 – 1992 Research Fellow (Otto Loewi-Grant of the Austrian Science Fund) at the Dept. of Pediatrics, Univ. of Vienna, working on T-cell regulation of allergic diseases (model: bee venom allergy) and on the allergenic profile of recombinant bee venom Phospholipase A2, the major bee- venom allergen 1988 – 1991 Research fellow at the Dept. of Dermatology, Univ. of Vienna, Ludwig Boltzmann-Institute for cell biology in immunodermatological reactions (Head: Prof. Dr. T.A. Luger), working on the cytokine regulation of inflammatory immune reponses in the skin Career-related Activities 2003 4th Advanced Vaccinology Course at the Fondation Mérieux 1999 Guest Scientist at the Scripps Research Institute, La Jolla, USA, working on immunomodulatory therapies by DNA vaccines and antibody-cytokine fusion proteins 1996 – 1998 Research Fellow (Erwin Schrödinger Grant of the Austrian Science Fund) at the Dept. of Pediatric Immunology (Head: Prof.Dr.G.A. Holländer), Basel, CH Awards 2006 Scientific award of the GNPI (Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin) for the original publication (first author) ‚Monocyte Toll-like receptor 4 expression and LPS-induced cytokine
  • 158. - 158 - production increase during gestational aging’ 2005 Poster-Award (last author) at the Annual Meeting of the Austrian Society of Pediatrics Sept.2005; „ Impaired Immune Responses to Bacterial Cell Wall Components in Preterm Newborns“ 1999 Hofrat von Domanig Award of the Van Swieten Gesellschaft to work as guest-scientist at the Scripps Research Institute, La Jolla, USA, with immunomodulating therapies through DNA-vaccines and antibody-cytokine fusion proteins Memberships Austrian Society for Allergology and Immunology Working Group for Pediatric Immunology (API) Austrian Society of Pediatrics European Society for Pediatric Infectious Diseases (ESPID) Van Swieten Gesellschaft Research Topics Neonatal and Pediatric Immunology, Immunological Immaturity and Immunodeficiencies, Preventive and therapeutic strategies against infectious diseases, vaccine failures due to immunodefiency and strategies to prevent such failures, vaccine adjuvant strategies and vaccine delivery systems (experimentally: DNA-vaccines) Publications 22 peer reviewed publications in scientific journals, 4 reviews & book chapters Peer reviewed manuscripts 2002-2008 (original research) Sadeghi K., Berger A., Langgartner M., Prusa A.R., Hayde M., Herkner K., Pollak A., Spittler A., Förster-Waldl E. Immaturity of infection control in preterm and term newborns is associated with impaired TLR signaling. J Infect Dis. 195: 296–302 (2007) Fest S., Huebener N., Weixler S., Zeng Y., Strandsby A., Bleeke M., Volkmer-Engert R., Landgraf C., Gaedicke G., Riemer A., Jensen-Jarolim E., Michalsky E., Jaeger I.S., Preissner R., Förster-Waldl E., Lode H.N.. Characterisation of GD2 Peptide Mimotope DNA Vaccines effective against spontaneous neuroblastoma metastasis. Cancer Res. 66 (21): 10567-75 (2006) Riemer A.B., Förster-Waldl E., Brämswig K., Pollak A., Zielinski C.C., Pehamberger H., Lode H.N., Scheiner O., Jensen-Jarolim E. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol.
  • 159. - 159 - 36(5):1267-74 (2006) Förster-Waldl E., K. Sadeghi, D. Tamandl, B. Gerhold, U. Hallwirth, K. Rohrmeister, M. Hayde, K. Herkner, G. Boltz-Nitulescu, A. Pollak, and A. Spittler. Monocyte Toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res. 58 (1):121-24. (2005) Förster-Waldl, E., A.B. Riemer, A.K. Dehof, D. Neumann, K. Brämswig, G. Boltz- Nitulescu, H. Pehamberger, C.C. Zielinski, O. Scheiner, A. Pollak, H. Lode, E. Jensen- Jarolim. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol Immunol. 42(3):319-25 (2005) Szalai K., Schöll I., Förster-Waldl E., Riemer AB, Boltz-Nitulescu G, Polito L, Bolognesi A., Stirpe F., Jensen-Jarolim E. Occupational sensitization to ribosome-inactivating proteins (RIPs) in Researchers. Clin Exp Allergy 35 (10):1354-60 (2005) Schöll I, Weissenböck A, Förster-Waldl E, Untersmayr E, Walter F, Willheim M, Boltz- Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E: Allergen-loaded biodegradable PLGA nanoparticles downregulate an ongoing Th2-response in the Balb/c mouse model. Clin.Exp.Allergy 34(2):315-21 (2004) Schuller E, Förster-Waldl E, Slavc I, Maurer W: Immunity against vaccine-preventable potentially neurotropic diseases in children treated for malignant brain tumours with HIT-91 chemo- and radiotherapy. Eur J Cancer 40(2):236-44 (2004) Förster-Waldl E, Marchetti M, Schöll I, Focke M, Radauer C, Kinaciyan T, Nentwich I, Schmid ER, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E: Type I Allergy to Elderberry is elicited by a 33.2 kDa Allergen with significant Homology to Ribosomal Inactivating Proteins (RIPs). Clin.Exp.Allergy, 33: 1703-10 (2003) Untersmayr E, Schöll I, Swoboda I, Beil W, Förster-Waldl E, Walter F, Riemer A, Kraml G, Kinaciyan T, Spitzauer S, Boltz-Nitulescu G, Scheiner O, Jensen-Jarolim E: Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in Balb/c mice. J Allergy Clin Immunol. 112:616-23 (2003) Förster-Waldl E, Cokoja L, Förster O, Maurer W: Mannose binding lectin: comparison of two assays for the quantification of MBL in serum of pediatric patients. J Immunol Methods. 276(1-2):143-46 (2003) Schöll I, Wiedermann U, Förster-Waldl E, Ganglberger E, Baier K, Boltz-Nitulescu G, Scheiner O, Ebner C, Jensen-Jarolim E: Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B-cell responses to the natural antigen using bystander T-cell help. Clin.Exp.Allergy 32:1583-88 (2002)
  • 160. - 160 - Curriculum Vitae Renate Fuchs Research Group for Cell Biology, Division of Cellular and Molecular Pathophysiology, Department of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Phone: +43 1 40400-5127, Fax: +43 1 40400-5130 Email: renate.fuchs@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/ipp Personal Data Date of Birth: 24.12.1950 Place of Birth: Vienna Nationality Austria Education 2.5.1984 Ph.D. (Dr.rer.nat.techn.) University of Agriculture, Vienna, Austria 1977-1983 Thesis:”Influence of vitamin D on chick small intestinal transport systems (interrupted by 2 maternal leaves) 7.7.1977 Master of Science in Food- and Biotechnology (Dipl.Ing.) 1976-1977 Diploma Thesis: „Glucosidehydrolases“ 1969-1977 Food- and Biotechnology, University of Agriculture, Vienna, Austria 1961-1969 High School; graduation with distinction Career History 2004 - present Associate Professor, Department of Pathophysiology, Medical University of Vienna, Austria 1994 Title: “tit. Ao.Prof.” 1991 Head of Research Group for Cell Biology 1990-2004 Associate Professor, Department of General and Experimental Pathology – 2000 renamed Department of Pathophysiology 1.3.1990 Habilitation (Venia docendi) in Experimental Pathology, Univ. Vienna, Austria 1989-1990 Assistant Professor, Department of General and Experimental Pathology, Univ. Vienna
  • 161. - 161 - 1986-1989 Research Associate, Department of General and Experimental Pathology, Univ. Vienna, Austria 1985-1986 Post-doctoral Associate, Dept. Cell Biology, Yale Univ., New Haven, USA 1984-1985 Post-doctoral Fellow: Dept. Cell Biology, Yale Univ., New Haven, USA 1983 Visiting Scientist at the Max Planck-Institute of Biophysics, Frankfurt, Germany 1979 Visiting Scientist at the Max Planck-Institute of Biophysics, Frankfurt, Germany 1977-1984 Department of General and Experimental Pathology, Univ. Vienna, Austria Career-related Activities 1990 - present Supervision of 14 Ph.D and 8 diploma students 1990 - present Reviewer for the following journals: MBC, JBC, EMBO J, Traffic, J Virol, Virology, Mol Ther, Clin Exp Allergy, Exp. Gerontol, Int. Hepatol. 1990 - present Grant reviewer for: Academy of Finland (chairman), ESF, ETH Swiss, CNRS France, German-Israel Foundation for Scientific Research, British Research Council (BBSRC), OeNB Awards 1996 Hoechst Research Award 1990 Kardinal-Innitzer-Förderungspreis 1988 Hans Popper Award of the American Liver Association 1986 Hoechst Research Award 1984 - 1986 Max-Kade Fellowship 1980 Hoechst Research Award Memberships American Society for Cell Biology American Society for Microbiology, Section Virology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year
  • 162. - 162 - 2004-2007 FWF 17590 Rhinovirus RNA uncoating and membrane 152 translocation 2004 AP00032OFF Visualization of placental membrane 6 Aktion Österreich- transporters Tschechien 2000-2004 Virologie-Fonds Viral receptors in human rhinovirus infection 44 Kooperation Dr. Blaas 1999-2002 OeNB 7511 Elektrophysiology of virus infection 6 2000-2004 FWF 14079-MED hFcRn expression in the placenta 58 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 1999-2003 Leitner Karl hFcRn/Beta-2-Mikroglobulin (β2m) expression in human placental sycytiotrophoblasts 2000-2004 Baravalle Günther Characterization of the intracellular pathways and requirements for infection of the minor group human rhinovirus serotype 2 2000-2004 Exner Bettina Functional expression of the human neonatal Fc- receptor, hFcRn, in Ewing´s sarcoma 1999-2007 Brabec Marianne Mechanism of entry and RNA release of human rhinovirus serotype 2 (HRV2) 2003 Busch Bernhard FcRn mediated IgG-transport 2005- Berka Ursula Human rhinovirus RNA translokation present Publications 52 peer reviewed publications in scientific journals; 16 publications: book chapters, handbooks and proceedings; 28 invited lectures. Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: Ellinger, I., Klapper, H., Courtoy, P.J., Vaerman, J.P.and Fuchs, R. (2002). Different temperature-sensitivity of endosomes involved in transport to lysosomes and transcytosis in rat hepatocytes: Analysis by free-flow electrophoresis. Electrophoresis, 23, 2117-2129. Leitner, K., Ellinger, A., Zimmer, K.P., Ellinger, I. and Fuchs, R. (2002). Localization of ß2- microglobulin in term villous syncytiotrophoblasts. Histochem. Cell Biol, 117, 187-193. Brabec, M., Baravalle, G., Blaas, D. and Fuchs, R (2003). Conformational changes, plasma membrane penetration and infection of human rhinovirus 2: role of receptors and low pH. J Virol, 77, 5370-5377. Baravalle, G., Snyers, L., Brabec, M., Blaas, D. and Fuchs, R. (2004). Human rhinovirus type
  • 163. - 163 - 2-antibody complexes enter and infect cells via Fc-gamma receptor IIB1. J. Virol., 78, 2729- 2735. Fuchs, R., Ellinger, I. (2004). Endocytic and transcytotic processes in villous syncytiotrophoblast: role in nutrient transport to the human fetus. Traffic, 5, 725-738. Brabec, M., Schober, D., Wagner, E., Bayer, N., Murphy, R.F. and Blaas, D. (2005). Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. J Virol, 79, 1008-1016. Baravalle, G., Schober, D., Huber, M., Bayer, N., Murphy, R.F. and Fuchs, R. (2005). Transferrin recycling and dextran transport to lysosomes is differentially affected by bafilomycin, nocodazole, and low temperature. Cell Tissue Res, 320, 99-113. Ellinger, I., Reischer, H., Lehner, C., Leitner, K., Hunziker, W. and Fuchs, R. (2005). Overexpression of the human neonatal Fc-receptor alpha-chain in trophoblast-derived BeWo cells increases cellular retention of beta2-microglobulin. Placenta ,26,171-182. Brabec, M., Blaas, D. and Fuchs, R. (2006) Wortmannin delays transfer of human rhinovirus serotype 2 to late endocytic compartments. Biochem Biophys Res Commun, 348,741-749. Brabec-Zaruba, M., Blaas, D. and Fuchs, R (2007). Induction of autophagy does not affect human rhinovirus type 2 production. J Virol, 81,10815-10817. Co-author manuscripts: Goncalves, C., Mennesson, E., Fuchs, R., Gorvel, J.P., Midoux, P., Pichon, C. (2004) Macropinocytosis of polyplexes and recycling of plasmid via the clathrin-dependent pathway impair the transfection efficiency of human hepatocarcinoma cells. Mol Ther, 10, 373-385. Roth-Walter, F., Scholl, I., Untersmayr, E., Fuchs, R., Boltz-Nitulescu, G., Weissenbock A., et al. (2004). M cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy. J Allergy Clin Immunol, 114, 1362-1368. Invited Talks 2002-2008 2002 • 23.8.-25.8.2002:Virus-cell interactions, Tvarminne, Finnland "Receptor independent uncoating of the minor group human rhinovirus HRV2” 2003 • 24.2.2003: Institut für Molekulare Pathologie, Universität Louvain, Brüssel „Influence of bafilomycin and nocodazole on HRV2 entry pathways“ • 26.2.2003: Institut für Med. Biochemie, Univ. Wien „HRV2 entry and uncoating“ 2004 • 26.11.2004: Frauenklinik Graz; „IgG Transport in der Plazenta“ 2005 • 9.2.2005: Kongreß “The brush border membrane”, Fulda, Deutschland; “IgG transport across epithelia mediated by the human neonatal Fc-Receptor, hFcRn” • 1.8.2005: Kongreß “Virus Cell Interactions”, Seli, Finnland; “Entry and replication of human rhinoviruses” • 24.8.2005: Microscopy Conference – Dreiländertagung, Davos, Schweiz; “Dynamics of human rhinovirus infections”
  • 164. - 164 - • 2.10. 2005: GRC Summer School, Hannover, Deutschland; “Entry and replication of human rhinoviruses” • 3.10. 2005: Dept. Biochemie, Universität Hannover, Deutschland; “IgG transport in the human placenta” 2006 • 17.6.-22.6.2006: FASEB Research Conference on Virus Assembly; Vermont Academy, VT, USA; “Entry and uncoating of human rhinoviruses. • 6.-9.9.2006: IFPA Meeting 2006, Kobe, Japan; “IgG transport in placental trophoblasts” • 26.11.-1.12.2006: EUROPIC 2006, Inari, Finnland; “Entry and uncoating of human rhinoviruses • 19.8.2005: Kongreß “Virus Cell Interactions”, Seli, Finnland; “Entry and replication of human rhinoviruses” 2007 • 19.8.-21.8.2007: Kongreß Virus Cell Interactions, Archipelago Research Institute, Seli, Finland: Entry and RNA release of the minor group virus HRV2. 2008 • 8. 2.2008: Univ. Cambridge, GB : Mechanism of human rhinovirus infections
  • 165. - 165 - Curriculum Vitae Ulrich Jäger Department of Internal Medicine I, Division of Hematology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Wien, Austria; Phone: +43-1-40400-4409, Fax: +43-1-40400-4030 Email: ulrich.jaeger@meduniwien.ac.at; Personal Data Date of Birth: 04.06.1956 Place of Birth: Lienz Nationality Austria Education 1996 Specialist of Hematology and Oncology 1990 Internist 1974 - 1982 University of Vienna, Medical School Career History Since 2004 Professor of Hematology 2001 - 2004 Director of Hematology Outpatient Service 1994 Habilitation in Internal Medicine, University of Vienna Medical School 1989 - 2001 Clinical studies: Minimal residual disease in lymphoma and leukaemia 1989 - present Group Leader - Div. of. Hematology, University of Vienna: Oncogene Laboratory. Scientific projects: Molecular biology of lymphoma and leukemia, mechanism of chromosomal translocations 1986 - 1989 Howard Hughes Medical Institute, Washington University, St. Louis, MO, USA (Prof. S.J.Korsmeyer) – Scientific projects: Molecular biology of lymphoma 1984-1986 Scientific projects in Hematology/Immunology 1984-1990 Specialized training in Hematology/Hemostaseology (Board certification:28-05-1996) 1982-1990 Training in General Internal Medicine, University of Vienna Medical School (Board certification: 07-08-90
  • 166. - 166 - Career-related Activities 2005 - Member of the Habilitations Commission (conservative) of the Medical University of Vienna 2005 - Editor of the Educational series of the Wiener Klinische Wochenschrift 2001 – 2006 Organizer: Young Investigators Meeting of the Austrian Society of Hematology and Oncology 2000 Secretary of the Annual Meeting of the Austrian Society of Hematology and Oncology 1998 - 1999 Postgradual Course in Medical Management Awards 2003, 2004 Aventis-Award 2002 Award of the „Erste Bank“ 1996 Award of the Austrian Cancer Society 1993, 1998, 2002, 2003 Wilhelm Tuerk Award of the Austrian Society of Hematology and Oncology Memberships Austrian Society of Hematology and Oncology Austrian Society of Medicine American Society of Hematology European Society of Hematology Society on Progress in Medicine Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2003-2005 ÖAW CeMM 20010 “Genetic instability of the 104 immune system” 2006-2008 bm:bwk Oncogenomics – GEN-AU CHILD 55 2006-2010 AGMT NHL-13 114 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2006-2009 Dr. Edit Porpaczy Biological function and signaling cascade of lipoprotein lipase in B-cell chronic lymphocytic leukemia (N094)
  • 167. - 167 - Publications 192 peer reviewed publications in scientific journals, 10 book chapters, > 70 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: • Skrabs C, Müller C, Agis H, Mannhalter C, Jaeger U. Treatment of HBV carrying lymphoma patients with Rituximab and CHOP: A diagnostic and therapeutic challenge. Leukemia 2002; 16: 1884-1886. • Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T, Fonatsch C, Haas OA, Mannhalter C, Lechner K, Jaeger U. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21), or inv(16). Hematol J/Haematologica 2002; 3: 283-289. • Heintel D, Streubel B, Welzel N, Le T, Schwarzinger I, Haas OA, Simonitsch I, Lechner K, Jaeger U. Burkitt Lymphoma following splenic marginal zone lymphoma: Evidence for two independent B-cell clones. Cancer Genet Cytogen 2003; 141: 86-88. • Jaeger U, Kainz B. Monitoring Minimal Residual Disease in AML: The right time for Real Time. Ann Hematol 2003; 82: 139-147. • Jaeger U. Innovative strategies in lymphoma therapy. Wien Klin Wochenschr 2003; 115: 13-14. • Simonitsch-Klupp I, Skrabs C, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U. Diffuse Large B-Cell Lymphomas with Plasmablastic/Plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia 2004; 18: 146-155. • Heintel D, Kroemer E, Kienle D , Schwarzinger I, Gleiß A , Schwarzmeier J, Marculescu R, Le T, Mannhalter C , Gaiger A, Stilgenbauer S, Fonatsch C, Jaeger U. Expression of activation-induced cytidine deaminase (AID) mRNA is a marker for IGVH gene mutational status and cytogenetic aberrations in patients with chronic lymphocytic leukemia. Leukemia 2004; 18: 756-762. • Mitterbauer G, Mannhalter C, Skrabs C, Mitterbauer M, Simonitsch I, Winkler K, Lechner K, Chott A, Jaeger U. Prognostic value of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL). Leukemia 2004; 18: 1102-1107. • Gaiger A, Heintel D, Jäger U. Novel Molecular Diagnostic and Therapeutic Targets in Chronic Lymphocytic Leukemia. Eur J Clin Invest 2004; 34 Suppl 2: 25-30. • Heintel D, Kienle D, Shehata M, Kröber A, Kroemer E, Schwarzinger I, Mitteregger D, Gleiß A, Mannhalter C, Chott A, Schwarzmeier J, Fonatsch C, Gaiger A, Döhner H, Stilgenbauer S, Jäger U. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216-1223. • Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I, Öhler L, Simonitsch-Klupp I, Reinhard F, Jäger U. Remission of pure red cell aplasia in T- cell receptor γδ-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005; 19: 2005-2008. • Bilban M, Heintel D, Scharl T, Wölfel T, Auer MM, Porpaczy E, Kainz B, Krober A, Carey VJ, Shehata M, Zielinski C, Pickl W, Stilgenbauer S, Gaiger A, Wagner O, Jäger U. Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 2006; 20:1080-8. • Hauswirth AW, Skrabs C, Schützinger C, Gaiger A, Lechner K, Jäger U. Autoimmune haemolytic anaemias (AIHA), Evans’ syndrome and pure red cell aplasia (PRCA) in Non- Hodgkin lymphomas. Leuk Lymph 2007; 48: 1139-1149 • Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, Le T, Kröber A, Heller G, Schwarzinger I, Demirtas D, Chott A, Döhner H, Zöchbauer-Müller S, Fonatsch C, Zielinski C, Stilgenbauer S, Gaiger A, Wagner O, Jäger U. Overexpression of the
  • 168. - 168 - paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukaemia. Int J Cancer 2007; 121: 1984-1993 • Coiffier B, Tabacof J, Shen ZX, Jäger U. Aggressive non-Hodgkin’s lymphoma – long- term survival for all patients? Hematology Meeting Reports 2007; 1: 27-41 • Hauswirth A, Skrabs C, Schützinger C, Raderer M, Lechner K, Jäger U. Autoimmune thrombocytopenia in Non-Hodgkin lymphomas. Haematol/ Hematol J 2007; 93: 447-450. • Schützinger C, Esterbauer H, Hron G, Skrabs C, Uffmann M, Raderer M, Hauswirth A, Mannhalter C, Dieckmann K, Wagner O, Formanek M, Stift A, Friedl J, Gaiger A, Chott A, Jäger U. Prognostic value of T-cell receptor γ rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas. Leuk Lymphoma 2008; 49: 237-246 • Hauswirth AW, Jäger U. Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukaemia. Haematol/Hematol J 2008; 93: 14- 19. Co-author manuscripts: • Marculescu R, Le T, Simon P, Jaeger U, Nadel B. V(D)J-mediated translocations in lymphoid neoplasms: A functional assessment of genomic instability by cryptic sites. J Exp Med 2002; 195: 85-98. • Marculescu R, Le T, Böcskör S, Mitterbauer G, Chott A, Mannhalter C, Jaeger U, Nadel B. Alternative end-joining in follicular lymphomas’ t(14;18) translocation. Leukemia 2002; 16: 120-126. • Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HAT, Karanikas G, Pötzi C, Raderer M, Dudzak R, Kletter K. Positron emission tomography with [18F]2-Fluoro-D-2- Deoxyglucose (FDG-PET) for relapse prediction of malignant lymphoma after high-dose therapy with stem cell support. Leukemia 2002; 16: 260-267. • Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, Skrabs C, Pirker R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8: 729-733. • Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, Jaeger U, Lechner K, Schneider B, Fonatsch C, Schwarzinger I. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117: 380-389. • Agis H, Weltermann A, Fonatsch C, Haas O, Mitterbauer G, Müllauer L, Schreiber S, Schwarzinger I, Juretzka W, Valent P, Jaeger U, Lechner K, Geissler K. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 2002; 81: 90-95. • Österborg A, Brandberg Y, Molostova V, Iosawa G, Abdulkadyrov K, Hedenus M, Messinger D for the Epoetin Beta Hematology Study Group (including Jaeger U). Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Erythropoietin, Epoetin Beta, in Hematologic Malignancies. J Clin Oncol 2002; 20: 2486-2494. • Selenko N, Majdic O, Jaeger U, Sillaber C, Stöckl J, Knapp W. Cross priming of cytotoxic T-cells promoted by apoptosis inducing tumor cell reactive antibodies? J Clin Immunol 2002; 22: 124-130. • Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H, Jordan JH, Chott A, Drach J, Jaeger U, Geissler K, Greschniok A, Horny HP, Lechner K, Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002; 43: 1097-1105. • Raderer M, Chott A, Drach J, Montalban C, Dragosics B, Jaeger U, Puspok A, Osterreicher C, Zielinski CC. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann Oncol 2002; 13: 1094-1098. • Parolini O, Kagerbauer B, Simonitsch-Klupp I, Ambros P, Jaeger U, Mann G, Haas OA,
  • 169. - 169 - Morra M, Gadner H, Terhorst C, Knapp W, Holter W. Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma. Ann Hematol 2002; 81: 441-447. • Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA. Infusional CDE with rituximab for the treatment of human immunodeficiency virus- associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results in Cancer Res 2002; 159: 149-153. • Hallek M, Bergmann M, Brittinger G, Dohner H, Dreger P, Herold M, Hopfinger G, Jäger U, Knauf W, Nerl C, Rummel M, Schmitt B, Wendtner CM, Emmerich B. Chronisch lymphatische Leukämie und verwandte Leukämien: Aktuelle Therapiekonzepte. Internist 2002; 43: 1245-1254. • Spina M, Sparano JA, Jaeger U, Rossi G, Tirelli U. Rituximab and chemotherapy is highly effective in patients with CD20-positive non-Hodgkin's lymphoma and HIV infection. AIDS 2003; 17: 137-138. • Marculescu R, Vanura K, Le T, Simon P, Jäger U, Nadel B. Distinct t(7;9)(q34;q32) breakpoints in healthy individuals and T-ALL patients: Signal joint reactivity as a novel pathway of V(D)J-mediated oncogene activation. Nat Genet 2003; 33: 342-344. • Feierl E, Dejaco C, Heintel D, Wagner A, Chatwani S, Stelzhammer R, Hammer J, Jaeger U, Thurnher S, End A. Arterial bleeding of the esophagus associated with diffuse large B- cell lymphoma. Gastrointest Endosc 2003; 57: 387-388. • Hauser AC, Brichta A, Pabinger-Fasching I, Jaeger U, Lechner K. Fibrinolytic therapy with r-tPA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome. Ann Hematol 2003; 82: 299-302. • Hoffmann M, Kletter K, Becherer A, Jäger U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003; 64: 336-340. • Berer A, Kainz B, Jäger U, Jäger E, Stengg S, Streubel B, Fonatsch C, Mitterbauer G, Lechner K, Geissler K, Ohler L. Relation of in vitro growth characteristics to cytogenetics and treatment outcome in acute myeloid leukemia: prognostic significance in patients with a normal karyotype. Int J Hematol 2003; 78: 241-247. • Becherer A, Jaeger U, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med 2003; 47: 14-21. • Becherer A, Jaeger U, Kletter K. Prognostic value of FDG-PET in malignant lymphoma. Q J Nucl Med 2003; 47: 14-21. • Vanura K, Marculescu R, Le T, Jaeger U, Nadel B. Physiological and Physiopathological Roles of Signal Joint Reactivity. Recent Research Developments in Immunology 2003; 5: 167-178. • Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kalhs P, Mitterbauer G, Jaeger U, Geissler K, Valent P, Sperr W, Knoebl P, Schwarzinger I, Gleiss A, Kainz B, Lechner K. The Impact of Cytogenetics on the Prognosis of Adults with de novo AML in First Relapse. Leukemia 2004; 18: 293-302. • Hoffmann M, Chott A, Püspök A, Jäger U, Kletter U, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 2004; 83: 276-278. • Mitterbauer M, Mitterbauer-Hohendanner G, Sperr WR, Kalhs P, Greinix HT, Fonatsch C, Haas OA, Jäger U, Mannhalter C, Lechner K. Molecular disease eradication is a prerequisite for long-term remission in patients with t(8;21) positive acute myeloid leukemia: A single center study. Leuk Lymphoma 2004; 45: 971-977. • Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knobl P, Jäger U, Lechner K, Valent P. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res 2004; 10: 3965-3971. • Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, Jäger U, Sperr W, Greinix HT, König M, Emberger W, Haas OA. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: Breakpoint cluster
  • 170. - 170 - region and clinical implications. Leukemia 2004; 18: 1115-1121. • Streubel B, Chott A, Huber D, Exner M, Jäger U, Wagner O, Schwarzinger I. Lymphoma- specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250-259. • Langerak A, Nadel B, de Torbal A, Wolvers-Tettero ILM, van Gastel-Mol EJ, Verhaaf B, Jäger U, Van Dongen JJ. Unraveling the consecutive recombination events in the human IGκ locus. J Immunol 2004; 173: 3878-3888. • Füreder W, Filipits M, Sperr WR, Kainz B, Jäger U, Fonatsch C, Schwarzinger I, Haas OA, Pirker R, Lechner K. Highly refractory acute myeloid leukemia. Wien Klin Wochenschr 2004; 116: 561-564. • Kaufmann H, Ackermann J, Baldia C, Nösslinger T, Wieser R, Seidl S, Sagaster V, Gisslinger H, Jäger U, Pfeilstöcker M, Zielinski C, Drach J. Both IgH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879-1882. • Hallek M, Bergmann M, Emmerich B for the German CLL Study Group (Incl. Jäger U). Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment. Onkologie 2004; 27: 97-104. • Ziegler S, Sperr W, Knöbl P, Lehr S, Weltermann A, Jäger U, Valent P, Lechner K. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors and impact on prognosis. Thromb Res 2005; 115: 59-64. • Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E, Berretta M, Cattaneo C, Rieger AC, Vaccher E, Tirelli U. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase II trials. Blood 2005; 105: 1891-1897. • Kainz B, Fonatsch C, Schwarzinger I, Sperr WR, Jäger U, Gaiger A. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukaemia. Hematol J / Haematologica 2005; 90: 695-696. • Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, Seymour JF. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom’s macroglobulinemia and related disorders. Clin Lymphoma 2005; 5: 294-297. • Raderer M, Streubel B, Wöhrer S, Püspök A, Jäger U, Formanek M, Chott A. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005; 11: 3349-3352. • Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, Kröber A, Jäger U, Lichter P, Döhner H, Stilgenbauer S. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23: 3780- 3792. • Böhm A, Piribauer M, Wimazal F, Geissler K, Gisslinger H, Knöbl P, Jäger U, Fonatsch C, Kyrle PA, Valent P, Lechner K, Sperr WR. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res 2005; 29: 609-615. • Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K, Valent P. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 2005; 11: 6536- 6543. • Woehrer S, Hejna M, Skrabs C, Drach J, Zielinski CC, Jaeger U, Raderer M. Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology 2005; 69: 499-502. • Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 8442-8446. • Schwarzmeier JD, Hubmann R, Düchler M, Jäger U, Shehata M. Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 2005;
  • 171. - 171 - 46: 157-165. • Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Schweighofer C, Wendtner CM, Brittinger G, Emmerich B, Hallek M. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891. • Kienle D, Benner A, Kröber A, Winkler D, Mertens D, Bühler A, Seiler T, Jäger U, Lichter P, Döhner H, Stilgenbauer S. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006; 107: 2090-2093. • Grünberger B, Wöhrer S, Streubel B, Formanek M, Petkov V, Püspök A, Häfner M, Hejna M, Jäger U, Chott A, Raderer M. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006; 24: 1370-1375. • Wöhrer S, Jäger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M, Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006; 17: 780-784. • Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jäger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Löffler M, for the MabThera International Trial (MInT) Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good- prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International (MInT) Study Group. Lancet Oncology 2006; 7: 379-391. • Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, Skrabs C, Gaiger A, Drach J, Püspök A, Formanek M, Hoffmann M, Hauff W, Chott A. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24: 3136-3141 • Strehl S, König M, Meyer C, Schneider B, Harbott J, Jäger U, von Bergh AR, Loncarevic IF, Jarosova M, Schmidt HH, Moore SD, Marschalek R, Haas OA. Molecular dissection of t(11;17) in acute myeloid leukemia reveals a variety of gene fusions with heterogeneous fusion transcripts and multiple splice variants. Genes Chromosomes Cancer 2006; 45: 1041-1049 • Raderer M, Wöhrer S, Streubel B, Drach J, Jäger U, Turetschek K, Troch M, Püspök A, Zielinski CC, Chott A. Activity of rituximab lus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411-417 • Marculescu R, Vanura K, Montpellier B, Roulland S, Le T, Navarro JM, Jäger U, McBlane F, Nadel B. Recombinase, chromosomal translocations and lymphoid neoplasia: targeting mistakes and repair failures. DNA Repair 2006; 5: 1246-1258. • Smolen JS, Keystone EC, Emry P, Breedveld FC, Betteridge N, Burmester GR, Dougados M, Ferraccioli G, Jaeger U, Klareskog L, Kvien TK, Martin-Mola E, Pavelka K; Working Group on the Rituximab Consensus Statement. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-150 • Wöhrer S, Troch M, Zwerina J, Schett G, Skrabs C, Gaiger A, Jäger U, Zielinski C, Raderer M. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 2007; 18: 647-651 • Choquet S, Trappe R, Leblond V, Jäger U, Davi F, Oertel S. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007; 92: 273-274 • Vanura K, Montpellier B, Le T, Spicuglia S, Navarro JM, Cabaud O, Roulland S, Vachez E, Prinz I, Ferrier P, Marculescu R, Jäger U, Nadel B. In vivo reinsertion of excised episomes by the V(D)J recombinase: a potential threat to genomic stability. PLoS Biol 2007 Feb 13;5(3):e43 • Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H,
  • 172. - 172 - Drach J, Gaiger A, Jäger U, Ludwig H. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia 2007 Aug 9; (Epub ahead of print) • Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007; 37: 808-813 • Agis H, Sperr WR, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas OA, Mannhalter C, Esterbauer H, Geissler K, Sillaber C, Jäger U, Valent P. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 2007; 18: 1834-1841 • Vales A, Kondo R, Aichberger KJ, Mayerhofer M, Kainz B, Sperr WR, Sillaber C, Jäger U, Valent P. Myeloid leukemias express a broad spectrum of FEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leuk Lymphoma 2007; 48: 1997-2007 Invited Talks 2002-2008 2002 • „MRD bei Lymphomen“. Symposion: Minimale residuelle Erkrankung bei soliden Tumoren und Hämoblastosen. Retz, 28. 2. - 1. 3. 2002. • „Antikörpertherapie bei Lymphomen“. Wissenschaftliche Sitzung der Gesellschaft für Innere Medizin für Wien und Niederösterreich, Wien, 21. 3. 2002. • „Mechanismen der Entstehung von Translokationen bei lymphatischen Neoplasien“; Frühjahrstagung der ÖGHO, Linz 25. 4. – 27. 4. 2002. • „Antikörpertherapie bei hämatologischen Erkrankungen“. 33.Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. Salzburg, 19. - 21. 9. 2002. • „Lymphome im Rahmen von AIDS“. 13.Österreichischer AIDS Kongress. Wien, 8. - 9. 11. 2002. • “Treatment modalities for Morbus Waldenström“. IV.International Workshop of the German CLL study group. Kloster Irsee, 13. - 15. 2. 2002. 2003 • ”EBV und AIDS-assoziierte Lymphome”. Deutsch - Österreichischer AIDS Kongress. Hamburg, 16. 5. 2003. 2004 • „EBV/Infektion und PTLD nach Organtransplantation2. ÖGN Wintermeeting. Flachau, 31. 3. – 3. 4. 2004. • „Lymphome“. State of the Art, Diagnostik und Therapie. Österreichische Gesellschaft für Innere Medizin. 25. 3. 2004. • „VDJ-mediated translocations in leukemia and lymphoma“. “From Basic Science to Clinical Application”. Wien, 3. 9. 2004. • „Molekulare Pathogenese von Lymphomen“. 2. Jahrestagung der Österreichischen Gesellschaften für Klinische Chemie und Laboratoriumsmedizin. Salzburg, 29. 9. – 2. 10. 2004. • „NHL inkl. CLL, M. Hodgkin: Staging, Therapie (inkl. Kosten), Prognose“. Seminar. 20. 9. und 27. 9. 2004. • „Monoklonale Antikörper“. 35. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. Wien, 16. – 18. 9. 2004. • „Prognosefaktoren bei NHL“. Herbsttagung der Österreichischen Gesellschaft für Pathologie. Retz, 15. – 16. 10. 2004. • „IgVH mutational status and LGL in CLL“. V. International Workshop of the German CLL Study Group. Irsee, 24. – 26. 9. 2004. • „Molekulare Diagnostik bei NHL“. Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie.
  • 173. - 173 - Innsbruck, 2. – 6. 10. 2004. • „Stehen wir vor einem Paradigmenwechsel in der Therapie der CLL und der indolenten Lymphome?“. Satelliten-Symposium „Überleben verlängern bei CLL und indolenten Lymphomen – Ferne Vision oder baldige Realität?“. Innsbruck, 3. 10. 2004. • „Hematological malignancies“. 29. ESMO Kongress. Wien, 29. 10. – 2. 11. 2004. 2006 • Vorsitze und zusammenfassende Vorträge. 4. MabThera Winterworkshop. Schladming, 13. – 15. 1. 2006. • „Klinische Aspekte der Erhaltungstherapie“. Symposium „Überlebensverlängerung beim follikulären NHL“ im Rahmen der Frühjahrstagung der Österreichischen Gesellschaft für Hämatologie und Onkologie. Wels, 27. – 29. April 2006. • „Follikuläres Lymphom: Was ist jetzt State-of-the-Art?“. MabThera Meeting. Wien, 15. – 16. 9. 2006. • “Lymphome”. Wissenschaftliche Sitzung “Hämatologie im Alter”. Gesellschaft der Ärzte. Wien, 16. 11. 2006 • „PI3K“. Studientreffen. Basel, 24. April 2006. • Educational “Aggressive Non-Hodgkin Lymphome”. Annual Joint Meeting of the German, Austrian and Swiss Societies of Hematology and Oncology 2005. Hannover, 1.-.5.October 2005. • Vorsitz und Vortrag beim Meeting “Challenging Cases in Hematologic Malignancy” des Oncology Network Europe (ONE). Wien, 23. 9. 2006. • Vorsitz und Vortrag “Current treatment strategies for B-CLL”. Satellitensymposium “Clinical Aspects of B-CLL and Related Entities”. Wien, 9. 10. 2006. 2007 • Vortrag “Update NHL-13” sowie Zusammenfassung der Sitzung “MCL + Autoimmun”. 5. MabThera Winterworkshop. Schladming, 12. – 14. 1. 2007. • Vortrag “What is the role of maintenance therapy in aggressive lymphoma?” beim Expert Investigator Forum “Maintaining life: optimal strategies to improve survival”. Lissabon, 20. – 22. 4. 2007. • Educational “Genetics in CLL: Impact for prognosis and treatment decisions”. EHA- Kongress. Wien, 7. – 10. 6. 2007. • Vortrag “Novel molecular risk factors and targets in CLL”. 3rd Joint Meeting on Experimental and Clinical Cancer Research Translational Research. Wien, 11. – 12. 10. 2007. • Organisation und abschließender Vortrag sowie Vortrag “Was ist die CLL? Risiko- und Prognosefaktoren, Krankheitsverlauf der CLL” beim Patienteninformationstag. 20. Arbeitstreffen der Deutschen CLL Studiengruppe. Wien, 9. – 10. 11. 2007. • Diskutant zum Thema “Clinical trial sponsorship”. Vienna Initiative to Save European Academic Research II (VISEAR II). Wien, 12. 11. 2007. • Vortrag “Mabthera in maintenance therapy”. NHL-13 Study Meeting. Sarajevo, 15. 11. 2007. • Vortrag “Overview of prognostic factors”. Annual Education Day des UK CLL Forum. 19. 11. 2007.
  • 174. - 174 - Curriculum Vitae Peter Pietschmann Department of Pathopyhsiology, Medical University of Vienna, Währinger Gürtel 18-20, A – 1090 Vienna, Austria, Phone +43-1-40400-51-26; Fax: +43-1-40-400-51-30; E-mail peter.pietschmann@meduniwien.ac.at Personal Data Date of Birth: May 13, 1960 Place of Birth: Vienna Nationality Austria Education 2002 Appointment as Associate Professor of Pathophysiology, Medical School,University of Vienna 2001 Certification as Specialist of Pathophysiology 1994 Certification as Specialist of Rheumatology 1992 Appointment as Associate Professor of Internal Medicine, Medical School,University of Vienna 1990 Certification as Specialist of Internal Medicine 1984 Graduation as Medical Doctor 1979 – 1984 Medical School, University of Vienna 1978 – 1979 Military Service 1970-1978 Secondary School (Vienna) 1966-1970 Elementary School (Vienna) Career History 2007- present Head of the Division of Cellular and Molecular Pathophysiology 2006 – present Deputy Head of the Department of Pathophysiology 2006 - 2007 Head of the Division of Molecular and Biochemical Pathology 2002 – present Associate Professor of Pathophysiology at the Department of Pathophysiology,Medical University of Vienna 1999-present Head of the “Bone, Cartilage and Connective Tissue Research Group” 1998-present Department of Pathophysiology (former Department of
  • 175. - 175 - General and Experimental Pathology), University of Vienna (since 2004: Medical University of Vienna) 1997-1998 Institute of Immunology, University of Vienna 1992-1997 Division of Rheumatology/Department of Internal Medicine 3, University of Vienna 1992-present Associate Professor of Internal Medicine,(Medical) University of Vienna 1991-1992 Rheumatic Diseases Division, Department of Internal Medicine, Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, USA 1990-1991 Department of General and Experimental Pathology, University of Vienna 1984-1990 Department of Medicine 2, University of Vienna Career-related Activities 2007-present President of the Austrian Society for Geriatrics and Gerontology 2000-present Treasurer of the Austrian Society for Bone and Mineral Research 1998-present Board member of the Austrian Society for Geriatrics and Gerontology 1993-present Scientific colaborationwith the Luwdig Boltzmann Institute of Aging Research, Vienna Awards 1986 Paracelsus Award Austrian Society for Internal Medicine 1996 Young Investigator Award World congress on Osteoporosis Memberships American Society for Bone and Mineral Research Austrian Society for Bone and Mineral Research (Member of the Board) Austrian Society for Geriatrics and Gerontology (Member of the Board) Society for Internal Medicine of Vienna and Lower Austria Austrian Society for Rheumatology Austrian Society for Endocrinology and Metabolism Austrian Society for Cytometry Austrian Diabetes Society Medical Society of Vienna
  • 176. - 176 - Affiliation with the Ludwig Boltzmann Institute for Aging Research, Vienna Sources of funding in last 5 years (2000-2005) Only FWF and equivalent projects Period Organization Short Title K€ 2007-2009 Jubiläumsfonds- Vergleichsstudie von Hüftknochen 47 projekt der Österreichischen Nationalbank, ProjektNr. 12544 2007-2009 FWF Cathepsin S: ein Modulator in der 82 Forschungsprojekt Osteoimmunologie P20239-B13 2002-2004 Medizinisch- Die Wirkung von Bone morphogenetic 26 wissenschaftlicher protein-5 auf die Generation von Fonds des Osteoklasten in Knochenmarkskulturen. Bürgermeisters der Bundeshauptstadt Wien, Projekt # 2240 2002-2004 Hochschuljubiläumsst The role of lymphocyte subpopulations in 4 iftung der Stadt Wien, osteoclast generation in murine bone Projekt # H- marrow cultures. 1166/2003 2001 – FWF Extended studies on the modulation of the - 2005 Forschungsprojekt ageing processes in the rat by physical P16060-B05 (Co- exercise and food restriction aplicant) 2001 Medizinisch- Die Bedeutung des Vitamin D-Rezeptors für 6 wissenschaftlicher die Zytokinproduktion von T-Lymphozyten Fonds des Bürgermeisters der Bundeshauptstadt Wien 2000-2001 Jubiläumsfonds der The relationship of cytokines, sex steroids 36 and bone turnover in aging men and women. Österreichischen Nationalbank Dr. rer.nat., Dr. sci.med.Dr. techn. or PhD supervisions in the last 6 years (2002-2008) Period Name of student Topic
  • 177. - 177 - 2005-2008 Daniela Stupphann Bone metabolism in HLA-B27 transgenic rats, an animal model for spondyloathropathies 2005-present Brigitte Behal Meta-Analysis of the spontaneous course of osteoporosis 2006-present Janina Patsch Microarchitecture of bone in osteoporotic men: relation with osteoblastic gene expression patterns and treatment effects 2006-present Martina Rauner Molecular mechanism of osteoblast differentiation: relevance to senile osteoporosis Publications 104 original publications and 20 reviews in peer reviewed scientific journals, 10 book chapters, over 200 invited lectures, Peer reviewed manuscripts 2000-2008 (original research and reviews) First, last or corresponding author manuscripts: Pietschmann P, Hahn P, Kudlacek S, Thomas R, Peterlik M (2000) Surface markers and transendothelial migration of dendritic cells from elderly subjects. Exp Gerontol 35: 213 - 224 Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, Kainberger F, Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P (2000) Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 59: 308 – 310 Pietschmann P, Stöckl J, Draxler S, Majdic O, Knapp W (2000) Functional and phenotypic characterization of dendritic cells generated in human plasma supplemented medium. Scand J Immunol 51: 377 – 383 Grisar J, Hahn P, Brosch S, Peterlik M, Smolen JS, Pietschmann P (2001) Phenotypic characteristics of human monocytes undergoing transendothelial migration. Arthritis Res 3: 127 - 132 Pietschmann P, Kudlacek S, Grisar J, Spitzauer S, Woloszczuk W, Willvonseder R, Peterlik M (2001) Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 31: 444 – 451 Pietschmann P, Grisar J, Thien R, Willheim M, Kerschan-Schindl K, Preisinger E, Peterlik M (2001) Immune phenotype and intracellular cytokine production of peripheral blood mononuclear cells from postmenopausal patients with osteoporotic fractures. Exp Gerontol 36: 1749-1759 Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002). Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29: 1430 – 1436
  • 178. - 178 - Lernbass I, Wutzl A, Grisar J, Schett G, Redlich K, Spitzauer S, Grampp S, Imhof H, Peterlik M, Pietschmann P (2002) Quantitative ultrasound in the assessment of bone status of patients suffering from rheumatic diseases. Skeletal Radiol 31: 270 – 276 Kerschan-Schindl K, Strametz-Juranek J, Heinze G, Grampp S, Biegelmayer C, Pacher R, Maurer G, Fialka-Moser V, Pietschmann P (2003) Pathogenesis of bone loss in heart transplant candidates and recipients. J Heart Lung Transpl 22: 843 – 850 Pietschmann P, Gollob E, Brosch S, Hahn P, Kudlacek S, Willheim M, Woloszczuk W, Peterlik M, Tragl KH (2003) The effect of age and gender on cytokine production by human peripheral blood mononuclear cells and markers of bone metabolism. Exp Gerontol 38: 1119 – 1127 Kerschan-Schindl K, Mitterbauer M, Füreder W, Kudlacek S, Grampp S, Biegelmayer C, Fialka-Moser V, Pietschmann P, Kahls P (2004) Post- transplant complications – Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplantation 34:491-496 Sipos W, Willheim M, Hofbauer G, Pietschmann P (2005) Evaluation of the suitability of monoclonal antibodies for flow cytometric intracellular cytokine detection in peripheral blood lymphocytes. J Vet Med A 52: 55-60 Kerschan-Schindl K, Hawa G, Kudlacek S, Woloszczuk W, Pietschmann P (2005) Serum levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40: 532 – 535 Sipos W, Duvigneau JC, Hofbauer G, Schmoll F, Baravalle G, Hartl R, Exel B, Dobretsberger M, Pietschmann P (2005) Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1α,25(OH)2D3. J Vet Med A52: 382-387 Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F, Peterlik M, Pietschmann P (2006) Bone morphogenetic proteins 5 and g stimulate osteoclast generation. J Biomed Mater Res A 77 (1): 75-83 Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P (2006) Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer. Eur J Clin Invest 36: 566-573 Brosch S, Shehata M, Hofbauer G, Peterlik M, Pietschmann P (2006) Alendronate stimulates expression of functional surface molecules ICAM-1, HLA-DR and B7-2 on human monocytes. Osteol 15: 188-196 Rauner M, Winzer M, Stupphann D, Krenbek D, Pietschmann P (2007) RANKL and OPG gene expression in bone marrow stromal cells and calvarial osteoblasts in mouse and rat. Osteol 16: 19-28 Pietschmann P, Skalicky M, Kneissel M, Rauner M, Hofbauer G, Stupphann D, Viidik A (2007) Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol 42: 1099-1108 Mikosch P, Kerschan-Schindl K, Woloszczuk W, Stettner H, Kudlacek S, Kresnik E, Gallowitsch HJ, Lind P, Pietschmann P (2008)High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy. Thyroid 18:27-33. Kerschan-Schindl K, Ruzicka M, Mahr S, Paireder M, Krestan C, Gleiss A, Bieglmayer C,
  • 179. - 179 - Fialka-Moser V, Pacher R, Grimm M, Pietschmann P (2008) Unexpected low incidence of vertebral fractures in heart transplant recipients: analysis of bone turnover. Transpl Int 21:255-262. Kerschan-Schindl K, Wendlova J, Kudlacek S, Gleiss A, Woloszczuk W, Pietschmann P (2008) Serum levels of receptor activator of nuclear factor kappaB ligand (RANKL) in healthy women and men. Exp Clin Endocrinol Diabetes, Epub ahead of print Stupphann D, Rauner M, Krenbek D, Patsch J, Pirker T, Muschitz C, Resch H, Pietschmann P (2008) Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatology Int: in press Co-author manuscripts: Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Silverman S, Felsenberg D, Vandormael K, Daifotis A, Lombardi A (2000) Alendronate treatment of osteoporosis in men. N Engl J Med 343: 604 – 610 Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G (2001) A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 37: 1247 – 1252 Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S, Cross HS (2001) Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis 22: 1429-1435 Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Türk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G (2002) Tumor necrosis factor α-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46: 785 – 792 Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R (2003) Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32: 681 –686 Sipos W, Duvigneau CJ, Pietschmann P, Willheim M, Höller K, Hartl RT, Wahl K, Steinborn R, Gemeiner M, Schmoll F (2003) Parameters of humoral and cellular immunity following vaccination of pigs with a European modified-live strain of porcine reproductive and respiratory syndrome virus (PRRSV), Viral Immunol 16: 335 – 346 Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004) Soluble RANKL and risk of non- traumatic fracture. JAMA 291: 1108 – 1113 Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A (2004) Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. J Nephrol 17: 87 – 94 Sipos W, Duvigneau JC, Willheim M, Schilcher F, Hartl RT, Hofbauer G, Exel B, Pietschmann P, Schmoll F (2004) Systemic cytokine profile in feeder pigs suffering from natural postweaning multisystemic wasting syndrome (PMWS) as determined by semiquantitative RT-PCR and flow cytometric intracellular cytokine detection. Vet Immunol Immunopathol 99: 63 – 71
  • 180. - 180 - Grisar J, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner CW, Zierhut B, Wagner L, Pietschmann P, Smolen JS (2004) Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 63: 1632-1637 Cavanagh LL, Boyce A, Smith L, Padmanabha J, Filgueira L, Pietschmann P, Thomas R (2005) Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther 7: R230-40 Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak R, Willheim M (2005) Relation of anti-TPO antibody titre and T-lymphocyte cytokine production patterns in Hashimoto’s thyroiditis. Clin Endocrinol 63: 191 – 196 Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M (2005) Interactions of 1α,25- dihydroxyvitamin D3 with IL-12 and IL-4 on cytokine expression of human T lymphocytes. J Allergy Clin Immunol 116: 683 – 689 Sipos W, Duvigneau JC, Pietschmann P, Schilcher F, Hofbauer G, Hartl RT, Schmoll F (2005) Porcine dermatitis and nephropathy syndrome (PDNS) is associated with a systemic cytokine expression profile indicative of proinflammation and a Th1 bias. Vet Immunol Immunopathol, A52: 382-387 Gugatschka M, Dobnig H, Fahrleitner-Pammer A, Pietschmann P, Kudlacek S, Strele A, Obermayer-Pietsch B (2005) Molecularly-defined malabsorption, milk consumption and anthropometric differences in adult males. Q J Med 98: 857-863 Fischer P, Gruenblatt E, Pietschmann P, Tragl KH (2006) Serotonin Transporter Polymorphism and LDL-Cholesterol. Mol Psychiatry 11 (8): 707-709 Wutzl A, Eisenmenger G, Hoffmann M, Czerny C, Moser D, Pietschmann P, Ewers R, Baumann A. (2006) Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr 118 (15-16): 473-478 Gugatschka M, Hoeller A, Fahrleitner-Pammer A, Dobnig H, Pietschmann P, Kudlacek S, Obermayer-Pietsch B (2007) Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men. J Endocrinol Invest 30 (1): 46-51 Reviews: Kudlacek S, Willvonseder R, Stohlawetz P, Hahn P, Pietschmann P (2000) Immunology and aging. The aging male 3: 137 – 142 Resch H, Gollob E, Kudlacek S, Pietschmann P (2001) Die Osteoporose beim Mann. Wien Med Wschr 151: 457-463 Pietschmann P (2001) Geschlechtsunterschiede bei Gelenkserkrankungen: pathophysiologische Grundlagen. Wien Med Wschr 151: 573-575 Mitringer A, Pietschmann P (2002) Osteoporose bei prämenopausalen Frauen. Wien Med Wschr 152: 586 - 590 Dimai HP, Pietschmann P, Resch H, Klaushofer K (2002) Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose. Wien Med Wschr 152: 596 - 612 Brosch S, Redlich K, Pietschmann P. (2003) Pathogenese der Osteoporose bei chronischer
  • 181. - 181 - Polyarthritis. Acta Med Austriaca 30: 1 – 5 Pietschmann P, Kerschan-Schindl K (2004) Osteoporosis: Gender specific aspects. Wien Med Wschr 154/17-18: 411- 415 Rauner M, Sipos W, Pietschmann P (2007) Osteoimmunology. Int Arch Allergy Immunol 143: 31-48 Patsch J, Muschitz C, Resch H, Pietschmann P (2007) Of mice and men: pathophysiology of male osteoporosis. JMHG 4(1): 87-93 Bröll H, Resch H, Pietschmann P, Sieghart S, Dobnig H, Erlacher L, Finkenstedt G, Holzer G, Pecherstorfer M, Pirich C (2007) Konsensus-Statement: Therapie der postmenopausalen Osteoporose -Anwendungsbereiche von parenteralen Bisphosphonaten. J Miner Stoffwechs 1: 45-48 Patsch J, Pietschmann P (2007) Controversial question- does histomorphometry still have a role to play?. Medicographia 29(2): 151 Burckhardt P, Concin H, Dimai H, Dobnig H, Erlacher L, Finkensedt G, Gasser R, Holzer G, Klaushofer K, Kotz R, Kraenzlin M, Minne HW, Obermayer-Pietsch B, Peichl P, Pietschmann P, Roschger P, Schütz W, Sieghart S, Windhager R (2007) Med ahead consensus- Osteoporose- Stellenwert der PTH-Therapie. Österreichische Ärztezeitung (Suppl März): 3- 10 Sipos W, Pietschmann P. Rauner M (2008) Strategies for novel therapeutic approaches targeting ytokines and signaling pathways of osteoclasto-and osteoblastgenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 15(2); 127-136
  • 182. - 182 - Curriculum Vitae Clemens Scheinecker Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria Phone: +43 1 40400 4300, Fax: +43 1 40400 4306 E-mail: clemens.scheinecker@meduniwien.ac.at Homepage: http://www.meduniwien.ac.at/rheuma/ Personal Data Date of Birth: 12.03.1966 Place of Birth: Eisenstadt Nationality Austria Education 1984 – 1991 Academic studies of medicine at the University of Vienna, Austria Graduation to Doctor medicinae: 19.12.1991 1984 University entrance qualification, BG – BRG Oberschützen Career History Since 2004 Associate (a.o. Univ. Prof.) Professor of Internal Medicine 9/2004 Habilitation in Internal Medicine 2004 Specialist in Internal Medicine 2000 - 2003 Postdoctoral fellowship at the Laboratory of Immunology, Lymphocyte Biology Section, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA 1999 - 2000 Training in Internal Medicine at the University of Vienna, General Hospital of Vienna, Div. of Rheumatology, Clinic for Internal Medicine III 1996 - 1999 Training in Internal Medicine at the Lainz Hospital, II. Dept. of Medicine with Rheumatology, Vienna 1995 - 1996 Training in General Medicine at the Wilhelminenspital, I. Dept. of Medicine with Oncology, Vienna
  • 183. - 183 - 1992 - 1995 Postdoctoral fellowship at the Institute of Immunology, University of Vienna Awards 2005 “Habilitationspreis 2005 des Vereins zur Förderung von Wissenschaft und Forschung in den neuen Unversitätskliniken am Allgemeinen Krankenhaus der Stadt Wien (vfwf) 2005 Fellows Award for Research Excellence, National Institutes of Health, Fellows Committee, Bethesda, MD, USA 2001 Erwin Schrödinger Postdoctoral Fellowship, FWF, “Analysis of the regulatory mechanism involved in support of peripheral tolerance for tissue specific self-antigens”, # J2059 2000 Erwin Schrödinger Postdoctoral Fellowship, FWF, “Analysis of the regulatory role of dendritic cells in support of peripheral self tolerance”, # J1863 Memberships Austrian Society for Allergology and Immunology Austrian Society of Rheumatology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2008-2010 ÖNB - „Die Wirkung von Abatacept und Rituximab 35 Jubiläumsfond auf regulatorische T Zellen in der Rheumatoiden Arthritis“ # AP12754ONB 2005 - 2008 FWF “Analysis of T cell –antigen presenting cell 81 interaction in collagen induced arthritis (CIA) and effect of cell based immunomodulatory therapies“, # P18374-B13. Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2004 - 2005 Michael Bonelli Analysis of regulatory T cells under steady state and autoimmune conditions
  • 184. - 184 - 2004 - 2006 Sonia Herman Untersuchung der Interaktion von regulatorischen T-Zellen und Dendritischen Zellen, in Hinblick auf Phänotyp und Funktion. Publications 26 peer reviewed publications in scientific journals, 3 book chapters, Peer reviewed manuscripts 2002-2008 (original research and reviews) 1. Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast- Akrad M, Hayer S, Neumuller J, Pinol-Roma S, Smolen JS, Steiner G: Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol. Jul 15;169(2):1068- 76, 2002. 2. Scheinecker C, McHugh R, Shevach EM, Germain RN: Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med. 2002 Oct 21;196(8):1079-90. Comment in: J Exp Med. 2002 Oct 21;196(8):1013-6. 3. Köller M, Zwölfer B, Steiner G, Smolen J and Scheinecker C: Phenotypic and functional deficiencies of monocyte derived dendritic cells in systemic lupus erythematodes (SLE) patients. Int Immunol. Nov;16(11):1595-604, 2004. 4. Scheinecker C: Application of in vivo microscopy: evaluating the immune response in living animals Arthritis Res Ther; 7(6):246-52, 2005 Review. 5. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN: Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell- dendritic cell interaction. Nature. Apr 13;440(7086):890-5, 2006. 6. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a master regulator of joint remodeling. Nature Med, Mar;13(2):156-163, 2007. 7. Zwerina J, Redlich K, Polzer K, Joosten L, Kroenke G, Distler J, Hess A, Pundt N, Pap T, Hoffmann O, Gasser J, Scheinecker C, Smolen JS, van den Berg W, Schett G.: TNF- induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci., 104:11742-7, 2007. 8. Bonelli M, von Dalwigk K, Savitskaya A, Smolen JS, and Scheinecker C: Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus (SLE): A comparative phenotypic analysis. Ann Rheum Dis. 2007 Aug 29; [Epub ahead of print] 9. Zenz R, Eferl R, Scheinecker C, Redlich K, Smolen J, Schonthaler HB, Kenner L, Tschachler E, Wagner EF: Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther. 2008 Jan 18;10(1):201 [Epub ahead of print]
  • 185. - 185 - Curriculum Vitae Veronika Sexl Institute of Pharmacology, Centre for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Währinger Strasse 13a, A-1090 Vienna, Austria; Phone +43 1 4277 64137; Fax +43 1 4277 9641 Personal Data Date of Birth: 27.2.1966 Place of Birth: Vienna Nationality Austria Education 1992 - 2002 training as medical specialist in Pharmacology and Toxicology 1984-1992 studies of Human Medicine 1976-1984 secondary school: Bundesgymnasium XIX, Vienna Career History 12/07 Full Professor for Signaltransduction and Development of Molecular Targeted Therapies, Medical University of Vienna 2001 – present associate Professor at the Department of Pharmacology, Medical University of Vienna, Head of the Working Group Experimental Hemato-Oncology 2000 Materenity leave 1998-1999 Postdocteral fellow ship, St. Judes Childrens Research Hospital, Memphis, TN, USA, with Prof. James N Ihle, Dpt of Biochemistry 1996-1997 Erwin Schroedinger postdoctoral fellowship, St. Judes Childrens Research Hospital, Memphis, TN, USA, with Charles Sherr, Dpt Tumor Cell Biology 1996 short-term visiting fellow, Hutchinson Cancer Research Center, Seattle, WA, USA, with Prof. James Roberts 1992-1996 university assistent, Institute of Pharmacology, University of Vienna 1990-1992 Voluntary thesis and laboratory work in the laboratory of Prof. W Base, Dpt of Internal Medicine Vienna University
  • 186. - 186 - Clinics Career-related Activities 2002-present Lecturer for Pharmacology and Toxicology at the Fachhochschule für Biotechnologie, Krems 2005-2007 Lecturer for Pharmacology at the Paracelsus Medical University (PMU) in Salzburg, Austria Awards 1989-1992 Award for outstanding performance “Leistungsstipendium”, Medical Dpt, University of Vienna 2003 Award for innovative interdisciplinary cancer research of the city of Vienna 2004 Award for innovative interdisciplinary cancer research of the city of Vienna 2004 Billroth Award of the Medical Society 2005 Sanofi-Aventis-Award 2006 Novartis Arward for Medicine 2006 Alos Sonnleitner Award of the Austrian Academy of Science Memberships Austrian Pharmacological Society (APHAR) Elected member of the European Academy of Science Sources of funding in last 5 years (2000-2005) Period Organization Short Title K€/year 2001-2003 FWF IFN gamma dependent tumor surveillance 40 2002-2005 FWF AP-1 and leukemia 60 2004-05 OENB PI3K and leukemia 50 2005-09 SFB 28-10 Jaks and Stats 90 2005-09 GenAU Functional Pharmaco-Genomics and - 70 proteomics 2007-10 FWF Cdk6-a therapeutic target in leukemia 90 PhD supervision in last 5 years (2000-2005) Period Name of student Topic 2002-2006 Rene G Ott JunB and B lymphoid leukemia
  • 187. - 187 - 2004- Andrea Hölbl Stat5 in Abelson induced leukemia 2004- Olivia Simma Role of Tyk2 in immune functions 2004- Christian Schuster Tyk2 and Emu-myc induced tumors 2006- Karoline Kollmann Cdk6 and leukemia formation 2006- Eva Eckelhart Jak2 and Abelson induced malignancies 2007- Eva-Maria Putz Stat1 – tumor suppressor or promoter? 2007- Nina Neugebauer Stat1 in mammary tumor formation Publications 35 peer reviewed publications in scientific journals, about 20 invited lectures Peer reviewed manuscripts 2002-2007 (original research and reviews) First, last or corresponding author manuscripts: Klinger M, Kudlacek O, Seidel MG, Freissmuth M, Sexl V (2002). MAP Kinase Stimulation by cAMP Does Not Require RAP1 but SRC Family Kinases. J Biol Chem 277:32490-7 Sexl V, Kovacic B, Piekorz R, Moriggl R, Stoiber D, Hoffmeyer A, Liebminger R, Kudlacek O, Weisz E, Rothammer K, Ihle JN (2003). Jak1 deficiency leads to enhanced Abelson- induced B-cell tumor formation. Blood 101: 4937-43. Szremska A, Kenner L, Weisz E, Passegué E, Artwohl M , Freissmuth M, Stoxreiter R, Theussl HC, Baumgartner Parzer S , Moriggl R, Wagner EF, Sexl V (2003). JunB inhibits proliferation and transformation in B lymphoid cells. Blood, 102:4159-4165. Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors (2004).Cancer Res;64(3):1087-93. Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine O, Müller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V. Tyk2 is a key regulator of the surveillance of B-lymphoid tumors (2004). J Clin Invest. 114:1650-1658. Hölbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, Beug H, Hennighausen L, Moriggl R, Sexl V. Clarifying the role of Stat5 in lymphoid development and Abelson induced transformation (2006). Blood 107:4898-906. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V. STAT1 acts as a tumor promoter for leukaemia development (2006). Cancer Cell 10:77-87. Ott RG, Simma O, Kollmann K, Weisz E, Zebedin EM, Schorpp-Kistner M, Heller G, Zochbauer S, Wagner EF, Freissmuth M, Sexl V. Jun Bis a gatekeeper for B-lymphoid leukemia (2007). Oncogene 26: 4863-71. Schuster C, Fernbach N, Rix U, Superti-Furga G, Holy M, Freissmuth M, Sitte HH, Sexl V. Selective serotonin reuptake.-inhibitors – a new modality for the treatment of lymphoma/leukemia? (2007). Biochem.Pharmacol. 74: 424-35.
  • 188. - 188 - Co-author manuscripts: Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L, Rehg J, Ihle JN (2002). The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J 21:653-664. Shelburne C, McCoy M, Piekorz R, Sexl V, Gillespie S, Bailey D, Gharse A, Mirmonsef P, N Mann M, Kashyap M, Wright H, Chong H, Bouton L, Ramirez C, Lantz C, Ryan J (2002). Stat5: an essential regulator of mast cell biology. Mol Immunol 38:1187-1191. Shelburne CP, McCoy ME, Piekorz R, Sexl V, Roh KH, Jacobs-Helber SM, Gillespie SR, Bailey DP, Mirmonsef P, Mann MN, Kashyap M, Wright H, Chong H, Bouton L, Ramirez C, Lantz C, Ryan J (2003). Stat5 expression is critical for mast cell development and survival. Blood 102:1290-1297. Moriggl R, Sexl V, Kenner L, Duntsch C, Stangl K, Gingras S, Hoffmeyer A, Bauer A, Piekorz R, Wang D, Bunting KD, Wagner EF, Sonneck K, Valent P, Ihle JN, Beug H. Stat5 Tetramers formation is associated with leukemogenesis (2005). Cancer Cell. 7:87-99. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wachek V, Gleave ME, Pehamberger H, Jansen B. Clusterin confers drug-resistance in melanoma cells (2005). J Invest Dermat. 124:1300-7. Höller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F, Sexl V, Pehamberger H. The non receptor associated tyrosine kinase p72Syk is a regulator of metastatic behaviour in human melanoma cells (2005). J Invest Dermat. 124: 1293-9. Staber PB, Veley P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G. The oncoprotein NPM-ALK of anaplastic large cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signalling (2007). Blood, 110:3374-83. Mayerhofer M, Gleixner KV, Mayerhofer J, Hoermann G, Jaeger E, Aichberger K, Ott RG, Greish K, Nakamura H, Derdak S, Samorapoompichit P, Pickl WF, Sexl V, Esterbauer H, Schwarzinger I, Sillaber C, MaedaH, Valent P. Targeting of heat shock protein 32 (HsP32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myleoid leukemia: a novel approach to overcome resistance against imatinib. (2007). Blood; epub ahead of print.
  • 189. - 189 - Curriculum Vitae Maria Sibilia Institute for Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria Phone: 43 1 40160-63011, Fax: +43 1 40160-963005 Email: Maria.Sibilia@meduniwien.ac.at http://www.meduniwien.ac.at/innere-med-1/krebsforschung http://www.meduniwien.ac.at/phd-iai/ http://www.meduniwien.ac.at/sfb23/ Personal Data Date of Birth: 26.11.1963 Place of Birth: Chur Nationality Switzerland Education 1970 – 1984 Schools in Thusis and Chur (GR), Switzerland. 1984 – 1989 Study of Biological Sciences, University of Pavia, Italy, with honours. 1986 – 1989 Experimental thesis (Laurea), Department of Genetics and Microbiology, University of Pavia, Italy. 1990 – 1992 Ph.D. Studies in Genetics and Molecular Biology, University of Pavia and Department of Biotechnology and Virology, Brescia, Italy. Career-related Activities 1993 – 1996 Postdoctoral fellow at the Institute of Molecular Pathology (IMP), Vienna, Austria. 1996 – 1998 Staff Scientist at the Institute of Molecular Pathology (IMP), Vienna, Austria. 01/1999 Assistant Professor / Group Leader (Univ. Ass.) at the Department of Dermatology, DIAID, University of Vienna Medical School, Vienna, Austria. 07/2002 Habilitation in Molecular Biology and Genetics, University of Vienna Medical School. Associate Professor (a.o. Univ. Prof.) at the Department of Dermatology, DIAID, University of Vienna Medical School, Vienna, Austria. 04/2007 Professor for Cellular and Molecular Tumorbiology, Institute for Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria Awards 1990 - 1992 Graduate Student Fellowship from the “Fondazione Istituto Zooprofilattico Sperimentale Brescia”.
  • 190. - 190 - 1992 - 1994 Postdoctoral fellowship from the “Associazione Italiana per la Ricerca sul Cancro (AIRC)”. 12/2000 ÖGDV-Unilever Dermatology Prize 2000 11/2002 Habilitation prize “Verein zur Förderung von Wissenschaft und Forschung in den Neuen Universitätskliniken am AKH der Stadt Wien” (VFWF). 05/2003 Otto-Kraupp-Prize: 1st Prize for the best Habilitation in Austria for the year 2002. 10/2005 Alois-Sonnleitner Prize, Austrian Academy of Sciences (ÖAW) for outstanding achievements in Cancer Research. Publications Research papers: M. B. Boniotti, C. Wirblich, M. Sibilia, G. Mayers, H.-J. Thiel and C. Rossi. “Identification and characterisation of a 3C-like protease from Rabbit Hemorrhagic Disease Virus, a Calicivirus”, J. Virology 68, 6487-6495 (1994). M. Sibilia, M.B. Boniotti, P. Angoscini, L. Capucci and C. Rossi. “Two independent pathways of expression lead to self-assembly of the Rabbit Hemorrhagic Disease Virus capsid protein”, J. Virology 69, 5812-5815 (1995). C. Wirblich, M. Sibilia, M.B. Boniotti, C. Rossi, H.-J. Thiel and G. Mayers. “3C-like protease of Rabbit Hemorrhagic Disease Virus: Identification of cleavage sites in the ORF1 polyprotein and analysis of cleavage specificity”, J. Virology 69, 7159-7168 (1995). M. Sibilia and E. F. Wagner. “Strain-dependent epithelial defects in mice lacking the EGF receptor”, Science 269, 234-238 (1995). M. Sibilia, J. P. Steinbach, L. Stingl, A. Aguzzi and E. F. Wagner. “A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor”, EMBO J. 17, 719-731, (1998). V. Tropepe, M. Sibilia, B. G. Ciruna, J. Rossant, E. F. Wagner and D. van der Kooy. “Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon”, Dev. Biology 208, 166-188 (1999). A. Behrens, M. Sibilia and E. F. Wagner. “Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation” Nature Genetics 21, 326-329 (1999). R. Eferl, M. Sibilia, F. Hilberg, A. Fuchsbichler, I. Kufferath, B. Guertl, R. Zenz, E. F. Wagner and K. Zatloukal. “Functions of c-Jun in liver and heart development”, J. Cell Biol. 145, 1049-1061 (1999). M. Sibilia*, A. Fleischmann, A. Behrens, L. Stingl, J. Carroll, F. M. Watt, J. Schlessinger and E. F. Wagner*. “The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development”, Cell 102, 211-220 (2000). (*corresponding authors) A. Behrens, W. Jochum, M. Sibilia and E. F. Wagner. “Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation“, Oncogene 19, 2657-2663 (2000). S. W. Stoll, S. Kansra, S. Peshick, D. W. Fry, W. R. Leopold, J. F. Wiesen, M. Sibilia, T. Zhang, Z. Werb, R. Derynck, E. F. Wagner and J. T. Elder. "Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant
  • 191. - 191 - keratinocytes", Neoplasia 3,339-350, 2001. A. H. F. M. Peters, D. O'Carroll, H. Scherthan, K. Mechtler, S. Sauer, C. Schöfer, K. Weipoltshammer, M. Pagani, M. Lachner, A. Kohlmaier, S. Opravil, M. Doyle, M. Sibilia and T. Jenuwein. "Loss of the Suv39h Histone Methyltransferases impairs mammalian heterochromatin and genome stability", Cell 107, 323-337 (2001). A. Behrens*, M. Sibilia*, J. P. David, U. Möhle-Steinlein, F. Tronche, G. Schütz and E. F. Wagner. “Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c- jun in the liver”, EMBO J. 21, 1782-1790, (2002). (*equally contributing authors) M. Sibilia, B. Wagner, A. Hoebertz, C. Elliott, S. Marino, W. Jochum and E. F. Wagner. “Mice humanized for the EGF receptor display hypomorphic phenotypes in skin, bone and heart”, Development 130, 4515-4525, (2003). R. Zenz, H. Scheuch, P. Martin, C. Frank, R. Eferl, L. Kenner, M. Sibilia and E. F. Wagner. “c-Jun regulates eyelid closure and skin tumor development through EGFR signaling”, Dev. Cell 4, 879-889, (2003). F. Palamara, S. Meindl, M. Holcmann, P. Lührs, G. Stingl and M. Sibilia. “Identification and characterization of ‘pDC-like cells’ in normal mouse skin and melanomas treated with Imiquimod”, J. Immunology 173, 3051-3061, (2004). B. Wagner, A. Natarajan, S. Grünaug, R. Kroismayr, E.F. Wagner and M. Sibilia. “Neuronal survival depends on EGF receptor signaling in cortical but not midbrain astrocytes”, EMBO J. 25, 752-762, (2006). K. Fortschegger, B. Wagner, R. Voglauer, H. Katinger, M. Sibilia and J. Grillari. “Early Embryonic Lethality of Mice Lacking the Essential Protein SNEV”, Mol. Cell Biol. 27, 3123- 3130 (2007). A. Natarajan, B. Wagner and M. Sibilia. “The EGF receptor is required for efficient liver regeneration”, PNAS, 104:17081-17086 (2007). E. Schraml, R. Voglauer, K. Fortschegger, M. Sibilia, I. Stelzer, J. Grillari and K. Schauenstein. “Haploinsufficiency of SNEV causes defects of hematopoietic stem cells functions“, Stem Cells Dev., in press (2008) U. Schmidt, N. Boucheron, E. Eckelhart, I. Bilic, M. Kneidinger, B. Unger, M. Hammer, M. Sibilia, P. Valent and W. Ellmeier. “The protein tyrosine kinase Tec regulates mast cell function“, J. Immunology, accepted pending revision (2008). M. Holcmann, B. Drobits, P. Lührs, G. Stingl, D. Maurer and M. Sibilia. “Tolerance induction in the skin under homeostatic conditions“, J. Immunology, accepted pending revision (2008). Book chapters and reviews C. Rossi, M. B. Boniotti, M. Sibilia, L. Capucci. “Expression by a recombinant Baculovirus of the capsid protein VP60 from the Rabbit Hemorrhagic Disease Virus results in assembly of empty capsids and production of an effective Vaccine”, in ‘State of the Art of the Italian Research in Biotechnology applied to Veterinary Sciences‘, Vol 35, 45-55 (1993). M. Sibilia and E. F. Wagner. “Transgenic animals”, European Review, Vol 4, No. 4, 371- 391 (1996).
  • 192. - 192 - E. F. Wagner and M. Sibilia. “Transgenics revisited”, Trends in Genetics, 13, 501-502 Book Comment to ‘Transgenic Animals: Generation and Use’ ed. L.M. Houdebine, Harwood Academic Publishers (1997). M. Sibilia, R. Kroismayr, A. Natarajan, B. M. Lichtenberger, M. Hecking, M. Holcmann. “The Epidermal Growth Factor Receptor: from development to tumorigenesis“. Differentiation, 75, 770-787 (2007)
  • 193. - 193 - Curriculum Vitae Peter Steinberger Division of Immune Receptors and T cell Activation, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse 8a, 1090 Wien, Austria; Phone: +43 1 4277-64941, Fax: +43 1 4277-9649; Email: peter.steinberger@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/immunologie/ellmeier Personal Data Date of Birth: 28.11.1965 Place of Birth: Leoben, Austria Nationality Austria Education 1992 – 1995 Ph.D. in Biochemistry at the University of Vienna, 1988 – 1992 Diploma degree in Zoology and Biochemistry; University of Vienna 1986 – 1988 Prediploma in Biology; University of Graz 1985 University entrance qualification, HBLA Raumberg Career History 06/2007 Habilitation at the Medical University of Vienna Since 03/2007 Independent group leader at the Institute of Immunology Since 06/2006 Permanent research position at the Institute of Immunology Since 02/2000 Institute of Immunology in the group of Prof. Walter Knapp and since 08/2004 in the group of Prof. Johannes Stöckl 06/1996-12/1999 Postdoctoral Studies at The Scripps Research Institute in the group of Professor Dr. Carlos F. Barbas III. 1992-1995 PhD Thesis at the Dept. of Pathophysiology in the group of Professor Rudolf Valenta Awards and Fellowships 06/1998 Austrian National Award for Alternatives to Animal Experimentation 1997-1998 Erwin Schroedinger Fellowship from the Austrian Science
  • 194. - 194 - Foundation 12/1995 Award for Ph. D. thesis of the Austrian Society of Allergy and Clinical Immunology 09/1995 Travel award from the Austrian Society for Allergology and Immunology Memberships Austrian Society for Allergology and Immunology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2008 - 2010 ONB Alternative costimulators in CD28-negative T 37 cells 2006 - 2008 FWF Role of B7-H3 during T cell activation 70 2005 - 2008 CCRI DC-reactive antibodies 55 2004 - 2006 ONB Search for HSP-Receptors 40 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 01/2006- Judith Leitner Identification of tumour antigens using antibodies present induced by DC-based vaccines Publications Scientific papers: 34 Reviews: 4 Book Chapters: 5 Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: 1 Pfistershammer, K, Klauser, C., Leitner, J., Stöckl, J, Majdic, O., Weichhart, T., Sobanov, J., Bochkov, V., Säemann, M., Zlabinger, G., Steinberger, P* Identification of the Scavenger Receptors SREC-I, SR-B1/Cla-1 and SR-A-1 as cellular receptors for Tamm-Horsfall Protein. J Leukoc Biol. 2008. 83: 131-8. 2 Pfistershammer, K., Klauser, C., Pickl, W. F., Stockl, J., Leitner, J., Zlabinger, G., Majdic, O. and Steinberger, P*., No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 2006. 36: 1104-1113. 3. Steinberger, P*., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C. Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172:2352. 4. Steinberger, P.*, A. Szekeres, S. Wille, J. Stockl, N. Selenko, E. Prager, G. Staffler, O. Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the
  • 195. - 195 - phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71:133. * corresponding author Co-author manuscripts: 1. Flicker, S., Steinberger, P., Eibensteiner, P. B., Lebecque, S., Kraft., D., and Valenta, R. Molecular characterization of a human IgG4 antibody specific for the major birch pollen allergen, Bet v 1. Clin. Exp. Allergy. in press 2. Swan, C. H., Buhler, B., Steinberger, P., Tschan, M. P., Barbas, C. F., 3rd and Torbett, B. E., T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 2007. 14: 626. 3. Flicker, S., Steinberger, P., Ball, T., Krauth, M. T., Verdino, P., Valent, P., Almo, S. and Valenta, R., Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol 2006. 117: 1336-1343. 4. Kirchberger, S., O. Majdic, P. Steinberger, S. Bluml, K. Pfistershammer, G. Zlabinger, L. Deszcz, E. Kuechler, W. Knapp, and J. Stockl. 2005. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol 175:1145. 5. Pfistershammer, K., O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P. Steinberger, and W. Knapp. 2004. CD63 as an activation-linked T cell costimulatory element. J Immunol 173:6000. 6. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer, G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stockl. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170:3637. 7. Flicker, S., P. Steinberger, L. Norderhaug, W. R. Sperr, Y. Majlesi, P. Valent, D. Kraft, and R. Valenta. 2002. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol 32:2156.
  • 196. - 196 - Curriculum Vitae Günter Steiner Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18, A 1090 Vienna; E-mail: guenter.steiner@meduniwien.ac.at Personal Data Date of Birth: 29.10.1953 Place of Birth: Vienna Nationality Austrian Education 1981-1986 PhD studies (Biochemistry) at the Institute of Biochemstry, University of Vienna Medical School 1979-1981 Diploma thesis at the Institute of Biochemstry, University of Vienna Medical School 1973-1979 Studies in Biochemistry, University of Vienna 1964-1972 High school, Bundesgymnasium 21, Vienna Career History 2000- Associate Professor (a.o.Univ.Prof), Head of Laboratory, Division of Rheumatology, Univ. of Vienna Medical School 2000 Habilitation in Biochemistry, Univ. of Vienna Medical School 1995-2000 Group leader, Division of Rheumatology, Internal Medicine III, Univ. of Vienna Medical School 1989-1995 Group leader, Ludwig Boltzmann-Institute for Rheumatology, Vienna 1986-1989 Postdoctoral Fellow, Ludwig Boltzmann-Institute for Clinical Endocrinology, Vienna Career-related Activities 2005-present Member of the International Organizing Committee of the International Congress on Autoimmunity 2002-2006 Board member, Austrian Society for Biochemistry and Molecular Biology 2002-2005 Scientific programme committee member, European League against Arthritis and Rheumatism (EULAR) 2001 Coorganizer, European Workshop for Rheumatoloy Research
  • 197. - 197 - 2000 - present International Advisory Board, Dresden Symposium on Autoantibodies 1999 Coorganizer, 4th European Conference on SLE 1997 Advisory board, 10th EULAR Workshop 1992 Coorganizer, Int. Symposium on Ribonucleoproteins 1991 Coorganizer, Int. Workshop on Cytokines in Rheumatology Awards 1997, 2000 Austrian State Award for Rheumatology 1992 Young Investigator´s Award of the European Workshop for Rheumatology Research (EWRR) 1990 Forschungsförderungspreis der 1. Österr. Sparkasse 1987 Theodor Körner Award Memberships Austrian Society for Biochemistry and Molecular Biology Austrian Society for Allergology and Immunology Austrian Society for Rheumatology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2008 - 2012 EU MASTERSWITCH (Integrated Project) 160 2006 - 2011 EU AUTOCURE (Integrated Project) 90 2005 - 2007 ÖAW CeMM 20060 121 2003 - 2004 ÖAW CeMM 20060 152 2002 ÖAW CeMM 20060 43 2001 - 2007 FWF SFB 017/F1705: RNA Fate and Function 49 PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 1999 - 2003 Silvia Hayer Molecular and cellular mechanisms leading to autoimmune responses and tissue destruction in rheumatoid arthritis 2002 - 2004 Atijeh Valai Interactions of hnRNP I and hnRNP K with autoantibodies and human Y1 RNA 2004-2008 Markus Hoffmann The role of the autoantigen hnRNP-A2/B1 (RA33) in the pathogenesis of rheumatoid arthritis
  • 198. - 198 - Publications 86 peer reviewed publications in scientific journals, 20 book chapters, > 30 invited lectures Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts Fritsch R, Eselböck D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad M, Hayer S, Neumüller J, Pinol-Roma S, Smolen J, Steiner G. Characterization of autoreactive T cells to the autoantigens RA33 (hnRNP A2) and filaggrin in patients with rheumatoid arthritis. J Immunol 169:1068-1076; 2002. Steiner G, Shovman O, Skriner K, Gilburd B, Langevitz P, Miholits M, Hoet R, Levy Y, Hoefler E, Smolen JS, Shoenfeld Y. Idiotypic manipulation with anti-RA33 antibody preparation in mice induces the production of anti-RA33 hnRNP autoantibodies and transient spread to snRNP complex of spliceosome. Clin Exp Rheumatol 20:517-524; 2002. Schett G, Smolen J, Hiessberger H, Hoefler E, Fournel S, Muller S, Rubin RL, Steiner G. The autoimmune response to chromatin antigens in systemic lupus erythematosus (SLE): autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 11:704-715; 2002. Schett G, Steiner CW, Xu Q, Smolen JS, Steiner G. TNFα mediates susceptibility to heat- induced apoptosis by protein phosphatase-mediated downregulation of the HSF-1/hsp70 stress response. Cell Death Diff 10:1126-1136; 2003. Smolen JS, Steiner G. Current and future therapeutic strategies for rheumatoid arthritis. Nature Rev Drug Disc 2:473-488; 2003. Belisova A, Semrad K, Kocian G, Mayer O, Waigmann E, Schroeder R, Steiner G. RNA chaperone activity of protein components of human Ro RNPs. RNA 11, 1084-1094; 2005. Nell VPK, Machold KM, Stamm TA, Eberl G, Heinzl H, Uffmann M, Smolen JS, Steiner G. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64:1731-6; 2005. Hayer S, Tohidast-Akrad M, Haralambous S, Jahn-Schmid B, Skriner K, Trembleau S, Dumortier H, Pinol-Roma S; Redlich K, Schett G, Muller S, Kollias G, Smolen J, Steiner G. Aberrant expression of the autoantigen hnRNP-A2/B1 (RA33) and spontaneous formation of rheumatoid arthritis associated anti-RA33 autoantibodies in TNFα transgenic mice. J Immunol 175:8327-36; 2005. Fritsch-Stork R, Mullegger D, Skriner K, Jahn-Schmid B, Smolen JS, Steiner G. The spliceosomal autoantigen heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) is a major T cell autoantigen in patients with systemic lupus erythematosus. Arthritis Res Ther. 8:R118; 2006. Steiner G. Autoantibodies and autoreactive T cells in rheumatoid arthritis: pathogenetic players and diagnostic tools. Clin Rev Allergy Immunol. 32:23-36; 2007. Hoffmann MH, Tuncel J, Skriner K, Tohidast-Akrad M, Türk B, Pinol-Roma S|, Serre G, Schett G, Smolen JS, Holmdahl R, Steiner G. The human autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritis. J Immunol. 179:7568-7576; 2007. Skriner K, Hueber W, Süleymanoglu E, Höfler E, Kren V, Smolen J, Steiner G.The regulator of TNFα mRNA decay AU-rich element binding factor 1 (AUF1) is targeted by autoantibodies of patients with systemic rheumatic diseases. Arthritis Rheum 58:511-520; 2008.
  • 199. - 199 - Stummvoll GH, Fritsch RD, Meyer B, Hoefler E, Aringer M, Smolen JS, Steiner G. Characterization of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythematosus. Ann Rheum Dis; Epub ahead of print; March 2008. Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Aringer M, Schett G, Matucci-Cerinic M, Smolen J, Steiner G. Autoantibodies to the translational suppressors TIA-1 and TIAR in patients with rheumatic diseases. Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Arthritis Rheum, in press. Co-author manuscripts Redlich K, Hayer S, Maier A, Dunstan CR, Lang S, Tohidast-Akrad M, Türk B, Pietschmann P, Woloszczuk W, Haralambos S, Kollias G, Steiner G, Smolen JS, Schett G. TNF-α- mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46:785-792; 2002. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hoefler E, Steiner CW, Radda I, Smolen JS, Graninger WB. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 11:102-108; 2002. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, Pottel H, Serre G, de Keyser F. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for anti-filaggrin autoantibody detection by Line Immunoassay. Arthritis Rheum. 46:1185-1195; 2002. Redlich K, Hayer S, Ricci R, David J-P, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF -mediated joint destruction. J Clin Invest 110:1419-1427; 2002. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice. Arthritis Rheum 48:2042-2051; 2003. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 48: 3308- 3319; 2003. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Single and combined inhibition of TNF, IL-1 and RANKL pathways in TNF-induced arthritis: effects on synovial inflammation, bone erosion and cartilage destruction. Arthritis Rheum 50: 277-290; 2004. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 164: 543-555; 2004. Redlich K, Görtz B, Hayer S, Zwerina J, Kollias G, Steiner G, Smolen JS, Schett G. Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum 50: 1001-1005; 2004. Görtz B, Hayer S, Redlich K, Zwerina J, Tohidast-Akrad M, Türk B, Hartmann C, Kollias G, Steiner G, Smolen JS, Schett G. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res 19: 980-988; 2004.
  • 200. - 200 - Koller M, Zwolfer B, Steiner G, Smolen JS, Scheinecker C. Phenotypic and functional deficiencies of monocyte-derived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol 16:1595-604; 2004. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arthritis Rheum 50: 3161-3169; 2004. Köller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G. JNK1 is not essential for TNF-mediated joint disease. Arthritis Res. Ther.:R166-73, 2005. Hayer S, Steiner G, Görtz B, Reiter E, Tohidast-Akrad M, Amling M, Hoffmann O, Redlich K, Zwerina J, Skriner K, Hilberg F, Wagner EF, Smolen JS, Schett G. CD44 as a regulator of inflammatory bone loss. J Exp Med 201:903-914, 2005. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger I, Wolozcszuk W, Steiner G, Smolen JS. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111:204-11, 2005. Smolen JS, Redlich K, Zwerina J, Aletaha D, Steiner G, Schett G. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol 28:239-48; 2005. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 46:342-349; 2007. Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56:274-279; 2007. Grisar JC, Aletaha D, Steiner CW, Kapral T, Steiner S, Saemann M, Schwarzinger I, Buranyi B, Steiner G, Smolen JS. Endothelial progenitor cells in active rheumatoid arthritis: Effects of TNF and of glucocorticoid therapy. Ann Rheum Dis. 66:1284-8;2007. Rozman B, Euènik S, Sodin-Semrl S, Czirják L, Varjú C, Distler O, Huscher D, Aringer M, Steiner G, Matucci-Cerinic M, Guiducci S, Stamenkoviæ B, Stankoviæ A, Kveder T. Prevalence and clinical associations of anti-KU antibodies in patients with systemic sclerosis: a European EUSTAR - initiated multicentre case-control study. Ann Rheum Dis, Epub ahead of print, Dec. 2007. Book chapters Steiner G, Skriner K, Fabini G, Jimenez-Boj E, Kedersha N, Zimmermann C, Tohidast-Akrad M, Schett G, Fritsch R, Höfler E, Anderson P, Smolen J. Translational regulators as autoantigens in systemic autoimmune diseases. In: Autoantigens, Autoantibodies, Autoimmunity; Volume 3. Conrad K, Fritzler M, Meurer M, Sack U, Shoenfeld Y, eds. Pabst Science Publishers, Lengerich, pp 116-121; 2002. Steiner G, Conrad K. Autoantigene. In: Molekularmedizinische Grundlagen von rheumatischen Erkrankungen. Ganten D, Ruckpaul K eds. Springer Verlag Berlin Heidelberg New York, pp123-164; 2003. Steiner G. Autoantibodies in rheumatoid arthritis. In: Rheumatology, 3rd edition. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Harcourt Sciences Ltd, pp833- 842; 2003. Steiner G, Belisova A, Valai A, Hayer S, Höfler E, Smolen J. Reflections about structure, function and pathogenetic significance of Ro ribonucleoproteins. In: Autoantigens, Autoantibodies, Autoimmunity; Volume 4. Conrad K, Bachmann MP, Chan EKL, Fritzler MJ,
  • 201. - 201 - Humbel RL, Sack U, Shoenfeld Y. eds. Pabst Science Publishers, Lengerich, pp 236-242; 2004. Steiner G, Smolen J. Anti-RA33 autoantibodies (antibodies to the hetereogeneous nuclear ribonucleoprotein A2). In: Autoantibodies 2nd edition. Shoenfeld Y, Gershwin E, Meroni P-L eds. Elsevier BV, pp 211-216; 2007. Steiner G, Hoffmann M, Hayer S, Fritsch R, Smolen J. Autoimmune responses in experimental models of rheumatoid arthritis. In: Autoantigens, Autoantibodies, Autoimmunity; Volume 5. Conrad K, Chan EKL, Fritzler MJ, Humbel RL, Sack U, Shoenfeld Y., Wiik AS eds. Pabst Science Publishers, Lengerich, pp 45-53; 2007. Voll R, Steiner G. Autoantikörper - Diagnostik und Pathogenese. In: Aktuelle Therapieoptionen beim systemischen Lupus erythematodes. Aringer M ed. Uni-Med Verlag, pp16-24; 2007. Steiner G, Serre G. Autoantibodies in rheumatoid arthritis. In: Rheumatology, 4tth edition. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH eds. Mosby Elsevier, pp 819-827; 2008. Invited Talks 2002-2008 Diagnostic criteria for early rheumatoid arthritis, Vienna, 25.-27. 1.2002. International Congress on Autoimmunity, Geneva, 20.-24.2. 002. First Meeting of the Global Arthritis Research Network, Luzern, 4.-6.4.2002. Dresden Symposium on Autoantibodies, Dresden, 4.-7.9.2002. European Workshop for Rheumatology Research, Marseille, 1.3.2003. International Symposium on Autoimmunity; Vienna, 4.4.2003. International Workshop on Autoantibodies and Autoimmunity; Berlin, 12.9.2003. Workshop for Use of New Technologies in Rheumatology Research; Stockholm, 3.10.2003. Yale University School of Medicine; New Haven, 7.5.2004. Dresden Symposium on Autoantibodies; Dresden, 1.-4.9.2004. Austrian Proteome Form; Wien, 14.-15.10.2004. Kennedy Institute of Rheumatology; London, 7.3.2005. Annual European Congress of Rheumatology, Vienna, 8.-11.6.2005. International Workshop on Autoantibodies and Autoimmunity, Gainesville, 29.9.-2.10.2005. Workshop New Trends in Rheumatology, Kühtai, 30.3.-1.4. 2006. First International Aesku.Kipp Institute Symposium Autoimmunity, Wendelsheim, 6.5.2006. 34. Kongress der Deutschen Gesellschaft für Rheumatologie, Wiesbaden, 18.-21.10.2006. Menarini Diagnostics International Symposium on Autoimmunity, Sorrento, 27.-28.11.2006. Third Cellaid Symposium, Florence, 20-22.2. 2007. Eighth Dresden Symposium on Autoantibodies, Dresden, 12.-15.9.2007. Jahrestagung der ÖGLKC und der DGKL, Vienna, 19.-21.9.2007. European Workshop for Rheumatology Research, Toulouse, 28.2.-1.3.2008.
  • 202. - 202 - Curriculum Vitae Johannes Stöckl Division of Immune-Regulation, Institute of Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria; Phone: +43 1 4277-64951, Fax: +43 1 4277-9649; Email: johannes.stoeckl@meduniwien.ac.at; Homepage: www.meduniwien.ac.at/immunologie Personal Data Date of Birth: 15.12.1965 Place of Birth: Vienna Nationality Austria Education 1992 – 1994 PhD studies (Immunology), University of Vienna 1992 Diploma thesis at the Institute of Immunology, in Vienna 1985 – 1991 Studies in Microbiology, University of Vienna 1984 University entrance qualification, BGR Hollabrunn Career History Since 10/2003 Habilitation in Immunology, University of Vienna Medical School, Associate Professor (a.o.Univ.Prof) Since 2000 University Assistant (Group leader) 1994 - 2000 Postdoctoral Fellow, University of Vienna Medical School Career-related Activities 2003 – present Member of the Editorial Board, JCMM 2004 - present Board Member of the Austrian Society of Allegology and Immunology Awards 2006 Wissenschaftspreis 2006 des Landes Niederösterreich 2004 Otto-Kraup Preis (Habilitation), sponsored by Aventis 2002 Aventis Prize 2001 START Prize, BMBWK und FWF 1997 Karl Landsteiner Prize (Austrian Society of Allergology and
  • 203. - 203 - Immunology) 1993 Thesis Prize (Austrian Society of Allergology and Immunology) Memberships Austrian Society for Allergology and Immunology Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2007 - 2009 FWF Regulatory T cells and SREC-I 95 2007 - 2009 FWF SFB F23 Immunological Tolerance: 68 Vision fund (together with Maria Sibilia) 2005 - 2007 FWF SFB F23 Immunological Tolerance: 110 Subproject 7 2004 - 2007 WWTF Oxidized phospholipids and DC 175 1995 - 2004 FWF SFB-05-02: Polarized phagocyte 105 differentiation 2000 - 2004 K-Plus BMT Molecular Analysis of Dendritic Cell Function 100 Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic 2002 - 2006 Stefanie Kirchberger Modulation of immune cell function by human rhinoviruses 2004 - 2007 Nina Gundacker Effects of oxidized phospholipids on dendritic cell protein expression 2007 - Maria Seyerl Novel pathways of anergy induction in human T present cells 2008 - Catharina Schrauf Recognition of viral RNA by DC present Publications 43 peer reviewed publications in scientific journals, 3 book chapters, 18 invited lectures, 2 patents Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: 1. Selenko, N., O. Majdic, U. Jager, C. Sillaber, J. Stockl, and W. Knapp. 2002. Cross- priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive
  • 204. - 204 - antibodies? J Clin Immunol 22:124. 2. Selenko-Gebauer, N., O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer, G. Zlabinger, P. Steinberger, W. F. Pickl, H. Stockinger, W. Knapp, and J. Stockl. 2003. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 170:3637. 3. Bluml, S., S. Kirchberger, V. N. Bochkov, G. Kronke, K. Stuhlmeier, O. Majdic, G. J. Zlabinger, W. Knapp, B. R. Binder, J. Stockl, and N. Leitinger. 2005. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 175:501. 4. Kirchberger, S., O. Majdic, P. Steinberger, S. Bluml, K. Pfistershammer, G. Zlabinger, L. Deszcz, E. Kuechler, W. Knapp, and J. Stockl. 2005. Human rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 expression. J Immunol 175:1145. 5. Kirchberger, S., H. Vetr, O. Majdic, H. Stockinger, and J. Stockl. 2006. Engagement of ICAM-1 by major group rhinoviruses activates the LFA-1/ICAM-3 cell adhesion pathway in mononuclear phagocytes. Immunobiology 211:537. 6. Kirchberger, S., O. Majdic, and J. Stockl. 2007. Modulation of the immune system by human rhinoviruses. Int Arch Allergy Immunol 142:1. 7. Seyerl, M., S. Bluml, S. Kirchberger, V. N. Bochkov, O. Oskolkova, O. Majdic, and J. Stockl. 2008. Oxidized phospholipids induce anergy in human peripheral blood T cells. Eur J Immunol 38:778. Co-author manuscripts: 1. Schoppmann, S. F., P. Birner, J. Stockl, R. Kalt, R. Ullrich, C. Caucig, E. Kriehuber, K. Nagy, K. Alitalo, and D. Kerjaschki. 2002. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947. 2. Steinberger, P., A. Szekeres, S. Wille, J. Stockl, N. Selenko, E. Prager, G. Staffler, O. Madic, H. Stockinger, and W. Knapp. 2002. Identification of human CD93 as the phagocytic C1q receptor (C1qRp) by expression cloning. J Leukoc Biol 71:133. 3. Lehner, M., J. Stockl, O. Majdic, W. Knapp, K. Huttner, T. Felzmann, and W. Holter. 2003. MHC class II antigen signaling induces homotypic and heterotypic cluster formation of human mature monocyte derived dendritic cells in the absence of cell death. Hum Immunol 64:762. 4. Pfistershammer, K., O. Majdic, J. Stockl, G. Zlabinger, S. Kirchberger, P. Steinberger, and W. Knapp. 2004. CD63 as an activation-linked T cell costimulatory element. J Immunol 173:6000. 5. Steinberger, P., O. Majdic, S. V. Derdak, K. Pfistershammer, S. Kirchberger, C. Klauser, G. Zlabinger, W. F. Pickl, J. Stockl, and W. Knapp. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol 172:2352. 6. Traxler, E., E. Bayer, J. Stockl, T. Mohr, C. Lenz, and C. Gerner. 2004. Towards a standardized human proteome database: quantitative proteome profiling of living cells. Proteomics 4:1314. 7. Gundacker, N., E. Bayer, E. Traxler, H. Zwickl, M. Kubicek, J. Stockl, and C. Gerner. 2006. Knowledge-based proteome profiling: considering identified proteins to evaluate separation efficiency by 2-D PAGE. Electrophoresis 27:2712.
  • 205. - 205 - 8. Pfistershammer, K., C. Klauser, W. F. Pickl, J. Stockl, J. Leitner, G. Zlabinger, O. Majdic, and P. Steinberger. 2006. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 36:1104. 9. Pfistershammer, K., J. Stockl, J. Siekmann, P. L. Turecek, H. P. Schwarz, and B. M. Reipert. 2006. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 96:309. 10. Koesters, C., B. Unger, I. Bilic, U. Schmidt, S. Bluml, B. Lichtenberger, M. Schreiber, J. Stockl, and W. Ellmeier. 2007. Regulation of dendritic cell differentiation and subset distribution by the zinc finger protein CTCF. Immunol Lett 109:165. Invited Talks 2002-2008 2002 • ENT-meeting, AKH, Vienna, Austria 2003 • EMDS meeting, Leicester, UK 2004 • University of Innsbruck, Austria 2005 • Vienna Biocenter, Austria 2006 • Semmelweis University, Budapest, Hungary 2007 • Medical University of Innsbruck, Austria 2008 • Novo Nordisk, Kopenhagen, Denmark
  • 206. - 206 - Curriculum Vitae Martin Willheim Division of Cellular and Molecular Pathophysiology, Institute of Pathophysiology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Wien, Austria; Phone: +43 1 40400-5133, Fax: +43 1 40400-5130; Email: martin.willheim@meduniwien.ac.at; Personal Data Date of Birth: 31.08.1962 Place of Birth: Linz Nationality Austria Education 2006 Certification as Specialist of Pathophysiology 2005 Certification as Specialist of Laboratory Medicine 1980 – 1994 Studies in Medicine, Medical Faculty, University of Vienna Career History Since 2001 Associate Professor (a.o.Univ.Prof) 2001 Venia docendi in „Pathophysiology“ since 2001 Head of the research group „Cytokine research“, Institute of Pathophysiology, Medical University of Vienna since 04/2005 Institute of Pathophysiology, Medical University of Vienna 10/2001 – 03/2005 Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna (Resident) 10/2000 – 09/2001 Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna (Resident) 03 – 09/2000 Error! Not a valid link. (Resident) 12/1995 – 02/2000 Institute of Pathophysiology, Medical University of Vienna (Resident) Career-related Activities 2006 - present Head of the Core Unit Cytometry, Medical University of Vienna 02/2001 – present President of the Austrian Society for Cytometry
  • 207. - 207 - Awards 2005 B.R.A.H.M.S Forschungspreis für Schilddrüsenerkrankungen 2005 Memberships Austrian Society for Cytometry Austrian Society for Allergology and Immunology International Society for Analytical Cytology Austrian Society for Bone and Mineral Research Sources of funding in last 6 years (2002-2008) Period Organization Short Title K€/year 2007 Medizinisch Tumorstammzellen im malignen Melanom 15 Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien 2006 Medizinisch Anti-TPO Autoantikörper Spiegel und 15 Wissenschaftlicher Zytokin-Produktionsmuster von Fonds des Lymphozyten als mögliche Indikatoren der Bürgermeisters der Aktivität einer Hashimoto Thyreoiditis unter Bundeshauptstadt dem Einfluss einer L-Thyroxin Wien Substitutionstherapie Dr.rer.nat., Dr.sci.med. Dr. techn. or PhD supervisions in last 6 years (2002-2008) Period Name of student Topic Thien Ralf 2004-2007 Ernstbrunner Lino Änderung der Wirkung von 1α,25(OH)2 Vitamin D3 auf das Zytokin-Produktionsmuster von T Lymphozyten im Laufe der kindlichen Entwicklung 03/2007 - Maldonado Eduardo Effect of the short–term thyrotropin increase after present administration of Recombinant Human Thyrotropin (Thyrogen) on T lymphocyte cytokine production pattern and bone metabolism in healthy subjects 11/2007 - Semrad Ursula Extended cytokine profiling of functional human present peripheral blood CD4+ T lymphocytes (Th1, Th2
  • 208. - 208 - and Th17) and the effect of different micro- environments on their differentiation Publications 76 peer reviewed publications in scientific journals Peer reviewed manuscripts 2002-2008 (original research and reviews) First, last or corresponding author manuscripts: 1α,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Josefa Pichler, Marianne Gerstmayr, Zsolt Szépfalusi, Radvan Urbanek, Meinrad Peterlik and Martin Willheim Pediatr Res, 52:12-8, 2002 Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivo. Reinisch W, Lichtenberger C, Steger G, Tillinger W, Scheiner O, Gangl A, Maurer D, Willheim M. Clin Exp Immunol. 2003 Sep;133(3):476-84. T-lymphocyte cytokine production patterns in nonimmune severe hypothyroid state and after thyroid hormone replacement therapy. Karanikas G, John P, Wahl K, Schuetz M, Dudczak R, Willheim M. Thyroid. 2004 Jul;14(7):488-92. Relation of anti-TPO Autoantibody Titer and T Lymphocyte Cytokine Production Patterns in Hashimoto’s Thyroiditis. Karanikas G, Schütz M, Wahl K, Paul M, Kontur S, Pietschmann P, Kletter K, Dudczak R, Willheim M. Clin Endocrinol (Oxf). 2005 Aug;63(2):191-6. Interactions of 1α,25-dihydroxyvitamin D3 with interleukin-12 and interleukin-4 on cytokine expression of human T lymphocytes. Thien R, Baier K, Pietschmann P, Peterlik M, Willheim M. J Allergy Clin Immunol 2005, 116/3, pp 683-689. T lymphocyte cytokine production patterns in hashimoto patients with elevated calcitonin levels and their relationship to tumor initiation. Matthias Schütz, Heying Duan, Katharina Wahl, Christian Pirich, Anna Antoni, Spyridoula Kommata, Kurt Kletter, Robert Dudczak, Georgios Karanikas, Martin Willheim Anticancer Res., 2006 Nov-Dec;26(6B):4591-6. No immunological benefit of Selenium in consecutive patients with autoimmune thyroiditis Georgios Karanikas, Matthias Schuetz, Sylvester Kontur, Heying Duan, Spyridoula Kommata, Robert Schoen, Anna Antoni, Kurt Kletter, Robert Dudczak, and Martin Willheim Thyroid, accepted July 2007